<SEC-DOCUMENT>0001437749-18-006050.txt : 20180402
<SEC-HEADER>0001437749-18-006050.hdr.sgml : 20180402
<ACCEPTANCE-DATETIME>20180402160244
ACCESSION NUMBER:		0001437749-18-006050
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		90
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180402
DATE AS OF CHANGE:		20180402

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		18728866

	BUSINESS ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		2020 AVON COURT
		STREET 2:		SUITE 4
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dffn20171231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<html>
<head>
	<title>dffn20171231_10k.htm</title>


	<!-- Created by RDG HTML Converter v1.1.0.0 3/12/2018 11:00:45 AM --><meta charset="utf-8" /><meta name="format-detection" content="telephone=no" />
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-right: 10px; margin-left: 10px; cursor: auto;">
<div contenteditable="false" docsect="2" id="10793" sectdesc="Cover Page">&nbsp;</div>

<div data-td-statement-type="cover" data-td-v2v-id="1520950994710">
<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>UNITED STATES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Washington, D.C. 20549</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Form<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;10-K</font></b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td colspan="2" style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Mark one)</p>
			</td>
		</tr>
		<tr>
			<td style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9746;</p>
			</td>
			<td style="width: 90%; vertical-align: middle;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the fiscal year ended December<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;31, 2017</font></b></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OR</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: 90%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="2" style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>For the transition period from<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to</font></b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Commission file numbers: 000-24477</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Exact name of Registrants as specified in their Charter)</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 50%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Delaware</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(State or Other Jurisdiction of Incorporation or Organization)</p>
			</td>
			<td style="width: 50%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>30-0645032</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(I.R.S. Employer Identification Number)</p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>1317 Carlton Avenue, Suite 200<br>
			<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Charlottesville, VA</font></b><br>
			<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Address of Principal Executive Offices)</font></p>
			</td>
			<td style="width: 50%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>22902</b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Zip Code)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>(434) 220-0718</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Registrants<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; telephone number, including area code)</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;12(b) of the Act:</font></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Common Stock, par value $0.001 per share</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Title of each class)</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Securities registered pursuant to Section<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;12(g) of the Act:</font></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>None</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9744;</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> No&nbsp;&#9746;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9744;</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> No&nbsp;&#9746;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9746;</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> No&nbsp;&#9744;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9746;&nbsp;&nbsp; </font>No<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9744;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&sect;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#9744;</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &ldquo;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &quot;emerging growth company&quot; in Rule 12b-2 of the Exchange Act.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 75%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Large accelerated filer <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</font></p>
			</td>
			<td style="width: 25%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accelerated filer <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 75%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-accelerated filer (Do not check if a smaller reporting company) <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</font></p>
			</td>
			<td style="width: 25%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Smaller reporting company <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9746;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 75%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 25%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Emerging growth company <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;&#9744;</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> No&nbsp;&#9746;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The aggregate market value of the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s common stock, excluding shares beneficially owned by affiliates, computed by reference to the closing sale price at which the common stock was last sold as of June 30, 2017 (the last business day of the registrant&rsquo;s second fiscal quarter) as quoted on the Nasdaq Capital Market on that date was approximately $25.3 million.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of March 13, 2018, <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50,526,547</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> shares of common stock of the registrant were outstanding.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Documents Incorporated by Reference</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Part III of this annual report on Form 10-K incorporates by reference information (to the extent specific sections are referred to herein) from the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s definitive proxy statement for its 2018 Annual Meeting of Stockholders or an amendment to this Annual Report on Form 10-K, in any case, to be filed within 120 days of the end of the period covered by this Annual Report.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<hr style="margin: 3pt 0px; border: currentColor; border-image: none; width: 100%; height: 1px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<hr style="margin: 0px 0px 3pt; border: currentColor; border-image: none; width: 100%; height: 3px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);">
<p style="margin: 0pt; text-align: justify; text-indent: 44pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="3" id="10794" sectdesc="Table of Contents">&nbsp;</div>

<div data-td-statement-type="toc" data-td-v2v-id="1520951005961">
<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>TABLE OF CONTENTS</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PART I</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 1.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">BUSINESS</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">1</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 1A.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">RISK FACTORS</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">29</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 1B.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">UNRESOLVED STAFF COMMENTS</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">66</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 2.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PROPERTIES</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">66</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 3.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">LEGAL PROCEEDINGS</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">66</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 4.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">MINE SAFETY DISCLOSURES</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">67</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PART II</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">67</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: top;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 5.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">MARKET FOR REGISTRANT<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">67</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="padding: 0pt 0pt 0pt 9pt; width: 10%; text-align: left; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 6.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">SELECTED FINANCIAL DATA</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">68</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 7.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">MANAGEMENT<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">68</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 7A.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">76</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 8.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">77</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 9.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">105</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 9A.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CONTROLS AND PROCEDURES</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">105</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 9B.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">OTHER INFORMATION</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">106</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PART III</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 10.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 11.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">EXECUTIVE COMPENSATION</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 12.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 13.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 14.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PRINCIPAL ACCOUNTING FEES AND SERVICES</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">107</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">PART IV</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">108</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 15.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">108</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 10%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 85%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 10%; vertical-align: bottom;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ITEM 16.</p>
			</td>
			<td style="width: 85%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">FORM 10-K SUMMARY</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">108</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="12" id="10795" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>This annual report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created by those sections. For more information, see &ldquo;Part I. Item 1. Business <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&mdash; Cautionary Note Regarding Forward-Looking Statements.&rdquo;</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>As previously disclosed, on January 8, 2016,<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Diffusion Pharmaceuticals Inc. (f/k/a RestorGenex Corporation), a Delaware corporation (the &ldquo;</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u><i>Company</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;), completed the merger (the &ldquo;</i><u><i>Merger</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;) of its wholly owned subsidiary, Arco Merger Sub, LLC (&ldquo;</i><u><i>Merger Sub</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;), with and into Diffusion Pharmaceuticals LLC, a Virginia limited liability company (&ldquo;</i><u><i>Diffusion LLC</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;), in accordance with the terms of the Agreement and Plan of Merger, dated as of December 15, 2015, among the Company, Merger Sub and Diffusion LLC (the &ldquo;</i><u><i>Merger Agreement</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;). As a result of the Merger, Diffusion LLC, the surviving company in the Merger, became a wholly owned subsidiary of the Company and, following the Merger, the Company changed its corporate name from RestorGenex Corporation to Diffusion Pharmaceuticals Inc.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>For accounting purposes, the Merger is<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;treated as a &ldquo;reverse acquisition&rdquo; under generally acceptable accounting principles in the United States (&ldquo;</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u><i>U.S. GAAP</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;) and Diffusion LLC is considered the accounting acquirer. Accordingly, Diffusion LLC&rsquo;s historical results of operations will have replaced the Company&rsquo;s historical results of operations for all periods prior to the Merger.</i></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Unless the context otherwise requires, references to &ldquo;Diffusion,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our&rdquo; or &ldquo;us&rdquo; in this report refer to Diffusion Pharmaceuticals Inc. and its subsidiaries, following the completion of the Merger and Diffusion Pharmaceuticals LLC prior to the completion of the Merger, references to &ldquo;RestorGenex&rdquo; refer to the Company prior to the completion of the Merger and references to &ldquo;Diffusion LLC&rdquo; refer to Diffusion Pharmaceuticals LLC.</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Except as otherwise noted, references to &ldquo;common stock&rdquo; in this report refer to common stock, par value $0.001 per share, of the Company.</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>This report contains the following trademarks, trade<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;names and service marks of ours: RestorGenex and Diffusion. All other trade names, trademarks and service marks appearing in this Annual Report on Form 10-K are the property of their respective owners. We have assumed that the reader understands that all such terms are source-indicating. Accordingly, such terms appear without the trade name, trademark or service mark notice for convenience only and should not be construed as being used in a descriptive or generic sense.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">&nbsp;</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PART I</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>BUSINESS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. We are developing our lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&ldquo;TSC&rdquo;), for use in the many cancer types in which tumor oxygen deprivation (&ldquo;hypoxia&rdquo;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&rsquo;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. TSC&rsquo;s helps regulate the diffusion of oxygen into oxygen-deprived cells (whether cancer cells or normal cells). TSC thus has potential uses in non-oncology indications such as stroke and cardio-vascular disease, where tissue hypoxia is implicated as an underlying causative factor in morbidity and mortality. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our lead development programs target TSC against cancers known to be inherently treatment-resistant, with a focus on brain cancers. A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (&ldquo;GBM&rdquo;), a particularly deadly form of primary brain cancer. This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care, including a 37% improvement in overall survival over the control group at two years. A particularly strong efficacy signal was seen in the inoperable patients, where survival of TSC-treated patients at two years was increased by almost four-fold over the controls. In December 2017, the Company initiated the <u>IN</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">vestigation of <u>T</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">SC <u>A</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">gainst <u>C</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ancerous <u>T</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">umors (INTACT) Phase 3 trial in the newly diagnosed inoperable GBM patient population. Patient enrollment began in January 2018. The trial will enroll 236 patients in total, with 118 in the treatment arm and 118 in the control arm. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Using its novel mechanism of action, TSC has been shown to safely re-oxygenate a range of tumor types in our preclinical and clinical studies. Diffusion believes its therapeutic potential is not limited to one specific tumor type, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers. Given TSC&#39;s safety profile and animal data, we can, with appropriate funding, move directly into Phase 2 studies in other cancers. We also believe that TSC has potential application in other indications involving hypoxia, such as stroke, cardiovascular disease, neurodegenerative diseases and emergency medicine. A program is now being developed in cooperation with UCLA and the University of Virginia, to test TSC in the treatment of acute ischemic stroke, with an in-ambulance Phase 2 trial being planned This trial, named the PreHospital Acute Stroke Therapy - TSC (PHAST - TSC) is expected to enroll 160 patients, with 80 in the treatment arm and 80 in the control arm. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to the TSC programs, we are exploring alternatives regarding how best to capitalize upon our product candidate RES-529, which may include possible out-licensing and other options. RES-529 is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase 1 clinical trials for age-related macular degeneration and was in preclinical development in oncology, specifically GBM. RES-529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Summary of Current Product Candidate Pipeline</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following tables, as of December 31, 2017, summarizes the planned clinical indications for Diffusion&rsquo;s lead molecule, TSC:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 116pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a1.jpg"></div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a2.jpg"></div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Technology Overview</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In oncology, our proprietary technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining our lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Under normally oxygenated cellular conditions, radiation and chemotherapy generally have a powerful killing effect upon cancerous tumor tissue. However, in many solid tumor types, cellular oxygen deprivation occurs as the result of rapid tumor growth, causing parts of the tumor to outgrow its blood supply. When tumor tissue becomes hypoxic, it is up to three times more resistant to the cancer-killing power of the standard therapies (radiation and chemotherapy) currently used in the treatment of the vast majority of cancer patients. Cancerous tumor cells are known to thrive under hypoxic conditions, as the resultant changes in the tumor microenvironment confer &ldquo;treatment-resistance&rdquo; to radiation and chemotherapy within the cell.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Many solid cancerous tumor types are hypoxic and therefore subject to this treatment-resistance. TSC safely re-oxygenates treatment-resistant hypoxic tumor tissue via a novel mechanism of action, without affecting the oxygenation of normal tissue, thereby increasing therapeutic effectiveness. To date, no addition of serious harmful side effects, or exacerbation of the known side effects of standard-of-care treatments, has been observed in our clinical studies.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TSC&rsquo;s distinctive re-oxygenation capabilities derive from its mechanism of action, which promotes enhanced diffusion of oxygen through blood plasma and into the hypoxic tumor microenvironment. Disruption of the treatment-resistance syndrome by re-oxygenation promotes enhanced cancer-killing power from radiation and chemotherapy, thereby safely extending patient survival. Because of the characteristics of this novel mechanism, oxygen levels of normal tissue remain unaffected, thereby avoiding side effects related to the syndrome referred to as &ldquo;oxygen toxicity.&rdquo; We believe this avoidance of oxygen toxicity confers a significant advantage to TSC&rsquo;s diffusion-based approach over previous attempts to diminish treatment-resistance based on enhancing the oxygen concentration levels of the blood.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our clinical development plan targets TSC at radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer, pancreatic cancer, and brain metastases. We have been granted orphan drug designations by the FDA for the treatment of brain cancers based on the acknowledged unmet medical need and number of patients affected. Such orphan drug designations allow certain favorable treatments under FDA regulations in connection with exclusivity periods and the new drug approval process.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Tumor Hypoxia</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We believe that our breakthrough small molecule approach to overcoming solid tumor treatment-resistance by the reduction of cellular hypoxia may have significant implications for the improved treatment of cancer. Hypoxia is a deficiency in the supply of oxygen. It is well known that tumors are especially susceptible to developing hypoxia, driven by a combination of rapid cellular growth, structural abnormalities of the tumor microvessels and disturbed circulation within the tumor. There are a number of known treatment-resistance consequences conferred by tumor hypoxia, including increases in:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Resistance to ionizing radiation;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinically aggressive phenotype;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Potential for more invasive growth; and,</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Regional and distal tumor spreading.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a3.jpg"></div>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The above-described phenomenon of hypoxia-related &ldquo;treatment-resistance&rdquo; has been known to the scientific and clinical communities for over half a century. The challenge has been to find an approach that can effectively mitigate treatment-resistance without the addition of toxic side effects or exacerbation of the side effects associated with radiation and chemotherapy treatments. We believe that TSC embodies such an approach.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Trans Sodium Crocetinate</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dr. John Gainer, our Chief Scientific Officer, one of our directors and Professor Emeritus of Chemical Engineering at the University of Virginia, was the first to propose the use of chemical compounds specifically to facilitate the diffusion of oxygen through blood plasma for the purpose of re-oxygenating hypoxic tissues. Dr. Gainer&rsquo;s early laboratory work systematically examined various means to alter the diffusivity of oxygen through the use of small molecules that would affect the intermolecular forces existing in blood plasma. He originally identified crocetin, a natural carotenoid compound, as a molecule that could increase oxygen diffusion through the plasma, and crocetin was shown to be an effective treatment in a rabbit model of atherosclerosis and other indications. This work continued from the 1970s into the mid-1990s with various animal models, including radiation sensitization and hemorrhagic shock.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Because crocetin is an isomeric mixture, Dr. Gainer examined whether it was the trans-isomer which was responsible for eliciting the therapeutic benefit. These experiments led to his development of a pure trans-isomer salt compound, which he named trans sodium crocetinate. (The USAN designated name is transcrocetinate sodium). TSC has been shown to be more effective than crocetin in a severe model of hemorrhagic shock in both rats and pigs. It also demonstrated safety and efficacy in animal models of stroke and myocardial infarction, as well as in enhancing the response of hypoxic tumors to the therapeutic effects of radiation and chemotherapy.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">It is proposed that TSC works by altering the molecular arrangement of the water molecules in blood plasma (which is composed of 90% water), with the altered structure being less dense - and thus less resistant to oxygen diffusion - than untreated blood plasma. A water molecule is composed of two hydrogen atoms and one oxygen atom, with a net positive charge found on the hydrogen atoms and a net negative charge found on the oxygen atom. This results in the formation of hydrogen bonds, which are an attraction between the net-negatively charged oxygen of one water molecule and the net-positively charged hydrogen atoms of another water molecule. Theoretically, one water molecule can form four hydrogen bonds with neighboring water molecules. However, the literature on the subject indicates that a water molecule actually forms, on average, 2 to 3.6 hydrogen bonds. By promoting an increase in the average number of hydrogen bonds among the water molecules comprising the bulk of blood plasma, TSC enhances the ability of oxygen to diffuse more easily through the plasma and into hypoxic tissue.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In March 2017, we received a patent relating to bipolar trans carotenoid salts and their uses. This patent expands the coverage of the therapeutic use of TSC and other related compounds to five hypoxia-related conditions including congestive heart failure, chronic renal failure, acute lung injury (ALI), chronic obstructive pulmonary disease (COPD) and respiratory distress syndrome (RDS).</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Trans Sodium Crocetinate Increases Oxygenation of Hypoxic Cancerous Tumors</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">While earlier studies focused on improved treatments for hemorrhagic shock, ischemia, and traumatic brain injury, the use of TSC as an agent to re-oxygenate hypoxic cancerous tumors became a central area of research for us following our founding in 2001. Because tumor hypoxia is a leading cause of solid tumor resistance to both radiation and chemotherapy, it was believed that an agent such as TSC <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&ndash; one that could safely increase the oxygenation of hypoxic tumor tissue &ndash; could prove effective in treatment-resistant cancers when combined with standard-of-care regimens of radiation and/or chemotherapy. This belief led to the development of preclinical and clinical development programs targeted against treatment-resistance in various cancers, with a focus on brain cancer types (both GBM and metastatic) and pancreatic cancer, all of which are known to be significantly hypoxic. The Company&rsquo;s longer term goal is to use TSC against treatment-resistance in the entire range of hypoxic cancers now treated with radiation and chemotherapy.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a4.jpg"></div>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Glioblastoma Program</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our lead program is targeted against newly diagnosed primary brain cancer, also known as glioblastoma (GBM). Glioblastoma is a grade IV brain tumor, characterized by a heterogeneous cell population, with a number of negative attributes. GBM cells are typically genetically unstable (and thus prone to mutation), highly infiltrative, angiogenic, and resistant to radiation and chemotherapy. The mutations typically found in GBM allow the tumor to grow and thrive in a hypoxic environment. GBM is classified into two major subclasses, primary or secondary, depending upon the clinical properties as well as the chromosomal and genetic alterations that are unique to each class. Primary GBM arises <i>de novo</i> from normal glial cells and typically occurs in those over the age of 40, while secondary GBM arises from transformation of lower grade tumors and is usually seen in younger patients. Primary GBM is believed to account for approximately 95% of all GBM diagnoses.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">While GBM is the most common form of primary brain tumor involving glial cells, it is still relatively rare, as approximately 12,000 people in the United States were diagnosed with GBM in 2017. The median age of GBM diagnosis is approximately 65 years, with the incidence of GBM in those over 65 increasing rapidly as shown by a doubling in incidence from 5.1 per 100,000 in the 1970s to 10.6 per 100,000 in the 1990s. Those diagnosed with the disease have a grim prognosis, with the median survival time of untreated patients being 4.5 months. Current standard-of-care treatment only provides 14-16 months of survival time after diagnosis.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Current Treatments for GBM</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The standard-of-care for GBM tumors generally begins with surgical resection, unless the tumor is deemed inoperable due to its location near vital centers of the brain. This surgery is performed both to alleviate the symptoms associated with the disease as well as to facilitate treatment of residual tumor cells. Even with advances in surgical technique, complete removal of the tumor with clean margins is difficult to achieve, as the tumors are highly infiltrative and typically extend into the normal brain parenchyma. Due to this, almost all GBM patients have recurrence of the tumor, with 90% of such recurrence occurring at the primary site.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Due to the invasive nature of the tumors, surgical resection is promptly followed by radiotherapy coupled with the use of chemotherapeutic agents. Radiotherapy involves the administration of irradiation to the whole brain. While nitrosoureas were historically a commonly used chemotherapeutic agent, temozolomide (&ldquo;TMZ&rdquo;) was approved in 2005 and is now a mainstay of the standard-of-care. This is based on a clinical trial that showed the addition of TMZ to surgery and radiation increased median survival in newly diagnosed GBM patients to 14.6 months compared to 12.1 months for the surgery and radiation only group.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Most chemotherapeutic drugs have a limited ability to cross the blood brain barrier, thus a strategy to attempt to circumvent this was the development of Gliadel&reg;, dissolvable chemotherapy wafers that could be placed in the tumor bed following surgical resection. Gliadel&reg; contains the nitrosourea chemotherapeutic agent carmustine that is released for several weeks, in contrast to systemically administered carmustine that has a very short half-life. While Gliadel&reg; wafers were shown to be safe, the drugs&rsquo; addition to radiation and TMZ did not result in a statistically significant increase in survival.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">GBM tumors show increased expression of vascular endothelial growth factor (&ldquo;VEGF&rdquo;), and the anti-angiogenesis drug bevacizumab has been approved by the FDA for the treatment of recurrent GBM. A Phase 2 study found that bevacizumab treatment in patients with recurrent GBM increased six-month progression-free survival from a historical 9-15% to 25% with overall six-month survival of 54%. Another Phase 2 study showed that recurrent GBM patients treated with bevacizumab at a lower dose but a higher frequency had even higher six-month progression-free survival of 42.6%.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">While bevacizumab has shown success in recurrent GBM, it is not utilized in newly diagnosed patients, our target patient population, as two separate clinical trials showed no difference in overall survival in patients treated with radiation, TMZ, and bevacizumab compared to patients treated with only radiation and TMZ. Bevacizumab treatment did result in an increase in progression free survival in both studies; however, the reason why this increase in progression free survival did not translate to an increase in overall survival is unclear. In addition, certain studies have reported that patients treated with bevacizumab had an increased symptom burden, a worse quality of life, and a decline in neurocognitive function.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>GBM Therapies Under Development</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There are a number of companies developing GBM therapies. For example, a search on the website www.clinicaltrials.gov yields over 300 results for &ldquo;glioblastoma multiforme&rdquo; and &ldquo;open trials.&rdquo; Most of these trials focus on the recurrent patient population, whereas our target population is newly diagnosed inoperable patients. In addition to the therapeutics previously mentioned, other GBM trials include Northwest Therapeutics&rsquo; DCVax&reg;-L, Bristol-Myers Squibb&rsquo;s Nivolumab/Ipilimumab and AbbVie&rsquo;s Veliparib. In addition, the medical device company Novocure has been developing a novel approach called Tumor Treating Fields (&ldquo;TTFields&rdquo;) using low intensity, alternating electric fields within the intermediate frequency range. TTFields are believed to disrupt cell division through physical interactions with key molecules during mitosis. This medical device approach has shown some success in the recurrent GBM patient population and in some geographic areas may be becoming a part of the standard of care.</font> There are a number of companies developing GBM therapies. For example, a search on the website www.clinicaltrials.gov yields over 300 results for &ldquo;glioblastoma multiforme&rdquo; and &ldquo;open trials.&rdquo; Most of these trials focus on the recurrent patient population, whereas our target population is newly diagnosed inoperable patients. In addition to the therapeutics previously mentioned, other GBM trials include Northwest Therapeutics<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; DCVax&reg;-L, Bristol-Myers Squibb&rsquo;s Nivolumab/Ipilimumab and AbbVie&rsquo;s Veliparib. In addition, the medical device company Novocure has been developing a novel approach called Tumor Treating Fields (&ldquo;TTFields&rdquo;) using low intensity, alternating electric fields within the intermediate frequency range. TTFields are believed to disrupt cell division through physical interactions with key molecules during mitosis. This medical device approach has shown some success in the recurrent GBM patient population and in some geographic areas may be becoming a part of the standard of care. Other recent approaches include combination immuno-oncology trials. For example, Inovio Pharmaceuticals, Inc. has a Phase 1b/2a immuno-oncology safety study underway in patients with newly diagnosed GBM designed to evaluate cemiplimab (also known as REGN2810), a PD-1 inhibitor developed by Regeneron Pharmaceuticals, Inc.), in combination with Inovio&rsquo;s INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding IL-12.&nbsp; The primary endpoints are safety and tolerability but the study will also evaluate immunological impact, progression-free survival and overall survival.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>GBM is an Orphan Disease</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">GBM is diagnosed in approximately 12,000 individuals every year, making it an &ldquo;orphan disease.&rdquo; The Orphan Drug Act of 1983 was designed to provide financial incentives for, and to reduce the costs associated with, developing drugs for rare diseases and disorders. A &ldquo;rare disease or disorder&rdquo; is defined by the Orphan Drug Act of 1983 as affecting fewer than 200,000 Americans at the time of designation or one for which &ldquo;there is no reasonable expectation that the cost of developing and making available in the United States&hellip;will be recovered from sales in the United States.&rdquo; A sponsor must request that the FDA designate a drug currently under development for a &ldquo;rare disease or condition&rdquo; as an orphan drug, and if the FDA agrees that the drug and indication meet the criteria set forth in the Orphan Drug Act of 1983, certain financial and marketing incentives become available.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In July 2011, we announced that TSC was granted Orphan Drug Designation by the FDA for the treatment of GBM.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Trans Sodium Crocetinate Phase 1/2 Clinical Trial in GBM</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have evaluated TSC in 128 human subjects in various Phase 1 and Phase 2 clinical trials to date, with no serious adverse events attributable to TSC. Our Phase 1/2 clinical trial of TSC in patients with newly diagnosed GBM completed in 2015 is described in more detail below. TSC is currently being tested in newly diagnosed inoperable GBM patients in our on-going Phase 3 INTACT clinical trial that.,</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our Phase 1/2 clinical trial in GBM enrolled 59 newly diagnosed patients who received TSC in conjunction with radiation and TMZ. In the Phase I portion of the trial, TSC was initially administered three times per week at half-dose to three patients prior to radiation. Subsequently, six additional patients received full-dose TSC for six weeks in combination with radiation. No dose-limiting toxicities were identified in the nine patients during the Phase I portion of the trial, nor were any serious adverse events relating to the drug observed. Fifty additional patients were enrolled in the Phase II trial and received full-dose TSC in combination with TMZ and radiation therapy. Four weeks after completion of radiation therapy, all patients underwent chemotherapy with higher doses of TMZ for five (5) days every four weeks, but no further TSC was administered.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">6</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We presented initial results from the trial at the 2015 American Society of Clinical Oncology (&ldquo;ASCO&rdquo;) Annual Meeting in June 2015, which discussed data from the 18 trial sites covering the first twenty-one months. Final results were published in the Journal of Neurosurgery online in May 2016. We compared results in relation to a historical control group from a 2005 study which showed that the addition of TMZ to standard-of-care (surgery plus radiation) increased overall survival from 12.1 months to 14.6 months. We reported that:</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TSC plus radiation and TMZ increased the patients<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; chance of survival at two years by 37% compared to the historical control group. The overall survival at two years was 36.3% in the TSC group compared to 26.5% in the historical control group.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the subgroup of patients considered inoperable, the chance of survival at two years for those who received TSC was increased by 380%, (40% alive at two years for TSC group versus 10% for control).</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">71% of those treated with TSC were alive at one year compared to<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;61% of those in the historical control group. In 11 of 56 patients, tumors regressed to undetectable.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">No serious safety findings attributed to TSC were observed in the TSC study and adverse events were consistent with those seen in previous trials of GBM featuring radiation and TMZ.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>End-of-Phase 2 FDA Meeting and TSC Phase 3 GBM Clinical Trial</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Following the announcement of the results of the 2015 Phase 1/2 clinical trial in GBM, we held an end of Phase 2 meeting with the FDA in August 2015 to discuss planning for a Phase 3 clinical trial. At the meeting and subsequent thereto, guidance was received on a trial design for the Phase 3 study, including:</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A single, randomized trial of the agreed upon design, if successful, can serve as the basis for an application for approval.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The trial will consist of 236 newly diagnosed inoperable GBM patients with half given TSC in conjunction with standard-of-care radiation and TMZ and half receiving standard-of-care radiation and TMZ only.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Based on the Phase 1/2 safety results with supporting toxicology, TSC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s dosing exposure will be substantially increased, which means that TSC can now be used for both the radiation + chemotherapy and subsequent TMZ chemotherapy-only phase of GBM treatment, extending the TSC treatment duration from 6 weeks to 30 weeks.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Diffusion will provide certain expanded information on animal toxicology, pharmacokinetics and manufacturing practices to the FDA before initiating the trial.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Phase 3 INTACT clinical trial has begun enrollment</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The INTACT clinical trial is an open-label, randomized, controlled, Phase 3 safety and efficacy registration trial. Subjects will be randomized at baseline to SOC for first-line treatment of GBM plus TSC, or to SOC alone. The SOC for GBM is temozolomide plus RT for 6 weeks followed by 28 days of rest, followed by 6 cycles of post-radiation temozolomide treatment.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TSC will be administered during both the RT and post-radiation temozolomide treatment periods to those subjects so randomized.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">7</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the RT treatment period subjects will receive:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Focal RT delivered as 60Gy/30 fractions scheduled at 2Gy/day for 5 days each week (Monday through Friday) for 6 weeks.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Temozolomide 75 mg/m<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>2 </sup>orally<sup>&nbsp;</sup>once daily (usually administered the night preceding each RT session) starting the evening before the first RT session over a period of 42 calendar days with a maximum of 49 days.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TSC 0.25 mg/kg IV for 3 days each week (e.g., Monday, Wednesday, Friday or other schedule that supplies a minimum 3 TSC doses per week) administered between 45 to 60 minutes prior to each RT session.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the 28-day rest period all subjects will receive no treatment.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the post-radiation 6-cycle temozolomide treatment period:</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All subjects will receive 28-day oral temozolomide (150 mg/m<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>2</sup> first cycle and 200 mg/m<sup>2</sup> all subsequent cycles as tolerated) administered on Day 1-5 (Monday through Friday) of each 28-day cycle.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Controls will receive oral temozolomide at night at home per the SOC and are not required to attend clinic visits during this period.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Subjects randomized to TSC will receive TSC 1.5 mg/kg (or another dose if recommended by the DSMB) 1.5 to 2 hours before their temozolomide dose during the daytime for 3 days during the first week of each 28-day cycle (Days 1, 3, 5; e.g., Monday, Wednesday, Friday or other schedule that supplies at minimum 3 TSC doses per week).<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp; The Tuesday, Thursday doses will be given at night at home.&nbsp; Long-acting antiemetics may be administered prior to daytime temozolomide dosing on Days 1, 3, 5.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The safety, tolerability and pharmacokinetics (&ldquo;PK&rdquo;) of TSC at higher doses than 0.25 mg/kg with temozolomide will be assessed during adjuvant therapy. TSC at doses between 0.25 mg/kg and up to 1.5 mg/kg in combination with concomitant temozolomide will be assigned (not randomized) in the first 8 subjects enrolled in the INTACT trial. These patients will undergo RT plus temozolomide plus TSC treatment (0.25 mg/kg) for 6 weekly cycles followed by 4 weeks of rest in standard fashion. At the Week 10 clinic visit the same 8 subjects will be assigned to treatment, with 2 subjects each assigned to TSC at doses of 0.25, 0.50, 1.0 and 1.5 mg/kg.&nbsp; These subjects will be studied in parallel for 2 full 28-day cycles with inclusion of appropriate blood sampling collection for TSC and temozolomide PK. The Data Safety Monitoring Board (&ldquo;DSMB&rdquo;) will examine the resultant safety data after 2 full cycles (Weeks 11 through 18 of post-radiation temozolomide treatment period; Days 1 to 56). The DSMB may recommend continued use of the 1.5 mg/kg TSC dose for the post-radiation temozolomide treatment period, or may prescribe another dose based on their observations. Subjects then entering into the INTACT trial will be randomized at baseline between TSC plus SOC, or SOC alone.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The baseline assessment for determining progression-free survival (&ldquo;PFS&rdquo;) and overall response rate (&ldquo;ORR&rdquo;) will be at 10 weeks via MRI using the &ldquo;modified Response Assessment in Neuro-Oncology&rdquo;&nbsp;(&ldquo;mRANO&rdquo;), and to rule out pseudo-progression. The hazard ratio for the trial will be 0.67, which corresponds to 22% two-year survival in the TSC arm, the lower limit of the 95% confidence interval for the biopsy-only subjects in Diffusion&rsquo;s Phase 2 trial, and 10% survival in the SOC arm. The estimated median survival is therefore 10 months for the SOC arm vs. 14.9 months for the TSC plus SOC arm. In order to achieve 80% power, the trial requires 118 subjects in each arm.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The study will achieve the designed 80% statistical power at 198 events, where an event is defined as death. The first analysis will occur at the earlier of two years follow-up for all subjects or 198 events. If the first analysis is at 198 events, the analysis will be a standard 2-sided stratified log-rank test at the </font>&#9744;&#9744;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">=0.05 significance level. If the first analysis is at two years, the Company will perform the analysis using the O&rsquo;Brien-Fleming Method.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a5.jpg"></div>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Pancreatic Cancer Program</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">One of the most hypoxic of all the solid cancers, and therefore one of the most treatment-resistant, is pancreatic cancer. According to the American Cancer Society, pancreatic cancer is responsible for 7% of all cancer deaths in both men and women, making it the fourth leading cause of cancer death in the U.S. Estimates are that 40% of pancreatic cancer cases are sporadic in nature, 30% are related to smoking and 20% may be associated with dietary factors, with only 5-10% of cases hereditary in nature.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pancreatic cancer is difficult to diagnose in early stages because initial symptoms are often nonspecific and subtle in nature, and include anorexia, malaise, nausea, fatigue, and back pain. Approximately 75% of all pancreatic carcinomas occur within the head or neck of the pancreas, 15-20% occur in the body of the pancreas, and 5-10% occur in the tail.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div style="text-align: center;"><img src="a6.jpg"></div>

<p style="margin: 0pt; text-align: center; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The only potential curative therapy for pancreatic cancer is complete surgical resection. Unfortunately, this is only possible for approximately 20% of cases, and even of those patients whose cancer is surgically resected, 80% will develop metastatic disease within two to three years following surgery. Patients with unresectable pancreatic cancer have a median overall survival of 10 to 14 months while patients diagnosed with Stage IV disease (indicative of metastases) have a 5-year overall survival of just 1%.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Multiple studies have confirmed that pancreatic cancers are highly hypoxic. A study reporting the direct measurement of oxygenation in human pancreatic tumors prior to surgery showed dramatic differences between tumors and normal tissue. The partial pressure of oxygen (&ldquo;pO2&rdquo;) ranged between 0-5.3 mmHg in tumors but in adjacent normal tissue it ranged from 9.3-92.7 mmHg. Hypoxic areas are also frequently found when examining tissue from mouse models of pancreatic cancer.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Current Treatment Options for Pancreatic Cancer</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Surgery remains the primary mode of treatment for patients with pancreatic cancer. However, there is an important role for chemotherapy and/or radiation in an adjuvant setting (given to prevent recurrence) or neoadjuvant setting (given before surgery to shrink the tumor to make complete resection more probable), as well as in patients with unresectable disease.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Since its approval in 1996, gemcitabine has been partnered with approximately 30 different agents in late-stage clinical trials in an attempt to improve upon the effectiveness of gemcitabine alone in treating patients with metastatic pancreatic cancer. Only two of these trials have demonstrated improved efficacy, leading to FDA approvals - erlotinib (Tarceva&reg;) and nab-paclitaxel (Abraxane&reg;).</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In patients with metastatic disease, the use of erlotinib with gemcitabine led to a significantly higher one-year survival rate than with the use of gemcitabine alone (23% vs. 17%, P = 0.023) as well as an increased median overall survival (6.24 months vs. 5.91 months, P = 0.038). A more recent study showed that the addition of nanoparticle albumin-bound (nab)-paclitaxel to gemcitabine significantly improved overall survival in treatment na&iuml;ve patients with metastatic cancer, as overall survival was approximately two (2) months longer in patients treated with combination therapy (8.5 vs. 6.7 months).</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Folfirinox (leucovorin + 5-fluorouracil + oxaliplatin + irinotecan) regimen was shown to significantly improve overall survival compared to treatment with gemcitabine (11.1 months vs. 6.8 months). While dramatically improving overall survival, the Folfirinox treatment was accompanied by serious adverse events and thus is only recommended for patients with good performance status.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other combinations of gemcitabine with cisplatin, oxaliplatin, irinotecan or docetaxel tested in Phase 3 trials have not been of superior benefit to gemcitabine alone. The combination therapy nab-Paclitaxel and gemcitabine was recently approved by the FDA as an additional standard-of-care for the treatment of patients with untreated pancreatic adenocarcinoma. However, the improvements were modest, and treatment of pancreatic cancer remains an area of intense research, with 92 products in all stages of clinical development with 14 of them in Phase 3 at this time according to clinicaltrials.gov.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, he FDA has approved Onivyde&reg; (irinotecan liposome injection) in combination with fluorouracil and leucovorin, to treat patients with metastatic pancreatic cancer who were previously treated with gemcitabine-based chemotherapy. In the pivotal clinical trial, patients treated with Onivyde&reg; plus fluorouracil/leucovorin lived an average of 6.1 months, compared to 4.2 months for those treated with only fluorouracil/leucovorin.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Pancreatic Cancer Market Analysis</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">It is estimated that every year approximately 49,000 people are diagnosed with pancreatic cancer in the United States. More than half of these patients will be diagnosed with metastatic disease. The five-year survival rates for patients with pancreatic cancer are dismal (&lt;14%) and are particularly bad for those with metastatic disease (~1%).</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The current standard-of-care for patients with metastatic pancreatic cancer includes gemcitabine combined with either erlotinib or nab-paclitaxel. Gemzar&reg; (gemcitabine) is now available as a generic, however prior to losing patent protection the drug generated peak revenues of approximately $700 million in the United States for Eli Lilly. Tarceva&reg; (erlotinib), which is approved for the treatment of metastatic non-small cell lung cancer and metastatic pancreatic cancer, is marketed by Roche and Astellas and sales of the drug generated $1.05 billion in revenue in 2016. Abraxane&reg; (nab-paclitaxel), which was approved for the treatment of breast cancer in 2005 and non-small cell lung cancer in 2012, was approved by the FDA in 2013 for the treatment of metastatic pancreatic cancer. Sales of Abraxane&reg; totaled $973 million in 2016 for all indications.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>TSC in Pancreatic Cancer</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We believe that targeting hypoxia in pancreatic cancer with TSC, especially in combination with standard-of-care therapies involving gemcitabine and nab-paclitaxel, may be beneficial in the treatment of pancreatic cancer. Pancreatic cancer is one of the most hypoxic malignant tumors, making it one of the most resistant tumors to therapy. Patients with advanced pancreatic cancer of exocrine origin have few therapeutic options and, for patients with advanced cancers, the overall survival rate of all stages is less than 1% at 5 years, with most patients dying within 1 year. Gemcitabine remains to-date, the backbone of treatment of pancreatic cancer.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The antitumor efficacy of gemcitabine is known to be hindered by a number of hypoxia-related factors including, but not limited to:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Limited Delivery of Gemcitabine to Intracellular Tumor Microenvironment</i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">. Hypoxia has been associated with resistance to nucleoside analogs such as gemcitabine by decreasing the expression of the human cross-cell membrane equilibrative nucleoside transporter 1 (hENT1), thereby decreasing transport of gemcitabine and other nucleoside analogues into tumor cells.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Gemcitabine Intratumor Cell Inhibition of Ribonucleotide Reductase Compromised</i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">. Hypoxia has been associated with a decrease in intracellular tumor ribonucleotide reductase, an enzyme required for the antitumor effect of gemcitabine. Indeed, this decrease leads to cell cycle arrest in G1 or G2 phase, thereby allowing DNA repair before progression to S or M phase.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Increased Breakdown of Gemcitabine</i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">. It has been also observed that under hypoxic conditions, intratumor cell levels of cytidine deaminase are substantially increased. Cytidine Deaminase is the main enzyme responsible for the breakdown of gemcitabine and similar nucleosides. As a result of this, the gemcitabine antitumor effect is substantially decreased under hypoxic conditions.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Nab-paclitaxel Potentiates Gemcitabine by Decreasing Cytidine Deaminase</i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">. One of the ways nab-paclitaxel decreases cytidine deaminase has been observed to be through increasing reactive oxygen species (&ldquo;<u>ROSs</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) which has been shown to deactivate cytidine deaminase.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Taken together, the four factors above are believed to explain, at least in part, the limitations of gemcitabine in hypoxic conditions and the efficacy observed with the gemcitabine plus nab-paclitaxel combination regimen for the treatment of pancreatic cancer. They also suggest that correction of hypoxia with an anti-hypoxia agent such as TSC may significantly improve the efficacy of the gemcitabine plus nab-paclitaxel combination regimen for the treatment of pancreatic cancer, including for the following reasons:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">TSC has been shown to improve the cytotoxic effect of gemcitabine in a pre-clinical rat model.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By correcting hypoxia, TSC may improve delivery of gemcitabine to intracellular tumor microenvironment by increasing levels of hENT-1.</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By reversing hypoxia-induced cell cycle arrest via reactivation of ribonucleotide reductase, TSC may restore gemcitabine<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s antitumor effect.</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By reversing the hypoxia-induced increase of cytidine deaminase, TSC may increase intratumoral gemcitabine levels. Addition of TSC to the gemcitabine plus nab-paclitaxel regimen could further improve the efficacy of the combination by further decreasing cytidine deaminase. Of note, hypoxia has also been implicated in conferring tumor resistance to taxane-based therapies.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Proposed Plans for TSC Phase 2 Clinical Trial in Pancreatic Cancer</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A planned Phase 2 clinical trial for TSC in pancreatic cancer is based on preclinical safety and efficacy data, and findings from the Phase 1/2 clinical trial in GBM, as well as the facts noted above, assuming appropriate funding. Global experts in the field agree that pancreatic cancer is an appropriate target for expansion of the use of TSC</font>.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Brain Metastases Program</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In contrast to the relative rarity of primary brain cancers, life-threatening cancers that metastasize to the brain are much more common and represent a serious complication in the treatment of many cancer types. Up to 30% of adult cancer patients will suffer from brain metastases. There are approximately 170,000 cases of metastatic brain cancer every year in the United States. Incidence of brain metastases varies depending upon the primary tumor type, although lung cancer appears to carry the greatest risk. The prognosis for patients with brain metastases is very grim, with current treatment options only resulting in median overall survival times of less than one year.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Treatment for brain metastases involves both controlling the symptoms associated with the condition as well as attacking the cancer directly. Brain metastases typically result in edema that can be controlled with the use of steroids; however, long-term use of steroids typically results in side effects that diminish a patient&rsquo;s quality of life. Approximately 25-45% of patients will experience seizures and require the use of anti-epileptic drugs. Surgery is only utilized in patients with a solitary brain metastatic lesion. Radiation therapy remains the standard-of-care for the vast majority of patients with brain metastases. There is very limited evidence for the use of chemotherapy, as few clinical trials have been conducted. There are no medications currently approved for the treatment of brain metastases.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Plans for TSC Phase 2/3 Clinical Trial in Metastatic Brain Cancer</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are planning to conduct a Phase 2/3 clinical trial in metastatic brain cancer after further discussions with experts and the FDA regarding trial design, end-points, and patient numbers, assuming appropriate funding.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In December 2012, the FDA granted us Orphan Drug Designation for the use of TSC in brain metastases.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Plans for TSC Phase 2 Clinical Trial in Acute Ischemic Stroke</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In January 2018 an abstract titled &ldquo;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>PreHospital Acute Stroke Therapy with Trans Sodium Crocetinate (PHAST-TSC),&rdquo;</i> was presented at the International Stroke Conference in Los Angeles. The abstract introduced the design and rationale for the planned Phase 2 PHAST-TSC study, highlighting the potential benefits of TSC in patients with acute ischemic or hemorrhagic stroke in a pre-hospital setting. The abstract noted that TSC is a promising neurotherapeutic that enhances the diffusion of oxygen in hypoxic tissues by altering the structure of water molecules in blood plasma, thus facilitating the transport of oxygen to the site of the stroke and helping prevent brain tissue damage and neuronal death. TSC has shown benefit for both ischemic and hemorrhagic stroke in preclinical studies, and has demonstrated safety and efficacy signals in human trials in patients with glioblastoma multiforme (GBM) and peripheral arterial disease (PAD).</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The planned Phase 2, randomized, double-blind, placebo-controlled trial calls for administering TSC to ambulance-transported patients within two hours of the onset of a suspected acute stroke. It is anticipated that 160 patients will be enrolled in this trial, which could begin in 2018, assuming appropriate funding. The pre-hospital, ambulance-based treatment strategy originated at UCLA with the FAST-MAG trial. Two of the physicians involved in that trial, Drs. Saver and Sanossian, will be principal investigators in Los Angeles. A smaller number of patients will be enrolled at the University of Virginia Medical Center in Charlottesville, with Drs. Johnston and Southerland as principal investigators.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description of Other Indications/Products</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have rights to and own technologies and potential products beyond those described above, including analog molecules as backups to TSC. It is our strategy to focus at the current time on our TSC for oncology, specifically GBM and pancreatic cancer, as well as acute eschemic stroke. At the current time, the bulk of our cash resources for clinical development is dedicated to the Phase 3 trial for TSC in inoperable GBM. While we believe we have adequate cash resources to continue operations through June 2019, we will need to raise additional funds in order to complete this trial. We do not expect to commence any clinical trials beyond the inoperable GBM trial unless we are able to raise additional capital or make alternative financing arrangements for any such trial. Beyond those described herein, we also intend to continue to review our technologies and potential products on a regular basis and consider internal development in the future and the potential to out-license portions of our technology and potential products to other biopharmaceutical companies with greater focus and resources than ours, or potentially in-license late stage products which are in or ready for human clinical trials.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As a result of the Merger, we acquired product candidates for ophthalmology, oncology and dermatology. One such product candidate is RES-529, a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in preclinical development in oncology, specifically GBM. The novel inhibition of the PI3K/Akt/mTOR pathway and targeting of the androgen receptor have also shown potential in a number of additional indications.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We&nbsp;are exploring partnering opportunities for our product candidates, such as strategic partnerships, alliances or licensing arrangements.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Competition</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our industry is highly competitive and subject to rapid and significant change. Potential competitors in the United States are numerous and include major pharmaceutical and specialty pharmaceutical companies, universities and other institutions. We generally divide our competition in the pharmaceutical industry into four categories: (1) companies with large research and developmental departments that develop and market products in many therapeutic areas; (2) companies that have moderate research and development capabilities and focus their product strategy on a small number of therapeutic areas; (3) small companies with limited development capabilities and only a few product offerings; and (4) university and other research institutions. Many of our competitors have longer operating histories, greater name recognition, substantially greater financial resources and larger research and development staffs than we do, as well as substantially greater experience than us in developing products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. A significant amount of research is carried out at academic and government institutions. These institutions are aware of the commercial value of their findings and are aggressive in pursuing patent protection and negotiating licensing arrangements to collect royalties for use of technology that they have developed.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There are several firms, including NuvOx and Azanta, currently marketing or developing products that may be competitive with our products, including therapeutics and devices. We believe TSC is a first-in-class novel small molecule that re-oxygenates hypoxic tissue, enhancing efficacy of radiation and chemotherapy without harmful side effects.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Our commercial opportunity could be reduced or eliminated if our competitors develop or market products or other novel therapies that are more effective, safer or less costly than our current or future product candidates, or obtain regulatory approval for their products more rapidly than we may obtain approval for our product candidates. In addition, the first product to reach the market in a therapeutic or preventative area is often at a significant competitive advantage relative to later entrants in the market and may result in certain marketing exclusivity as per federal legislation. Acceptance by physicians and other health care providers, including managed care groups, also is critical to the success of a product versus competitor products. Our success will be based in part on our ability to identify, develop and manage a portfolio of product candidates that are safer and more effective than competing products.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Research and Product Development</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We incurred approximately $5.1 million in 2017 and $7.3 million in 2016 on research and product development activities that related primarily to activities associated with the synthesis and formulations of our products then in development, additional preclinical studies and planning for Phase I/Phase II studies. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">13</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Intellectual Property</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our success depends and will continue to depend in part upon our ability to maintain proprietary protection for our products and technologies, to preserve our proprietary information, trademarks and trade secrets and to operate without infringing the proprietary rights of others. Our policy is to attempt to protect our technology by, among other things, filing patent applications on inventions that are important to the development and conduct of our business with the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;), and its foreign counterparts or obtaining license rights for technology that we consider important to the development of our business.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2017, we owned approximately 13 issued U.S. patents and 4 issued foreign patents, which include granted European, Japanese, Chinese and Indian patent rights, and over 30 pending patent applications worldwide, covering the product candidates we currently intend to develop. Our current patents expire between 2023 and 2031. TSC has been granted Orphan Drug Designation for the treatment of both GBM and metastatic brain cancer and an application is pending for pancreatic cancer. A formulation patent provides protection for the TSC oral drug product until 2031 with extensions possible.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to patents, we use other forms of protection, such as trademark, copyright and trade secret protection, to protect our intellectual property, particularly where we do not believe patent protection is appropriate or obtainable. We aim to take advantage of all of the intellectual property rights that are available to us and believe that this comprehensive approach will provide us with proprietary positions for our product candidates, where available.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We also protect our proprietary information by requiring our employees, consultants, contractors and other advisors to execute nondisclosure and assignment of invention agreements upon commencement of their respective employment or engagement. Agreements with our employees also prevent them from bringing the proprietary rights of third parties to us. In addition, we also require confidentiality or service agreements from third parties that receive our confidential information or materials.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Manufacturing and Supply</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We do not have any facilities suitable for manufacturing on a commercial scale any of our product candidates nor do we have any experience in volume manufacturing. We currently use third-party cGMP contract manufacturing organizations (&ldquo;CMOs&rdquo;) to manufacture our product candidates for our preclinical studies and clinical trials and intend to continue doing so in the future in accordance with FDA and other appropriate regulations. We anticipate that these CMOs will have capacity to support commercial scale, but we do not have any formal agreements at this time with any of these CMOs to cover commercial production. We also may elect to pursue other CMOs for manufacturing supplies for later-stage trials and for commercialization. We currently have no plans to establish a manufacturing capability, but rather plan to continue to rely on third-party cGMP manufacturers for any future trials and commercialization of our product candidates for which we retain manufacturing responsibility.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Sales and Marketing</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently have no sales and marketing personnel to sell any of our product candidates on a commercial basis if and when our product candidates received required regulatory approvals. If and when we are ready to commercially launch a product, we will either contract with or hire qualified sales and marketing personnel or seek a joint marketing partner or licensee to assist us with this function.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">14</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Government Regulation</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>FDA Drug Approval Process</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug, and Cosmetic Act (the &ldquo;<u>FDC Act</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending new drug applications (&ldquo;<u>NDAs</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties and criminal prosecution.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pharmaceutical product development for a new product or certain changes to an approved product in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an investigational new drug application (&ldquo;IND&rdquo;) which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Preclinical tests include laboratory evaluation of product chemistry, formulation and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements, including good laboratory practices. The results of preclinical testing are submitted to the FDA as part of an IND, along with other information, including information about product chemistry, manufacturing and controls and a proposed clinical trial protocol. Long term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinical trials involve the administration of the investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted: (1) in compliance with federal regulations; (2) in compliance with good clinical practice (&ldquo;GCP&rdquo;) an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; and (3) under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time, or impose other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The study protocol and informed consent information for patients in clinical trials must also be submitted to an institutional review board (&ldquo;IRB&rdquo;) for approval at each site at which the clinical trial will be conducted. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&rsquo;s requirements, or may impose other conditions.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap, especially in cancer indications. In Phase 1, the initial introduction of the drug into healthy human subjects or patients, the drug is tested to assess pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. Phase 2 usually involves trials in a limited patient population to determine metabolism, pharmacokinetics, the effectiveness of the drug for a particular indication, dosage tolerance and optimum dosage, and to identify common adverse effects and safety risks. If a compound demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug and to provide adequate information for the labeling of the drug. In most cases the FDA requires two adequate and well-controlled Phase 3 clinical trials with statistically significant results to demonstrate the efficacy of the drug. With suitable FDA agreement, a single Phase 3 clinical trial with other confirmatory evidence may be sufficient. In those instances, the study is usually a large multicenter trial demonstrating internal consistency and a statistically persuasive finding of an effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and confirmation of the result in a second trial would be practically or ethically impossible.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA. FDA approval of the NDA is required before marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&rsquo;s pharmacology, chemistry, manufacture and controls. The cost of preparing and submitting an NDA is substantial. The submission of most NDAs is additionally subject to a substantial application user fee, and the manufacturer and sponsor under an approved new drug application are also subject to annual product and establishment user fees. These fees are typically increased annually.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA has sixty (60) days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&rsquo;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the review of new drug applications. Priority review can be applied to drugs that the FDA determines offer major advances in treatment, or provide a treatment where no adequate therapy exists. For certain drugs, priority review is further limited only for drugs intended to treat a serious or life-threatening disease relative to the currently approved products. The review process for both standard and priority review may be extended by the FDA for three (3) additional months to consider certain late-submitted information, or information intended to clarify information already provided in the submission.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or the facilities at which the drug is manufactured. The FDA will not approve the product unless compliance with current good manufacturing practice (&ldquo;cGMP&rdquo;) is satisfactory and the NDA contains data that provide substantial evidence that the drug is safe and effective in the indication studied.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&rsquo;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six (6) months depending on the type of information included.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy (&ldquo;REMS&rdquo;) to help ensure that the benefits of the drug outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals and elements to assure safe use (&ldquo;ETASU&rdquo;). ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&rsquo;s safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">16</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The Hatch-Waxman Act</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Orange Book Listing</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&rsquo;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&rsquo;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application (&ldquo;<u>ANDA</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;). An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &ldquo;generic equivalents&rdquo; to the listed drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The ANDA applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA&rsquo;s Orange Book. Specifically, the applicant must certify that: (1) the required patent information has not been filed; (2) the listed patent has expired; (3) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (4) the listed patent is invalid or will not be infringed by the new product. The ANDA applicant may also elect to submit a section viii statement certifying that its proposed ANDA label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. If the applicant does not challenge the listed patents, the ANDA will not be approved until all the listed patents claiming the referenced product have expired.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A certification that the new product will not infringe the already approved product&rsquo;s listed patents, or that such patents are invalid, is called a Paragraph IV certification. If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then commence a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within forty-five (45) days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of thirty (30) months, expiration of the patent, settlement of the lawsuit, or a decision in the infringement case that is favorable to the ANDA applicant.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The ANDA also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the referenced product has expired.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Exclusivity</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon NDA approval of a new chemical entity (&ldquo;NCE&rdquo;) which is a drug that contains no active moiety that has been approved by the FDA in any other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot receive any ANDA seeking approval of a generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package insert, are associated with a three-year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the change.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">An ANDA may be submitted one year before NCE exclusivity expires if a Paragraph IV certification is filed. If there is no listed patent in the Orange Book, there may not be a Paragraph IV certification and, thus, no ANDA may be filed before the expiration of the exclusivity period.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>REMS</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA has the authority to require a REMS to ensure the safe use of the drug. In determining whether a REMS is necessary, the FDA must consider the size of the population likely to use the drug, the seriousness of the disease or condition to be treated, the expected benefit of the drug, the duration of treatment, the seriousness of known or potential adverse events, and whether the drug is a new molecular entity. If the FDA determines a REMS is necessary, the drug sponsor must agree to the REMS plan at the time of approval. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&rsquo;s risks, limitations on who may prescribe or dispense the drug, or other measures that the FDA deems necessary to assure the safe use of the drug. REMS can include medication guides, communication plans for healthcare professionals, and ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy. The FDA may also impose a REMS requirement on a drug already on the market if the FDA determines, based on new safety information, that a REMS is necessary to ensure that the drug&rsquo;s benefits outweigh its risks. The requirement for a REMS can materially affect the potential market and profitability of a drug.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Patent Term Extension</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">After NDA approval, owners of relevant drug patents may apply for up to a five-year patent extension. The allowable patent term extension is calculated as half of the drug&rsquo;s testing phase, the time between IND application and NDA submission, and all of the review phase, the time between NDA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed 14 years.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the drug covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a drug for which an NDA has not been submitted.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Post-Approval Requirements</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Once an NDA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Adverse event reporting and submission of periodic reports is required following FDA approval of an NDA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on an approval that could restrict the distribution or use of the product. In addition, quality-control, drug manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">18</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Pediatric Information</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Under the Pediatric Research Equity Act, NDAs or supplements to NDAs must contain data to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partial waivers, or deferrals, for submission of data.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Best Pharmaceuticals for Children Act (&ldquo;BPCA&rdquo;) provides NDA holders a six-month extension of any exclusivity, patent or non-patent, for a drug if certain conditions are met. Conditions for exclusivity include the FDA&rsquo;s determination that information relating to the use of a new drug in the pediatric population may produce health benefits in that population, the FDA making a written request for pediatric studies and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as priority applications, with all of the benefits that designation confers.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>The Orphan Drug Act of 1983</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Orphan Drug Act of 1983 was designed to provide financial incentives for, and to reduce the costs associated with, developing drugs for rare diseases and disorders. A &ldquo;rare disease or disorder&rdquo; is defined by the Orphan Drug Act of 1983 as affecting fewer than 200,000 Americans at the time of designation or one for which &ldquo;there is no reasonable expectation that the cost of developing and making available in the United States&hellip;will be recovered from sales in the United States.&rdquo; A sponsor must request that the FDA designate a drug currently under development for a &ldquo;rare disease or condition&rdquo; as an orphan drug, and if the FDA agrees that the drug and indication meet the criteria set forth in the Orphan Drug Act of 1983, certain financial and marketing incentives become available. As mentioned previously, we have received&nbsp;Orphan Drug&nbsp;designations for GBM and metastatic brain cancer.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Disclosure of Clinical Trial Information</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sponsors of clinical trials of FDA-regulated products, including drugs, are required to register and disclose certain clinical trial information. Information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved. Competitors may use this publicly-available information to gain knowledge regarding the progress of development programs.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Regulation Outside of the United States</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to regulations in the United States, we will be subject to regulations of other countries governing any clinical trials and commercial sales and distribution of our product candidates. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of countries outside of the United States before we can commence clinical trials in such countries and approval of the regulators of such countries or economic areas, such as the European Union, before we may market products in those countries or areas. Certain countries outside of the United States have a process similar to the FDA&rsquo;s that requires the submission of a clinical trial application (&ldquo;CTA&rdquo;) much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted to each country&rsquo;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the CTA is approved in accordance with a country&rsquo;s requirements, clinical trial development may proceed. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">19</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Under European Union regulatory systems, a company may submit marketing authorization applications either under a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders or diabetes and is optional for those medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states. Within ninety (90) days of receiving the applications and assessments report, each member state must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Anti-Kickback and False Claims Laws</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal laws have been applied to restrict certain marketing practices in the pharmaceutical industry. These laws include, among others, anti-kickback statutes, false claims statutes and other statutes pertaining to healthcare fraud and abuse. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively referred to as the Affordable Care Act amended the intent element of the federal anti-kickback statute so that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other regulatory sanctions, the exceptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or safe harbor.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Federal false claims laws prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false claim for payment to the federal government, or knowingly making, or causing to be made, a false statement to have a false claim paid. This includes claims made to programs where the federal government reimburses, such as Medicaid, as well as programs where the federal government is a direct purchaser, such as when it purchases off the Federal Supply Schedule. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly inflating drug prices they report to pricing services, which in turn were used by the government to set Medicare and Medicaid reimbursement rates, and for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. In addition, certain marketing practices, including off-label promotion, may also violate federal false claims laws. Additionally, Affordable Care Act amended the federal healthcare program anti-kickback statute such that a violation of that statute can serve as a basis for liability under certain federal false claims laws.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">20</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Other federal statutes pertaining to healthcare fraud and abuse include the civil monetary penalties statute, which prohibits, among other things, the offer or payment of remuneration to a Medicaid or Medicare beneficiary that the offerer or payor knows or should know is likely to influence the beneficiary to order or receive a reimbursable item or service from a particular supplier, and the healthcare fraud and false statements statutes, which prohibit, among other things, knowingly and willfully executing or attempting to execute a scheme to defraud any healthcare benefit program or obtain by means of false or fraudulent pretenses, representations, or promises any money or property owned by or under the control of any healthcare benefit program in connection with the delivery of or payment for healthcare benefits, items, or services.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Violations of these federal healthcare fraud and abuse laws are punishable by imprisonment, criminal fines, civil monetary penalties and exclusion from participation in federal healthcare programs.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">It is uncertain whether there will be any legislation that will replace or amend the Affordable Care Act.&nbsp;In addition, the Trump Administration has and will appoint many new secretaries, directors and the like into positions of authority in the U.S. Federal government dealing with the pharmaceutical and healthcare industries that may potentially have a negative impact on the prices and regulatory pathways for certain pharmaceuticals and healthcare products developed by the Company to market and sell its products in the U.S.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Other Federal and State Regulatory Requirements</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Centers for Medicare &amp; Medicaid Services (&ldquo;CMS&rdquo;) has issued a final rule pursuant to Affordable Care Act that requires certain manufacturers of prescription drugs to annually collect and report information on payments or transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Manufacturers were required to begin collecting information on August 1, 2013, with the first reports due March 31, 2014. The reported data is posted in searchable form on a public website. Failure to submit required information may result in civil monetary penalties.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, several states now require prescription drug companies to report expenses relating to the marketing and promotion of drug products and to report gifts and payments to individual healthcare practitioners and entities in these states. Other states prohibit various other marketing-related activities. Still other states require the posting of information relating to clinical studies and their outcomes. In addition, California, Connecticut, Nevada and Massachusetts require pharmaceutical companies to implement compliance programs and marketing codes. Several additional states are considering similar proposals. Some of the state laws are broader in scope than federal laws. Compliance with these laws is difficult and time consuming, and companies that do not comply with these state laws face civil penalties.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Reimbursement</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sales of any of our product candidates that are approved will depend, in part, on the extent to which the costs of our approved products will be covered by third-party payors, such as government health programs, commercial insurance and managed healthcare organizations. These third-party payors are increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our expected net revenue and results. If any of our products are approved and these third-party payors do not consider our approved products to be cost-effective compared to other therapies, they may not cover our approved products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our approved products on a profitable basis.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&ldquo;<u>MMA</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), imposed new requirements for the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not standardized. Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our approved products covered by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments from non-governmental payors.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The American Recovery and Reinvestment Act of 2009 provides funding for the federal government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures will be made to the U.S. Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is not clear what effect, if any, the research will have on the sales of any approved product, if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative effectiveness research demonstrating benefits in a competitor&rsquo;s product could adversely affect the sales of our product candidates. If third-party payors do not consider our approved products to be cost-effective compared to other available therapies, they may not cover our approved products as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our approved products on a profitable basis.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Affordable Care Act was enacted in March 2010, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the Affordable Care Act of importance to the pharmaceutical and biotechnology industry are the following:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs, that began in 2011;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for branded and generic drugs, respectively;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts to negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s outpatient drugs to be covered under Medicare Part D;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">extension of manufacturers<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; Medicaid rebate liability;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">22</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a licensure framework for follow-on biologic products;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">new requirements under the federal Open Payments program for drug manufacturers to report information related to payments and other transfers of value made to physicians and other healthcare providers as well as ownership or investment interests held by physicians and their immediate family members;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a new requirement to annually report drug samples that manufacturers and distributors provide to physicians, effective April 1, 2012;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">creation of the Independent Payment Advisory Board which, beginning in 2014, will have authority to recommend certain changes to the Medicare program that could result in reduced payments for prescription drugs and those recommendations could have the effect of law even if Congress does not act on the recommendations; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending that began on January 1, 2011.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">It is uncertain whether there will be any legislation that will replace or amend the Affordable Care Act.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>21</i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup><b><i>st</i></b></sup> <b><i>Century Cures Act</i></b></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The 21st Century Cures Act, which the U.S. House of Representatives passed in July 2015 and President Obama signed into law in December 2016, provides for a wide range of reforms, such as broadening the types of data required to support drug approval, extending protections from genetic competition, accelerating approval of breakthrough therapies, expanding the orphan drug product program, and clarifying how manufacturers communicate about their products.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Employees</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2017, we had 11 employees, including 5 in product development and 6 in management or administrative positions. We also have engaged several independent consultants to support our organization.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Directors and Executive Officers</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The table below sets forth, as of March 15, 2018, certain information concerning our current directors and executive officers. No family relationships exist among any of our directors or executive officers.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 45%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Name</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 8%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Age</b></p>
			</td>
			<td style="width: 1%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 45%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Position with Diffusion</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David G. Kalergis</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">69</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chairman and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">John L. Gainer, Ph.D.</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">79</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director and Chief Scientific Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David R. Jones, M.D.</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Medical Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ben L. Shealy</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">60</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Senior Vice President <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&ndash; Finance, Treasurer and Secretary</font></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">William Hornung</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Business Officer</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Thomas Byrne</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">60</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General Counsel</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Isaac Blech</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">68</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vice Chairman</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Robert Adams</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">67</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mark T. Giles</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">63</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Alan Levin</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Robert Ruffolo</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">67</p>
			</td>
			<td style="width: 1%; vertical-align: top;">&nbsp;</td>
			<td style="width: 45%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following is a biographical summary of the experience of our directors and executive officers:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David G. Kalergis</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Kalergis has served as our Chairman of the Board and Chief Executive Officer since the completion of the Merger in January 2016. Mr. Kalergis, along with Dr. Gainer is the Company&rsquo;s co-founder and has served as a director of Diffusion LLC since its inception in 2001 and as its Chief Executive Officer since 2004. Prior to joining the Company, Mr. Kalergis held positions with the University of Virginia; as the general counsel and director of business development for Pharmaceutical Research Associates, Inc., a pharmaceutical contract research organization; as an intelligence analyst for the U.S. Government; and with the law firm Dewey, Ballantine, Bushby, Palmer &amp; Wood, practicing in the areas of corporate finance, public offerings and mergers and acquisitions. In addition, from July 1998 until May 2012, Mr. Kalergis served on the board of directors and audit committee of Virginia National Bank. Mr. Kalergis received a B.A. in psychology, as well as an M.B.A. and J.D., from the University of Virginia, and is a graduate of the Harvard Business School&rsquo;s Leadership and Strategy in the Pharmaceutical and Biotechnology Industry program.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">John L. Gainer, Ph.D.</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Dr. Gainer has served as a director and as our Chief Scientific Officer since the completion of the Merger in January 2016. Dr. Gainer, along with Mr. Kalergis, is the Company&rsquo;s co-founder and has served as one of Diffusions LLC&rsquo;s directors and as its Chief Scientific Officer since its inception in 2001. From 1966 until his retirement in 2005, Dr. Gainer was a professor of chemical engineering at the University of Virginia. During his career, Dr. Gainer authored more than 100 scientific journal articles, including more than 30 published in medical journals, and spent two sabbaticals investigating drug actions and related research at Karolinska Institute in Stockholm and the laboratory of a major pharmaceutical company. He has been a member of the International Society for Oxygen Transport in Tissues since its inception in 1973. Dr. Gainer received a BSChE from West Virginia University, a MS in chemical engineering from the Massachusetts Institute of Technology, and a Ph.D. in chemical engineering from the University of Delaware.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David R. Jones, M.D.</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Dr. Jones serves as our Chief Medical Officer. Dr. Jones was appointed Chief Medical Officer in connection with the completion of the Merger, and has served as Diffusion LLC&rsquo;s Chief Medical Officer since September 2012. In addition to serving as the Company&rsquo;s Chief Medical Officer, Dr. Jones is also the Fiona and Stanley Druckenmiller Endowed Professor for Lung Cancer Research and Chief of Thoracic Surgery at Memorial Sloan-Kettering Cancer Center in New York, NY, a position he has held since 2013. From 2007 to 2013, Dr. Jones was Professor of Surgery and Division Chief of Thoracic &amp; Cardiovascular Surgery at the University of Virginia. In addition to his clinical practice, Dr. Jones has published more than 220 scientific articles, authored or co-authored over 35 book chapters, and served as Principal Investigator or Co-Investigator of over 30 clinical trials. Dr. Jones received an undergraduate degree in chemistry and an M.D. from West Virginia University, and completed his thoracic surgery residency and postdoctoral research fellowship in molecular oncology at the University of North Carolina - Chapel Hill.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Ben L. Shealy</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Shealy serves as our Senior Vice President &ndash; Finance and Treasurer. Mr. Shealy was appointed Senior Vice President &ndash; Finance and Treasurer in connection with the completion of the Merger. Mr. Shealy has served as Diffusion LLC&rsquo;s Senior Vice President &ndash; Finance and Treasurer, since December 2015, and prior to that had served as Diffusion LLC&rsquo;s Chief Financial Officer since 2004. Prior to joining the Company, Mr. Shealy spent more than 20 years in the financial management industry focusing on private and public corporate financings, including serving as the Vice President of REBAR Inc. and positions with Donaldson, Lufkin &amp; Jenrette, Prudential-Bache Capital Funding and the John Hancock Derivatives Group. Mr. Shealy received a B.S. in accounting from San Jose State University, an M.B.A. in finance from Columbia University and is a CFA Charter holder.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">24</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Thomas Byrne</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Byrne was appointed as our General Counsel in connection with the completion of the Merger. Mr. Byrne served as a director of Diffusion LLC from 2001 to January 2016, as a director of the Company from January 2016 until April 2016 and has served as Diffusion LLC&rsquo;s Secretary and Director of Patent Strategy since 2007. Prior to joining Diffusion LLC, Mr. Byrne served in in-house counsel positions at both Genentech Inc. and Amgen Inc., where he co-invented the erythropoiesis stimulating agent darbepoietin alpha (Aranesp&reg;). From 1992 to 2000, he was a partner in the intellectual property law firm of Nixon and Vanderhye P.C. Mr. Byrne also currently acts as a consultant for start-up biotechnology companies on intellectual property, contract and business issues. He received a B.S. in chemical engineering and nuclear engineering, as well as a J.D., from the University of Virginia, and an M.S. in biochemical engineering from Yale University.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>William Hornung</b></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Hornung serves as our Chief Business Officer, a position he has held since August 2017. Mr. Hornung joined Diffusion from Contravir Pharmaceuticals, where he served as Chief Financial Officer from June 2014 to November 2015 and helped the company up-list to NASDAQ and raise nearly $30 million. Prior to Contravir, from 2002 through 2014 Mr. Hornung held positions of increasing responsibility with PTC Therapeutics, most recently serving as Vice President of Finance from April 2012 to March 2014. While at PTC Therapeutics he oversaw the IPO process and raised more than $1 billion. From 1998 through 2002 Mr. Hornung was with Elan Pharmaceuticals (formerly The Liposome Company) in various financial roles. At Liposome and Elan he was responsible for strategic planning and operations of the company&#39;s UK-based European headquarters. Earlier in his career Mr. Hornung worked for a clinical research organization where he was responsible for project management and nearly all financial aspects of the company. Mr. Hornung holds a Bachelor of Science in Accounting from the William Paterson State University of New Jersey</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Isaac Blech</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>&ndash;</b> Mr. Blech has served as a director since August 2016. Mr. Blech&rsquo;s current roles include serving as vice chairman of the board of directors of Edge Therapeutics, Inc., a clinical-stage biotechnology company, founder and director of Cerecor, Inc., a CNS company, director of ContraFect Corporation, an infectious disease company, director of Medgenics, Inc., a biotechnology company, and vice chairman of InspireMD, a stent company. He is vice chairman of the boards of directors of Centrexion Corporation, a private company which is developing new modalities of pain control, Regenovation, Inc., a private company developing new ways to regenerate human tissue, X4 Pharmaceuticals, a private cancer immunology company, Sapience Therapeutics, a private oncology company, Aridis Pharmaceuticals, a private company with a product to treat pneumonia, WaveGuide Corporation, a private company developing the world&rsquo;s smallest NMR machine, SpendSmart Networks, Inc., a private electronic rewards company, and root9B Technologies, a private cyber security company. Over the past 35 years, Mr. Blech has founded and served on the boards of directors of companies which have produced major advances in a broad array of diseases, including the diagnosis of chlamydia, herpes, syphilis and HIV and the treatment of cystic fibrosis, sexual dysfunction, multiple myeloma and brain cancer. Mr. Blech was previously a member of the board of directors of the Company prior to the Merger.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Robert Adams</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Adams has served as a director since the completion of the Merger in January 2016 and as a director of Diffusion LLC since 2002. Prior to his retirement in 2015, Mr. Adams was a partner in the intellectual property law firm of Nixon &amp; Vanderhye P.C, where he had practiced for over 25 years, focusing on patent litigation and international patent licensing and negotiations. During that time period, Mr. Adams was lead litigation counsel in more than 50 major intellectual property lawsuits, where he directly handled, for example, all intellectual property valuations and settlements on behalf of his U.S. and foreign clients. Moreover, Mr. Adams served as the head negotiator for a well-known Japanese consumer products company for 15 years in various complicated licensing situations. Those negotiations typically involved the cross-licensing of up to hundreds of U.S. and foreign patent rights. His lead licensing activities on behalf of that client included, among other things, multi-year negotiations with Texas Instruments, Advanced Micro Devices and Freescale. Mr. Adams received a B.A. from the University of Maryland and a J.D. from George Washington University (with honors), and is a member of the Virginia State Bar.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">25</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Mark T. Giles</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Giles has served as a director since the completion of the Merger in January 2016 and as a director of Diffusion LLC since 2008. Since July 2007, Mr. Giles has been the sole managing member of Panda Holdings, LLC, which engages in the investment and management of private capital. Prior to joining Panda Holdings, Mr. Giles served as the Chief Executive Officer of Virginia National Bank from July 1998 until June 2007 and thereafter continued to serve as the non-executive Chairman until December 2011. Prior to joining Virginia National Bank, Mr. Giles also served as the president of two publicly traded bank holding companies and subsidiary banks in Texas and practiced law with the banking group of a Houston law firm. He chairs the boards of Relay Foods, Inc. and Expedition Trust Company. He also serves on the boards of The Paramount Theater Foundation, The Paramount Theater Operating Company and the Computers4Kids Program. Mr. Giles received a B.S. from the McIntire School of Commerce at the University of Virginia and a J.D. from the University of Virginia School of Law.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Alan Levin</font></i></b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Mr. Levin has served as a director since the completion of the Merger in January 2016 and as a director of Diffusion LLC since June 2015. He previously served as Executive Vice President and Chief Financial Officer of Endo Health Solutions Inc. (&ldquo;<u>Endo</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), a global specialty healthcare company, from June 2009 until his retirement in September 2013. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he was Senior Vice President &amp; Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including Treasurer and Senior Vice President of Finance &amp; Strategic Management for the company&rsquo;s research and development organization. Mr. Levin received a bachelor&rsquo;s degree from Princeton University and a master&rsquo;s degree from New York University&rsquo;s Stern School of Business. Mr. Levin is a certified public accountant. He is a member of the board of directors of Aceto Corp, a NASDAQ-traded company specialized in generics and pharmaceutical intermediate products. He is also a member of the Advisory Board of Auven Therapeutics, a private equity fund; and the Critical Path Institute, a nonprofit collaboration between the Food and Drug Administration and pharmaceutical industry participants focused on streamlining and accelerating the development and regulatory pathways for innovative medicines.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><b>Robert R. Ruffolo, Jr</b></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> &ndash; Dr. Ruffolo has served as a director since July 2017 and is currently the President of Ruffolo Consulting, LLC, a position he has held since 2008. Prior to starting his consulting firm, he formerly served as President of Research and Development and as Corporate Senior Vice President for Wyeth Pharmaceuticals from 2002 to 2008, prior to Wyeth&#39;s acquisition by Pfizer in 2009. Before joining Wyeth in 2000, Dr. Ruffolo spent 17 years at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) where he was Senior Vice President and Director of Biological Sciences, Worldwide, and prior to that, he spent 6 years at Lilly Research Laboratories where he was Chairman of the Cardiovascular Research Committee. Dr. Ruffolo received a B.S in pharmacy and his Ph.D. in pharmacology from The Ohio State University.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Corporate Information and History</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a Delaware corporation that was originally incorporated in the State of Nevada on January 10, 1995. We&nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">reincorporated into the State of Delaware on June 18, 2015. Our corporate headquarters are located at 1317 Carlton Avenue,&nbsp;Suite 200, Charlottesville, Virginia 22902, our telephone number is (434) 220-0718, and our Internet web site address is&nbsp;www.diffusionpharma.com. The information contained on our web site or connected to our web site is not incorporated by&nbsp;reference into and should not be considered part of this annual report on Form 10-K.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Merger with RestorGenex</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On January 8, 2016, we completed the Merger with Diffusion LLC in accordance with the terms of the Merger Agreement. As a result of the Merger, Diffusion LLC, the surviving company in the Merger, became a wholly&nbsp;owned subsidiary of the Company.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the effective time of the Merger (the &ldquo;<u>Effective Time</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), each outstanding unit of membership interest of Diffusion LLC (the &ldquo;<u>Diffusion Units</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) was converted into the right to receive 0.3652658 shares of our common stock, as determined pursuant to the Merger Agreement (the &ldquo;<u>Exchange Ratio</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;). Also, at the Effective Time, the rights of the holders of each outstanding convertible promissory note convertible into Diffusion Units (the &ldquo;Diffusion Convertible Notes&rdquo;) to convert such Diffusion Convertible Notes into Diffusion Units, was converted into the right to convert such securities into a number of shares of common stock equal to the number of Diffusion Units such Diffusion Convertible Note would be convertible into pursuant to its terms multiplied by the Exchange Ratio. In addition, at the Effective Time and as a result of the Merger, all outstanding options to purchase Diffusion Units were converted into and became options to purchase common stock on terms substantially identical to those in effect prior to the Effective Time, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Immediately following the Merger, the former equity holders of Diffusion LLC owned approximately 84.1% of the Company&rsquo;s common stock, and the stockholders of RestorGenex immediately prior to the Merger owned approximately 15.9% of the Company&rsquo;s common stock, in each case, on a fully-diluted basis (subject to certain exceptions and adjustments) and calculated in accordance with the terms of the Merger Agreement.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For accounting purposes, the Merger is treated as a &ldquo;reverse acquisition&rdquo; under generally acceptable accounting principles in the United States (&ldquo;<u>U.S. GAAP</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) and Diffusion LLC is considered the accounting acquirer. Accordingly, Diffusion LLC&rsquo;s historical results of operations have replaced the Company&rsquo;s historical results of operations for all periods prior to the Merger.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>Reverse Stock Split</i></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On August 17, 2016, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a 1-to-10 reverse stock split (the &ldquo;<u>Reverse Stock Split</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) of the common stock. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise would have been entitled to receive fractional shares of common stock had their holdings rounded up to the next whole share. Proportional adjustments were made to the Company&rsquo;s outstanding warrants, stock options and other equity securities and to the Company&rsquo;s 2015 Equity Incentive Plan, as amended, to reflect the Reverse Stock Split, in each case, in accordance with the terms thereof. Unless the context otherwise requires, all share and per share amounts in this annual report on Form 10-K have been adjusted to reflect the Reverse Stock Split.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Available Information</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We make available, free of charge and through our Internet web site, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to any such reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. We also make available, free of charge and through our Internet web site, to any stockholder who requests, the charters of our board committees, our Corporate Governance Guidelines and our Code of Business Conduct and Ethics. Requests for copies can be directed to Investor Relations at (434) 220-0718.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Cautionary Note Regarding Forward-Looking Statements</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">This Annual Report on Form 10-K (this &ldquo;<u>Annual Report</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) includes forward-looking statements. We may, in some cases, use terms such as &ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;expects,&rdquo; &ldquo;plans,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;approximately&rdquo; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements appear in a number of places throughout this Annual Report and include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates, our intellectual property position, the degree of clinical utility of our products, particularly in specific patient populations, our ability to develop commercial functions, expectations regarding clinical trial data, our results of operations, cash needs, financial condition, liquidity, prospects, growth and strategies, the industry in which we operate and the trends that may affect the industry or us.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained or incorporated by reference in this Annual Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained or incorporated by reference in this Annual Report. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained or incorporated by reference in this Annual Report, they may not be predictive of results or developments in future periods.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">27</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Actual results could differ materially from our forward-looking statements due to a number of factors, including risks related to:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to obtain additional financing;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our estimates regarding expenses,<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;capital requirements and needs for additional financing;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success and timing of our preclinical studies and clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the difficulties in obtaining and maintaining regulatory approval of our products and product candidates, and the labeling under any approval we may obtain;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our plans and ability to develop and commercialize our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the accuracy of our estimates of the size and characteristics of the potential markets for our product candidates and our ability to serve those markets;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory developments in the United States and foreign countries;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the rate and degree of market acceptance of any of our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to operate our business without infringing the intellectual property rights of others;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">recently enacted and future legislation regarding the healthcare system;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to maintain our listing on the Nasdaq Capital Market;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the success of competing products that are or become available; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the performance of third parties, including contract research organizations and manufacturers.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">You should also read carefully the factors described in the &ldquo;Risk Factors&rdquo; section of this Annual Report and elsewhere to better understand the risks and uncertainties inherent in our business and underlying any forward-looking statements. As a result of these factors, we cannot assure you that the forward- looking statements contained or incorporated by reference in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified timeframe, or at all.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any forward-looking statements that we make contained or incorporated by reference in this Annual Report speak only as of the date of such statement, and, except as required by applicable law, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events. Comparisons of results for current and any prior periods are not intended to express any future trends or indications of future performance, unless expressed as such, and should only be viewed as historical data.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">28</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1A.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>RISK FACTORS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following are significant factors known to us that could materially harm our business, operating results or financial condition or could cause our actual results to differ materially from our anticipated results or other expectations, including those expressed in any forward-looking statement made in this report:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Our Financial Needs</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>have limited cash resources,</i> <i>have incurred significant losses since our inception and have a history of net losses and negative cash flow from operations.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a clinical-stage biotechnology company and, as a result, we have a limited operating history and there is little historical basis from which to assess how we will respond to competitive or economic challenges or other challenges to our business. Our business and prospects must be considered in light of the risks and uncertainties frequently encountered by similarly situated companies.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have limited cash resources, have generated substantial net losses and negative cash flow from operations since our inception, and we continue to incur significant research, development and other expenses related to our ongoing operations for other product candidates. We expect to incur losses and negative cash flow for the foreseeable future. Our ability to generate sufficient revenues from our product candidates, if approved, will depend on numerous factors described in the following risk factors and elsewhere in this report. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&rsquo; equity.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently generate no revenue from the sale of products and may never become profitable.</font></i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To date, we have not generated any revenues from our product candidates. Even if we are able to successfully achieve regulatory approval for our product candidates, we do not know when any of these products will generate revenue for us, if at all. Our ability to generate revenue from our current product candidates or future products also depends on a number of additional factors, including our ability to:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">successfully complete development activities, including the necessary clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">complete and submit NDAs to the FDA and obtain regulatory approval for indications for which there is a commercial market;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">develop a commercial organization capable of sales, marketing and distribution for the products we intend to sell ourselves in the markets in which we have retained commercialization rights; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 36pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">find suitable distribution partners to help us market, sell and distribute our approved products in other markets.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, because of the numerous risks and uncertainties associated with product development, including that our product candidates may not advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased expenses, or when or if we will be able to achieve or maintain profitability. Even if we are able to complete the process described above, we anticipate incurring significant costs associated with commercializing these products.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">29</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We will</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>require additional capital to fund our operations which may not be available on acceptable terms or at all. If we fail to obtain necessary financing, we may be unable to complete the development and commercialization of our product candidates.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of our product candidates and to commercialize any product candidates for which we receive regulatory approval. At the current time, the bulk of our cash resources for clinical development is dedicated to the Phase 3 trial for TSC in inoperable GBM. While we believe we have adequate cash resources to continue operations through June 2019, we will need to raise additional funds in order to complete this trial. We do not expect to commence any clinical trials beyond the inoperable GBM trial unless we are able to raise additional capital or make alternative financing arrangements for any such trial.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Conditions in the credit markets and the financial services industry may make equity and debt financing more difficult to obtain, and may negatively impact our ability to complete financing transactions. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. Any debt financing, if available, may involve restrictive covenants, such as limitations on our ability to incur additional indebtedness and other operating restrictions that could adversely impact our ability to conduct our business.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us we may have to significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives. We also could be required to:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available; or</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">relinquish or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves.</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &ldquo;Risk Factors&rdquo; section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the initiation, progress, timing, costs and results of clinical trials for our product candidates and any future product candidates we may in-license;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the clinical development plans we establish for these product candidates;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the number and characteristics of product candidates that we in-license and develop;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the cost of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effect of competing technological and market developments; and</p>
			</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the cost and timing of completion of becoming a commercial organization.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">30</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may seek additional capital through a combination of private and public equity offerings, debt financings, receivables or royalty financings, strategic partnerships and alliances and licensing arrangements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt, receivables and royalty financings may be coupled with an equity component, such as warrants to purchase stock, which could also result in dilution of our existing stockholders&rsquo; ownership. The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business and may result in liens being placed on our assets and intellectual property. If we were to default on such indebtedness, we could lose such assets and intellectual property. If we raise additional funds through strategic partnerships and alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Development, Regulatory Approval and Commercialization</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our business is dependent on the successful development, regulatory approval and commercialization of our product candidates, which include products primarily for the treatment of glioblastoma multiforme, pancreatic cancer, stroke and brain metastases.</font></i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our portfolio of product candidates includes TSC, which is a novel small molecule that re-oxygenates hypoxic tissue, enhancing the efficacy of radiation and chemotherapy without harmful side effects in Phase 3 clinical development for glioblastoma multiforme. In addition, TSC may have potential applications in pancreatic cancer, stroke and brain metastases. The success of our business, including our ability to finance our company and generate any revenue in the future, primarily will depend on the successful development, regulatory approval and commercialization of our product candidates. In the future, we may also become dependent on one or more other product candidates or any future product candidates that we may in-license, acquire or develop. There have been many failures in drugs that other companies have tried to develop to treat the indications the company is or may be pursuing, including glioblastoma multiforme, pancreatic cancer, stroke and brain metastases. There can be no assurance that the company will have success where others have failed.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The clinical and commercial success of our product candidates will depend on a number of factors, including the following:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">timely completion of our clinical trials, which may be significantly slower or cost more than we currently anticipate and will depend substantially upon the performance of third-party contractors;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical trials beyond those planned to support the approval and commercialization of our product candidates or any future product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our product candidates by the FDA and similar foreign regulatory authorities;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities, the safety and efficacy of our product candidates or any future product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the prevalence, duration and severity of potential side effects experienced with our product candidates or future approved products, if any;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain, compliance with our contractual obligations and with all regulatory requirements applicable to our product candidates or any future product candidates or approved products, if any;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of third parties with whom we contract to manufacture clinical trial and commercial supplies of our product candidates or any future product candidates, remain in good standing with regulatory agencies and develop, validate and maintain commercially viable manufacturing processes that are compliant with cGMP;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a continued acceptable safety profile during clinical development and following approval of our product candidates or any future product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to successfully commercialize our product candidates or any future product candidates in the United States and internationally, if approved for marketing, sale and distribution in such countries and territories, whether alone or in collaboration with others;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">acceptance by physicians and patients of the benefits, safety and efficacy of our product candidates or any future product candidates, if approved, including relative to alternative and competing treatments;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our and our partners<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; ability to establish and enforce intellectual property rights in and to our product candidates or any future product candidates;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our and our partners<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; ability to avoid third-party patent interference or intellectual property infringement claims; and</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to in-license or acquire additional product candidates or commercial-stage products that we believe can be successfully developed and commercialized.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we do not achieve one or more of these factors, many of which are beyond our control, in a timely manner or at all, we could experience significant delays or an inability to obtain regulatory approvals or commercialize our product candidates. Even if regulatory approvals are obtained, we may never be able to successfully commercialize any of our product candidates. Accordingly, we cannot assure you that we will be able to generate sufficient revenue through the sale of our product candidates or any future product candidates to continue our business.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinical drug development for our product candidates is very expensive, time-consuming and uncertain. Our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates, which could prevent or delay regulatory approval and commercialization.</font></i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Clinical drug development for our product candidates is very expensive, time-consuming, difficult to design and implement and its outcome is inherently uncertain. Before obtaining regulatory approval for the commercial sale of a product candidate, we must demonstrate through clinical trials that a product candidate is both safe and effective for use in the target indication. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization. Our product candidates are in early stages of development. We expect that clinical trials for these product candidates will take several years, but may take significantly longer than expected to complete. In addition, we, any partner with which we may in the future collaborate, the FDA, an IRB or other regulatory authorities, including state and local agencies and counterpart agencies in foreign countries, may suspend, delay, require modifications to or terminate our clinical trials at any time, for various reasons, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">discovery of serious or unexpected toxicities or side effects experienced by study participants or other safety issues;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">lack of effectiveness of any product candidate during clinical trials or the failure of our product candidates to meet specified endpoints;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">slower than expected rates of subject recruitment and enrollment rates in clinical trials resulting from numerous factors, including the prevalence of other companies<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; clinical trials for their product candidates for the same indication, or clinical trials for indications for which patients do not as commonly seek treatment;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty in retaining subjects who have initiated a clinical trial but may withdraw at any time due to adverse side effects from the therapy, insufficient efficacy, fatigue with the clinical trial process or for any other reason;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty in obtaining IRB approval for studies to be conducted at each site;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in manufacturing or obtaining, or inability to manufacture or obtain, sufficient quantities of materials for use in clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inadequacy of or changes in our manufacturing process or the product formulation or method of delivery;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">changes in applicable laws, regulations and regulatory policies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays or failure in reaching agreement on acceptable terms in clinical trial contracts or protocols with prospective clinical research organizations (&ldquo;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>CROs</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), clinical trial sites and other third-party contractors;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability to add a sufficient number of clinical trial sites;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">uncertainty regarding proper dosing;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of our CROs or other third-party contractors to comply with contractual and regulatory requirements or to perform their services in a timely or acceptable manner;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure by us, our employees, our CROs or their employees or any partner with which we may collaborate or their employees to comply with applicable FDA or other regulatory requirements relating to the conduct of clinical trials or the handling, storage, security and recordkeeping for drug products;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">scheduling conflicts with participating clinicians and clinical institutions;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure to design appropriate clinical trial protocols;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">insufficient data to support regulatory approval;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability or unwillingness of medical investigators to follow our clinical protocols; or</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty in maintaining contact with subjects during or after treatment, which may result in incomplete data.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">33</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We or any partner with which we may collaborate may suffer significant setbacks in our or their clinical trials similar to the experience of a number of other companies in the pharmaceutical and biotechnology industries, even after receiving promising results in earlier trials. In the event that we or our potential partners abandon or are delayed in the clinical development efforts related to our product candidates, we may not be able to execute on our business plan effectively and our business, financial condition, operating results and prospects would be harmed.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For example, we recently opened for enrollment and dosed our first patient under the protocol permitted by the FDA with respect to our Phase 3 clinical study of TSC. Although enrollment and dosing has commenced, there can be no assurance that we will not in the future encounter difficulties and/or delays in enrolling patients, opening additional clinical sites or other aspects of the study. In addition, we do not anticipate receiving data from the Phase 3 clinical study for a number of years, which time period could be further delayed by any such difficulties. Any of the foregoing could have a negative impact on our business, financial condition or prospects.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be unable to obtain regulatory approval for TSC or our other future product candidates for the indications of which we are seeking under applicable regulatory requirements. The FDA and foreign regulatory bodies have substantial discretion in the approval process, including the ability to delay, limit or deny approval of product candidates. The delay, limitation or denial of any regulatory approval would adversely impact commercialization, our potential to generate revenue, our business and our operating results.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize any of our current or future product candidates. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to our drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and in foreign countries, and such regulations differ from country to country. We are not permitted to market any of our current product candidates in the United States until we receive approval of an NDA or other applicable regulatory filing from the FDA. We are also not permitted to market any of our current product candidates in any foreign countries until we receive the requisite approval from the applicable regulatory authorities of such countries.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To gain approval to market a new drug, such as TSC, the FDA and foreign regulatory authorities must receive preclinical and clinical data that adequately demonstrate the safety, purity, potency, efficacy and compliant manufacturing of the product for the intended indication applied for in an NDA or other applicable regulatory filing. The development and approval of new drug products involves a long, expensive and uncertain process, and delay or failure can occur at any stage. A number of companies in the pharmaceutical and biopharmaceutical industry have suffered significant setbacks in clinical trials, including in Phase 3 clinical development, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we or our partners may conduct.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA and foreign regulatory bodies have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of product candidates for many reasons, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may disagree with the design or implementation of one or more clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may not deem a product candidate safe and effective for its proposed indication, or may deem a product candidate<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s safety or other perceived risks to outweigh its clinical or other benefits;</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">34</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may not find the data from preclinical studies and clinical trials sufficient to support approval, or the results of clinical trials may not meet the level of statistical or clinical significance required by the FDA or the applicable foreign regulatory body for approval;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may disagree with our interpretation of data from preclinical studies or clinical trials performed by us or third parties, or with the interpretation of any partner with which we may collaborate;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the data collected from clinical trials may not be sufficient to support the submission of an NDA or other applicable regulatory filing;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may require additional preclinical studies or clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory agency may identify deficiencies in the formulation, quality control, labeling or specifications of our current or future product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory agency may require clinical trials in pediatric patients in order to establish pharmacokinetics or safety for this more drug-sensitive population;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional post-approval clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory agency also may approve our current or any future product candidates for a more limited indication or a narrower patient population than we originally requested;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or applicable foreign regulatory agency may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may not approve of the manufacturing processes, controls or facilities of third-party manufacturers or testing labs with which we contract; or</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or the applicable foreign regulatory body may change its approval policies or adopt new regulations in a manner rendering our clinical data or regulatory filings insufficient for approval.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Of the large number of drugs in development, only a small percentage successfully complete the FDA or other regulatory approval processes and are commercialized. Our product candidates may not be approved by the FDA or applicable foreign regulatory agencies even if they meet specified endpoints in our clinical trials. The FDA or applicable foreign regulatory agencies may ask us to conduct additional costly and time-consuming clinical trials in order to obtain marketing approval or approval to enter into an advanced phase of development, or may change the requirements for approval even after such agency has reviewed and commented on the design for the clinical trials.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our product candidates and would harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Even if our product candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The commercial success of any of our current or future product candidates, if approved, will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications, and may not be commercially successful. The degree and rate of physician and patient adoption of our current or future product candidates, if approved, will depend on a number of factors, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the clinical indications for which the product is approved and patient demand for approved products that treat those indications;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">35</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effectiveness of our product as compared to other available therapies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the availability of coverage and adequate reimbursement from managed care plans and other healthcare payors for any of our product candidates that may be approved;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the cost of treatment with our product candidates in relation to alternative treatments and willingness to pay for the product, if approved, on the part of patients;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">acceptance by physicians, major operators of clinics and patients of the product as a safe and effective treatment;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">proper training and administration of our product candidates by physicians and medical staff;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">patient satisfaction with the results and administration of our product candidates and overall treatment experience;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the willingness of patients to pay for certain of our product candidates relative to other discretionary items, especially during economically challenging times;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the revenue and profitability that our product candidate may offer a physician as compared to alternative therapies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the prevalence and severity of side effects;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">limitations or warnings contained in the FDA-approved labeling for our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any FDA requirement to undertake a REMS;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the effectiveness of our sales, marketing and distribution efforts;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">adverse publicity about our product candidates or favorable publicity about competitive products; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential product liability claims.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our product candidates, if approved, will face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing and marketing of health care products competitive with those that we are developing. We face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions, many of which have greater financial resources, marketing capabilities, sales forces, manufacturing capabilities, research and development capabilities, clinical trial expertise, intellectual property portfolios, experience in obtaining patents and regulatory approvals for product candidates and other resources than us. Some of the companies that offer competing products also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our expected target physicians, which could inhibit our market penetration efforts.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Many pharmaceutical companies currently offer products, and continue to develop additional alternative product candidates and technologies, for indications similar to those targeted by our product candidates. We anticipate that, if we obtain regulatory approval of our product candidates, we will face significant competition from other approved therapies. If approved, our product candidates may also compete with unregulated, unapproved and off-label treatments. Certain of our product candidates, if approved, will present novel therapeutic approaches for the approved indications and will have to compete with existing therapies, some of which are widely known and accepted by physicians and patients. To compete successfully in this market, we will have to demonstrate that the relative cost, safety and efficacy of our products, when and if approved, provide an attractive alternative to existing and other new therapies. Such competition could lead to reduced market share for our product candidates and contribute to downward pressure on the pricing of our product candidates, which could harm our business, financial condition, operating results and prospects. For more information about the competition we face, see &ldquo;Business&mdash;Competition.&rdquo;</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">36</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Due to less stringent regulatory requirements in certain foreign countries, there are many more products and procedures available for use in those international markets than are approved for use in the United States. In certain international markets, there are also fewer limitations on the claims that our competitors can make about the effectiveness of their products and the manner in which they can market them. As a result, we expect to face more competition in these markets than in the United States.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any product candidates that we commercialize, or that any partner with which we may collaborate commercializes, will be subject to ongoing and continued regulatory review.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Even after we or our partners achieve U.S. regulatory approval for a product candidate, if any, we or our partners will be subject to continued regulatory review and compliance obligations. For example, with respect to our product candidates, the FDA may impose significant restrictions on the approved indicated uses for which the product may be marketed or on the conditions of approval. A product candidate&rsquo;s approval may contain requirements for potentially costly post-approval studies and surveillance, including Phase 4 clinical trials or a REMS, to monitor the safety and efficacy of the product. We will also be subject to ongoing FDA obligations and continued regulatory review with respect to, among other things, the manufacturing, processing, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for our product candidates. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP requirements and with the FDA&rsquo;s GCP requirements and good laboratory practice (&ldquo;<u>GLP</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) requirements, which are regulations and guidelines enforced by the FDA for all of our product candidates in clinical and preclinical development, and for any clinical trials that we conduct post-approval. To the extent that a product candidate is approved for sale in other countries, we may be subject to similar restrictions and requirements imposed by laws and government regulators in those countries.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where, or processes by which, the product is manufactured, a regulatory agency may impose restrictions on that product or us, including requesting that we initiate a product recall, or requiring notice to physicians, withdrawal of the product from the market or suspension of manufacturing.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we, our product candidates or the manufacturing facilities for our product candidates fail to comply with applicable regulatory requirements, a regulatory agency may:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impose restrictions on the marketing or manufacturing of the product, suspend or withdraw product approvals or revoke necessary licenses;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">require us or our partners to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">37</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">issue warning letters, show cause notices or untitled letters describing alleged violations, which may be publicly available;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">commence criminal investigations and prosecutions;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impose injunctions, suspensions or revocations of necessary approvals or other licenses;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impose other civil or criminal penalties;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">suspend any ongoing clinical trials;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delay or refuse to approve pending applications or supplements to approved applications filed by us or our potential partners;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">refuse to permit drugs or precursor chemicals to be imported or exported to or from the United States;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">suspend or impose restrictions on operations, including costly new manufacturing requirements; or</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">seize or detain products or require us or our partners to initiate a product recall.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The regulations, policies or guidance of the FDA and other applicable government agencies may change and new or additional statutes or government regulations may be enacted that could prevent or delay regulatory approval of our product candidates or further restrict or regulate post-approval activities. We cannot predict the likelihood, nature or extent of adverse government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market our product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have conducted and may in the future conduct clinical trials for our product candidates outside the United States and the FDA and applicable foreign regulatory authorities may not accept data from such trials.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have conducted and may in the future choose to conduct one or more of our clinical trials outside the United States. Although the FDA or applicable foreign regulatory authority may accept data from clinical trials conducted outside the United States or the applicable jurisdiction, acceptance of such study data by the FDA or applicable foreign regulatory authority may be subject to certain conditions. Where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless those data are applicable to the U.S. population and U.S. medical practice; the studies were performed by clinical investigators of recognized competence; and the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Many foreign regulatory bodies have similar requirements. In addition, such foreign studies would be subject to the applicable local laws of the foreign jurisdictions where the studies are conducted. There can be no assurance the FDA or applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or applicable foreign regulatory authority does not accept such data, it would likely result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our product candidates may cause undesirable side effects or have other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label or result in post-approval regulatory action.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved, after the approved product has been marketed. Undesirable side effects caused by product candidates could cause us, any partners with which we may collaborate or regulatory authorities to interrupt, modify, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign authorities. In such an event, trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us, or our potential partners, to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">38</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by our product candidates after obtaining U.S. or foreign regulatory approval or other products with the same or related active ingredients, a number of potentially negative consequences could result, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may withdraw their approval of the product;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may require a recall of the product or we or our potential partners may voluntarily recall a product;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or field alerts to physicians and pharmacies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients or institute a REMS;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may have limitations on how we promote the product;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may be required to change the way the product is administered or modify the product in some other way;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the FDA or applicable foreign regulatory authority may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">sales of the product may decrease significantly;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we could be sued and held liable for harm caused to patients; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our brand and reputation may suffer.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any of the above events resulting from undesirable side effects or other previously unknown problems could prevent us or our potential partners from achieving or maintaining market acceptance of the affected product candidate and could substantially increase the costs of commercializing our product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Because the results of preclinical studies and early-stage clinical trials are not necessarily predictive of future results, any product candidate we advance into additional clinical trials may not continue to have favorable results or receive regulatory approval.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Success in preclinical studies and early clinical trials does not ensure that later clinical trials will generate adequate data to demonstrate the efficacy and safety of an investigational drug. Many companies in the pharmaceutical and biotechnology industries, including those with greater resources and experience, have suffered significant setbacks in clinical trials, even after reporting promising results in earlier clinical trials. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety or otherwise provide adequate information to result in regulatory approval to market any of our product candidates in any particular jurisdiction. If later-stage clinical trials do not produce favorable results, our ability to achieve regulatory approval for any of our product candidates may be compromised.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">39</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<div contenteditable="false" docsect="12" id="10796" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may face product liability exposure, and if successful claims are brought against us, we may incur substantial liability if our insurance coverage for those claims is inadequate.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. This risk exists even if a product is approved for commercial sale by the FDA and manufactured in facilities licensed and regulated by the FDA or an applicable foreign regulatory authority. Our products and product candidates are designed to affect important bodily functions and processes. Any side effects, manufacturing defects, misuse or abuse associated with our product candidates could result in injury to a patient or even death. We cannot offer any assurance that we will not face product liability suits in the future, nor can we assure you that our insurance coverage will be sufficient to cover our liability under any such cases.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, a liability claim may be brought against us even if our product candidates merely appear to have caused an injury. Product liability claims may be brought against us by consumers, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our product candidates, among others. If we cannot successfully defend ourselves against product liability claims we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">withdrawal of clinical trial participants;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">termination of clinical trial sites or entire trial programs;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the inability to commercialize our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">decreased demand for our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impairment of our business reputation;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">product recall or withdrawal from the market or labeling, marketing or promotional restrictions;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">substantial costs of any related litigation or similar disputes;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">distraction of management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s attention and other resources from our primary business;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">substantial monetary awards to patients or other claimants against us that may not be covered by insurance; or</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">loss of revenue.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have obtained product liability insurance coverage for our clinical trials. However, large judgments have been awarded in class action or individual lawsuits based on drugs that had unanticipated side effects and our insurance coverage may not be sufficient to cover all of our product liability related expenses or losses and may not cover us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost, in sufficient amounts or upon adequate terms to protect us against losses due to product liability. We will need to increase our product liability coverage if any of our product candidates receive regulatory approval, which will be costly, and we may be unable to obtain this increased product liability insurance on commercially reasonable terms, or at all. A successful product liability claim or series of claims brought against us could cause our stock price to decline and, if judgments exceed our insurance coverage, could decrease our cash and could harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">40</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If any of our product candidates are approved for marketing and we are found to have improperly promoted off-label uses, or if physicians misuse our products or use our products off-label, we may become subject to prohibitions on the sale or marketing of our products, product liability claims and significant fines, penalties and sanctions, and our brand and reputation could be harmed.</font></i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&rsquo;s approved labeling and comparative safety or efficacy claims cannot be made without direct comparative clinical data. If we are found to have promoted off-label uses of any of our product candidates, we may receive warning or untitled letters and become subject to significant liability, which would materially harm our business. Both federal and state governments have levied large civil and criminal fines against companies for alleged improper promotion and have enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management&rsquo;s attention could be diverted from our business operations, significant legal expenses could be incurred and our brand and reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have engaged in the promotion of our products for off-label use, we could be subject to FDA regulatory or enforcement actions, including the issuance of an untitled letter, a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our business activities constitute promotion of an off-label use, which could result in significant penalties, including criminal, civil or administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment or restructuring of our operations.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We cannot, however, prevent a physician from using our product candidates outside of those indications for use when in the physician&rsquo;s independent professional medical judgment he or she deems appropriate. Physicians may also misuse our product candidates or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If our product candidates are misused or used with improper technique, we may become subject to costly litigation by physicians or their patients. Furthermore, the use of our product candidates for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation among physicians and patients.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may choose not to continue developing or commercializing any of our product candidates at any time during development or after approval, which would reduce or eliminate our potential return on investment for those product candidates.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At any time, we may decide to discontinue the development of any of our product candidates or not to continue commercializing one or more of our approved product candidates for a variety of reasons, including changes in our internal product, technology or indication focus, the appearance of new technologies that make our product obsolete, competition from a competing product or changes in or failure to comply with applicable regulatory requirements. If we terminate a program in which we have invested significant resources, we will not receive any return on our investment and we will have missed the opportunity to have allocated those resources to potentially more productive uses.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We or our prospective partners may be subject to product recalls in the future that could harm our brand and reputation and could negatively affect our business.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We or our prospective partners may be subject to product recalls, withdrawals or seizures if any of our product candidates, if approved for marketing, fail to meet specifications or are believed to cause injury or illness or if we are alleged to have violated governmental regulations including those related to the manufacture, labeling, promotion, sale or distribution. Any recall, withdrawal or seizure in the future could materially and adversely affect consumer confidence in our brands and lead to decreased demand for our approved products. In addition, a recall, withdrawal or seizure of any of our approved products would require significant management attention, would likely result in substantial and unexpected expenditures and would harm our business, financial condition and operating results.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">41</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we or any partners with which we may collaborate are unable to achieve and maintain coverage and adequate levels of reimbursement for any of our product candidates for which we receive regulatory approval, or any future products we may seek to commercialize, their commercial success may be severely hindered.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For any of our product candidates that become available only by prescription, successful sales by us or by any partners with which we may collaborate depend on the availability of coverage and adequate reimbursement from third-party payors. Patients who are prescribed medicine for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. The availability of coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and private third-party payors is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available. If any of our product candidates do not demonstrate attractive efficacy profiles, they may not qualify for coverage and reimbursement. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, the market for our product candidates will depend significantly on access to third-party payors&rsquo; drug formularies, or lists of medications for which third-party payors provide coverage and reimbursement. The industry competition to be included in such formularies often leads to downward pricing pressures on pharmaceutical companies. Also, third-party payors may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In addition, in the United States, although private third-party payors tend to follow Medicare, no uniform policy of coverage and reimbursement for drug products exists among third-party payors. Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Further, we believe that future coverage and reimbursement will likely be subject to increased restrictions both in the United States and in international markets. Third-party coverage and reimbursement for any of our product candidates for which we may receive regulatory approval may not be available or adequate in either the United States or international markets, which could harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Healthcare reform measures could hinder or prevent the commercial success of our products and product candidates.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future revenue and profitability and the future revenue and profitability of any partner with which we may collaborate. Federal and state lawmakers regularly propose and, at times, enact legislation that results in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, in March 2010, President Obama signed one of the most significant healthcare reform measures in decades the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010, collectively referred to as the Affordable Care Act. It contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which are expected to impact existing government healthcare programs and result in the development of new programs. The Affordable Care Act, among other things, (1) increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to certain individuals enrolled in Medicaid managed care organizations, (2) established annual fees on manufacturers of certain branded prescription drugs and (3) enacted a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&rsquo;s outpatient drugs to be covered under Medicare Part D.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">42</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&rsquo;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on April 1, 2013. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, further reduced Medicare payments to several providers, including hospitals and imaging centers.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Further, the Protecting Access to Medicare Act of 2014, signed into law in April 2014, provides for a 0.5% change from 2013 federal payment rates under the Medicare Physician Fee Schedule through 2014 and a 0% update from January 1 until April 1, 2015. Congressional failure to intervene to prevent these changes in payment rates may adversely affect our future revenue and operating results. The 21st Century Cures Act, which the U.S. House of Representatives passed in July 2015 and President Obama signed into law in December 2016, provides a wide range of reforms, such as broadening the types of data required to support drug approval, extending protections from genetic competition, accelerating approval of breakthrough therapies, expanding the orphan drug product program, and clarifying how manufacturers communicate about their products.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. The Trump administration and members of the U.S. Congress have indicated that they may continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. More recently, the Tax Cuts and Jobs Acts was enacted, which, among other things, removes penalties for not complying with the individual mandate to carry health insurance. It is uncertain the extent to which any such changes may impact our business or financial condition.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, we cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. Namely, the Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&rsquo;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, which requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&rsquo;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&rsquo;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>We operate in a highly regulated industry such that the potential for legislative reform provides uncertainty and potential threats to our operating models and results.</i></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The delivery of healthcare services and products is highly regulated in most of the countries in which we may operate. Proposals for legislative reform in these countries are often introduced to improve access to care, address quality of care issues and manage costs of the healthcare system. In the US, the Trump administration and the 115th Congress have publicly announced their intention to pursue, and may enact, significant changes to existing health care programs. Certain health insurance provisions of Affordable Care Act, if not many more Affordable Care Act provisions, are likely targets for change. Changes of this nature could have significant effects on our businesses, both positive and negative, but the outcomes are impossible to predict.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">43</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may also be subject to healthcare laws, regulation and enforcement and our failure to comply with those laws could adversely affect our business, operations and financial condition.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients&rsquo; rights are and will be applicable to our business. We are subject to regulation by both the federal government and the states in which we or our partners conduct our business. The laws and regulations that may affect our ability to operate include:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, any person or entity from knowingly and willfully offering, soliciting, receiving or providing any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce either the referral of an individual or in return for the purchase, lease, or order of any good, facility item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as the Medicare and Medicaid programs;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">federal civil and criminal false claims laws and civil monetary penalty laws, including, for example, the federal civil False Claims Act, which impose criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>HIPAA</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which impose obligations on covered entities, including healthcare providers, health plans, and healthcare clearinghouses, as well as their respective business associates that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the federal physician sunshine requirements under the Affordable Care Act, which require manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value provided to physicians and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be provided to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to healthcare providers or marketing expenditures; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additional health care reform legislation further strengthened these laws. For example, the Affordable Care Act, among other things, amended the intent requirement of the federal Anti-Kickback Statute and certain criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of the statute or specific intent to violate it. In addition, the Affordable Care Act provided that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Achieving and sustaining compliance with these laws may prove costly. In addition, any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&rsquo;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws or regulations that apply to us, we may be subject to penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment or the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">44</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our employees, independent contractors, principal investigators, consultants, vendors, CROs and any partners with which we may collaborate may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are exposed to the risk that our employees, independent contractors, principal investigators, consultants, vendors, CROs and any partners with which we may collaborate may engage in fraudulent or other illegal activity. Misconduct by these persons could include intentional, reckless or negligent conduct or unauthorized activity that violates: laws or regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA or foreign regulatory authorities; manufacturing standards; federal, state and foreign healthcare fraud and abuse laws and data privacy; or laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of business activities, including research, manufacturing, distribution, pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations, and serious harm to our reputation. In addition, federal procurement laws impose substantial penalties for misconduct in connection with government contracts and require certain contractors to maintain a code of business ethics and conduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our operating results.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Our Dependence on Third Parties</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to rely on third-party CROs and other third parties to conduct and oversee our clinical trials and other aspects of product development. If these third parties do not meet our requirements or otherwise conduct the trials as required, we may not be able to satisfy our contractual obligations or obtain regulatory approval for, or commercialize, our product candidates when expected or at all.</font></i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to rely on third-party CROs to conduct and oversee our clinical trials and other aspects of product development. We also rely upon various medical institutions, clinical investigators and contract laboratories to conduct our trials in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&rsquo;s regulations and GCPs, which are an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors, and state regulations governing the handling, storage, security and recordkeeping for drug products. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data from the clinical trials. We rely heavily on these parties for the execution of our clinical trials and preclinical studies, and control only certain aspects of their activities. We and our CROs and other third-party contractors are required to comply with GCP and GLP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCP and GLP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP and GLP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or other regulatory authority may require us to perform additional clinical trials before approving our or our partners&rsquo; marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical or preclinical trials complies with applicable GCP and GLP requirements. In addition, our clinical trials must generally be conducted with product produced under cGMP regulations. Our failure to comply with these regulations and policies may require us to repeat clinical trials, which would delay the regulatory approval process.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">45</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If any of our CROs or clinical trial sites terminate their involvement in one of our clinical trials for any reason, we may not be able to enter into arrangements with alternative CROs or clinical trial sites, or do so on commercially reasonable terms. In addition, if our relationship with clinical trial sites is terminated, we may experience the loss of follow-up information on patients enrolled in our ongoing clinical trials unless we are able to transfer the care of those patients to another qualified clinical trial site. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We rely completely on third-party contractors to supply, manufacture and distribute clinical drug supplies for our product candidates, including certain sole-source suppliers and manufacturers, we intend to rely on third parties for commercial supply, manufacturing and distribution if any of our product candidates receive regulatory approval and we expect to rely on third parties for supply, manufacturing and distribution of preclinical, clinical and commercial supplies of any future product candidates. We do not currently have, nor do we plan to acquire, the infrastructure or capability to supply, manufacture or distribute preclinical, clinical or commercial quantities of drug substances or products.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ability to develop our product candidates depends and our ability to commercially supply our products will depend, in part, on our ability to successfully obtain the</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>active pharmaceutical ingredients (&ldquo;</i><u><i>APIs</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;)</i> <i>and other substances and materials used in our product candidates from third parties and to have finished products manufactured by third parties in accordance with regulatory requirements and in sufficient quantities for preclinical and clinical testing and commercialization. If we fail to develop and maintain supply relationships with these third parties, we may be unable to continue to develop or commercialize our product candidates.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We do not have direct control over the ability of our contract suppliers and manufacturers to maintain adequate capacity and capabilities to serve our needs, including quality control, quality assurance and qualified personnel. Although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on our contract suppliers and manufacturers for day-to-day compliance with cGMPs for production of both APIs and finished products. Facilities used by our contract suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass inspection and be approved by the FDA and other relevant regulatory authorities. Our contract suppliers and manufacturers must comply with cGMP requirements enforced by the FDA through its facilities inspection program and review of submitted technical information. If the safety of any product or product candidate or component is compromised due to a failure to adhere to applicable laws or for other reasons, we may not be able to successfully commercialize or obtain regulatory approval for the affected product or product candidate, and we may be held liable for injuries sustained as a result. Any of these factors could cause a delay or termination of preclinical studies, clinical trials or regulatory submissions or approvals of our product candidates, and could entail higher costs or result in our being unable to effectively commercialize our approved products on a timely basis, or at all.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We also rely and will continue to rely on certain third parties as the sole source of the materials they supply or the finished products they manufacture. In the event an existing supplier fails to supply product on a timely basis or in the requested amount, supplies product that fails to meet regulatory requirements, becomes unavailable through business interruption or financial insolvency or loses its regulatory status as an approved source or if we or our manufacturers are unable to renew current supply agreements when such agreements expire and we do not have a second supplier, we likely would incur added costs and delays in identifying or qualifying replacement manufacturers and materials and there can be no assurance that replacements would be available to us on a timely basis, on acceptable terms or at all. In certain cases we may be required to get regulatory approval to use alternative suppliers, and this process of approval could delay production of our products or development of product candidates indefinitely. We and our manufacturers do not currently maintain inventory of these APIs and other substances and materials. Any interruption in the supply of an active pharmaceutical ingredient (&quot;API&quot;) or other substance or material or in the manufacture of a finished product could have a material adverse effect on our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">46</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, these contract manufacturers are engaged with other companies to supply and manufacture materials or products for such companies, which also exposes our suppliers and manufacturers to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&rsquo;s or manufacturer&rsquo;s facility. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the supply or manufacture of our product candidates, or if it withdraws its approval in the future, we may need to find alternative supply or manufacturing facilities, which would negatively impact our ability to develop, obtain regulatory approval of or market our product candidates, if approved.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To date, our drug substances and product candidates have been manufactured in small quantities for preclinical studies and early-stage clinical trials. As we prepare for later-stage clinical trials and potential commercialization, we will need to take steps to increase the scale of production of our drug substances and product candidates, which may include transferring production to new third-party suppliers or manufacturers. In order to conduct larger or late-stage scale clinical trials for our product candidates and supply sufficient commercial quantities of the resulting drug product and its components, if that product candidate is approved for sale, our contract manufacturers and suppliers will need to produce our drug substances and product candidates in larger quantities, more cost effectively and, in certain cases, at higher yields than they currently achieve. These third-party contractors may not be able to successfully increase the manufacturing capacity for any of such drug substance and product candidates in a timely or cost-effective manner or at all. Significant scale up of manufacturing may require additional processes, technologies and validation studies, which are costly, may not be successful and which the FDA and foreign regulatory authorities must review and approve. In addition, quality issues may arise during those scale-up activities because of the inherent properties of a product candidate itself or of a product candidate in combination with other components added during the manufacturing and packaging process, or during shipping and storage of the APIs or the finished product. If our third-party contractors are unable to successfully scale up the manufacture of any of our product candidates in sufficient quality and quantity and at commercially reasonable prices, and we are unable to find one or more replacement suppliers or manufacturers capable of production at a substantially equivalent cost in substantially equivalent volumes and quality, and we are unable to successfully transfer the processes on a timely basis, the development of that product candidate and regulatory approval or commercial launch for any resulting products may be delayed, or there may be a shortage in supply, either of which could significantly harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to continue to depend on third-party contract suppliers and manufacturers for the foreseeable future. Our supply and manufacturing agreements, if any, do not guarantee that a contract supplier or manufacturer will provide services adequate for our needs. We and our contract suppliers and manufacturers continue to improve production processes, certain aspects of which are complex and unique, and we may encounter difficulties with new or existing processes. While we attempt to build in certain contractual obligations on such third-party suppliers and manufacturers, we may not be able to ensure that such third parties comply with these obligations. Depending on the extent of any difficulties encountered, we could experience an interruption in clinical or commercial supply, with the result that the development, regulatory approval or commercialization of our product candidates may be delayed or interrupted. In addition, third-party suppliers and manufacturers may have the ability to increase the price payable by us for the supply of the APIs and other substances and materials used in our product candidates, in some cases without our consent.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additionally, any damage to or destruction of our third-party manufacturers&rsquo; or suppliers&rsquo; facilities or equipment may significantly impair our ability to have our product candidates manufactured on a timely basis. Furthermore, if a contract manufacturer or supplier becomes financially distressed or insolvent, or discontinues our relationship beyond the term of any existing agreement for any other reason, this could result in substantial management time and expense to identify, qualify and transfer processes to alternative manufacturers or suppliers, and could lead to an interruption in clinical or commercial supply.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">47</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our products or product candidates or their components into the United States or other countries as a result of, among other things, regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation or defective packaging.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Because we currently rely on a sole supplier to manufacture the active pharmaceutical ingredients of certain of our product candidates, any production problems with our supplier could adversely affect us.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have relied upon supply agreements with third parties for the manufacture and supply of the bulk active pharmaceutical ingredients used in certain of our product candidates for purposes of preclinical testing and clinical trials. We presently depend upon a single source as the sole manufacturer of our supply of APIs for certain of our product candidates. Although we have identified alternate sources for these supplies, it would be time-consuming and costly to qualify these sources. Since we currently obtain our API from this manufacturer on a purchase-order basis, either we or the supplier may terminate our arrangements, without cause, at any time without notice. If our supplier was to terminate our arrangement or fail to meet our supply needs we might be forced to delay our development.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Manufacturing and supply of the APIs and other substances and materials used in our product candidates and finished drug products is a complex and technically challenging undertaking, and there is potential for failure at many points in the manufacturing, testing, quality assurance and distribution supply chain, as well as the potential for latent defects after products have been manufactured and distributed.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Manufacturing and supply of APIs, other substances and materials and finished drug products is technically challenging. Changes beyond our direct control can impact the quality, volume, price and successful delivery of our product candidates and can impede, delay, limit or prevent the successful development and commercialization of our product candidates. Mistakes and mishandling are not uncommon and can affect successful production and supply. Some of these risks include:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">failure of our manufacturers to follow cGMP requirements or mishandling of product while in production or in preparation for transit;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability of our contract suppliers and manufacturers to efficiently and cost-effectively increase and maintain high yields and batch quality, consistency and stability;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty in establishing optimal drug delivery substances and techniques, production and storage methods and packaging and shipment processes;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">transportation and import/export risk, particularly given the global nature of our supply chain;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in analytical results or failure of analytical techniques that we depend on for quality control and release of product;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">natural disasters, labor disputes, financial distress, lack of raw material supply, issues with facilities and equipment or other forms of disruption to business operations of our contract manufacturers and suppliers; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">latent defects that may become apparent after product has been released and which may result in recall and destruction of product.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any of these factors could result in delays or higher costs in connection with our clinical trials, regulatory submissions, required approvals or commercialization of our products, which could harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">48</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we are not able to establish and maintain collaborations, we may have to alter our development and commercialization plans.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The development and potential commercialization of our product candidates will require substantial additional cash to fund expenses. In order to fund further development of our product candidates, we may collaborate with pharmaceutical and biotechnology companies for the development and potential commercialization of those product candidates. We face significant competition in seeking appropriate partners. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the partner&rsquo;s resources and experience, the terms and conditions of the proposed collaboration and the proposed partner&rsquo;s evaluation of a number of factors. Those factors may include the design or results of clinical trials; the likelihood of approval by the FDA or other regulatory authorities; the potential market for the subject product candidate; the costs and complexities of manufacturing and delivering such product candidate to patients; the potential of competing products; any uncertainty with respect to our ownership of our intellectual property; and industry and market conditions generally. The partner may also consider alternative product candidates or technologies for similar indications that may be available for collaboration and whether such a collaboration could be more attractive than the one with us for our product candidate. We may also be restricted under future license agreements from entering into agreements on certain terms with potential partners. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future partners. Collaborations typically impose detailed obligations on each party. If we were to breach our obligations, we may face substantial consequences, including potential termination of the collaboration, and our rights to our partners&rsquo; product candidates, in which we have invested substantial time and money, would be lost.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not be successful in our efforts to implement collaborations or other alternative arrangements for the development of our product candidates. When we partner with a third party for development and commercialization of a product candidate, we can expect to relinquish to the third party some or all of the control over the future success of that product candidate. Our collaboration partner may not devote sufficient resources to the commercialization of our product candidates or may otherwise fail in their commercialization. The terms of any collaboration or other arrangement that we establish may not be favorable to us. In addition, any collaboration that we enter into may be unsuccessful in the development and commercialization of our product candidates. In some cases, we may be responsible for continuing preclinical and initial clinical development of a partnered product candidate or research program, and the payment we receive from our collaboration partner may be insufficient to cover the cost of this development.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Our Business and Financial Operations</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in executing our growth strategy and managing any growth.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our management, personnel, systems and facilities currently in place are not adequate to support our business plan and future growth. We will need to further expand our scientific, clinical, managerial, operational, financial and other resources to support our planned research, development and commercialization activities, all of which will require additional capital resources.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">49</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our need to manage our operations, growth and various projects effectively requires that we:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue to improve our operational, clinical, financial, management and regulatory compliance controls and reporting systems and procedures;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">attract and retain sufficient numbers of talented employees;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage our preclinical and clinical trials effectively;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage our third-party supply and manufacturing operations effectively and in a cost-effective manner, while increasing production capabilities for our current product candidates to commercial levels;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage our development efforts effectively while carrying out our contractual obligations to partners and other third parties;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">manage our commercialization activities for our product candidates effectively and in a cost-effective manner; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">establish and maintain relationships with development and commercialization partners.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, historically, we have utilized and continue to utilize the services of part-time outside consultants to perform a number of tasks for us, including tasks related to preclinical and clinical testing. Our growth strategy may also entail expanding our use of consultants to implement these and other tasks going forward. We rely on consultants for certain functions of our business and will need to effectively manage these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. There can be no assurance that we will be able to manage our existing consultants or find other competent outside consultants, as needed, on economically reasonable terms, or at all. If we are not able to effectively manage our growth and expand our organization by hiring new employees and expanding our use of consultants, we might be unable to implement successfully the tasks necessary to execute effectively on our planned research, development and commercialization activities and, accordingly, might not achieve our research, development and commercialization goals.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our ability to compete in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified managerial, clinical, scientific, medical, sales and marketing and other personnel. We are highly dependent on our management and scientific personnel, including our Chief Executive Officer, Chief Scientific Officer, Chief Business Officer and our Senior Vice President &ndash; Finance, Treasurer and Secretary, certain consultants and members of our Board who are well known and respected in our industry. The loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our product candidates or in-licensing or acquisition of new assets and could negatively impact our ability to successfully implement our business plan. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We do not maintain &ldquo;key man&rdquo; insurance policies on the lives of these individuals or the lives of any of our other employees. With the exception of our Chief Executive Officer, Chief Scientific Officer, Chief Business Officer and our Senior Vice President &ndash; Finance, Treasurer and Secretary, each of whom is subject to an employment agreement, we employ our executive officers and key personnel on an at-will basis and their employment can be terminated by us or them at any time, for any reason and without notice. In order to retain valuable employees at our company, in addition to salary and cash incentives, we provide stock options that vest over time. The value to employees of stock options that vest over time will be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract offers from other companies.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses, particularly in the Charlottesville, Virginia area where we are headquartered. We could have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">50</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently have no sales and marketing personnel or capabilities. If we are unable to establish sales and marketing capabilities on our own or through third parties when we are ready to commercialize our product candidates, we will be unable to successfully commercialize our product candidates, if approved, or generate product revenue.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We currently have no sales and marketing personnel or capabilities. To commercialize our product candidates, if approved, in the United States, Canada, the European Union and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. We as a company have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose to collaborate with additional third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize our product candidates. The inability to successfully commercialize our product candidates, either on our own or through collaborations with one or more third parties, would harm our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we implement activities to in-license and acquire product candidates and we in-license and acquire commercial-stage products or engage in other strategic transactions,</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>it</i> <i>could impact our liquidity, increase our expenses and present significant distractions to our management.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we implement a strategy to in-license and acquire product candidates, we may in-license and acquire commercial-stage products or engage in other strategic transactions. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions entail numerous potential operational and financial risks, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">exposure to unknown liabilities;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">disruption of our business and diversion of our management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s time and attention in order to develop acquired products, product candidates or technologies;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">incurrence of substantial debt or dilutive issuances of equity securities to pay for acquisitions;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">substantial acquisition and integration costs;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">write-downs of assets or impairment charges;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">increased amortization expenses;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">51</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impairment of relationships with key suppliers, partners or customers of any acquired businesses due to changes in management and ownership; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">inability to retain our key employees or those of any acquired businesses.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accordingly, there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, and any transaction that we do complete could harm our business, financial condition, operating results and prospects. We have no current plan, commitment or obligation to enter into any other transaction described above.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our near-term operations will be limited primarily to researching and developing our product candidates and undertaking preclinical studies and clinical trials of our product candidates. We have not yet obtained regulatory approvals for any of our product candidates. Consequently, any predictions you make about our future success or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. From time to time, we may enter into collaboration agreements and license agreements with other companies that include development funding and significant upfront and milestone expenditures and payments, and we expect that amounts earned from or paid pursuant to these agreements will be a significant source of our capital expenditures and an important source of our revenue. Accordingly, our revenue and profitability may depend on development funding and the achievement of development and clinical milestones under potential future collaboration and license agreements and sales of our products, if approved. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next. In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award as determined by our Board, and recognize the cost as an expense over the employee&rsquo;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and estimated volatility, the magnitude of the expense that we must recognize may vary significantly. Furthermore, our operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the following:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delays in the commencement, enrollment and the timing of clinical testing for our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the timing and success or failure of clinical trials for our product candidates or competing product candidates, or any other change in the competitive landscape of our industry, including consolidation among our competitors or partners;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any delays in regulatory review and approval of product candidates in clinical development;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the timing and cost of, and level of investment in, research and development activities relating to our product candidates, which may change from time to time;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the cost of manufacturing our product candidates, which may vary depending on FDA guidelines and requirements, and the quantity of production;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to obtain additional funding to develop our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">expenditures that we will or may incur to acquire or develop additional product candidates and technologies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the level of demand for our product candidates, should they receive approval, which may vary significantly;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">potential side effects of our product candidates that could delay or prevent commercialization or cause an approved drug to be taken off the market;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">52</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our product candidates, if approved;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our dependency on third-party manufacturers to supply or manufacture our product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to establish an effective sales, marketing and distribution infrastructure in a timely manner;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">market acceptance of our product candidates, if approved, and our ability to forecast demand for those product candidates;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to receive approval and commercialize our product candidates outside of the United States;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to establish and maintain collaborations, licensing or other arrangements;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability and third parties<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; abilities to protect intellectual property rights;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">costs related to and outcomes of potential litigation or other disputes;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to adequately support future growth;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to attract and retain key personnel to manage our business effectively;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">our ability to maintain adequate insurance policies; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">future accounting pronouncements or changes in our accounting policies.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur significant costs.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with our research and development activities and our manufacture of materials and product candidates, we are subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes. Although we believe that we have complied with the applicable laws, regulations and policies in all material respects and have not been required to correct any material noncompliance, we may be required to incur significant costs to comply with environmental and health and safety regulations in the future. Current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our operating results and liquidity needs could be negatively affected by market fluctuations and economic downturn.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our operating results and liquidity could be negatively affected by economic conditions generally, both in the United States and elsewhere around the world. Domestic and international equity and debt markets have experienced and may continue to experience heightened volatility and turmoil based on domestic and international economic conditions and concerns. In the event these economic conditions and concerns continue or worsen and the markets continue to remain volatile, our operating results and liquidity could be adversely affected by those factors in many ways, including weakening demand for certain of our product candidates and making it more difficult for us to raise funds if necessary, and our stock price may decline. Additionally, although we plan to market our products primarily in the United States, our partners may have extensive global operations, indirectly exposing us to risk.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">53</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Security breaches and other disruptions in our information technology systems could limit our capacity to effectively monitor and control our operations, compromise our or third parties&rsquo; confidential information or otherwise adversely affect our operating results or business reputation.</font></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our information technology systems, some of which are managed by third parties, facilitate our ability to monitor and control our operations and adjust to changing market conditions, including processing, transmitting, storing, managing and supporting a variety of business processes, activities and information. Further, as we pursue our growth and business development strategy and pursue new initiatives that improve our operations, we are also expanding and improving our information technologies, resulting in a larger technological presence and corresponding exposure to cybersecurity risk. Any disruption in any of these systems or the failure of any of these systems to operate as expected could, depending on the magnitude of the problem, adversely affect our operating results by limiting our capacity to effectively monitor and control our operations and adjust to changing market conditions.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Additionally, we collect and store sensitive data, including proprietary business information and the proprietary business information of third parties, in data centers and on information technology networks, including cloud-based networks. The secure operation of these information technology networks and the processing and maintenance of this information is critical to our business operations and strategy. Despite security measures and business continuity plans, our information technology networks and infrastructure may be vulnerable to damage, disruptions or shutdowns due to attacks by cyber criminals or breaches due to employee error or malfeasance or other disruptions during the process of upgrading or replacing computer software or hardware, power outages, computer viruses, telecommunication or utility failures, terrorist acts or natural disasters or other catastrophic events. Further, the growing use and rapid evolution of technology, including mobile devices, has heightened the risk of unintentional data breaches or leaks. The occurrence of any of these events could compromise our networks, and the information stored there could be accessed, publicly disclosed, lost or stolen. In addition, as security threats continue to evolve we may need to invest additional resources to protect the security of our systems or to comply with privacy, data security, cybersecurity and data protection laws applicable to our business. Any failure to effectively prevent, detect and/or recover from any such access, disclosure or other loss of information, or to comply with any such current or future law related thereto, could result in legal claims or proceedings, liability or regulatory penalties under laws protecting the privacy of personal information, disrupt operations, and damage our reputation, which could adversely affect our business.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our ability to utilize our net operating loss (&ldquo;</i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u><i>NOL</i></u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&rdquo;) carryforwards and other deferred tax assets may be limited.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December 31, 2017, the Company had $41.2 million in NOL carryforwards available to reduce future taxable income, if any, for income tax purposes. If not utilized, the federal and Virginia NOL carryforwards will begin expiring during the year ended December 31, 2034. Under Section 382 of Internal Revenue Code of 1986, as amended (the &ldquo;<u>Code</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), if a corporation undergoes an &ldquo;ownership change,&rdquo; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&rsquo;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. We believe that our reverse merger in January 2016, and other transactions that have occurred, triggered an &ldquo;ownership change&rdquo; limitation that significantly limited our ability to utilize our NOL carryforwards. Our 2017 and 2018 financing transactions may have also triggered an ownership change, which could further limit our ability to utilize our NOL carryforwards. We have yet to determine this potential limitation. We may also experience ownership changes in the future as a result of equity offerings and other shifts in our stock ownership. As a result, if we earn net taxable income, our ability to use our pre-change NOL carryforwards and other deferred tax assets&nbsp;to offset U.S. federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us. In addition, similar limitations may apply&nbsp;at the state level&nbsp;and there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be adversely affected by natural disasters and other catastrophic events, and by man-made problems such as terrorism, that could disrupt our business operations and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our corporate headquarters are located in Charlottesville, Virginia. If a disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as enterprise financial systems, manufacturing resource planning or enterprise quality systems, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Our contract manufacturers&rsquo; and suppliers&rsquo; facilities are located in multiple locations, where other natural disasters or similar events, such as blizzards, tornadoes, earthquakes, fires, explosions or large-scale accidents or power outages, could severely disrupt our operations and have a material adverse effect on our business, financial condition, operating results and prospects. In addition, acts of terrorism and other geo-political unrest could cause disruptions in our business or the businesses of our partners, manufacturers or the economy as a whole. All of the aforementioned risks may be further increased if we do not implement a disaster recovery plan or our partners&rsquo; or manufacturers&rsquo; disaster recovery plans prove to be inadequate. To the extent that any of the above should result in delays in the regulatory approval, manufacture, distribution or commercialization of our product candidates, our business, financial condition, operating results and prospects would suffer.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">54</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Our Intellectual Property</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not be able to obtain or enforce patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our success with respect to our product candidates and technologies will depend in part on our ability to obtain and maintain patent protection in both the United States and other countries, to preserve our trade secrets and to prevent third parties from infringing upon our proprietary rights. Our ability to protect any of our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our patent portfolio includes patents and patent applications in the United States and foreign jurisdictions where we believe there is a market opportunity for our products. The covered technology and the scope of coverage vary from country to country. For those countries where we do not have granted patents, we may not have any ability to prevent the unauthorized use of our technologies. Any patents that we may obtain may be narrow in scope and thus easily circumvented by competitors. Further, in countries where we do not have granted patents, third parties may be able to make, use or sell products identical to or substantially similar to, our product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, these and any of our patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to proper priority claims, inventorship, claim scope or patent term adjustments. If our current licensors, or any future licensors or licensees, are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised and we might not be able to prevent third parties from making, using and selling competing products. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and unenforceable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial condition and operating results.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. Accordingly, rights under any existing patents or any patents we might obtain or license may not cover our product candidates, or may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. In addition, we cannot guarantee that any patents will issue from any pending or future patent applications owned by or licensed to us. Even if patents have issued or will issue, we cannot guarantee that the claims of these patents are or will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">55</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Competitors in the fields of oncology have created a substantial amount of prior art, including scientific publications, patents and patent applications. Our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Although we believe that our technology includes certain inventions that are unique and not duplicative of any prior art, we do not have outstanding issued patents covering all of the recent developments in our technology and we are unsure of the patent protection that we will be successful in obtaining, if any. Even if the patents do successfully issue, third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The laws of some foreign jurisdictions do not provide intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The degree of future protection of our proprietary rights is uncertain. Patent protection may be unavailable or severely limited in some cases and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we might not have been the first to invent or the first to file the inventions covered by each of our pending patent applications and issued patents;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">the patents of others may have an adverse effect on our business;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any patents we obtain or our licensors<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; issued patents may not encompass commercially viable products, may not provide us with any competitive advantages or may be challenged by third parties;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">any patents we obtain or our in-licensed issued patents may not be valid or enforceable; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">we may not develop additional proprietary technologies that are patentable.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be open to competition from generic versions of our product candidates. Further, the extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which we can market a product candidate under patent protection, which may particularly affect the profitability of our early-stage product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our suppliers, manufacturers and other third parties. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secret information.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">56</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The United States has enacted and is currently implementing wide-ranging patent reform legislation. Further, U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the scope and value of patents, once obtained.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For our U.S. patent applications containing a priority claim after March 16, 2013, there is a greater level of uncertainty in the patent law. In September 2011, the Leahy-Smith America Invents Act, also known as the America Invents Act (&ldquo;<u>AIA</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have an adverse effect on our business. An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a &ldquo;first-to-file&rdquo; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and providing opportunities for third parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that may weaken our and our licensors&rsquo; ability to obtain new patents or to enforce existing patents we and our licensors or partners may obtain in the future.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may not be able to protect our intellectual property rights throughout the world.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">57</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain developing countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates, our competitors might be able to enter the market, which would have an adverse effect on our business.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. We cannot assure you that marketing and selling such candidates and using such technologies will not infringe existing or future patents. Numerous U.S. and foreign issued patents and pending patent applications owned by third parties exist in the fields relating to our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that others may assert that our product candidates, technologies or methods of delivery or use infringe their patent rights. Moreover, it is not always clear to industry participants, including us, which patents cover various drugs, biologics, drug delivery systems or their methods of use, and which of these patents may be valid and enforceable. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing our product candidates, technologies or methods.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">58</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, there may be issued patents of third parties that are infringed or are alleged to be infringed by our product candidates or proprietary technologies. Because some patent applications in the United States may be maintained in secrecy until the patents are issued, because patent applications in the United States and many foreign jurisdictions are typically not published until eighteen (18) months after filing and because publications in the scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our own and in-licensed issued patents or our pending applications. Our competitors may have filed, and may in the future file, patent applications covering our product candidates or technology similar to ours. Any such patent application may have priority over our own and in-licensed patent applications or patents, which could further require us to obtain rights to issued patents covering such technologies. If another party has filed a U.S. patent application on inventions similar to those owned or in-licensed to us, we or, in the case of in-licensed technology, the licensor may have to participate, in the United States, in an interference proceeding to determine priority of invention.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates or proprietary technologies infringe such third parties&rsquo; intellectual property rights, including litigation resulting from filing under Paragraph IV of the Hatch-Waxman Act. These lawsuits could claim that there are existing patent rights for such drug and this type of litigation can be costly and could adversely affect our operating results and divert the attention of managerial and technical personnel, even if we do not infringe such patents or the patents asserted against us are ultimately established as invalid. There is a risk that a court would decide that we are infringing the third party&rsquo;s patents and would order us to stop the activities covered by the patents. In addition, there is a risk that a court will order us to pay the other party damages for having violated the other party&rsquo;s patents.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There is a substantial amount of litigation involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries generally. To date, no litigation asserting infringement claims has been brought against us. If a third party claims that we infringe its intellectual property rights, we may face a number of issues, including:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to litigate and may divert our management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s attention from our core business;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">substantial damages for infringement, which we may have to pay if a court decides that the product or technology at issue infringes or violates the third party<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s rights, and if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&rsquo;s attorneys&rsquo; fees;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">a court prohibiting us from selling or licensing the product or using the technology unless the third party licenses its intellectual property rights to us, which it is not required to do;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">if a license is available from a third party, we may have to pay substantial royalties or upfront fees or grant cross-licenses to intellectual property rights for our products or technologies; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">redesigning our products or processes so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could harm our ability to raise additional funds or otherwise adversely affect our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Because we may in the future rely on certain third-party licensors and partners, if one of those licensors or partners is sued for infringing a third party&rsquo;s intellectual property rights, our business, financial condition, operating results and prospects could suffer in the same manner as if we were sued directly. In addition to facing litigation risks, we may agree in the future to indemnify certain third-party licensors and partners against claims of infringement caused by our proprietary technologies, and we may enter into cost-sharing agreements with some our licensors and partners that could require us to pay some of the costs of patent litigation brought against those third parties whether or not the alleged infringement is caused by our proprietary technologies. In certain instances, these cost-sharing agreements could also require us to assume greater responsibility for infringement damages than would be assumed just on the basis of our technology.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">59</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The occurrence of any of the foregoing could adversely affect our business, financial condition, operating results and prospects.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may become involved in lawsuits to protect or enforce our patents or other intellectual property which could be expensive and time-consuming.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Competitors may infringe our intellectual property, including our patents. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. This can be expensive, particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patent claims do not cover its technology or that the factors necessary to grant an injunction against an infringer are not satisfied. An adverse determination of any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly or amended such that they do not cover our product candidates. Moreover, such adverse determinations could put our patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates or to prevent others from marketing similar products.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Interference, derivation or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patent applications or those of our licensors or potential partners. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and distraction to our management. We may not be able, alone or with our licensors or potential partners, to prevent misappropriation of our proprietary rights, particularly in countries where the laws may not protect such rights as fully as in the United States.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. In addition, during the course of this kind of litigation or proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative, the market price for Common Stock could be significantly harmed.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As is common in the biotechnology and pharmaceutical industries, certain of our employees were formerly employed by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Moreover, we engage the services of consultants to assist us in the development of our product candidates, many of whom were previously employed at or may have previously been or are currently providing consulting services to, other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees and consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers or their former or current customers. Although we have no knowledge of any such claims being alleged to date, if such claims were to arise, litigation may be necessary to defend against any such claims. Even if we are successful in defending against any such claims, any such litigation could be protracted, expensive, a distraction to our management team, not viewed favorably by investors and other third parties and may potentially result in an unfavorable outcome.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">60</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Risks Related to Ownership of Our Common Stock and Other Securities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If we cannot continue to satisfy the NASDAQ Capital Market continued listing standards and other NASDAQ rules, our Common Stock could be delisted, which would harm our business, the trading price of our Common Stock, our ability to raise additional capital and the liquidity of the market for our Common Stock.</font></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our common stock is currently listed on the Nasdaq Capital Market. To maintain the listing of our common stock on the Nasdaq Capital Market, we are required to meet certain listing requirements, including, among others, either: (i) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and stockholders&rsquo; equity of at least $2.5 million; or (ii) a minimum closing bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and a total market value of listed securities of at least $35 million.</font></p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There is no assurance that we will continue to meet the minimum closing price requirement and other listing requirements. For example, on March 2, 2018, we received a written notice from the staff (the &ldquo;Staff&rdquo;) of the Listing Qualifications Department of NASDAQ indicating we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days from the date of such notice, or until August 29, 2018, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for our common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>The trading volume of our Common Stock has historically been low and extremely volatile, which may result in decreased periods of liquidity or large, short-term fluctuations in our stock price.</i></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The number of shares of our Common Stock being traded on a daily basis has historically been low and extremely volatile. Since January 8, 2016, the date we completed the Merger, through March 13, 2018, the daily trading volume for our Common Stock ranged from zero shares to 14,032,030 shares (after giving effect to the Reverse Stock Split). The quotation of our Common Stock on the NASDAQ Capital Market does not assure that a meaningful, consistent and liquid trading market currently exists.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Any holder of our Common Stock wishing to sell his, her or its shares may cause a significant fluctuation in the trading price of our Common Stock. In addition, low trading volume of a stock increases the possibility that, despite rules against such activity, the price of the stock may be manipulated by persons acting in their own self-interest. We may not have adequate market makers and market making activity to prevent manipulation in our Common Stock. Such volatility may be the result of broad market and industry factors. In addition to market and industry factors, the price and trading volume for Common Stock may be highly volatile for factors specific to our own operations, many of which are beyond our control, including those described elsewhere in and incorporated into this Memorandum and our public filings.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Future sales of common stock or securities convertible into common stock may depress our stock price.</i></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sales of a substantial number of shares of Common Stock or securities convertible into Common Stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of Common Stock. If a large number of shares of Common Stock or securities convertible into Common Stock are sold in the public market, the sales could reduce the trading price of Common Stock and impede our ability to raise future capital. In connection with the equity financing from January 2018, all of the Series A Convertible Preferred Stock converted to shares of Common Stock, and make-whole and accrued dividends on the Series A Convertible Preferred Stock were paid in shares of Common Stock, with an aggregate of [X] shares of Common Stock being issued. All of such shares are covered by effective registration statements, pursuant to which the holders can sell such shares into the public market. In addition, in connection with the same financing, the Company issued warrants to purchase [Y] shares of Common Stock, which when added to the other warrants outstanding to purchase shares of Common Stock, total [Z] shares, which upon the exercise thereof, could result in an additional aggregate of [AA] shares of Common Stock being sold into the public market.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">61</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of Common Stock.</i></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of Common Stock. In addition, any future testing by us conducted in connection with Section 404 of the Sarbanes-Oxley Act of 2002, as amended (&ldquo;<u>SOX</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;), or any required subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are required, pursuant to Section 404 of SOX, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting as of December 31, 2017. However, our independent registered public accounting firm is not required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. Under the supervision and with the participation of our Chief Executive Officer and Senior Vice President - Finance our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December 31, 2017. An independent assessment of the effectiveness of our internal controls could detect problems that our management&rsquo;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are subject to the periodic reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We incur significant costs as a result of our public company status and devote substantial management time to operating as a public company.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As a public company, we incur significant legal, accounting and other expenses to comply with the reporting requirements of the Exchange Act and applicable requirements of SOX and the Dodd-Frank Wall Street Reform and Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC and NASDAQ, including the establishment and maintenance of effective disclosure and financial controls, changes in corporate governance practices and required filing of annual, quarterly and current reports with respect to our business and operating results. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. In addition, our management and other personnel devote significant time and attention to these public company requirements, which diverts their time attention from operational and other business matters.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">62</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Delaware law and provisions in our restated articles of incorporation and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of Common Stock.</i></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The anti-takeover provisions under Delaware corporate law may discourage, delay or prevent a change of control by prohibiting us from engaging in a business combination with stockholders owning in excess of 15 percent (15%) of our outstanding voting stock for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our restated articles of incorporation and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35pt;">&nbsp;</td>
			<td style="width: 22pt; vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&bull;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that only our Board will have the right to fill a vacancy created by the expansion of our Board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35pt;">&nbsp;</td>
			<td style="width: 22pt; vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&bull;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that only our Chairman of the Board, our Chief Executive Officer or a majority of our Board will be authorized to call a special meeting of stockholders;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35pt;">&nbsp;</td>
			<td style="width: 22pt; vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&bull;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">authorize the issuance of undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval, and which may include rights superior to the rights of the holders of Common Stock;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35pt;">&nbsp;</td>
			<td style="width: 22pt; vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&bull;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that our Board is expressly authorized to make, alter or repeal our bylaws; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35pt;">&nbsp;</td>
			<td style="width: 22pt; vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">&bull;</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">establish advance notice requirements for nominations for elections to our Board or for proposing matters that can be acted upon by stockholders at stockholder meetings.</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These provisions could also discourage proxy contests and make it more difficult for our stockholders to elect directors of their choosing so as to cause us to take certain corporate actions our stockholders may desire to take.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The trading market for common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for common stock would be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for common stock could decrease, which could cause our stock price and trading volume to decline.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Future sales of</font></i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <i>substantial number of shares of our common stock in the public market or other issuances of our common stock or rights to purchase common stock, including pursuant to equity incentive plans,</i> <i>could result in additional dilution of the percentage ownership of our stockholders and</i> <i>could cause our stock price to fall.</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We&nbsp;need to raise substantial additional funds to continue our operations, fund additional clinical trials of our product candidates and potentially commercialize our product candidates. We plan to continue to finance our operations with a combination of equity issuances, debt arrangements and a possible partnership or license of development and/or commercialization rights to our product candidates. Any issuance of convertible debt securities, preferred stock or common stock may be at a discount from the then current trading price of our common stock. If we issue additional common or preferred stock or securities convertible into common stock, our stockholders will experience additional dilution, which may be significant.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, pursuant to our 2015 Equity Incentive Plan, as amended, our compensation committee is authorized to grant equity-based incentive awards to our directors, executive officers and other employees and service providers, including officers, employees and service providers of our subsidiaries and affiliates. As of March 13, 2018, the number of shares of our common stock we have reserved for issuance under our 2015 Equity Incentive Plan is 185,076 and future option grants and issuances of common stock under our 2015 Equity Incentive Plan will dilute the percentage ownership of our investors and may adversely affect the market price of our common stock.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">63</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Further, future sales of a substantial number of shares of common stock or securities convertible into common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock and impede our ability to raise future capital. The exercise of our outstanding warrants into common stock would dilute the ownership interest of existing holders of common stock.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our directors, executive officers and principal stockholders exert significant influence over us and could impede a change of corporate control.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of March 13, 2018, our directors, executive officers and holders of more than five percent of common stock, together with their affiliates, beneficially owned, in the aggregate, 5.5% </font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">of our outstanding common stock (See &ldquo;Security Ownership of Certain Beneficial Owners and Management&rdquo;). As a result, these stockholders, acting together, would have the ability to exert significant influence on matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets. In addition, these stockholders, acting together, would have the ability to significantly influence the management and affairs of our company. Accordingly, this concentration of ownership could harm the market price of common stock by:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">delaying, deferring or preventing a change of control of us;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">impeding a merger, consolidation, takeover or other business combination involving us; or</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of us.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: justify;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Delaware law and provisions in our restated articles of incorporation and restated bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of Common Stock.</font></i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The anti-takeover provisions under Delaware corporate law may discourage, delay or prevent a change of control by prohibiting us from engaging in a business combination with stockholders owning in excess of 15 percent of our outstanding voting stock for a period of three years after the person becomes an interested stockholder, even if a change of control would be beneficial to our existing stockholders. In addition, our restated articles of incorporation and restated bylaws contain provisions that may make the acquisition of our company more difficult, including the following:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that only our Board will have the right to fill a vacancy created by the expansion of our Board or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our Board;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that only our Chairman of the Board, our Chief Executive Officer or a majority of our Board will be authorized to call a special meeting of stockholders;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">authorize the issuance of undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval, and which may include rights superior to the rights of the holders of common stock;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">provide that our Board is expressly authorized to make, alter or repeal our bylaws;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">establish advance<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;notice requirements for&nbsp;nominations for elections to our Board or for proposing matters that can be acted upon by stockholders at stockholder meetings; and</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9679;</p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">certain priorities, voting rights and other rights of the holders of our Series A Convertible Preferred Stock</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">64</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These provisions could also discourage&nbsp;proxy contests and make it more difficult for our stockholders to elect directors of their choosing so as to cause us to take certain corporate actions our stockholders may desire to take.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The trading market for Common Stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for Common Stock would be negatively impacted. If we obtain securities or industry analyst coverage and if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for Common Stock could decrease, which could cause our stock price and trading volume to decline.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We may be at an increased risk of securities litigation, which is expensive and could divert management attention.</font></i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The market price of our Common Stock may be volatile, and in the past companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s attention from other business concerns, which could seriously harm our business.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have never paid dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future.</font></i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have never declared nor paid cash dividends on our capital stock. We currently intend to retain any future earnings to finance the operation and expansion of our business, and we do not expect to declare or pay any dividends in the foreseeable future. Consequently, stockholders must rely on sales of their Common Stock after price appreciation, which may never occur, as the only way to realize any future gains on their investment.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">65</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 1B.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>UNRESOLVED STAFF COMMENTS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 2.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PROPERTIES</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our principal executive office is located in a leased facility in Charlottesville, Virginia, where we lease approximately 8,000 square feet of office space for approximately $10,000 per month.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 3.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>LEGAL PROCEEDINGS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From time to time, we are subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. We record a liability in our consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when we have assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, we record the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. We disclose a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect our consolidated results of operations, financial position or cash flows.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On August 7, 2014, a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company&rsquo;s former Chief Executive Officer under the caption <i>Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH</i> (Case No. BC553996). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&rsquo; fees and costs. On December 30, 2014, we filed a petition to compel arbitration and a motion to stay the action. On April 1, 2015, the plaintiff filed a petition in opposition to our petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on April 14, 2015, the Court granted our petition to compel arbitration and a motion to stay the action. On January 8, 2016, the plaintiff filed an arbitration demand with the American Arbitration Association. No arbitration hearing has yet been scheduled. We believe this matter is without merit and we intend to defend the arbitration vigorously. Because this matter is in an early stage, we are unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter may have on our financial position. Depending on the outcome or resolution of this matter, it could have a material effect on our financial position.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">66</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 4.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MINE SAFETY DISCLOSURES</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PART II</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 5.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MARKET FOR REGISTRANT<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Market Price</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our common stock trades publicly on the NASDAQ Capital Market under the symbol &ldquo;DFFN.&rdquo; Prior to November 9, 2016, our common stock traded on the OTCQX over-the-counter bulletin board. The following table sets forth the high and low daily sale prices for our Common Stock, as quoted by the NASDAQ Capital Market or the OTCQX, as applicable, for each calendar quarter during 2017 and 2016, after giving effect to the Reverse Stock Split. The over-the-counter market quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 48.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u><b>2017</b></u></p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>High</u></p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Low</u></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.16</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.06</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.04</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">1.34</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.93</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.26</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">15.50</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.01</p>
			</td>
		</tr>
		<tr>
			<td style="width: 48.8%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u><b>2016</b></u></p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>High</u></p>
			</td>
			<td style="width: 0.8%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Low</u></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fourth Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$7.00</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$1.94</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Third Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">9.25</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5.27</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Second Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">11.50</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.00</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 48.8%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">First Quarter</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 25.2%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">17.00</p>
			</td>
			<td style="width: 0.8%; vertical-align: top;">&nbsp;</td>
			<td style="width: 24.4%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">8.50</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Number of Record Holders</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of March&nbsp;13, 2018, there were 557</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;record holders of our common stock.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Dividends</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To date, we have not declared or paid any cash dividends on our common stock and do not intend to do so in the near future. Our Series A stockholders were entitled to a dividend, payable in shares of common stock, and continued to receive this dividend until mandatory conversion of the Series A Preferred Stock in the January 2018.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For certain information concerning securities authorized for issuance under our equity compensation plan, see Item 12 &mdash; Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Recent Sales of Unregistered Equity Securities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the fourth quarter ended December 31, 2017, we did not issue or sell any Diffusion equity securities without registration under the Securities Act.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">67</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Issuer Purchases of Equity Securities</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the fourth quarter ended December 31, 2017, we did not purchase any shares of Diffusion common stock or other Diffusion equity securities.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our Board of Directors has not authorized any repurchase plan or program for the purchase of shares of our common stock or other securities on the open market or otherwise.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 6.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SELECTED FINANCIAL DATA</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Item 6 is not applicable to us as a smaller reporting company and has been omitted.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 7.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>MANAGEMENT<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font></b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Introduction</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">This Management&rsquo;s Discussion and Analysis provides material historical and prospective disclosures intended to enable investors and other users to assess our financial condition and results of operations. Statements that are not historical are forward-looking and involve risks and uncertainties discussed under the headings &ldquo;<i>Part I. Item 1. Business&mdash;Cautionary Note Regarding Forward-Looking Statements</i>&rdquo; and &ldquo;<i>Part I. Item 1A. Risk Factors</i>&rdquo; of this report. The following discussion of our results of operations and financial condition should be read in conjunction with our financial statements and the related notes thereto included elsewhere in this report. These risks could cause our actual results to differ materially from any future performance suggested below.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Business Overview</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We are a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. We are developing our lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&ldquo;TSC&rdquo;), for use in the many cancer types in which tumor oxygen deprivation (&ldquo;hypoxia&rdquo;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&rsquo;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy. TSC&rsquo;s helps regulate the diffusion of oxygen into oxygen-deprived cells (whether cancer cells or normal cells). TSC thus has potential uses in non-oncology indications such as stroke and cardio-vascular disease, where tissue hypoxia is implicated as an underlying causative factor in morbidity and mortality. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our lead development programs target TSC against cancers known to be inherently treatment-resistant, with a focus on brain cancers. A Phase 2 clinical program, completed in the second quarter of 2015, evaluated 59 patients with newly diagnosed glioblastoma multiforme (&ldquo;GBM&rdquo;), a particularly deadly form of primary brain cancer. This open label, historically controlled study demonstrated a favorable safety and efficacy profile for TSC combined with standard of care, including a 37% improvement in overall survival over the control group at two years. A particularly strong efficacy signal was seen in the inoperable patients, where survival of TSC-treated patients at two years was increased by almost four-fold over the controls. In December 2017, the Company initiated the <u>IN</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">vestigation of <u>T</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">SC <u>A</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">gainst <u>C</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ancerous <u>T</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">umors (INTACT) Phase 3 trial in the newly diagnosed inoperable GBM patient population. Patient enrollment began in January 2018. The trial will enroll 236 patients in total, with 118 in the treatment arm and 118 in the control arm. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">68</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Using its novel mechanism of action, TSC has been shown to safely re-oxygenate a range of tumor types in our preclinical and clinical studies. Diffusion believes its therapeutic potential is not limited to one specific tumor type, thereby making it potentially useful to improve standard-of-care treatments of other life-threatening cancers. Given TSC&#39;s safety profile and animal data, we can, with appropriate funding, move directly into Phase 2 studies in other cancers. We also believe that TSC has potential application in other indications involving hypoxia, such as stroke, cardiovascular disease, neurodegenerative diseases and emergency medicine. A program is now being developed in cooperation with UCLA and the University of Virginia, to test TSC in the treatment of acute ischemic stroke, with an in-ambulance Phase 2 trial being planned This trial, named the PreHospital Acute Stroke Therapy - TSC (PHAST - TSC) is expected to enroll 160 patients, with 80 in the treatment arm and 80 in the control arm. </font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition to the TSC programs, we are exploring alternatives regarding how best to capitalize upon our product candidate RES-529, which may include possible out-licensing and other options. RES-529 is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase 1 clinical trials for age-related macular degeneration and was in preclinical development in oncology, specifically GBM. RES-529 has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On January 8, 2016, we completed the Merger with Diffusion LLC. As a result of the Merger, Diffusion LLC, the surviving company in the Merger, became a wholly-owned subsidiary of the Company. Immediately following the Merger, the former equity holders of Diffusion LLC owned approximately 84.1% of the Company&rsquo;s common stock, and the stockholders of RestorGenex immediately prior to the Merger owned approximately 15.9% of the Company&rsquo;s common stock, in each case, on a fully-diluted basis&nbsp;and calculated in accordance with the terms of the Merger Agreement. Also in connection with the Merger, the pre-Merger directors and officers of the Company tendered their resignations and the pre-Merger directors and officers of Diffusion LLC were appointed as the new directors and officers of the Company. Following the completion of the Merger, the Company changed its corporate name from &ldquo;RestorGenex Corporation&rdquo; to &ldquo;Diffusion Pharmaceuticals Inc.&rdquo; and changed the trading symbol of the Company&rsquo;s Common Stock from &ldquo;RESX&rdquo; to &ldquo;DFFN.&rdquo; In November 2016, our common stock was approved for listing on the NASDAQ Capital Market and will continue to trade under the ticker symbol &ldquo;DFFN&rdquo;.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For accounting purposes, the Merger is treated as a &ldquo;reverse acquisition&rdquo; under U.S. GAAP and Diffusion LLC is considered the accounting acquirer. Accordingly, Diffusion LLC&rsquo;s historical results of operations replaced the Company&rsquo;s historical results of operations for all periods prior to the Merger. Unless otherwise stated, all comparisons in this Management&rsquo;s Discussion and Analysis to prior year periods are to the results of Diffusion Pharmaceuticals LLC for such period on a stand-alone basis.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Recent Development</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On January 22, 2018, we closed our previously announced underwritten public offering of 15,000,000 shares of our common stock, par value $0.001 per share (&quot;Common Stock&quot;), and warrants to purchase 15,000,000 shares of Common Stock. At the closing, we also issued warrants to purchase an additional 1,970,625 shares of Common Stock pursuant to the underwriter&rsquo;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of $0.80 per share and warrant, for total gross proceeds of approximately $12.0 million. The warrants have an exercise price of $0.80 per share and a term of five years from the date of issuance.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to 750,000 shares of Common Stock. The underwriter&rsquo;s warrants have an exercise price of $1.00 per share, a term of five years from the date of issuance and otherwise substantially similar terms to the form of the investor warrant.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As a result of the offering, all outstanding shares of the Company&#39;s Series A convertible preferred stock converted into 20,568,632 shares (the &quot;Conversion Shares) of common stock (including accrued dividends paid in kind and shares of common stock issued pursuant to the &quot;make-whole&quot; adjustment feature thereof).</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">69</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Critical Accounting Policies</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Certain of our critical accounting estimates require the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition or results of operations. We believe the following accounting estimates are the most critical to aid in fully understanding and evaluating our financial statements as they require our most subjective or complex judgments:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Estimated fair value of Common Stock Warrants</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common stock</font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> </font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">warrants issued in conjunction with our Series A convertible preferred stock offering are accounted for as freestanding financial instruments. These warrants originally were classified as liabilities on our consolidated balance sheet and were recorded at their estimated fair value. At the end of each reporting period, changes in the estimated fair value during the period were recorded in our consolidated statement of operations. On November 1, 2017, we held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to our Certificate of Incorporation to permit us to pay dividends on our Series A Convertible Preferred Stock in either cash or shares of our Common, which was approved by the stockholders. As a result of this amendment, we are able to assert there will be sufficient authorized shares available to settle the Series A warrants. Upon this assertion, the Series A warrants were remeasured on November 1, 2017 and reclassified from liabilities to stockholders&rsquo; equity. The warrants will no longer be adjusted to fair value each reporting period. The estimated fair value of common stock warrants was determined by using the Black-Scholes option-pricing model.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Goodwill</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. We apply Accounting Standards Codification (ASC) 350 &ldquo;<i>Goodwill and Other Intangible Assets</i>,&rdquo; which requires testing goodwill for impairment on an annual basis. We assess goodwill for impairment as part of our annual reporting process on October 1 of each year. In between valuations, we conduct additional tests if circumstances indicate a need for testing. We evaluate goodwill on a consolidated basis as we are organized as a single reporting unit. We consider certain triggering events when evaluating whether an interim goodwill impairment analysis is warranted. Among these would be a significant long-term decrease in our market capitalization. There was no impairment to our goodwill during the years ended December 31, 2017 and 2016.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Intangible Assets</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our sole intangible asset as of December 31, 2017 consists of an in-process research and development (&ldquo;<u>IPR&amp;D</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) intangible asset acquired as part of the Merger. The fair value of the IPR&amp;D assets was determined as of the acquisition date using the cost approach, which establishes a value based on the cost of reproducing or replacing the asset, often referred to as current replacement cost. The cost approach was chosen as we were not able to estimate an income stream attributable to the IPR&amp;D assets given the fact that the related products have only completed limited preclinical and clinical trials and the timeline to commercial viability, if the FDA approval process is successful, is somewhat uncertain and would take a number of years, and the costs would be significant. In August 2016, we abandoned future development efforts for the IPR&amp;D asset associated with our RES-440 product candidate and recorded an impairment charge equal to the acquired value of RES-440. As the development efforts for our remaining RES-529 IPR&amp;D asset continue, based on the facts and circumstances at the time of a future valuation for the purposes of assessing impairment, it is possible that the value for RES-529 could be substantially reduced or eliminated, which could result in a maximum pretax charge to operations equal to the current carrying value of our intangible asset of $8.6 million as of December 31, 2017. We tested the IPR&amp;D intangible asset for impairment on October 1, which is our annual impairment testing date. We consider certain triggering events when evaluating whether an interim IPR&amp;D impairment analysis is warranted. There was no impairment to RES-529 during the years ended December 31, 2017 and 2016.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">70</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Research and development</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development costs are expensed as incurred and consist primarily of funds paid to third parties for the provision of services for product candidate development, clinical and preclinical development and related supply and manufacturing costs, and regulatory compliance costs. At the end of the reporting period, the Company compares payments made to third-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the service provided, the Company may record net prepaid or accrued expense relating to these costs. Upfront payments made to third parties who perform research and development services on the Company&rsquo;s behalf are expensed as services are rendered.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Stock-Based Compensation</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We account for stock-based compensation based on the grant date fair value of the award. We recognize this cost as an expense over the requisite service period, which is generally the vesting period of the respective award.&nbsp;We use the Black-Scholes option-pricing model to determine the estimated fair value of stock options.&nbsp;Inputs into the Black-Scholes option-pricing model include: the grant date fair value of our common stock; the option exercise price; the expected term of the option in years; the annualized volatility of the stock; and the risk-free interest rate.&nbsp;If any of the assumptions used in the Black-Scholes model changes significantly, stock-based compensation for future awards may differ materially compared with the awards granted previously. The inputs that create the most sensitivity in our option valuation are the volatility and expected term.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Given our limited history as a publicly traded company following the Merger in January 2016, we did not have sufficient trading data to calculate volatility based on our own common stock, and the expected volatility was calculated as of each grant date based on a peer group of publicly traded companies. The expected term of the stock options was determined based upon the simplified approach for employees, allowed under SEC Staff Accounting Bulletin No. 110, which assumes that the stock options will be exercised evenly from vesting to expiration. As data associated with future exercises is obtained, the expected term of future grants will be adjusted accordingly. For non-employee awards, we use the remaining contractual term.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Summary</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At December 31, 2017, we had cash and cash equivalents balances of $8.9 million. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable operations. We incurred a net loss of $1.4 million and $18.0 million for the years ended December 31, 2017 and 2016, respectively. Our accumulated deficit as of December 31, 2017, was $61.6 million, and we expect to continue to incur substantial losses in future periods. We anticipate that our operating expenses will increase substantially as we continue to advance our lead, clinical-stage product candidate, TSC. We anticipate that our expenses will substantially increase as we:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue our Phase III clinical trials for TSC;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">continue the research, development and scale-up manufacturing capabilities to optimize products and dose forms for which we may obtain regulatory approval;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">conduct other preclinical and clinical studies to support the filing of a NDA for TSC with the FDA;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">maintain, expand and protect our global intellectual property portfolio;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">hire additional clinical, manufacturing, and scientific personnel; and</p>
			</td>
		</tr>
		<tr>
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr style="vertical-align: top;">
			<td style="width: 45pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Add, acquire of develop operational, financial and management information systems and personnel, including personnel to support our drug development and potential future commercialization efforts.</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">71</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC. We expect that our existing cash as of December 31, 2017, together with the proceeds from public underwritten offering received in January 2018 will enable us to fund our operating expenses and capital expenditure requirements into June 2019.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Financial Operations Overview</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Revenues</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have not yet generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Research and Development Expense</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development costs include, but are not limited to, third-party contract research arrangements, employee-related expenses, including salaries, benefits, stock-based compensation and travel expense reimbursement, as well as impairment of our in-process research and development assets. Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As we advance our product candidates, we expect the amount of research and development costs will continue to increase for the foreseeable future. Research and development costs are charged to expense as incurred.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>General and Administrative Expense</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative expenses consist principally of salaries and related costs for executive and other personnel, including stock-based compensation, expenses associated with investment bank and other financial advisory services, and travel expenses. Other general and administrative expenses include costs associated with the Merger, professional fees that were incurred in connection with preparing to operate and operating as a public company, settlement of litigation matters, facility-related costs, communication expenses and professional fees for legal, patent prosecution and maintenance, and consulting and accounting services.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Interest Expense, Net</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Interest expense, net consisted principally of the interest expense recorded in connection with our convertible debt instruments offset by the interest earned from our cash and cash equivalents and our certificate of deposit.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Change in Fair Value of Warrant Liabilities, Warrant Related Expenses, and Other Financing Expenses</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with our private placement in March 2017, we recorded warrant expense associated with the change in fair value of the common stock warrants from issuance, the excess fair value of the common stock warrants over the gross cash proceeds from the Series A convertible preferred stock offering, and placement agent commissions and other offering costs. Until their reclassification into stockholders<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; equity in November 2017 in connection with the amendment of our certificate of incorporation, the warrants were liability classified and remeasured at each reporting period with changes in fair value recorded through earnings.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">72</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Income Tax Benefit</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Since inception, we have incurred net losses and have not recorded any U.S. federal or state income tax benefits for the losses as they have been offset by valuation allowances. Indefinite lived intangibles, such as IPR&amp;D, cannot be utilized for purposes of future realization of deferred tax assets. For the year ended December 31, 2017, we recognized&nbsp;an income tax benefit&nbsp;for the revaluation of our deferred tax liability as a result of the Tax Cuts and Jobs Act, which reduced our corporate tax rate to 21%. See Note 13 for further details. For the year ended December 31, 2016, we recognized&nbsp;an income tax benefit&nbsp;from the impairment charge related to our abandonment of the future development efforts for the RES-440 IPR&amp;D asset.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Results of Operations for Year Ended December 31, 2017 Compared to Year Ended December 31, 2016 </b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table sets forth our results of operations for the years ended December 31, 2017 and 2016:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Change</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">5,088,621</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,252,241</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,163,620</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">6,191,845</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,094,146</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(4,902,301</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">67,981</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">25,342</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">42,639</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">11,348,447</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,371,729</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(7,023,282</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Interest expense, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">48,006</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">29,686</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">18,320</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22,072,322</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(22,072,322</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrant related expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,225,846</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">10,225,846</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other financing expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,870,226</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&mdash;</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,870,226</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Loss from operations before income tax benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(2,420,203</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">(18,401,415</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">7,041,602</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(1,055,685</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(364,796</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">(690,889</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(1,364,518</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(18,036,619</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">7,732,491</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Research and development expenses were $5.1 million during the year ended December 31, 2017 compared to $7.3 million during the year ended December 31, 2016. This decrease was primarily attributable to a decrease of $1.3 million of expenses related to animal toxicology studies, a decrease of $0.9 million of pancreatic expenses, a decrease of $0.6 million related to stock based compensation expense and a $0.3 million decrease in manufacturing related expenses. We also recognized a $1.0 million impairment charge upon our abandonment of future development efforts related to our RES-440 IPR&amp;D asset in 2016. These decreases were slightly offset by increases in GBM trial expenses of $1.6 million as we began enrollment in our Phase 3 clinical trial for TSC in the second half of 2017, increases in salaries and wages expenses of $0.2 million as a result of an increase in in headcount and an increase in rent and other expenses of $0.1 million. We expect that our research and development expenses will increase significantly in future periods compared to prior periods due to the commencement of our Phase 3 clinical trial for TSC in 2017, assuming funding, the Phase 2 trial being planned for the PreHospital Acute Stroke Therapy, and the overall efforts to advance the research and development of our technologies and product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">General and administrative expenses were $6.2 million during the year ended December 31, 2017 compared to $11.1 million during the year ended December 31, 2016. The decrease was primarily attributable to a decrease of $3.2 million in professional fees incurred in 2016 in connection with completing the Merger and preparing to operate as a public company. We also recognized a $2.5 million noncash charge upon the settlement of a litigation matter during the year ended December 31, 2016. The decreases were offset by increases in salaries and wages and stock-based compensation expense of $0.4 million and $0.4 million, respectively, due to our increase in headcount.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Interest expense, net increased by approximately $18,000 in 2017 due to the timing of when we issued a $1.9 million convertible note in September 2016 and that remained outstanding until settlement in September 2017. </font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the private placement of our Series A convertible preferred stock and common stock warrants, we determined the warrants to be classified as liabilities and subject to remeasurement at each reporting period, until November 1, 2017 (See Note 14 of the notes to our audited consolidated financial statements under Item 8). As a result of the liability classification, during 2017, we recorded a $22.1 million non-cash gain for the change in fair value of our common stock warrant liabilities which was primarily attributable to the decrease in the market price for our common stock. We also recognized $10.2 million in excess fair value of the common stock warrants over the gross proceeds from our private placement and $2.9 million in placement agent commissions and other offering costs.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">73</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the year ended December 31, 2017, we recognized&nbsp;an income tax benefit&nbsp;for the revaluation of our deferred tax liability as a result of the Tax Cuts and Jobs Act, which reduced our corporate tax rate to 21%. During the year ended December 31, 2016, we recognized a tax benefit of $0.4 million in connection with the impairment charge associated with the write-down of our RES-440 IPR&amp;D intangible asset.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Liquidity and Capital Resources</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Working Capital (Deficit)</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes our working capital (deficit) as of December 31, 2017 and 2016:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">8,896,468</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">1,552,852</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses, deposits and other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">769,946</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">50,844</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">2,690,807</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">4,438,422</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Working capital (deficit)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">6,975,607</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(2,834,726</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of our product candidates.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Cash Flows</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table sets forth our cash flows for the years ended December 31, 2017 and 2016:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash (used in) provided by:</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">(12,332,355</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">(10,768,265</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Investing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">(447,823</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">8,498,271</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">20,123,794</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">1,825,654</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">7,343,616</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">(444,340</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Operating Activities</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net cash used in operating activities of $12.3 million during the year ended December 31, 2017 was primarily attributable to our net loss of $1.4 million, a $9.0 million net non-cash gain related to warrants and other financing expenses, a $1.1 million change in our deferred tax liability due to the change in tax rate, and our net change in operating assets and liabilities of $2.3 million. The net change in our operating assets and liabilities is primarily attributable to the increase in our prepaid assets related to clinical trial activities and an increase in accrued expenses. This amount was offset by $1.4 million in non-cash charges, which was made up of stock-based compensation, common stock issued for advisory services, depreciation and non-cash interest expense.</p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net cash used in operating activities of $10.8 million during the year ended December 31, 2016 was primarily attributable to our net loss of $18.0 million, offset by $6.0 million of non-cash charges and $1.3 million for the net change in our operating assets and liabilities. Noncash charges primarily consisted of stock-based compensation expenses of $1.4 million, the issuance of 148,073 shares of our common stock for advisory services at an estimated fair value of $1.4 million, a $1.0 million impairment charge in connection with abandoning future development efforts of our RES-440 IPR&amp;D asset, and a $2.5 million noncash litigation settlement charge. The net change in our operating assets and liabilities is primarily attributable to the increase in our accounts payable and accrued expenses due to the timing of when bonuses were paid and timing of payments to our vendors for professional services and costs associated with our clinical and preclinical activities.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">74</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Investing Activities</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net cash used in investing activities was $0.4 million during the year ended December 31, 2017. We purchased, and had mature, a certificate of deposit in the amount of $10.0 million and had approximately $0.4 million in fixed asset purchases, mainly related to the build out of our new headquarters. Net cash provided by investing activities was $8.5 million during the year ended December 31, 2016. We acquired $8.5 million of cash as a result of the Merger during the year ended December 31, 2016.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Financing Activities</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net cash provided by financing activities was $20.1 million during the during the year ended December 31, 2017, which was attributable to the $22.1 million in proceeds received upon the closing of our Series A private placement offset by approximately $0.1 million in payments for offering costs. This amount was further offset by the repayment of a convertible note in the amount of $1.9 million. Net cash provided by financing activities was $1.8 million during the year ended December 31, 2016 and was primarily attributable to the $1.9 million cash proceeds received in connection with the issuance of 6.0% convertible notes in September 2016.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Capital Requirements</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We expect to continue to incur substantial expenses and generate significant operating losses as we continue to pursue our business strategy of developing our lead product candidate, TSC, for use in the treatment of GBM, pancreatic cancer, stroke and brain metastases.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To date, we have funded our ongoing business operations and short-term liquidity needs, primarily through the sale and issuance of preferred stock, common stock and convertible promissory notes. We expect to continue this practice for the foreseeable future. We believe our cash and cash equivalents as of December<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;31, 2017, together with the $12.0 million in gross proceeds from our underwritten public offering of our common stock received in January 2018, will be sufficient to fund our planned operations through June 2019.</font></p>

<p style="margin: 0pt 7.5pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;31, 2017, we did not have credit facilities under which we could borrow funds or any other sources of committed capital. We will&nbsp;seek to raise additional funds through various sources, such as equity and debt financings, or through strategic collaborations and licensing agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify or delay the development of our product candidates and our operations, or we may need to obtain funds through collaborators that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise any additional capital in the near-term and/or we cannot significantly reduce our expenses and are forced to terminate our operations, investors may experience a complete loss of their investment.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To the extent that we raise additional capital through the sale of our common stock, the interests of our current stockholders may be diluted. If we issue additional preferred stock or convertible debt securities, it could affect the rights of our common stockholders or reduce the value of our common stock or any outstanding classes of preferred stock. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On March 2, 2018, we received a written notice from the NASDAQ Staff indicating we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days from the date of such notice, or until August 29, 2018, to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for our common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. In the event that we are unable to regain compliance, it could adversely affect our ability to obtain future funding.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">75</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Contractual Obligations</b></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of December&nbsp;31, 2017, we had the following contractual commitments:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="18" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Payments due by period</b></b></p>
			</td>
			<td id=".trail.D6" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 40%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Contractual Obligations</b></p>
			</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Total</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Less than 1 year</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>1-3 years</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>3-5 years</b></b></p>
			</td>
			<td id=".trail.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D6" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>More than 5 years</b></b></p>
			</td>
			<td id=".trail.D6" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating lease (1)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">501,481</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">112,354</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">349,393</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">39,735</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Principal on Convertible Notes (2)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">550,000</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">550,000</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&mdash;</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest on Convertible Notes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">40,122</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">40,122</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&mdash;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&mdash;</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">590,122</td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">590,122</td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&mdash;</td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&mdash;</td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&mdash;</td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(1) Operating lease obligations reflect our obligation to make payments in connection with our corporate headquarters in Charlottesville, Virginia.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(2) The Company issued convertible notes in March of 2011, bearing interest at 1%. Unless converted earlier, the convertible notes mature in June 2018.</p>

<p style="margin: 0pt 0pt 0pt 18pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Off-Balance Sheet Arrangements</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Recently Issued Accounting Pronouncements</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Recently issued accounting pronouncements are addressed in Note 3 in the Notes to Consolidated Financial Statements.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 7A.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Item 7A is not applicable to us as a smaller reporting company and has been omitted.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">76</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 8.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description</b></p>
			</td>
			<td style="width: 5%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Page</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Report of Independent Registered Public Accounting Firm</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">78</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Balance Sheets as of December 31, 2017 and 2016</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">79</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Operations for the years ended December 31, 2017 and 2016</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">80</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Changes in Stockholders<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; Equity for the years ended December 31, 2017 and 2016</font></p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">81</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2017 and 2016</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">82</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="width: 95%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 5%; vertical-align: bottom;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 95%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Notes to the Consolidated Financial Statements for the years ended December 31, 2017 and 2016</p>
			</td>
			<td style="width: 5%; text-align: right; vertical-align: bottom;">83</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">77</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">To the Stockholders and Board of Directors</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Diffusion Pharmaceuticals Inc.:</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Opinion on the Consolidated Financial Statements</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have audited the accompanying consolidated balance sheets of Diffusion Pharmaceuticals Inc. and<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;subsidiaries (the Company) as of December&nbsp;31, 2017 and 2016, the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2017 and 2016, and the results of their operations and their cash flows for the years then ended, in conformity with U.S.&nbsp;generally accepted accounting principles.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Basis for Opinion</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">These consolidated financial statements are the responsibility of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ KPMG LLP</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We have served as the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s auditor since 2015.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">McLean, Virginia</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">April 2, 2018</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">78</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<div contenteditable="false" docsect="4" id="10797" sectdesc="Balance Sheet">&nbsp;</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="balance-sheet" data-td-taggable-table="" data-td-v2v-id="1520951079055" id="thunderdome-statement-848468">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257190" style="font-weight: inherit; font-style: normal;">8,896,468</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257191" style="font-weight: inherit; font-style: normal;">1,552,852</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Prepaid expenses, deposits and other current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257192" style="font-weight: inherit; font-style: normal;">769,946</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257193" style="font-weight: inherit; font-style: normal;">50,844</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total current assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257194" style="font-weight: inherit; font-style: normal;">9,666,414</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257195" style="font-weight: inherit; font-style: normal;">1,603,696</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257196" style="font-weight: inherit; font-style: normal;">460,652</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257197" style="font-weight: inherit; font-style: normal;">79,755</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257198" style="font-weight: inherit; font-style: normal;">8,639,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257199" style="font-weight: inherit; font-style: normal;">8,639,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257200" style="font-weight: inherit; font-style: normal;">6,929,258</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257201" style="font-weight: inherit; font-style: normal;">6,929,258</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257202" style="font-weight: inherit; font-style: normal;">450,491</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257203" style="font-weight: inherit; font-style: normal;">232,675</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257204" style="font-weight: inherit; font-style: normal;">26,145,815</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257205" style="font-weight: inherit; font-style: normal;">17,484,384</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities, Convertible Preferred Stock and Stockholders<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; Equity</font></b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Current portion of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257206" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257207" style="font-weight: inherit; font-style: normal;">1,880,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accounts payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257208" style="font-weight: inherit; font-style: normal;">511,956</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257209" style="font-weight: inherit; font-style: normal;">1,684,158</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accrued expenses and other current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257210" style="font-weight: inherit; font-style: normal;">1,628,851</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257211" style="font-weight: inherit; font-style: normal;">874,264</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total current liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257212" style="font-weight: inherit; font-style: normal;">2,690,807</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257213" style="font-weight: inherit; font-style: normal;">4,438,422</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257214" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257215" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257216" style="font-weight: inherit; font-style: normal;">2,223,678</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257217" style="font-weight: inherit; font-style: normal;">3,279,363</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257218" style="font-weight: inherit; font-style: normal;">1,386</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257219" style="font-weight: inherit; font-style: normal;">31,915</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257220" style="font-weight: inherit; font-style: normal;">4,915,871</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257221" style="font-weight: inherit; font-style: normal;">8,299,700</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Commitments and Contingencies</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible preferred stock, $0.001 par value:</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257222" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257223" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Series A - 13,750,000 shares authorized, 12,376,329 and 8,306,278 shares issued and outstanding, respectively at December 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $16,778,682 at December 31, 2017)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257224" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257225" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt;">Stockholders<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; Equity:</font></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock, $0.001 par value:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">1,000,000,000 shares authorized; 14,519,629 and 10,345,637 shares issued and outstanding at December 31, 2017 and 2016, respectively</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257226" style="font-weight: inherit; font-style: normal;">14,520</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257227" style="font-weight: inherit; font-style: normal;">10,346</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additional paid-in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257228" style="font-weight: inherit; font-style: normal;">82,770,313</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257229" style="font-weight: inherit; font-style: normal;">69,363,575</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accumulated deficit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257230" style="font-weight: inherit; font-style: normal;">(61,554,889</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257231" style="font-weight: inherit; font-style: normal;">(60,189,237</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total stockholders&#39; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257232" style="font-weight: inherit; font-style: normal;">21,229,944</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257233" style="font-weight: inherit; font-style: normal;">9,184,684</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities, convertible preferred stock and stockholders&#39; equity</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257234" style="font-weight: inherit; font-style: normal;">26,145,815</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257235" style="font-weight: inherit; font-style: normal;">17,484,384</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">79</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<div contenteditable="false" docsect="5" id="10798" sectdesc="Income Statement">&nbsp;</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="income" data-td-taggable-table="" data-td-v2v-id="1520951086125" id="thunderdome-statement-848469">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257243" style="font-weight: inherit; font-style: normal;">5,088,621</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257244" style="font-weight: inherit; font-style: normal;">7,252,241</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257245" style="font-weight: inherit; font-style: normal;">6,191,845</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257246" style="font-weight: inherit; font-style: normal;">11,094,146</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257247" style="font-weight: inherit; font-style: normal;">67,981</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257248" style="font-weight: inherit; font-style: normal;">25,342</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Loss from operations</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257249" style="font-weight: inherit; font-style: normal;">11,348,447</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257250" style="font-weight: inherit; font-style: normal;">18,371,729</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Interest expense, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257251" style="font-weight: inherit; font-style: normal;">48,006</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257252" style="font-weight: inherit; font-style: normal;">29,686</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of warrant liability (Note 14)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257253" style="font-weight: inherit; font-style: normal;">(22,072,322</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257254" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Warrant related expenses (Note 10)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257255" style="font-weight: inherit; font-style: normal;">10,225,846</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257256" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other financing expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257257" style="font-weight: inherit; font-style: normal;">2,870,226</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257258" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Loss from operations before income tax benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257259" style="font-weight: inherit; font-style: normal;">(2,420,203</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257260" style="font-weight: inherit; font-style: normal;">(18,401,415</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Income tax benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257261" style="font-weight: inherit; font-style: normal;">(1,055,685</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257262" style="font-weight: inherit; font-style: normal;">(364,796</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257263" style="font-weight: inherit; font-style: normal;">(1,364,518</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257264" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accretion of Series A cumulative preferred dividends</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257265" style="font-weight: inherit; font-style: normal;">(1,252,394</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257266" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257267" style="font-weight: inherit; font-style: normal;">(2,616,912</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257268" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Per share information:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, basic</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257269" style="font-weight: inherit; font-style: normal;">(0.21</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257270" style="font-weight: inherit; font-style: normal;">(1.76</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257271" style="font-weight: inherit; font-style: normal;">(1.94</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257272" style="font-weight: inherit; font-style: normal;">(1.76</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257273" style="font-weight: inherit; font-style: normal;">12,447,641</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257274" style="font-weight: inherit; font-style: normal;">10,232,791</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257275" style="font-weight: inherit; font-style: normal;">12,755,316</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257276" style="font-weight: inherit; font-style: normal;">10,232,791</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">80</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<div contenteditable="false" docsect="7" id="10799" sectdesc="Stockholders' Equity">&nbsp;</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo; EQUITY</font></b></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-statement-type="stockholders-equity" data-td-taggable-table="" data-td-v2v-id="1520951096420" id="thunderdome-statement-848470">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="width: 17111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Convertible Preferred Stock</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="18" id=".amt.D8" style="width: 21474836.47%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Stockholders&#39; Equity</b></b></p>
			</td>
			<td id=".trail.D8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="width: 17111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Series A</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.D5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td colspan="6" id=".amt.D5" style="width: 16111%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Common Stock</b></b></p>
			</td>
			<td id=".trail.D5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.D6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td colspan="2" id=".amt.D6" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Additional</b></b></p>
			</td>
			<td id=".trail.D6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.D7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td colspan="2" id=".amt.D7" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td id=".trail.D7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.D8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td colspan="2" id=".amt.D8" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Total</b></b></p>
			</td>
			<td id=".trail.D8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Shares</b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Amount</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.D4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Shares</b></b></p>
			</td>
			<td id=".trail.D4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Amount</b></b></p>
			</td>
			<td id=".trail.D5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".symb.B6" rowspan="1" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Paid-in</b></b></p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Capital</b></b></p>
			</td>
			<td id=".trail.B6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".symb.B7" rowspan="1" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Accumulated</b></b></p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Deficit</b></b></p>
			</td>
			<td id=".trail.B7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".symb.B8" rowspan="1" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Stockholders&#39;</b></b></p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Equity</b></b></p>
			</td>
			<td id=".trail.B8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Balance at January 1, 2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257279" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257280" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257281" style="font-weight: inherit; font-style: normal;">8,118,939</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257282" style="font-weight: inherit; font-style: normal;">8,119</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257283" style="font-weight: inherit; font-style: normal;">42,102,876</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257284" style="font-weight: inherit; font-style: normal;">(42,152,618</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257285" style="font-weight: inherit; font-style: normal;">(41,623</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Fair value of RestorGenex shares</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257286" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257287" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257288" style="font-weight: inherit; font-style: normal;">1,861,503</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257289" style="font-weight: inherit; font-style: normal;">1,862</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257290" style="font-weight: inherit; font-style: normal;">19,544,138</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257291" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257292" style="font-weight: inherit; font-style: normal;">19,546,000</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Estimated fair value of RestorGenex stock options outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257293" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257294" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257295" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257296" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257297" style="font-weight: inherit; font-style: normal;">1,321,000</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257298" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257299" style="font-weight: inherit; font-style: normal;">1,321,000</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Estimated fair value of RestorGenex warrants outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257300" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257301" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257302" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257303" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257304" style="font-weight: inherit; font-style: normal;">384,000</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257305" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257306" style="font-weight: inherit; font-style: normal;">384,000</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common stock issued for advisory services</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257307" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257308" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257309" style="font-weight: inherit; font-style: normal;">148,073</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257310" style="font-weight: inherit; font-style: normal;">148</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257311" style="font-weight: inherit; font-style: normal;">1,409,215</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257312" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257313" style="font-weight: inherit; font-style: normal;">1,409,363</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Conversion of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257314" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257315" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257316" style="font-weight: inherit; font-style: normal;">217,122</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257317" style="font-weight: inherit; font-style: normal;">217</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257318" style="font-weight: inherit; font-style: normal;">711,278</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257319" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257320" style="font-weight: inherit; font-style: normal;">711,495</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 18pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Settlement of litigation matter upon issuance of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257321" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257322" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257323" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257324" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257325" style="font-weight: inherit; font-style: normal;">2,500,000</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257326" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257327" style="font-weight: inherit; font-style: normal;">2,500,000</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257328" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257329" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257330" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257331" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257332" style="font-weight: inherit; font-style: normal;">1,391,068</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257333" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257334" style="font-weight: inherit; font-style: normal;">1,391,068</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257335" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257336" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: thin; border-bottom-width: thin; border-right-style: solid; border-bottom-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257337" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257338" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257339" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257340" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257341" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Balance at December 31, 2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257342" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257343" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257344" style="font-weight: inherit; font-style: normal;">10,345,637</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257345" style="font-weight: inherit; font-style: normal;">10,346</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257346" style="font-weight: inherit; font-style: normal;">69,363,575</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257347" style="font-weight: inherit; font-style: normal;">(60,189,237</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257348" style="font-weight: inherit; font-style: normal;">9,184,684</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Cumulative effect of change in accounting principle <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup>(a)</sup></font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257349" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257350" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257351" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257352" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257353" style="font-weight: inherit; font-style: normal;">1,134</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257354" style="font-weight: inherit; font-style: normal;">(1,134</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257355" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Sale of Series A convertible preferred stock and common stock warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257356" style="font-weight: inherit; font-style: normal;">12,376,329</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257357" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257358" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257359" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257360" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257361" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257362" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Reclassification of the fair market value of the Series A warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257363" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257364" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257365" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257366" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257367" style="font-weight: inherit; font-style: normal;">13,153,524</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257368" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257369" style="font-weight: inherit; font-style: normal;">13,153,524</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Common stock issued for advisory services</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257370" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257371" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257372" style="font-weight: inherit; font-style: normal;">17,606</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257373" style="font-weight: inherit; font-style: normal;">18</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257374" style="font-weight: inherit; font-style: normal;">49,982</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257375" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257376" style="font-weight: inherit; font-style: normal;">50,000</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Series A cumulative preferred dividend</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257377" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257378" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257379" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257380" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257381" style="font-weight: inherit; font-style: normal;">(1,252,394</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257382" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257383" style="font-weight: inherit; font-style: normal;">(1,252,394</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Reclassification of accrued dividends upon conversion of Series A</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257384" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257385" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257386" style="font-weight: inherit; font-style: normal;">86,335</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257387" style="font-weight: inherit; font-style: normal;">86</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257388" style="font-weight: inherit; font-style: normal;">189,994</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257389" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257390" style="font-weight: inherit; font-style: normal;">190,080</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Conversion of Series A convertible preferred stock to common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257391" style="font-weight: inherit; font-style: normal;">(4,070,051</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257392" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257393" style="font-weight: inherit; font-style: normal;">4,070,051</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257394" style="font-weight: inherit; font-style: normal;">4,070</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257395" style="font-weight: inherit; font-style: normal;">(4,070</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257396" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257397" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Beneficial conversion feature for accrued interest of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257398" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257399" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257400" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257401" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257402" style="font-weight: inherit; font-style: normal;">28,017</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257403" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257404" style="font-weight: inherit; font-style: normal;">28,017</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257405" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257406" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257407" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257408" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257409" style="font-weight: inherit; font-style: normal;">1,240,551</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257410" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257411" style="font-weight: inherit; font-style: normal;">1,240,551</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257412" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257413" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-right-width: thin; border-right-style: solid;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257414" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257415" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257416" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257417" style="font-weight: inherit; font-style: normal;">(1,364,518</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257418" style="font-weight: inherit; font-style: normal;">(1,364,518</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 32%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt 0pt 0pt 9pt; text-indent: -9pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Balance at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257419" style="font-weight: inherit; font-style: normal;">8,306,278</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257420" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-right-color: rgb(0, 0, 0); border-bottom-color: rgb(0, 0, 0); border-right-width: thin; border-bottom-width: 3px; border-right-style: solid; border-bottom-style: double;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.4" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257421" style="font-weight: inherit; font-style: normal;">14,519,629</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.5" style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257422" style="font-weight: inherit; font-style: normal;">14,520</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.6" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.6" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257423" style="font-weight: inherit; font-style: normal;">82,770,313</em></td>
			<td id=".trail.6" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.7" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.7" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257424" style="font-weight: inherit; font-style: normal;">(61,554,889</em></td>
			<td id=".trail.7" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.8" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.8" style="width: 7%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257425" style="font-weight: inherit; font-style: normal;">21,229,944</em></td>
			<td id=".trail.8" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(a) In 2017, the Company adopted provisions of ASU 2016-09<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>, Improvements to Employee Share Based Payment Accounting</i>, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of ASU 2016-09.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>See accompanying notes to consolidated financial statements.</i></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">81</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<div contenteditable="false" docsect="8" id="10800" sectdesc="Cash Flows">&nbsp;</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOW</b></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-statement-type="cash-flows" data-td-taggable-table="" data-td-v2v-id="1520951103543" id="thunderdome-statement-848471">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year Ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Operating activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257426" style="font-weight: inherit; font-style: normal;">(1,364,518</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257427" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257428" style="font-weight: inherit; font-style: normal;">67,981</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257429" style="font-weight: inherit; font-style: normal;">25,342</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Loss on sale or disposal of assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257430" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257431" style="font-weight: inherit; font-style: normal;">6,761</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257432" style="font-weight: inherit; font-style: normal;">1,240,551</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257433" style="font-weight: inherit; font-style: normal;">1,391,068</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock issued for advisory services</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257434" style="font-weight: inherit; font-style: normal;">50,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257435" style="font-weight: inherit; font-style: normal;">1,409,363</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Warrant related expense, change in fair value, and other financing expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257436" style="font-weight: inherit; font-style: normal;">(8,976,250</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257437" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Abandonment of in-process research and development intangible asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257438" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257439" style="font-weight: inherit; font-style: normal;">951,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in deferred income taxes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257440" style="font-weight: inherit; font-style: normal;">(1,055,685</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257441" style="font-weight: inherit; font-style: normal;">(364,796</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Settlement of litigation matter</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257442" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257443" style="font-weight: inherit; font-style: normal;">2,500,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-cash interest expense, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257444" style="font-weight: inherit; font-style: normal;">33,517</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257445" style="font-weight: inherit; font-style: normal;">38,446</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Changes in operating assets and liabilities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Prepaid expenses, deposits and other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257446" style="font-weight: inherit; font-style: normal;">(664,162</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257447" style="font-weight: inherit; font-style: normal;">319,545</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accounts payable, accrued expenses and other liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257448" style="font-weight: inherit; font-style: normal;">(1,663,789</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257449" style="font-weight: inherit; font-style: normal;">991,625</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257450" style="font-weight: inherit; font-style: normal;">(12,332,355</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257451" style="font-weight: inherit; font-style: normal;">(10,768,265</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flows (used in) provided by investing activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Purchases of property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257452" style="font-weight: inherit; font-style: normal;">(447,823</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257453" style="font-weight: inherit; font-style: normal;">(2,331</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Purchases of certificates of deposit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257454" style="font-weight: inherit; font-style: normal;">(10,000,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257455" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Maturities of certificates of deposit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257456" style="font-weight: inherit; font-style: normal;">10,000,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257457" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Cash received in reverse merger transaction</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257458" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257459" style="font-weight: inherit; font-style: normal;">8,500,602</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash (used in) provided by investing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257460" style="font-weight: inherit; font-style: normal;">(447,823</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257461" style="font-weight: inherit; font-style: normal;">8,498,271</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash flows provided by financing activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Proceeds from the sale of Series A convertible preferred stock and warrants, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257462" style="font-weight: inherit; font-style: normal;">22,129,774</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257463" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Proceeds from the issuance of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257464" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257465" style="font-weight: inherit; font-style: normal;">1,880,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Repayment of convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257466" style="font-weight: inherit; font-style: normal;">(1,880,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257467" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Payment of offering costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257468" style="font-weight: inherit; font-style: normal;">(125,980</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257469" style="font-weight: inherit; font-style: normal;">(54,346</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by financing activities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257470" style="font-weight: inherit; font-style: normal;">20,123,794</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257471" style="font-weight: inherit; font-style: normal;">1,825,654</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net increase (decrease) in cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257472" style="font-weight: inherit; font-style: normal;">7,343,616</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257473" style="font-weight: inherit; font-style: normal;">(444,340</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257474" style="font-weight: inherit; font-style: normal;">1,552,852</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257475" style="font-weight: inherit; font-style: normal;">1,997,192</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of year</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257476" style="font-weight: inherit; font-style: normal;">8,896,468</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257477" style="font-weight: inherit; font-style: normal;">1,552,852</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Supplemental disclosure of cash flow information:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for interest</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257478" style="font-weight: inherit; font-style: normal;">112,800</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257479" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Supplemental disclosure of non-cash investing and financing activities:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Reclassification of the fair market value of the Series A warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257480" style="font-weight: inherit; font-style: normal;">13,153,524</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257481" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Series A cumulative preferred dividends</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257482" style="font-weight: inherit; font-style: normal;">1,252,394</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257483" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Conversion of accrued dividends related to convertible preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257484" style="font-weight: inherit; font-style: normal;">190,080</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257485" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Offering costs in accounts payable and accrued expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257486" style="font-weight: inherit; font-style: normal;">146,776</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257487" style="font-weight: inherit; font-style: normal;">126,110</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Conversion of convertible notes and related accrued interest into common stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257488" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257489" style="font-weight: inherit; font-style: normal;">711,495</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Consideration in connection with RestorGenex Corporation merger transaction</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257490" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257491" style="font-weight: inherit; font-style: normal;">21,261,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">See accompanying notes to consolidated financial statements.</font></i></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">82</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<b> </b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div contenteditable="false" docsect="9" id="10801" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951114227" id="thunderdome-statement-848472">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257746" style="font-weight: inherit; font-style: normal;">1.</em> Organization and Description of Business</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Diffusion Pharmaceuticals Inc. &ldquo;Diffusion&rdquo; or &ldquo;the Company&rdquo; is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&ldquo;TSC&rdquo;), for use in the many cancer types in which tumor oxygen deprivation (&ldquo;hypoxia&rdquo;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 15, 2015, </em>the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s predecessor for accounting purposes, Diffusion Pharmaceuticals LLC (&ldquo;Diffusion LLC&rdquo;) entered into a definitive merger agreement with the Company, then known as &ldquo;RestorGenex Corporation&rdquo; and traded on the over-the-counter stock exchange under the ticker symbol &ldquo;RESX.&rdquo; On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 8, 2016 </em>the Company completed the merger with Diffusion LLC under which a newly formed subsidiary of the Company merged with and into Diffusion LLC in an all-stock transaction, with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the merger, the Company was renamed &ldquo;Diffusion Pharmaceuticals Inc.&rdquo; and the Company&rsquo;s ticker symbol was changed to &ldquo;DFFN.&rdquo; On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 9, 2016, </em>the Company&rsquo;s common stock (&ldquo;Common Stock&rdquo;) began trading on the NASDAQ Capital Market exchange.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The merger transaction was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s pre-transaction owners held an <em data-td-fact-id="29257747" style="font-weight: inherit; font-style: normal;">84.1%</em> economic and voting interest in the combined company immediately following the closing of the merger, Diffusion LLC is considered to be the acquirer of RestorGenex for accounting purposes (See Note <em data-td-fact-id="29257748" style="font-weight: inherit; font-style: normal;">4</em>). </font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s members&rsquo; capital at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1, 2016 </em>has been recast as common stock and additional paid in capital. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 17, 2016, </em>the Company effected a <em data-td-fact-id="29257749" style="font-weight: inherit; font-style: normal;">1</em>-for-<em data-td-fact-id="29257750" style="font-weight: inherit; font-style: normal;">10</em> reverse split of its common stock. The accompanying consolidated financial statements and these notes give retroactive effect to this reverse stock split.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Each outstanding unit of membership interest of Diffusion LLC (the &ldquo;Diffusion Units&rdquo;) was converted into the right to receive <em data-td-fact-id="29257751" style="font-weight: inherit; font-style: normal;">0.3652658</em> shares of Common Stock (the &ldquo;Exchange Ratio&rdquo;). Additionally, the right of holders of <em data-td-fact-id="29257752" style="font-weight: inherit; font-style: normal;">$1.1</em> million outstanding convertible notes of Diffusion LLC to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the original terms of the notes multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise converted into <em data-td-fact-id="29257753" style="font-weight: inherit; font-style: normal;">1,495,615</em> options to purchase Common Stock on terms substantially identical to those in effect prior to the merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10802" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951126505" id="thunderdome-statement-848473">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257754" style="font-weight: inherit; font-style: normal;">2.</em> Liquidity</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has <em data-td-fact-id="29257755" style="font-weight: inherit; font-style: normal;">not</em> generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger) and convertible notes, as well as through the reverse merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. <em data-td-fact-id="29257756" style="font-weight: inherit; font-style: normal;">No</em> assurance can be given that any such financing will be available when needed or that the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s research and development efforts will be successful.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with <em data-td-fact-id="29257757" style="font-weight: inherit; font-style: normal;">third</em> parties and other strategic alliances and business transactions. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 22, 2018, </em>the Company closed its previously announced underwritten public offering of <em data-td-fact-id="29257758" style="font-weight: inherit; font-style: normal;">15,000,000</em> shares of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s common stock, par value <em data-td-fact-id="29257759" style="font-weight: inherit; font-style: normal;">$0.001</em> per share, and warrants to purchase <em data-td-fact-id="29257760" style="font-weight: inherit; font-style: normal;">15,000,000</em> shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional <em data-td-fact-id="29257761" style="font-weight: inherit; font-style: normal;">1,970,625</em> shares of Common Stock pursuant to the underwriter&rsquo;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of <em data-td-fact-id="29257762" style="font-weight: inherit; font-style: normal;">$0.80</em> per share and warrant for total gross proceeds of approximately <em data-td-fact-id="29257763" style="font-weight: inherit; font-style: normal;">$12.0</em> million. The warrants have an exercise price of <em data-td-fact-id="29257764" style="font-weight: inherit; font-style: normal;">$0.80</em> per share and a term of <em data-td-fact-id="29257765" style="font-weight: inherit; font-style: normal;">five</em> years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to <em data-td-fact-id="29257766" style="font-weight: inherit; font-style: normal;">750,000</em> shares of Common Stock. The underwriter&rsquo;s warrants have an exercise price of <em data-td-fact-id="29257767" style="font-weight: inherit; font-style: normal;">$1.00,</em> a term of <em data-td-fact-id="29257768" style="font-weight: inherit; font-style: normal;">five</em> years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company&#39;s Series A convertible preferred stock converted into <em data-td-fact-id="29257769" style="font-weight: inherit; font-style: normal;">20,568,632</em> shares (the &quot;Conversion Shares) of common stock (including accrued dividends paid in kind and issuance of shares in respect of the &quot;make-whole&quot; adjustment feature thereof).</font></p>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">83</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONTINUE</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>D</b></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company currently does <em data-td-fact-id="29257770" style="font-weight: inherit; font-style: normal;">not</em> have any commitments to obtain additional funds and <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>be unable to obtain sufficient funding in the future on acceptable terms, if at all. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 2, 2018, </em>the Company received a written notice from the NASDAQ Staff indicating the Company was <em data-td-fact-id="29257771" style="font-weight: inherit; font-style: normal;">not</em> in compliance with Nasdaq Listing Rule <em data-td-fact-id="29257772" style="font-weight: inherit; font-style: normal;">5550</em>(a)(<em data-td-fact-id="29257773" style="font-weight: inherit; font-style: normal;">2</em>) because the bid price for the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s common stock had closed below <em data-td-fact-id="29257774" style="font-weight: inherit; font-style: normal;">$1.00</em> per share for the previous <em data-td-fact-id="29257775" style="font-weight: inherit; font-style: normal;">30</em> consecutive business days. In accordance with Nasdaq Listing Rule <em data-td-fact-id="29257776" style="font-weight: inherit; font-style: normal;">5810</em>(c)(<em data-td-fact-id="29257777" style="font-weight: inherit; font-style: normal;">3</em>)(A), the Company has <em data-td-fact-id="29257778" style="font-weight: inherit; font-style: normal;">180</em> calendar days from the date of such notice, or until <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 29, 2018, </em>to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company&rsquo;s common stock must close at <em data-td-fact-id="29257779" style="font-weight: inherit; font-style: normal;">$1.00</em> per share or more for a minimum of <em data-td-fact-id="29257780" style="font-weight: inherit; font-style: normal;">10</em> consecutive business days. In the event the Company is unable to regain compliance, it could adversely affect the Company&rsquo;s ability to obtain future funding. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with <em data-td-fact-id="29257781" style="font-weight: inherit; font-style: normal;">third</em> parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>receive lower consideration upon commercialization of such products than if it had <em data-td-fact-id="29257782" style="font-weight: inherit; font-style: normal;">not</em> entered into such arrangements or if it entered into such arrangements at later stages in the product development process.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 44pt;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&rsquo;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&rsquo;s financial condition and future operations. The Company believes its cash and cash equivalents as of <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> December&nbsp;</em><em data-td-fact-id="29257783" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257784" style="font-weight: inherit; font-style: normal;">2017,</em> together with the proceeds from public underwritten offering received in <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> January 2018, </em>are sufficient to fund operations through <em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> June </em><em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> 2019.</em></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>

<div contenteditable="false" docsect="9" id="10803" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951141163" id="thunderdome-statement-848474">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257785" style="font-weight: inherit; font-style: normal;">3.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Basis of Presentation and Summary of Significant Accounting Policies</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Basis of Presentation</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (&ldquo;ASC&rdquo;) and Accounting Standards Updates (&ldquo;ASU&rdquo;) of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;).</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Use of Estimates</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">84</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Fair Value of Financial Instruments</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The carrying amounts of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257786" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257787" style="font-weight: inherit; font-style: normal;">2017,</em> the fair value of the Company&#39;s outstanding Series B convertible note was approximately <em data-td-fact-id="29257788" style="font-weight: inherit; font-style: normal;">$0.6</em> million. As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257789" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257790" style="font-weight: inherit; font-style: normal;">2016,</em> the fair value of the Company&rsquo;s outstanding <em data-td-fact-id="29257791" style="font-weight: inherit; font-style: normal;">2016</em> convertible note and Series B convertible note was approximately <em data-td-fact-id="29257792" style="font-weight: inherit; font-style: normal;">$2.0</em> million and <em data-td-fact-id="29257793" style="font-weight: inherit; font-style: normal;">$0.6</em> million, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level <em data-td-fact-id="29257794" style="font-weight: inherit; font-style: normal;">3</em> of the fair value hierarchy.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><i>&nbsp;</i></b></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Concentration of Credit Risk</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Cash and Cash Equivalents</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of <em data-td-fact-id="29257795" style="font-weight: inherit; font-style: normal;">three</em> months or less to be cash and cash equivalents.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Property and Equipment</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <em data-td-fact-id="29257796" style="font-weight: inherit; font-style: normal;">2</em> to <em data-td-fact-id="29257797" style="font-weight: inherit; font-style: normal;">15</em> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Long-Lived Assets</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em><em data-td-fact-id="29257798" style="font-weight: inherit; font-style: normal;">not</em> be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has <em data-td-fact-id="29257799" style="font-weight: inherit; font-style: normal;">not</em> recognized any impairment of long-lived assets during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257800" style="font-weight: inherit; font-style: normal;">2016.</em></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Intangible Assets</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets are comprised of identifiable in-process research and development (IPR&amp;D) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> October 1 </em>or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 2016, </em>the Company abandoned the future development efforts with respect to its RES-<em data-td-fact-id="29257801" style="font-weight: inherit; font-style: normal;">440</em> product candidate, and the value of the associated IPR&amp;D asset was written down to <em data-td-fact-id="29257802" style="font-weight: inherit; font-style: normal;">zero</em> (See Note <em data-td-fact-id="29257803" style="font-weight: inherit; font-style: normal;">4</em>).</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Goodwill</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is <em data-td-fact-id="29257804" style="font-weight: inherit; font-style: normal;">not</em> amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">85</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company performs its annual goodwill impairment test on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> October 1 </em>of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s goodwill is less than the carrying value of the reporting unit&rsquo;s goodwill. The Company did <em data-td-fact-id="29257805" style="font-weight: inherit; font-style: normal;">not</em> recognize any impairment of goodwill during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257806" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257807" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016.</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Offering Costs</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Offering costs are either expensed upon completion or abandonment of the related financing or offset against the proceeds of the offering, depending upon the accounting treatment of the offering. Offering costs consist principally of legal and accounting costs incurred through the balance sheet date related to the Company&rsquo;s underwritten public offering, private placement financings and are recognized in other assets on the consolidated balance sheet.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Research and Development</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s behalf). Costs incurred for research and development are expensed as incurred.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the end of the reporting period, the Company compares payments made to <em data-td-fact-id="29257808" style="font-weight: inherit; font-style: normal;">third</em>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>record net prepaid or accrued expenses relating to these costs.</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upfront payments made to <em data-td-fact-id="29257809" style="font-weight: inherit; font-style: normal;">third</em> parties who perform research and development services on the Company&rsquo;s behalf are expensed as services are rendered.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Patent Costs</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Income Taxes</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prior to the Merger, Diffusion LLC was treated as a partnership for federal and state income tax purposes. Diffusion LLC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s taxable income or loss, as well as certain other tax attributes, were passed through directly to its members and were reported in each member&rsquo;s individual income tax return.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon completion of the Merger as discussed in Note <em data-td-fact-id="29257810" style="font-weight: inherit; font-style: normal;">1,</em> the Company converted from a partnership to a corporation for accounting purposes. As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than <em data-td-fact-id="29257811" style="font-weight: inherit; font-style: normal;">not</em> that some portion or all of a deferred tax asset will <em data-td-fact-id="29257812" style="font-weight: inherit; font-style: normal;">not</em> be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than <em data-td-fact-id="29257813" style="font-weight: inherit; font-style: normal;">not</em> to be sustained.</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">86</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 22, 2017 </em>the President of the United States signed into law the Tax Cuts and Jobs Act (&quot;The <em data-td-fact-id="29257814" style="font-weight: inherit; font-style: normal;">2017</em> Tax Act&quot;).&nbsp;This legislation makes significant changes in the U.S. tax laws including, but <em data-td-fact-id="29257815" style="font-weight: inherit; font-style: normal;">not</em> limited to, reducing the corporate tax rate to <em data-td-fact-id="29257816" style="font-weight: inherit; font-style: normal;">21%</em> starting in <em data-td-fact-id="29257817" style="font-weight: inherit; font-style: normal;">2018.</em> The <em data-td-fact-id="29257818" style="font-weight: inherit; font-style: normal;">2017</em> Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of <em data-td-fact-id="29257819" style="font-weight: inherit; font-style: normal;">21%.</em>&nbsp;&nbsp;As a result of the change, the Company recorded a current period tax benefit of <em data-td-fact-id="29257820" style="font-weight: inherit; font-style: normal;">$1.1</em> million in its consolidated statement of operations and a corresponding reduction in the deferred tax liability on its consolidated balance sheet.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Stock-based Compensation</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s common stock, the expected term of the Company&rsquo;s stock options, the expected dividend yield and the fair value of the Company&rsquo;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The expected term of stock options was estimated using the &ldquo;simplified method&rdquo; for employee options as the Company has <em data-td-fact-id="29257821" style="font-weight: inherit; font-style: normal;">no</em> historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <em data-td-fact-id="29257822" style="font-weight: inherit; font-style: normal;">no</em> dividend yield because dividends are <em data-td-fact-id="29257823" style="font-weight: inherit; font-style: normal;">not</em> expected to be paid in the near future, which is consistent with the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s history of <em data-td-fact-id="29257824" style="font-weight: inherit; font-style: normal;">not</em> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company <em data-td-fact-id="29257825" style="font-weight: inherit; font-style: normal;">no</em> longer estimates forfeitures and accounts for forfeitures in the periods they occur.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Net Loss Per Share</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the &ldquo;if-converted&rdquo; method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would <em data-td-fact-id="29257826" style="font-weight: inherit; font-style: normal;">not</em> have been incurred if the warrants had been converted into common stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">87</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951141159" id="thunderdome-statement-848475">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year ended December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net loss per common share calculation:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257499" style="font-weight: inherit; font-style: normal;">(1,364,518</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257500" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accretion of Series A cumulative preferred dividends</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257501" style="font-weight: inherit; font-style: normal;">(1,252,394</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257502" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257503" style="font-weight: inherit; font-style: normal;">(2,616,912</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257504" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257505" style="font-weight: inherit; font-style: normal;">12,447,641</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257506" style="font-weight: inherit; font-style: normal;">10,232,791</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common, basic</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257507" style="font-weight: inherit; font-style: normal;">(0.21</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257508" style="font-weight: inherit; font-style: normal;">(1.76</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss per common share calculation:</p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257509" style="font-weight: inherit; font-style: normal;">(2,616,912</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257510" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257511" style="font-weight: inherit; font-style: normal;">(22,072,322</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257512" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257513" style="font-weight: inherit; font-style: normal;">(24,689,234</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257514" style="font-weight: inherit; font-style: normal;">(18,036,619</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding, basic</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257515" style="font-weight: inherit; font-style: normal;">12,447,641</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257516" style="font-weight: inherit; font-style: normal;">10,232,791</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock equivalents arising from warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257517" style="font-weight: inherit; font-style: normal;">307,675</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257518" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257519" style="font-weight: inherit; font-style: normal;">12,755,316</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257520" style="font-weight: inherit; font-style: normal;">10,232,791</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, diluted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257521" style="font-weight: inherit; font-style: normal;">(1.94</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257522" style="font-weight: inherit; font-style: normal;">(1.76</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951141160" id="thunderdome-statement-848476">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257525" style="font-weight: inherit; font-style: normal;">214,385</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257526" style="font-weight: inherit; font-style: normal;">757,909</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257527" style="font-weight: inherit; font-style: normal;">447,721</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257528" style="font-weight: inherit; font-style: normal;">460,721</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257529" style="font-weight: inherit; font-style: normal;">8,306,278</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257530" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257531" style="font-weight: inherit; font-style: normal;">2,555,989</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257532" style="font-weight: inherit; font-style: normal;">2,207,409</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock awards</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257533" style="font-weight: inherit; font-style: normal;">3,066</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257534" style="font-weight: inherit; font-style: normal;">9,204</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257535" style="font-weight: inherit; font-style: normal;">11,527,439</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257536" style="font-weight: inherit; font-style: normal;">3,435,243</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amounts in the table reflect the common stock equivalents of the noted instruments.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Comprehensive Loss</i></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has <em data-td-fact-id="29257827" style="font-weight: inherit; font-style: normal;">no</em> items of comprehensive income or loss other than net loss.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Recent Accounting Pronouncements</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> July 2017, </em>the FASB issued ASU <em data-td-fact-id="29257828" style="font-weight: inherit; font-style: normal;">2017</em>-<em data-td-fact-id="29257829" style="font-weight: inherit; font-style: normal;">11,</em> <i>Earnings Per Share (Topic <em data-td-fact-id="29257830" style="font-weight: inherit; font-style: normal;">260</em>); Distinguishing Liabilities from Equity (Topic <em data-td-fact-id="29257831" style="font-weight: inherit; font-style: normal;">480</em>); Derivatives and Hedging (Topic <em data-td-fact-id="29257832" style="font-weight: inherit; font-style: normal;">815</em>): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. </i>The <em data-td-fact-id="29257833" style="font-weight: inherit; font-style: normal;">first</em> part of this update addresses the complexity of accounting for certain financial instruments with down round features and the <em data-td-fact-id="29257834" style="font-weight: inherit; font-style: normal;">second</em> part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 15, 2018 </em>and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">88</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> May 2017, </em>the FASB issued ASU <em data-td-fact-id="29257835" style="font-weight: inherit; font-style: normal;">No.</em> <em data-td-fact-id="29257836" style="font-weight: inherit; font-style: normal;">2017</em>-<em data-td-fact-id="29257837" style="font-weight: inherit; font-style: normal;">09,</em> <i>Modification Accounting for Share-Based Payment Arrangements</i>, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC <em data-td-fact-id="29257838" style="font-weight: inherit; font-style: normal;">718.</em> Specifically, an entity would <em data-td-fact-id="29257839" style="font-weight: inherit; font-style: normal;">not</em> apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 15, 2017 </em>and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company does <em data-td-fact-id="29257840" style="font-weight: inherit; font-style: normal;">not</em> expect this new guidance to have a material impact on its consolidated financial statements.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29257841" style="font-weight: inherit; font-style: normal;">2016,</em> the FASB issued ASU <em data-td-fact-id="29257842" style="font-weight: inherit; font-style: normal;">2016</em>-<em data-td-fact-id="29257843" style="font-weight: inherit; font-style: normal;">09,</em> <i>Compensation &ndash; Improvements to Employee Share-Based Payment Accounting</i>, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 15, 2016 </em>and interim periods within those years. The Company adopted this standard in <em data-td-fact-id="29257844" style="font-weight: inherit; font-style: normal;">2017</em> by electing to account for forfeitures in the period that they occur. Under ASU <em data-td-fact-id="29257845" style="font-weight: inherit; font-style: normal;">2016</em>-<em data-td-fact-id="29257846" style="font-weight: inherit; font-style: normal;">09,</em> accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately <em data-td-fact-id="29257847" style="font-weight: inherit; font-style: normal;">$1,000</em> on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1, 2017.</em></font></p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> February 2016, </em>the FASB issued ASU <em data-td-fact-id="29257848" style="font-weight: inherit; font-style: normal;">2016</em>-<em data-td-fact-id="29257849" style="font-weight: inherit; font-style: normal;">02,</em> <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Leases (Topic <em data-td-fact-id="29257850" style="font-weight: inherit; font-style: normal;">842</em>)</i>. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257851" style="font-weight: inherit; font-style: normal;">15,</em> <em data-td-fact-id="29257852" style="font-weight: inherit; font-style: normal;">2018,</em> including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. Upon adoption in <em data-td-fact-id="29257853" style="font-weight: inherit; font-style: normal;">2018,</em> the Company will determine the fair of the operating lease and recognize this amount as a lease asset and corresponding liability on its consolidated balance sheet. The Company does <em data-td-fact-id="29257854" style="font-weight: inherit; font-style: normal;">not</em> expect this new guidance to have a material impact on its consolidated financial statements.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10804" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951151353" id="thunderdome-statement-848477">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257855" style="font-weight: inherit; font-style: normal;">4.</em> Acquisitions</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Merger with Diffusion Pharmaceuticals LLC</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 15, 2015, </em>the Company entered into a merger agreement (the &ldquo;Merger Agreement&rdquo;) with Diffusion LLC. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 8, 2016, </em>the Company completed the merger (the &ldquo;Merger&rdquo;), with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the Merger, the Company was renamed &ldquo;Diffusion Pharmaceuticals Inc.&rdquo; and the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s ticker symbol was changed from &ldquo;RESX&rdquo; to &ldquo;DFFN.&rdquo; In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 2016, </em>the Company&rsquo;s Common Stock was approved for listing on the NASDAQ Capital Market and continues to trade under the ticker symbol &ldquo;DFFN&rdquo;. The Company and Diffusion LLC entered into the Merger Agreement in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Merger was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s pre-transaction owners held an <em data-td-fact-id="29257856" style="font-weight: inherit; font-style: normal;">84.1%</em> economic and voting interest in the combined company immediately following the completion of the Merger, Diffusion LLC is considered to be the acquirer of the Company for accounting purposes.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Each Diffusion Unit was converted into the right to receive <em data-td-fact-id="29257857" style="font-weight: inherit; font-style: normal;">0.3652658</em> shares of Common Stock based on the Exchange Ratio. Additionally, the rights of holders of Diffusion LLC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s outstanding convertible notes to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the terms of the notes in effect immediately prior to the consummation of the Merger multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise such options for Diffusion Units converted into a right to exercise such options for Common Stock on terms substantially identical to those in effect prior to the Merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">89</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger, the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s former Board of Directors authorized, declared and effected a distribution of contingent value rights (&ldquo;CVRs&rdquo;) to stockholders of the Company as of the close of business on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 7, 2016. </em>Each CVR is a non-transferable right to potentially receive certain cash payments in the event the Company receives net cash payments during the <em data-td-fact-id="29257858" style="font-weight: inherit; font-style: normal;">five</em> (<em data-td-fact-id="29257859" style="font-weight: inherit; font-style: normal;">5</em>) year period after the Merger as a result of the sale, transfer, license or similar transaction or any other agreement to the extent relating to the development of the Company&rsquo;s product currently known as RES-<em data-td-fact-id="29257860" style="font-weight: inherit; font-style: normal;">440,</em> a &ldquo;soft&rdquo; anti-androgen. See below for additional fair value information.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Diffusion LLC, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Diffusion LLC that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951151352" id="thunderdome-statement-848548">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s pre-Merger shares outstanding</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257537" style="font-weight: inherit; font-style: normal;">19,546,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s pre-Merger stock options outstanding</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257538" style="font-weight: inherit; font-style: normal;">1,321,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s pre-Merger warrants outstanding</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257539" style="font-weight: inherit; font-style: normal;">384,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">CVRs <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&ndash; RES-440 product candidate</font></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257540" style="font-weight: inherit; font-style: normal;">10,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total purchase price</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257541" style="font-weight: inherit; font-style: normal;">21,261,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;D was the cost approach.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951151352" id="thunderdome-statement-848549">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257542" style="font-weight: inherit; font-style: normal;">8,500,602</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257543" style="font-weight: inherit; font-style: normal;">195,200</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257544" style="font-weight: inherit; font-style: normal;">57,531</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257545" style="font-weight: inherit; font-style: normal;">9,600,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257546" style="font-weight: inherit; font-style: normal;">6,929,258</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued liabilities</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257547" style="font-weight: inherit; font-style: normal;">(377,432</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257548" style="font-weight: inherit; font-style: normal;">(3,644,159</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257549" style="font-weight: inherit; font-style: normal;">21,261,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Qualitative factors supporting the recognition of goodwill due to the Merger include the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the Merger to the Company&rsquo;s later state product portfolio. The goodwill is <em data-td-fact-id="29257861" style="font-weight: inherit; font-style: normal;">not</em> deductible for income tax purposes. The values allocated to IPR&amp;D intangible assets are <em data-td-fact-id="29257862" style="font-weight: inherit; font-style: normal;">$8.6</em> million for the RES-<em data-td-fact-id="29257863" style="font-weight: inherit; font-style: normal;">529</em> compound and <em data-td-fact-id="29257864" style="font-weight: inherit; font-style: normal;">$1.0</em> million for the RES-<em data-td-fact-id="29257865" style="font-weight: inherit; font-style: normal;">440</em> compound, each with indefinite useful lives. See Note <em data-td-fact-id="29257866" style="font-weight: inherit; font-style: normal;">6</em> for additional information.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">90</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pro Forma Financial Information (Unaudited)</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1, 2016. </em>The pro forma financial information is <em data-td-fact-id="29257867" style="font-weight: inherit; font-style: normal;">not</em> necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951151352" id="thunderdome-statement-848480">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year ended December</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <b>31, 2016</b></font></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td>
			<td id=".amt.B2" style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257550" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257551" style="font-weight: inherit; font-style: normal;">(16,471,398</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted loss per share</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257552" style="font-weight: inherit; font-style: normal;">(1.60</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-recurring pro forma transaction costs directly attributable to the Merger were <em data-td-fact-id="29257868" style="font-weight: inherit; font-style: normal;">$1.6</em> million for the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016 </em>and have been deducted from the net loss presented above. The costs deducted from the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016 </em>period included a success fee and other transaction costs<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;of <em data-td-fact-id="29257869" style="font-weight: inherit; font-style: normal;">$1.1</em> million and approximately <em data-td-fact-id="29257870" style="font-weight: inherit; font-style: normal;">46,000</em> shares of common stock with a fair market value of <em data-td-fact-id="29257871" style="font-weight: inherit; font-style: normal;">$0.5</em> million paid to a financial advisor upon the closing of the Merger on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 8, 2016. </em>Additionally, RestorGenex incurred approximately <em data-td-fact-id="29257872" style="font-weight: inherit; font-style: normal;">$3.0</em> million in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately <em data-td-fact-id="29257873" style="font-weight: inherit; font-style: normal;">$2.7</em> million in share-based compensation expense as a result of the acceleration of vesting of stock options at the time of Merger. These costs are excluded from the pro forma financial information for the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016. </em><em data-td-fact-id="29257874" style="font-weight: inherit; font-style: normal;">No</em> such costs were recorded during the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017. </em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">91</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10805" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951161165" id="thunderdome-statement-848550">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257875" style="font-weight: inherit; font-style: normal;">5.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Property and Equipment</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Property and equipment consists of the following:</p>

<p style="margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951161165" id="thunderdome-statement-848551">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257553" style="font-weight: inherit; font-style: normal;">182,357</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257554" style="font-weight: inherit; font-style: normal;">182,357</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257555" style="font-weight: inherit; font-style: normal;">155,113</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257556" style="font-weight: inherit; font-style: normal;">137,290</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257557" style="font-weight: inherit; font-style: normal;">430,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257558" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257559" style="font-weight: inherit; font-style: normal;">767,470</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257560" style="font-weight: inherit; font-style: normal;">319,647</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257561" style="font-weight: inherit; font-style: normal;">(306,818</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257562" style="font-weight: inherit; font-style: normal;">(239,892</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257563" style="font-weight: inherit; font-style: normal;">460,652</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257564" style="font-weight: inherit; font-style: normal;">79,755</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depreciation expense was approximately <em data-td-fact-id="29257876" style="font-weight: inherit; font-style: normal;">$68,000</em> and <em data-td-fact-id="29257877" style="font-weight: inherit; font-style: normal;">$25,000</em> for the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257878" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10806" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951170091" id="thunderdome-statement-848483">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257879" style="font-weight: inherit; font-style: normal;">6.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Goodwill and Intangible Assets</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company completes its annual impairment test on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> October 1 </em>each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company&#39;s goodwill balance at both <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257880" style="font-weight: inherit; font-style: normal;">2016</em> was <em data-td-fact-id="29257881" style="font-weight: inherit; font-style: normal;">$6.9</em> million. There have been <em data-td-fact-id="29257882" style="font-weight: inherit; font-style: normal;">no</em> changes to the carrying value of goodwill during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257883" style="font-weight: inherit; font-style: normal;">2016.</em></p>

<p style="margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger, the Company acquired indefinite-lived In-Process Research and Development Assets (&ldquo;IPR&amp;D&rdquo;) RES-<em data-td-fact-id="29257884" style="font-weight: inherit; font-style: normal;">529</em> and RES-<em data-td-fact-id="29257885" style="font-weight: inherit; font-style: normal;">440,</em> with estimated fair values of <em data-td-fact-id="29257886" style="font-weight: inherit; font-style: normal;">$8.6</em> million and <em data-td-fact-id="29257887" style="font-weight: inherit; font-style: normal;">$1.0</em> million, respectively. The Company&rsquo;s novel <em data-td-fact-id="29257888" style="font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</em> pathway inhibitor, RES-<em data-td-fact-id="29257889" style="font-weight: inherit; font-style: normal;">529,</em> is in preclinical development for oncology. Through a series of in vitro and in vivo animal models, RES-<em data-td-fact-id="29257890" style="font-weight: inherit; font-style: normal;">529</em> has been shown&nbsp;to have activity in several cancer types due to its ability to target and inhibit the <em data-td-fact-id="29257891" style="font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</em> signal transduction pathway. RES-<em data-td-fact-id="29257892" style="font-weight: inherit; font-style: normal;">529</em> is a <em data-td-fact-id="29257893" style="font-weight: inherit; font-style: normal;">first</em>-in-class inhibitor of both <em data-td-fact-id="29257894" style="font-weight: inherit; font-style: normal;">TORC1</em> and <em data-td-fact-id="29257895" style="font-weight: inherit; font-style: normal;">TORC2</em> that is mechanistically differentiated from other <em data-td-fact-id="29257896" style="font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</em> pathway inhibitors currently in development. RES-<em data-td-fact-id="29257897" style="font-weight: inherit; font-style: normal;">529</em> has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 2016, </em>the Board of Directors determined that RES-<em data-td-fact-id="29257898" style="font-weight: inherit; font-style: normal;">440,</em> a &ldquo;soft&rdquo; anti-androgen compound for the treatment of acne vulgaris, was outside the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s core product focus, and was <em data-td-fact-id="29257899" style="font-weight: inherit; font-style: normal;">not</em> a priority. Therefore, future development efforts were abandoned in the <em data-td-fact-id="29257900" style="font-weight: inherit; font-style: normal;">third</em> quarter of <em data-td-fact-id="29257901" style="font-weight: inherit; font-style: normal;">2016.</em> In connection with its review of such abandonment, the Company concluded RES-<em data-td-fact-id="29257902" style="font-weight: inherit; font-style: normal;">440</em> was impaired in its entirety. The abandonment resulted in a net impairment charge of <em data-td-fact-id="29257903" style="font-weight: inherit; font-style: normal;">$1.0</em> million and was recorded as a component of research and development expenses within the Company&rsquo;s consolidated statement of operations for the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016. </em>The abandonment also resulted in an income tax benefit of <em data-td-fact-id="29257904" style="font-weight: inherit; font-style: normal;">$0.4</em> million.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">92</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10807" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951178938" id="thunderdome-statement-848484">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257905" style="font-weight: inherit; font-style: normal;">7.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Accrued Expenses and Other Current Liabilities</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accrued expenses and other current liabilities consist of the following:</p>

<p style="margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951178937" id="thunderdome-statement-848485">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued interest payable</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257565" style="font-weight: inherit; font-style: normal;">37,415</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257566" style="font-weight: inherit; font-style: normal;">29,359</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued Series A dividends</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257567" style="font-weight: inherit; font-style: normal;">1,062,314</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257568" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257569" style="font-weight: inherit; font-style: normal;">312,221</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257570" style="font-weight: inherit; font-style: normal;">399,740</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257571" style="font-weight: inherit; font-style: normal;">122,711</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257572" style="font-weight: inherit; font-style: normal;">72,855</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257573" style="font-weight: inherit; font-style: normal;">63,350</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257574" style="font-weight: inherit; font-style: normal;">220,978</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257575" style="font-weight: inherit; font-style: normal;">30,840</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257576" style="font-weight: inherit; font-style: normal;">151,332</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257577" style="font-weight: inherit; font-style: normal;">1,628,851</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257578" style="font-weight: inherit; font-style: normal;">874,264</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10808" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951188012" id="thunderdome-statement-848486">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257906" style="font-weight: inherit; font-style: normal;">8.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Convertible Debt</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;The components of debt outstanding are as follows:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951188011" id="thunderdome-statement-848487">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><b><b>December 31, </b></b></td>
			<td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016 convertible notes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257579" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257580" style="font-weight: inherit; font-style: normal;">1,880,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pre-Merger convertible notes</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257581" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257582" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257583" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257584" style="font-weight: inherit; font-style: normal;">2,430,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257585" style="font-weight: inherit; font-style: normal;">(550,000</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257586" style="font-weight: inherit; font-style: normal;">(1,880,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257587" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257588" style="font-weight: inherit; font-style: normal;">550,000</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257907" style="font-weight: inherit; font-style: normal;">2016,</em> the Company recognized interest expense of approximately <em data-td-fact-id="29257908" style="font-weight: inherit; font-style: normal;">$0.1</em> million and <em data-td-fact-id="29257909" style="font-weight: inherit; font-style: normal;">$37,000,</em> respectively in connection with its convertible debt instruments. Accrued interest was <em data-td-fact-id="29257910" style="font-weight: inherit; font-style: normal;">$37,000</em> and <em data-td-fact-id="29257911" style="font-weight: inherit; font-style: normal;">$29,000</em> as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29257912" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><em data-td-fact-id="29257913" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> September 27, 2016, </em>the Company issued and sold convertible promissory notes (<em data-td-fact-id="29257914" style="font-weight: inherit; font-style: normal;">&ldquo;2016</em> Convertible Notes&rdquo;) in an aggregate principal amount of <em data-td-fact-id="29257915" style="font-weight: inherit; font-style: normal;">$1.9</em> million. The <em data-td-fact-id="29257916" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes were issued to an investor and certain other parties in connection with the settlement of a litigation matter. The <em data-td-fact-id="29257917" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes had a term of <em data-td-fact-id="29257918" style="font-weight: inherit; font-style: normal;">one</em> (<em data-td-fact-id="29257919" style="font-weight: inherit; font-style: normal;">1</em>) year and bore interest at a rate of <em data-td-fact-id="29257920" style="font-weight: inherit; font-style: normal;">6.0%</em> per annum with the principal and accrued interest due upon the earlier of the maturity date or conversion date. The Company accounted for the issuance of the convertible promissory notes in accordance with ASC <em data-td-fact-id="29257921" style="font-weight: inherit; font-style: normal;">470</em>-<em data-td-fact-id="29257922" style="font-weight: inherit; font-style: normal;">10</em>-<em data-td-fact-id="29257923" style="font-weight: inherit; font-style: normal;">25</em> and, at the time of issuance, recorded a litigation settlement expense of <em data-td-fact-id="29257924" style="font-weight: inherit; font-style: normal;">$2.5</em> million which represents the difference between the estimated fair value of the <em data-td-fact-id="29257925" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes issued and the cash received from the noteholders. Upon maturity of the <em data-td-fact-id="29257926" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes during the <em data-td-fact-id="29257927" style="font-weight: inherit; font-style: normal;">third</em> quarter of <em data-td-fact-id="29257928" style="font-weight: inherit; font-style: normal;">2017,</em> the Company repaid the outstanding principal and interest of <em data-td-fact-id="29257929" style="font-weight: inherit; font-style: normal;">$1.9</em> million and <em data-td-fact-id="29257930" style="font-weight: inherit; font-style: normal;">$0.1</em> million, respectively.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Pre-Merger Convertible Notes</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 2009 </em>through <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 2015, </em>the Company issued unsecured convertible promissory notes (the &ldquo;Pre-Merger Convertible Notes&rdquo;) for aggregate gross proceeds of <em data-td-fact-id="29257931" style="font-weight: inherit; font-style: normal;">$22.4</em> million. The Pre-Merger Convertible Notes bore interest at either <em data-td-fact-id="29257932" style="font-weight: inherit; font-style: normal;">1%</em> or <em data-td-fact-id="29257933" style="font-weight: inherit; font-style: normal;">1.5%</em> per annum, however, all Pre-Merger Convertible Notes outstanding at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>bear interest at a rate of <em data-td-fact-id="29257934" style="font-weight: inherit; font-style: normal;">1%</em> per annum. The Pre-Merger Convertible Notes accrue interest beginning on the date of issuance, with the principal and accrued interest due upon the earlier of the maturity date or conversion date. At any time prior to the maturity date, the holders <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>elect to convert, in whole or in part, the Pre-Merger Convertible Notes and any related accrued but unpaid interest into common stock of the Company at a price per share equal to the conversion price. In the event of a Change of Control or a Qualified Financing (each as defined below), the holders of the Pre-Merger Convertible Notes <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>declare the aggregate outstanding amount of the Pre-Merger Convertible Notes to be immediately due and payable or <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>elect to convert the Convertible Notes and any accrued but unpaid interest as if such conversion took place on the maturity date. A Change of Control is defined as: (i) a merger or consolidation in which the owners immediately prior to the transaction do <em data-td-fact-id="29257935" style="font-weight: inherit; font-style: normal;">not</em> own, directly or indirectly, more than <em data-td-fact-id="29257936" style="font-weight: inherit; font-style: normal;">50%</em> of the surviving company; (ii) the acquisition of more than <em data-td-fact-id="29257937" style="font-weight: inherit; font-style: normal;">50%</em> of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s outstanding shares by a single person, entity or group or persons or entities acting in concert or (iii) the sale or transfer of all or substantially all of the assets of the Company. A Qualified Financing is defined as a sale of shares or other transaction that results in gross proceeds to the Company of at least <em data-td-fact-id="29257938" style="font-weight: inherit; font-style: normal;">$50.0</em> million, including proceeds received in connection with the conversion of any Pre-Merger Convertible Notes. Through the date the financial statements were available to be issued, there have been <em data-td-fact-id="29257939" style="font-weight: inherit; font-style: normal;">no</em> Change of Control or Qualified Financing events. The Company <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>prepay the Pre-Merger Convertible Notes, in full or in part, at any time on a pari passu basis. Upon receipt of notice that the Company intends to prepay the Pre-Merger Convertible Notes, holders will have the option to convert their notes in lieu of payment.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">93</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the effective time of the Merger, <em data-td-fact-id="29257940" style="font-weight: inherit; font-style: normal;">$1.1</em> million in aggregate principal amount of Pre-Merger Convertible Notes were outstanding and<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;the rights of the holders of each such outstanding Pre-Merger Convertible Notes convertible into Diffusion Units were converted into the right to convert such securities into a number of shares of the Company&rsquo;s common stock equal to the number of Diffusion Units such Pre-Merger Convertible Notes would be convertible into pursuant to its terms multiplied by the Exchange Ratio.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016,</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Pre-Merger Convertible Notes&nbsp;of <em data-td-fact-id="29257941" style="font-weight: inherit; font-style: normal;">$0.7</em> million&nbsp;and related accrued interest of approximately <em data-td-fact-id="29257942" style="font-weight: inherit; font-style: normal;">$16,000</em>&nbsp;were converted into <em data-td-fact-id="29257943" style="font-weight: inherit; font-style: normal;">217,122</em> shares of common stock.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</font></p>
</div>

<div contenteditable="false" docsect="9" id="10809" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951197754" id="thunderdome-statement-848488">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257944" style="font-weight: inherit; font-style: normal;">9.</em>&nbsp;Commitments and Contingencies</b></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Office Space Lease Commitment</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company leases office and laboratory facilities in Charlottesville, Virginia. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 31, 2017, </em>the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29257945" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257946" style="font-weight: inherit; font-style: normal;">2017,</em> the Company capitalized approximately <em data-td-fact-id="29257947" style="font-weight: inherit; font-style: normal;">$0.4</em> million in leasehold improvements as part of the build-out of the new office and laboratory location. Rent expense related to the Company&#39;s operating leases for the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257948" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257949" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29257950" style="font-weight: inherit; font-style: normal;">2016</em> was approximately <em data-td-fact-id="29257951" style="font-weight: inherit; font-style: normal;">$0.1</em> million and <em data-td-fact-id="29257952" style="font-weight: inherit; font-style: normal;">$66,000,</em> respectively. For the new operating lease, lease payments commenced on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> May 1, 2017 </em>and expire on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> April 30, 2022. </em>The Company will continue to recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but <em data-td-fact-id="29257953" style="font-weight: inherit; font-style: normal;">not</em> yet paid. Future minimum rental payments under the Company&#39;s new non-cancelable operating lease at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257954" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257955" style="font-weight: inherit; font-style: normal;">2017</em> was as follows:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951197753" id="thunderdome-statement-848489">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Rental</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Commitments</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257589" style="font-weight: inherit; font-style: normal;">112,354</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257590" style="font-weight: inherit; font-style: normal;">114,409</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257591" style="font-weight: inherit; font-style: normal;">116,464</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257592" style="font-weight: inherit; font-style: normal;">118,519</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257593" style="font-weight: inherit; font-style: normal;">39,735</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257594" style="font-weight: inherit; font-style: normal;">501,481</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Arrangement with Clinical Research Organization</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> July 5, 2017, </em>the Company entered into a Master Services Agreement (&quot;MSA&quot;)<em data-td-invalid-detail="1" style="font-weight: inherit; font-style: normal;"> </em>with a contract research organization (&quot;CRO&quot;) to provide clinical trial services for individual studies and projects by executing individual work orders. The MSA and associated work orders are designed such that quarterly payments are to be made in advance of the work to be performed.&nbsp; The Company recognized research and development expenses related to this MSA of <em data-td-fact-id="29257956" style="font-weight: inherit; font-style: normal;">$1.0</em> million during the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017.&nbsp; </em>As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29257957" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29257958" style="font-weight: inherit; font-style: normal;">2017,</em> there was <em data-td-fact-id="29257959" style="font-weight: inherit; font-style: normal;">$0.8</em> million of prepaid research and development costs that are estimated to be recognized during the <em data-td-fact-id="29257960" style="font-weight: inherit; font-style: normal;">first</em> quarter of fiscal <em data-td-fact-id="29257961" style="font-weight: inherit; font-style: normal;">2018.</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">94</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Legal Proceedings</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 7, 2014, </em>a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s former Chief Executive Officer under the caption <i>Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH</i> (Case <em data-td-fact-id="29257962" style="font-weight: inherit; font-style: normal;">No.</em> <em data-td-fact-id="29257963" style="font-weight: inherit; font-style: normal;">BC553996</em>). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&rsquo; fees and costs. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 30, 2014, </em>the Company filed a petition to compel arbitration and a motion to stay the action. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> April 1, 2015, </em>the plaintiff filed a petition in opposition to the Company&rsquo;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> April 14, 2015, </em>the Court granted the Company&rsquo;s petition to compel arbitration and a motion to stay the action. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 8, 2016, </em>the plaintiff filed an arbitration demand with the American Arbitration Association. <em data-td-fact-id="29257964" style="font-weight: inherit; font-style: normal;">No</em> arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>have on the Company&rsquo;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&rsquo;s financial position.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> September 21, 2015, </em>David Schmidt, a former member of Diffusion LLC and current stockholder of the Company, filed suit (the &ldquo;Original Complaint&rdquo;) in the Circuit Court for Albemarle County, Virginia (Case. <em data-td-fact-id="29257965" style="font-weight: inherit; font-style: normal;">No.</em> <em data-td-fact-id="29257966" style="font-weight: inherit; font-style: normal;">CL15</em>-<em data-td-fact-id="29257967" style="font-weight: inherit; font-style: normal;">791,</em> David G. Schmidt v. Diffusion Pharmaceuticals LLC), which Complaint was amended on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> April 14, 2016 (</em>the &ldquo;Amended Complaint&rdquo;). The Original Complaint alleged that a breach of contract with respect to Mr. Schmidt&rsquo;s previously converted convertible note, and requested relief of specific performance requiring Diffusion LLC to issue him additional units, representing the additional number of units he would have received had he converted at the renegotiated conversion price.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> September 27, 2016, </em>the Company, Diffusion LLC, Mr. Schmidt and the other parties thereto entered into a Settlement Agreement (the &ldquo;Settlement Agreement&rdquo;) pursuant to which, among other things, (i) Mr. Schmidt and Diffusion each agreed to submit a consent order to the Court dismissing all claims set forth in the Amended Complaint with prejudice and without an admission of liability by any party, (ii) Mr. Schmidt and Diffusion each released, on behalf of such party and its heirs, assigns, representatives, affiliates and agents, all claims and causes of action of any nature against the other party existing as of the date of the Settlement Agreement and (iii) as consideration therefor, the Company agreed to issue and sell, to Mr. Schmidt and the other parties to the Settlement Agreement, the <em data-td-fact-id="29257968" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes in an aggregate principal amount of <em data-td-fact-id="29257969" style="font-weight: inherit; font-style: normal;">$1.9</em> million and are convertible into shares of Common Stock at an initial conversion price of <em data-td-fact-id="29257970" style="font-weight: inherit; font-style: normal;">$3.50</em> per share.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company recognized a litigation settlement charge of <em data-td-fact-id="29257971" style="font-weight: inherit; font-style: normal;">$2.5</em> million which represents the difference between the fair value of the <em data-td-fact-id="29257972" style="font-weight: inherit; font-style: normal;">2016</em> Convertible Notes issued and the cash received from Mr. Schmidt and other parties. The settlement charge was recorded as a component of general and administrative expenses within the Company&rsquo;s consolidated statement of operations for the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016.</em></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10810" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951209191" id="thunderdome-statement-848490">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29257973" style="font-weight: inherit; font-style: normal;">10.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Convertible Preferred Stock and Stockholder&rsquo;s Equity</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In contemplation of completing the private placement described below, the Company amended and restated its articles of incorporation and authorized <em data-td-fact-id="29257974" style="font-weight: inherit; font-style: normal;">13,750,000</em> shares of Series A convertible preferred stock.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">95</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Series<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;A Convertible Preferred Stock Transaction</font></i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 2017, </em>the Company completed a <em data-td-fact-id="29257975" style="font-weight: inherit; font-style: normal;">$25.0</em> million private placement of its securities in which the Company offered and sold units consisting of <em data-td-fact-id="29257976" style="font-weight: inherit; font-style: normal;">one</em> share of the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s Series A convertible preferred stock and a warrant to purchase <em data-td-fact-id="29257977" style="font-weight: inherit; font-style: normal;">one</em> share of common stock for each share of Series A convertible preferred stock purchased in the offering. Each share of Series A convertible preferred stock entitles the holder to an <em data-td-fact-id="29257978" style="font-weight: inherit; font-style: normal;">8.0%</em> cumulative dividend payable in shares of the Company&#39;s common stock on a semi-annual basis. The holders <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may, </em>at their option, convert each share of Series A convertible preferred stock into <em data-td-fact-id="29257979" style="font-weight: inherit; font-style: normal;">one</em> share of the Company&rsquo;s common stock based on the initial conversion price of <em data-td-fact-id="29257980" style="font-weight: inherit; font-style: normal;">$2.02</em> per share, subject to adjustment. Each warrant entitles the holder to purchase <em data-td-fact-id="29257981" style="font-weight: inherit; font-style: normal;">one</em> share of common stock at an initial exercise price of <em data-td-fact-id="29257982" style="font-weight: inherit; font-style: normal;">$2.22,</em> subject to adjustment and expires on the <em data-td-fact-id="29257983" style="font-weight: inherit; font-style: normal;">fifth</em> anniversary of their original issuance date. </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company sold <em data-td-fact-id="29257984" style="font-weight: inherit; font-style: normal;">12,376,329</em> units in the private placement and received approximately <em data-td-fact-id="29257985" style="font-weight: inherit; font-style: normal;">$22.1</em> million in aggregate net cash proceeds, after deducting commissions and other expenses of approximately <em data-td-fact-id="29257986" style="font-weight: inherit; font-style: normal;">$2.9</em> million. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of <em data-td-fact-id="29257987" style="font-weight: inherit; font-style: normal;">1,179,558</em> shares of common stock at an initial exercise price of <em data-td-fact-id="29257988" style="font-weight: inherit; font-style: normal;">$2.22</em> per share, which expire on the <em data-td-fact-id="29257989" style="font-weight: inherit; font-style: normal;">fifth</em> anniversary of their original issuance date.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC <em data-td-fact-id="29257990" style="font-weight: inherit; font-style: normal;">815</em>-<em data-td-fact-id="29257991" style="font-weight: inherit; font-style: normal;">40,</em> <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Derivatives and Hedging, Contracts in an Entity&rsquo;s own Equity</i> (&ldquo;ASC <em data-td-fact-id="29257992" style="font-weight: inherit; font-style: normal;">815</em>-<em data-td-fact-id="29257993" style="font-weight: inherit; font-style: normal;">40&rdquo;</em>). The conditions within ASC <em data-td-fact-id="29257994" style="font-weight: inherit; font-style: normal;">815</em>-<em data-td-fact-id="29257995" style="font-weight: inherit; font-style: normal;">40</em> are <em data-td-fact-id="29257996" style="font-weight: inherit; font-style: normal;">not</em> subject to a probability assessment. As the Company was obligated to issue a variable number of shares to settle the cumulative dividends on the Series A convertible preferred stock, the Company could <em data-td-fact-id="29257997" style="font-weight: inherit; font-style: normal;">not</em> assert that there would be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants were classified as liabilities. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 1, 2017 </em>the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&rsquo;s Certificate of Incorporation to permit the Company to pay dividends on the Company&rsquo;s Series A Convertible Preferred Stock in either cash or shares of the Company&rsquo;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert that there will be sufficient authorized shares available to settle the Series A warrants, and as a result, the Series A warrants were reclassified from liabilities to stockholders&rsquo; equity in the <em data-td-fact-id="29257998" style="font-weight: inherit; font-style: normal;">fourth</em> quarter of <em data-td-fact-id="29257999" style="font-weight: inherit; font-style: normal;">2017.</em></font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are <em data-td-fact-id="29258000" style="font-weight: inherit; font-style: normal;">no</em> proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was <em data-td-fact-id="29258001" style="font-weight: inherit; font-style: normal;">$10.2</em> million in the aggregate and was recorded as warrant related expenses in the statement of operations for the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258002" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258003" style="font-weight: inherit; font-style: normal;">2017.</em> </font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As a result of the completion of our common stock offering in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2018, </em>all outstanding shares of the Company&#39;s Series A convertible preferred stock converted into <em data-td-fact-id="29258004" style="font-weight: inherit; font-style: normal;">20,568,632</em> shares (the &quot;Conversion Shares&quot;) of common stock of which (i) <em data-td-fact-id="29258005" style="font-weight: inherit; font-style: normal;">8,306,278</em> shares were issued for the automatic conversion of Series A convertible preferred stock (ii) <em data-td-fact-id="29258006" style="font-weight: inherit; font-style: normal;">593,933</em> shares were issued upon settlement of accrued dividends and (iii) <em data-td-fact-id="29258007" style="font-weight: inherit; font-style: normal;">11,668,421</em> shares were issued for the settlement of the &ldquo;make-whole&rdquo; adjustment feature.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Dividends</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Until the conversion of all outstanding Series A convertible preferred stock in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2018, </em>the cumulative preferred dividend on the Series A convertible preferred stock was payable at a rate of <em data-td-fact-id="29258008" style="font-weight: inherit; font-style: normal;">8.0%</em> per annum, payable only in shares of common stock, semi-annually in arrears on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> April 1 </em>and <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> October 1 </em>of each year commencing on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> October 1, 2017. </em>This cumulative preferred dividend was <em data-td-fact-id="29258009" style="font-weight: inherit; font-style: normal;">not</em> subject to declaration. The Company recognized approximately <em data-td-fact-id="29258010" style="font-weight: inherit; font-style: normal;">$1.3</em> million in dividends during the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258011" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258012" style="font-weight: inherit; font-style: normal;">2017,</em> of which <em data-td-fact-id="29258013" style="font-weight: inherit; font-style: normal;">$0.2</em> million was settled upon by the issuance of <em data-td-fact-id="29258014" style="font-weight: inherit; font-style: normal;">86,335</em> shares of the Company&#39;s common stock. As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017, </em>there were approximately <em data-td-fact-id="29258015" style="font-weight: inherit; font-style: normal;">$1.1</em> million in accrued dividends that were subsequently settled in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2018. </em></font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">96</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Voting</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &ldquo;Certificate of Designation&rdquo;) or as required by law, the holders of the Series A convertible preferred stock voted together with the holders of common stock as a single class on an adjusted as-converted basis. In accordance with NASDAQ listing rules, in any matter voted on by the holders of the common stock, each share of Series A convertible preferred stock entitled the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance of such shares of Series A convertible preferred stock. Accordingly, shares of Series A convertible preferred stock issued in the initial closing of the private placement on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 14, 2017 </em>were entitled to <em data-td-fact-id="29258016" style="font-weight: inherit; font-style: normal;">0.84874</em> votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 31, 2017 </em>were entitled to <em data-td-fact-id="29258017" style="font-weight: inherit; font-style: normal;">0.50627</em> votes per share, in each case, subject to adjustment as described in the Certificate of Designation.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Liquidation Preference</i></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Series A convertible preferred stock was senior to the common stock. In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A convertible preferred stock would be entitled to receive their original investment amount. If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution would be distributed ratably among the holders of the Series A convertible preferred stock in proportion to the full amounts to which they would otherwise be entitled.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Conversion</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Series A convertible preferred stock was convertible, at the holder<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s option, into common stock. The Series A convertible preferred stock was also mandatorily convertible into common stock upon (a) the <em data-td-fact-id="29258018" style="font-weight: inherit; font-style: normal;">thirty</em>-day moving average of the closing price of the Company&rsquo;s common stock exceeding <em data-td-fact-id="29258019" style="font-weight: inherit; font-style: normal;">$8.00</em> per share, (b) a financing of at least <em data-td-fact-id="29258020" style="font-weight: inherit; font-style: normal;">$10.0</em> million in gross proceeds or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock. The conversion price of the Series A convertible preferred stock was subject to adjustment as described in the Certificate of Designation. During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258021" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258022" style="font-weight: inherit; font-style: normal;">2017,</em> <em data-td-fact-id="29258023" style="font-weight: inherit; font-style: normal;">4,070,051</em> shares of Series A convertible preferred stock were converted into common stock. Upon completion of the Company&rsquo;s public offering of its common stock in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2018, </em>all remaining shares of Series A convertible preferred stock issued and outstanding were converted into common stock.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Make-Whole Provision</i></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Until <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 2020 </em>and subject to certain exceptions, if the Company issued at least <em data-td-fact-id="29258024" style="font-weight: inherit; font-style: normal;">$10.0</em> million of its common stock or securities convertible into or exercisable for common stock at a per share price less than <em data-td-fact-id="29258025" style="font-weight: inherit; font-style: normal;">$2.02</em> (such lower price, the &ldquo;Make-Whole Price&rdquo;) while any shares of Series A convertible preferred stock remain outstanding, the Company would be required to issue to these holders of Series A convertible preferred stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A convertible preferred stock would be convertible into if the conversion price of such shares was equal to <em data-td-fact-id="29258026" style="font-weight: inherit; font-style: normal;">105%</em> of the Make-Whole Price (the &ldquo;Make-Whole Adjustment&rdquo;). The Make-Whole Adjustment was evaluated and was <em data-td-fact-id="29258027" style="font-weight: inherit; font-style: normal;">not</em> required to be bifurcated from the Series A convertible preferred stock.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Make-Whole Adjustment was triggered and settled in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2018 </em>in connection with the Company&#39;s common stock offering. The Company issued <em data-td-fact-id="29258028" style="font-weight: inherit; font-style: normal;">11,668,421</em> shares as part of the Make-Whole Adjustment.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">97</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Common Stock</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger (See Note <em data-td-fact-id="29258029" style="font-weight: inherit; font-style: normal;">4</em>) the Company ascribed non-cash consideration of <em data-td-fact-id="29258030" style="font-weight: inherit; font-style: normal;">$0.4</em> million to <em data-td-fact-id="29258031" style="font-weight: inherit; font-style: normal;">478,200</em> warrants outstanding prior to the Merger. During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258032" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258033" style="font-weight: inherit; font-style: normal;">2016,</em> the Company issued <em data-td-fact-id="29258034" style="font-weight: inherit; font-style: normal;">2,226,698</em> shares of its Common Stock of which <em data-td-fact-id="29258035" style="font-weight: inherit; font-style: normal;">1,861,503</em> are shares held by the pre-Merger stockholders of the Company, <em data-td-fact-id="29258036" style="font-weight: inherit; font-style: normal;">45,643</em> shares were issued for advisory services provided in connection with the Merger, <em data-td-fact-id="29258037" style="font-weight: inherit; font-style: normal;">102,430</em> shares were issued for general financial advisory services provided to the Company and <em data-td-fact-id="29258038" style="font-weight: inherit; font-style: normal;">217,122</em> shares were issued pursuant to conversions of convertible debt as discussed in Note <em data-td-fact-id="29258039" style="font-weight: inherit; font-style: normal;">8.</em> In <em data-td-fact-id="29258040" style="font-weight: inherit; font-style: normal;">2017,</em> the Company issued <em data-td-fact-id="29258041" style="font-weight: inherit; font-style: normal;">17,606</em> shares for advisory services. The Company did <em data-td-fact-id="29258042" style="font-weight: inherit; font-style: normal;">not</em> purchase or retire any shares of its common stock.</font></p>

<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Common Stock Warrants</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258043" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258044" style="font-weight: inherit; font-style: normal;">2017,</em> the Company had the following warrants outstanding to acquire shares of its common stock:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951209189" id="thunderdome-statement-848491">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Outstanding</b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".amt.D3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Range of exercise </b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>price per share</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to Merger</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257595" style="font-weight: inherit; font-style: normal;">447,721</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.D3" style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$20.00</p>
			</td>
			<td style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257597" style="font-weight: inherit; font-style: normal;">-</em></td>
			<td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257598" style="font-weight: inherit; font-style: normal;">$49.00</em></td>
			<td id=".trail.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in Series A</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257599" style="font-weight: inherit; font-style: normal;">13,555,887</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".symb.3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257602" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257601" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257600" style="font-weight: inherit; font-style: normal;">$2.22</em></em></em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257603" style="font-weight: inherit; font-style: normal;">14,003,608</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257604" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".amt.B3" style="width: 1%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257605" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257606" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258045" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258046" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258047" style="font-weight: inherit; font-style: normal;">2016,</em> <em data-td-fact-id="29258048" style="font-weight: inherit; font-style: normal;">13,000</em> and <em data-td-fact-id="29258049" style="font-weight: inherit; font-style: normal;">17,479</em> warrants issued prior to the Merger expired, respectively; these common stock warrants will expire periodically through <em data-td-fact-id="29258050" style="font-weight: inherit; font-style: normal;">2019.</em> The common stock warrants issued in connection with the <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 2017 </em>Series A private placement expire in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> March 2022. </em>During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258051" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258052" style="font-weight: inherit; font-style: normal;">2017,</em> the Company recognized a gain of <em data-td-fact-id="29258053" style="font-weight: inherit; font-style: normal;">$22.1</em> million upon the change in fair value of the warrant until they were reclassified to permanent equity in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 2017 </em>and <em data-td-fact-id="29258054" style="font-weight: inherit; font-style: normal;">$10.2</em> million in warrant related charges associated with the Series A private placement, which consisted primarily of the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. &nbsp;</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10811" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951219057" id="thunderdome-statement-848492">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258055" style="font-weight: inherit; font-style: normal;">11.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Stock-Based Compensation</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i><em data-td-fact-id="29258056" style="font-weight: inherit; font-style: normal;">2015</em> Equity Plan</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The <em data-td-fact-id="29258057" style="font-weight: inherit; font-style: normal;">2015</em> Equity Plan, as amended in <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> July 2016, </em>currently allows for the issuance of up to a maximum of <em data-td-fact-id="29258058" style="font-weight: inherit; font-style: normal;">500,000</em> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, <em data-td-fact-id="29258059" style="font-weight: inherit; font-style: normal;">not</em> including shares subject to awards assumed in connection with certain transactions, including the Merger. As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258060" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258061" style="font-weight: inherit; font-style: normal;">2017,</em> there were <em data-td-fact-id="29258062" style="font-weight: inherit; font-style: normal;">104,291</em> shares of common stock available for future issuance under the <em data-td-fact-id="29258063" style="font-weight: inherit; font-style: normal;">2015</em> Equity Plan. In addition, beginning on <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1, 2017, </em>on each <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1</em><sup>st</sup> through the term of the plan, up to <em data-td-fact-id="29258064" style="font-weight: inherit; font-style: normal;">4.0%</em> of the total shares of the Company&rsquo;s common stock outstanding as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31</em><sup>st</sup> will be added to the plan reserve, unless a lesser amount is stipulated by the Compensation Committee of the Company&rsquo;s Board of Directors. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 1, 2018, </em>the maximum number of shares of the <em data-td-fact-id="29258065" style="font-weight: inherit; font-style: normal;">2015</em> Equity Plan increased by <em data-td-fact-id="29258066" style="font-weight: inherit; font-style: normal;">580,785</em> shares, or <em data-td-fact-id="29258067" style="font-weight: inherit; font-style: normal;">4.0%</em> of the total shares of the Company&rsquo;s common stock outstanding at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258068" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258069" style="font-weight: inherit; font-style: normal;">2017.</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951219053" id="thunderdome-statement-848493">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="6" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Year ended</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31,</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257607" style="font-weight: inherit; font-style: normal;">95,040</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257608" style="font-weight: inherit; font-style: normal;">674,643</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257609" style="font-weight: inherit; font-style: normal;">1,145,511</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257610" style="font-weight: inherit; font-style: normal;">716,425</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257611" style="font-weight: inherit; font-style: normal;">1,240,551</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257612" style="font-weight: inherit; font-style: normal;">1,391,068</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">98</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the activity related to all stock option grants to employees and non-employees:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951219054" id="thunderdome-statement-848494">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Number of</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Options</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Weighted</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>average</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>exercise price</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>per share</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Weighted</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>average</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>remaining</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>contractual life</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(in years)</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D5" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Aggregate</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Intrinsic</b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Value</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><sup><b>(A)</b></sup></font></b></p>
			</td>
			<td id=".trail.D5" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257613" style="font-weight: inherit; font-style: normal;">1,495,615</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257614" style="font-weight: inherit; font-style: normal;">3.92</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257615" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257616" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">RestorGenex options outstanding</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257617" style="font-weight: inherit; font-style: normal;">301,156</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257618" style="font-weight: inherit; font-style: normal;">40.13</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257619" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257620" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cancelled</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257621" style="font-weight: inherit; font-style: normal;">(48,190</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257622" style="font-weight: inherit; font-style: normal;">61.30</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257623" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257624" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257625" style="font-weight: inherit; font-style: normal;">458,828</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257626" style="font-weight: inherit; font-style: normal;">6.25</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257627" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257628" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257629" style="font-weight: inherit; font-style: normal;">2,207,409</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257630" style="font-weight: inherit; font-style: normal;">8.09</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257631" style="font-weight: inherit; font-style: normal;">7.8</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257632" style="font-weight: inherit; font-style: normal;">94,599</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257633" style="font-weight: inherit; font-style: normal;">350,041</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257634" style="font-weight: inherit; font-style: normal;">2.46</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257635" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257636" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257637" style="font-weight: inherit; font-style: normal;">(1,461</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257638" style="font-weight: inherit; font-style: normal;">15.00</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B4" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257639" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.B5" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257640" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B5" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257641" style="font-weight: inherit; font-style: normal;">2,555,989</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257642" style="font-weight: inherit; font-style: normal;">7.32</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257643" style="font-weight: inherit; font-style: normal;">7.13</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257644" style="font-weight: inherit; font-style: normal;">4,734</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257645" style="font-weight: inherit; font-style: normal;">1,858,073</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257646" style="font-weight: inherit; font-style: normal;">8.25</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257647" style="font-weight: inherit; font-style: normal;">6.49</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257648" style="font-weight: inherit; font-style: normal;">4,734</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257649" style="font-weight: inherit; font-style: normal;">2,555,989</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257650" style="font-weight: inherit; font-style: normal;">7.32</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.4" style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257651" style="font-weight: inherit; font-style: normal;">7.13</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.5" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.5" style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257652" style="font-weight: inherit; font-style: normal;">4,734</em></td>
			<td id=".trail.5" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 18pt; vertical-align: top;">
			<p style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">(A)</p>
			</td>
			<td style="vertical-align: top;">
			<p style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">The difference, if positive, between the stock option<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s exercise price and the closing price of the Company&rsquo;s common stock at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258070" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258071" style="font-weight: inherit; font-style: normal;">2017.</em></font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Generally, the options have a <em data-td-fact-id="29258072" style="font-weight: inherit; font-style: normal;">ten</em> (<em data-td-fact-id="29258073" style="font-weight: inherit; font-style: normal;">10</em>) year<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;contractual term and vest in equal monthly installments over <em data-td-fact-id="29258074" style="font-weight: inherit; font-style: normal;">three</em> (<em data-td-fact-id="29258075" style="font-weight: inherit; font-style: normal;">3</em>) years. In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 2016, </em>the Company granted an option to purchase <em data-td-fact-id="29258076" style="font-weight: inherit; font-style: normal;">204,907</em> shares of Common Stock to a director in connection with the director&rsquo;s appointment to the board of directors. The options will vest in equal quarterly installments over <em data-td-fact-id="29258077" style="font-weight: inherit; font-style: normal;">ten</em> (<em data-td-fact-id="29258078" style="font-weight: inherit; font-style: normal;">10</em>) years and any options exercised are restricted from being sold until <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 2021.</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Non-employee Stock Options</u></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. There were <em data-td-fact-id="29258079" style="font-weight: inherit; font-style: normal;">9,394</em> stock options granted to non-employees during the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258080" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258081" style="font-weight: inherit; font-style: normal;">2017.</em> The total fair value of non-employee stock options vested during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258082" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258083" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258084" style="font-weight: inherit; font-style: normal;">2016</em> was approximately <em data-td-fact-id="29258085" style="font-weight: inherit; font-style: normal;">$90,000</em> and <em data-td-fact-id="29258086" style="font-weight: inherit; font-style: normal;">$0.8</em> million, respectively. At <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258087" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258088" style="font-weight: inherit; font-style: normal;">2017,</em> there was <em data-td-fact-id="29258089" style="font-weight: inherit; font-style: normal;">$14,000</em> of unrecognized compensation cost related to <em data-td-fact-id="29258090" style="font-weight: inherit; font-style: normal;">14,080</em> unvested stock options and subject to re-measurement until vested. The total unrecognized compensation expense will be recognized as expense over a weighted-average period of <em data-td-fact-id="29258091" style="font-weight: inherit; font-style: normal;">1.5</em> years.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Employee Stock Options</u></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The weighted average grant date fair value of stock option awards granted to employees was <em data-td-fact-id="29258092" style="font-weight: inherit; font-style: normal;">$2.10</em> and <em data-td-fact-id="29258093" style="font-weight: inherit; font-style: normal;">$5.55</em> during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258094" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258095" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258096" style="font-weight: inherit; font-style: normal;">2016,</em> respectively. The total fair value of options vested during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258097" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258098" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258099" style="font-weight: inherit; font-style: normal;">2016</em> were <em data-td-fact-id="29258100" style="font-weight: inherit; font-style: normal;">$1.1</em> million and <em data-td-fact-id="29258101" style="font-weight: inherit; font-style: normal;">$0.6</em> million, respectively. <em data-td-fact-id="29258102" style="font-weight: inherit; font-style: normal;">No</em> options were exercised during any of the periods presented. At <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258103" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258104" style="font-weight: inherit; font-style: normal;">2017,</em> there was <em data-td-fact-id="29258105" style="font-weight: inherit; font-style: normal;">$2.6</em> million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&nbsp;<em data-td-fact-id="29258106" style="font-weight: inherit; font-style: normal;">5.37</em> years.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">99</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The grant date fair value of employee stock options is determined using the Black-Scholes model. The following assumptions were used during the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258107" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258108" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258109" style="font-weight: inherit; font-style: normal;">2016:</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951219055" id="thunderdome-statement-848495">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 72%;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="3" id=".amt.D2" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><b><b>2017</b></b></td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; padding-bottom: 1px;">&nbsp;</td>
			<td colspan="3" id=".amt.D3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><b><b>2016</b></b></td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257653" style="font-weight: inherit; font-style: normal;">5.27</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257654" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257655" style="font-weight: inherit; font-style: normal;">6.00</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257656" style="font-weight: inherit; font-style: normal;">5.76</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257657" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257658" style="font-weight: inherit; font-style: normal;">7.48</em></td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257659" style="font-weight: inherit; font-style: normal;">&nbsp;1.8%</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257660" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".amt.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257661" style="font-weight: inherit; font-style: normal;">2.4%</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257662" style="font-weight: inherit; font-style: normal;">&nbsp;1.2%</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257663" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".amt.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257664" style="font-weight: inherit; font-style: normal;">2.0%</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257665" style="font-weight: inherit; font-style: normal;">&nbsp;109.8%</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257666" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".amt.2" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257667" style="font-weight: inherit; font-style: normal;">136.7%</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257668" style="font-weight: inherit; font-style: normal;">&nbsp;106.8%</em></td>
			<td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257669" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".amt.3" style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257670" style="font-weight: inherit; font-style: normal;">125.5%</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".symb.2" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257673" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257672" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257671" style="font-weight: inherit; font-style: normal;">&mdash;</em></em></em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="3" id=".symb.3" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><em data-td-fact-id="29257676" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257675" style="font-weight: inherit; font-style: normal;"><em data-td-fact-id="29257674" style="font-weight: inherit; font-style: normal;">&mdash;</em></em></em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><i>&nbsp;</i></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Restricted Stock Awards</i></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258110" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258111" style="font-weight: inherit; font-style: normal;">2017,</em> there were <em data-td-fact-id="29258112" style="font-weight: inherit; font-style: normal;">3,066</em> unvested shares of restricted stock. During the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258113" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258114" style="font-weight: inherit; font-style: normal;">2017,</em> <em data-td-fact-id="29258115" style="font-weight: inherit; font-style: normal;">6,132</em> shares vested. The fair value as of the respective vesting dates of the restricted stock awards was both <em data-td-fact-id="29258116" style="font-weight: inherit; font-style: normal;">$12,000</em> for <em data-td-fact-id="29258117" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258118" style="font-weight: inherit; font-style: normal;">2016.</em> The grant date fair value of each restricted stock award granted during the year ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258119" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258120" style="font-weight: inherit; font-style: normal;">2016</em> was <em data-td-fact-id="29258121" style="font-weight: inherit; font-style: normal;">$1.97.</em> There were <em data-td-fact-id="29258122" style="font-weight: inherit; font-style: normal;">no</em> restricted stock awards granted in <em data-td-fact-id="29258123" style="font-weight: inherit; font-style: normal;">2017.</em> At <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258124" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258125" style="font-weight: inherit; font-style: normal;">2017,</em> there was <em data-td-fact-id="29258126" style="font-weight: inherit; font-style: normal;">$6,000</em> of unrecognized compensation cost related to unvested restricted stock that will be recognized as expense over a weighted average period of less than <em data-td-fact-id="29258127" style="font-weight: inherit; font-style: normal;">1</em> year.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10812" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951228686" id="thunderdome-statement-848496">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258128" style="font-weight: inherit; font-style: normal;">12.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Defined Contribution Retirement Plan</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has established a <em data-td-fact-id="29258129" style="font-weight: inherit; font-style: normal;">401</em>(k)<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;defined contribution plan (the <em data-td-fact-id="29258130" style="font-weight: inherit; font-style: normal;">401</em>(k) Plan) that covers all employees who qualify under the terms of the plan. Eligible employees <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>elect to contribute to the <em data-td-fact-id="29258131" style="font-weight: inherit; font-style: normal;">401</em>(k) Plan up to <em data-td-fact-id="29258132" style="font-weight: inherit; font-style: normal;">90%</em> of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <em data-td-fact-id="29258133" style="font-weight: inherit; font-style: normal;">4%</em> of the participant&rsquo;s compensation. The Company made matching contributions under the <em data-td-fact-id="29258134" style="font-weight: inherit; font-style: normal;">401</em>(k) Plan of approximately <em data-td-fact-id="29258135" style="font-weight: inherit; font-style: normal;">$49,000</em> and <em data-td-fact-id="29258136" style="font-weight: inherit; font-style: normal;">$28,000</em> for the years ended <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258137" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258138" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258139" style="font-weight: inherit; font-style: normal;">2016,</em> respectively.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">100</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10813" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951242320" id="thunderdome-statement-848497">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258140" style="font-weight: inherit; font-style: normal;">13.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Income Taxes</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prior to the Merger, the Company was treated as a partnership for federal income tax purposes.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 2017, </em>the <em data-td-fact-id="29258141" style="font-weight: inherit; font-style: normal;">2017</em> Tax Act was enacted, which includes a number of changes to previously existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from <em data-td-fact-id="29258142" style="font-weight: inherit; font-style: normal;">35%</em> to <em data-td-fact-id="29258143" style="font-weight: inherit; font-style: normal;">21%</em> for tax years beginning after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017. </em>The <em data-td-fact-id="29258144" style="font-weight: inherit; font-style: normal;">2017</em> Tax Act also provides for a <em data-td-fact-id="29258145" style="font-weight: inherit; font-style: normal;">one</em>-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed into service after <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> September 27, 2017 </em>as well as prospective changes beginning in <em data-td-fact-id="29258146" style="font-weight: inherit; font-style: normal;">2018,</em> including repeal of the domestic manufacturing deduction, acceleration of tax revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest.</font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp; In <em data-td-fact-id="29258147" style="font-weight: inherit; font-style: normal;">2016,</em> the Company recorded a deferred tax liability of <em data-td-fact-id="29258148" style="font-weight: inherit; font-style: normal;">$3.6</em> million for the basis differences associated with indefinite-lived in-process R&amp;D assets.&nbsp;In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> August 2016, </em>the Company abandoned future development efforts for the IPR&amp;D asset associated with RES-<em data-td-fact-id="29258149" style="font-weight: inherit; font-style: normal;">440</em> and recorded an impairment charge of <em data-td-fact-id="29258150" style="font-weight: inherit; font-style: normal;">$1.0</em> million which is equal to its acquired value. Upon recognizing the impairment, the Company recognized an income tax benefit of <em data-td-fact-id="29258151" style="font-weight: inherit; font-style: normal;">$0.4</em> million and reduced the carrying value of the related deferred tax liability as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258152" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258153" style="font-weight: inherit; font-style: normal;">2016</em> (See Note <em data-td-fact-id="29258154" style="font-weight: inherit; font-style: normal;">4</em>). In <em data-td-fact-id="29258155" style="font-weight: inherit; font-style: normal;">2017,</em> this deferred tax liability was further reduced by <em data-td-fact-id="29258156" style="font-weight: inherit; font-style: normal;">$1.1</em> million as a result of the <em data-td-fact-id="29258157" style="font-weight: inherit; font-style: normal;">2017</em> Tax Act. </font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Significant components of the Company&#39;s deferred tax assets for federal income taxes consisted of the following:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951242316" id="thunderdome-statement-848498">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31, 2017</b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31, 2016</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Deferred tax assets</b></td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257677" style="font-weight: inherit; font-style: normal;">5,310,628</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257678" style="font-weight: inherit; font-style: normal;">7,547,296</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257679" style="font-weight: inherit; font-style: normal;">2,141,973</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257680" style="font-weight: inherit; font-style: normal;">2,720,186</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257681" style="font-weight: inherit; font-style: normal;">2,537,039</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257682" style="font-weight: inherit; font-style: normal;">1,218,069</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257683" style="font-weight: inherit; font-style: normal;">5,247,469</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257684" style="font-weight: inherit; font-style: normal;">4,690,843</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257685" style="font-weight: inherit; font-style: normal;">(15,237,109</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257686" style="font-weight: inherit; font-style: normal;">(16,176,394</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</p>
			</td>
			<td id=".lead.2" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257687" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.B3" style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257688" style="font-weight: inherit; font-style: normal;">&nbsp;</em></td>
			<td id=".trail.B3" style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td>&nbsp;</td>
			<td id=".lead.B2">&nbsp;</td>
			<td id=".symb.B2">&nbsp;</td>
			<td id=".amt.B2">&nbsp;</td>
			<td id=".trail.B2">&nbsp;</td>
			<td id=".lead.B3">&nbsp;</td>
			<td id=".symb.B3">&nbsp;</td>
			<td id=".amt.B3">&nbsp;</td>
			<td id=".trail.B3">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax liabilities</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257689" style="font-weight: inherit; font-style: normal;">(2,223,678</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257690" style="font-weight: inherit; font-style: normal;">(3,279,363</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257691" style="font-weight: inherit; font-style: normal;">(2,223,678</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257692" style="font-weight: inherit; font-style: normal;">(3,279,363</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company does <em data-td-fact-id="29258158" style="font-weight: inherit; font-style: normal;">not</em> have unrecognized tax benefits as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258159" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258160" style="font-weight: inherit; font-style: normal;">2017</em> or <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2016. </em>The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company had net operating loss carryforwards (&ldquo;NOL&rdquo;) for federal and state income tax purposes at <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<em data-td-fact-id="29258161" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258162" style="font-weight: inherit; font-style: normal;">2017</em>&nbsp;of approximately:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951242317" id="thunderdome-statement-848499">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Combined NOL Carryforwards:</b></p>
			</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31, 2017</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257695" style="font-weight: inherit; font-style: normal;">20,629,817</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257696" style="font-weight: inherit; font-style: normal;">20,640,700</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The net operating loss carryforwards begin expiring in <em data-td-fact-id="29258163" style="font-weight: inherit; font-style: normal;">2034</em> for federal income tax purposes and <em data-td-fact-id="29258164" style="font-weight: inherit; font-style: normal;">2034</em> for state income tax purposes. In <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 2016, </em>the number of outstanding shares of RestorGenex common stock increased in connection with the Merger discussed in note <em data-td-fact-id="29258165" style="font-weight: inherit; font-style: normal;">4.</em> This increase in the number of shares outstanding<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;resulted in&nbsp;a change of ownership, under the provisions of Internal Revenue Code Section <em data-td-fact-id="29258166" style="font-weight: inherit; font-style: normal;">382</em> and similar state provisions, and limits the Company&rsquo;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation.&nbsp;The Company&#39;s <em data-td-fact-id="29258167" style="font-weight: inherit; font-style: normal;">2017</em> and <em data-td-fact-id="29258168" style="font-weight: inherit; font-style: normal;">2018</em> financings <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> may </em>have also triggered an ownership change, which could further limit the Company&#39;s ability to utilize its NOL carryforwards. The Company has yet to determine this potential limitation. The Company recorded a <em data-td-fact-id="29258169" style="font-weight: inherit; font-style: normal;">100%</em> valuation allowance of the deferred tax assets as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December&nbsp;</em><em data-td-fact-id="29258170" style="font-weight: inherit; font-style: normal;">31,</em> <em data-td-fact-id="29258171" style="font-weight: inherit; font-style: normal;">2017,</em> because of the uncertainty of their realization.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 31, 2017 </em>and <em data-td-fact-id="29258172" style="font-weight: inherit; font-style: normal;">2016</em> is as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951242318" id="thunderdome-statement-848500">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Rate reconciliation:</b></p>
			</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><b>December 31, 2017</b></b></b></p>
			</td>
			<td id=".trail.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".lead.D3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b><b>December 31, 2016</b></b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257697" style="font-weight: inherit; font-style: normal;">(34.0</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><em data-td-fact-id="29257698" style="font-weight: inherit; font-style: normal;">(34.0</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257699" style="font-weight: inherit; font-style: normal;">(16.3</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257700" style="font-weight: inherit; font-style: normal;">(2.3</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of warrant</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257701" style="font-weight: inherit; font-style: normal;">(126.1</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257702" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in tax rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257703" style="font-weight: inherit; font-style: normal;">205.5</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257704" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Litigation settlement charge</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257705" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257706" style="font-weight: inherit; font-style: normal;">4.6</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisition costs</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257707" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257708" style="font-weight: inherit; font-style: normal;">2.8</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257709" style="font-weight: inherit; font-style: normal;">(36.0</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257710" style="font-weight: inherit; font-style: normal;">(4.4</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257711" style="font-weight: inherit; font-style: normal;">(38.8</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257712" style="font-weight: inherit; font-style: normal;">27.2</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257713" style="font-weight: inherit; font-style: normal;">1.2</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257714" style="font-weight: inherit; font-style: normal;">4.2</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257715" style="font-weight: inherit; font-style: normal;">1.0</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><em data-td-fact-id="29257716" style="font-weight: inherit; font-style: normal;">(0.1</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Total provision</b></p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257717" style="font-weight: inherit; font-style: normal;">(43.5</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257718" style="font-weight: inherit; font-style: normal;">(2.0</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</p>
			</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s <em data-td-fact-id="29258173" style="font-weight: inherit; font-style: normal;">2014</em> to <em data-td-fact-id="29258174" style="font-weight: inherit; font-style: normal;">2016</em> tax years remain open and subject to examination.</font></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">102</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10814" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951251478" id="thunderdome-statement-848501">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258175" style="font-weight: inherit; font-style: normal;">14.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Fair Value Measurements</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in <em data-td-fact-id="29258176" style="font-weight: inherit; font-style: normal;">one</em> of the following <em data-td-fact-id="29258177" style="font-weight: inherit; font-style: normal;">three</em> levels of the fair value hierarchy, of which the <em data-td-fact-id="29258178" style="font-weight: inherit; font-style: normal;">first</em> <em data-td-fact-id="29258179" style="font-weight: inherit; font-style: normal;">two</em> are considered observable and the last is considered unobservable:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em data-td-fact-id="29258180" style="font-weight: inherit; font-style: normal;">1</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&mdash;Quoted prices in active markets for identical assets or liabilities.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em data-td-fact-id="29258181" style="font-weight: inherit; font-style: normal;">2</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&mdash;Observable inputs (other&nbsp;than Level <em data-td-fact-id="29258182" style="font-weight: inherit; font-style: normal;">1</em> quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are <em data-td-fact-id="29258183" style="font-weight: inherit; font-style: normal;">not</em> active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 36pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&#9679;</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <em data-td-fact-id="29258184" style="font-weight: inherit; font-style: normal;">3</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&mdash;Unobservable inputs that are supported by little or <em data-td-fact-id="29258185" style="font-weight: inherit; font-style: normal;">no</em> market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</font></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The asset<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s or liability&rsquo;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table presents the Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s assets and liabilities that are measured at fair value on a recurring basis:</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951251475" id="thunderdome-statement-848502">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="10" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31, 2017</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 1)</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 2)</b></b></p>
			</td>
			<td id=".trail.D3" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 3)</b></b></p>
			</td>
			<td id=".trail.D4" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257719" style="font-weight: inherit; font-style: normal;">8,896,468</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257720" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257721" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities</b></p>
			</td>
			<td id=".lead.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257722" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257723" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257724" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951251476" id="thunderdome-statement-848552">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="10" id=".amt.D4" style="width: 21474836.47%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>December 31, 2016</b></b></p>
			</td>
			<td id=".trail.D4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom;">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 1)</b></b></p>
			</td>
			<td id=".trail.D2" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D3" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 2)</b></b></p>
			</td>
			<td id=".trail.D3" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D4" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>(Level 3)</b></b></p>
			</td>
			<td id=".trail.D4" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257727" style="font-weight: inherit; font-style: normal;">1,552,852</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257728" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257729" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities</b></p>
			</td>
			<td id=".lead.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B2" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B3" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".lead.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".amt.B4" style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
			<td id=".trail.B4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257730" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.3" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.3" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257731" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.3" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
			<td id=".lead.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.4" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.4" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257732" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.4" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level <em data-td-fact-id="29258186" style="font-weight: inherit; font-style: normal;">3</em>) is as follows:</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951251476" id="thunderdome-statement-848553">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom;">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".lead.D2" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" id=".amt.D2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Common Stock </b></b></p>

			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><b>Warrant Liability</b></b></p>
			</td>
			<td id=".trail.D2" style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2016</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257735" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issued in connection with the Series A convertible preferred stock</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257736" style="font-weight: inherit; font-style: normal;">35,225,846</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257737" style="font-weight: inherit; font-style: normal;">(22,072,322</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Reclassification of Series A warrants to additional paid in capital</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257738" style="font-weight: inherit; font-style: normal;">(13,153,524</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2017</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><em data-td-fact-id="29257739" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">103</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>.</b></font></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENT</b><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>S</b></font></p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The common stock warrants issued in connection with the Series A convertible preferred stock were previously classified as liabilities, and were marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&rsquo; equity. On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 1, 2017 </em>the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&rsquo;s Certificate of Incorporation to permit the Company to pay dividends on the Company&rsquo;s Series A Convertible Preferred Stock in either cash or shares of the Company&rsquo;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert there will be sufficient authorized shares available to settle the Series A warrants. Upon this assertion, the Series A warrants were reclassified from liabilities to stockholders&rsquo; equity.</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrant liability as of <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> November 1, 2017, </em>which was the date of the reclassification, were as follows:</font></p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div data-td-parse-id="1" data-td-taggable-table="table" data-td-v2v-id="1520951251476" id="thunderdome-statement-848505">
<table border="0" cellpadding="0" cellspacing="0" class="finTable" id="null" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock price</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257740" style="font-weight: inherit; font-style: normal;">1.44</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257741" style="font-weight: inherit; font-style: normal;">2.22</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257742" style="font-weight: inherit; font-style: normal;">4.38</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257743" style="font-weight: inherit; font-style: normal;">1.9</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257744" style="font-weight: inherit; font-style: normal;">104.1</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</p>
			</td>
		</tr>
		<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
			<td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p>
			</td>
			<td id=".lead.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".symb.2" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td id=".amt.2" style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><em data-td-fact-id="29257745" style="font-weight: inherit; font-style: normal;">&mdash;</em></td>
			<td id=".trail.2" nowrap="true" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td>
		</tr>

</table>
</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><b>&nbsp;</b></p>
</div>

<div contenteditable="false" docsect="9" id="10815" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951260495" id="thunderdome-statement-848506">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258187" style="font-weight: inherit; font-style: normal;">15.</em> Related Party Transactions</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s Director of Information Technologies is also the son of the Chief Executive Officer and he has held that position since <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> December 2014.</em></font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
</div>

<div contenteditable="false" docsect="9" id="10816" sectdesc="Note to Financial Statements">&nbsp;</div>

<div data-td-parse-id="1" data-td-statement-type="note" data-td-v2v-id="1520951274714" id="thunderdome-statement-848507">
<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b><em data-td-fact-id="29258188" style="font-weight: inherit; font-style: normal;">16.</em><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Subsequent Event</font></b></p>

<p style="margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <em data-td-invalid-detail="1" style="font-style: normal; font-weight: inherit;"> January 22, 2018, </em>Diffusion Pharmaceuticals Inc. (the &ldquo;Company&rdquo;) closed its previously announced underwritten public offering of <em data-td-fact-id="29258189" style="font-weight: inherit; font-style: normal;">15,000,000</em> shares of the Company&rsquo;s common stock, par value <em data-td-fact-id="29258190" style="font-weight: inherit; font-style: normal;">$0.001</em> per share (&ldquo;Common Stock&rdquo;), and warrants to purchase <em data-td-fact-id="29258191" style="font-weight: inherit; font-style: normal;">15,000,000</em> shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional <em data-td-fact-id="29258192" style="font-weight: inherit; font-style: normal;">1,970,625</em> shares of Common Stock pursuant to the underwriter&rsquo;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of <em data-td-fact-id="29258193" style="font-weight: inherit; font-style: normal;">$0.80</em> per share and warrant for total gross proceeds of approximately <em data-td-fact-id="29258194" style="font-weight: inherit; font-style: normal;">$12.0</em> million. The warrants have an exercise price of <em data-td-fact-id="29258195" style="font-weight: inherit; font-style: normal;">$0.80</em> per share and a term of <em data-td-fact-id="29258196" style="font-weight: inherit; font-style: normal;">five</em> years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to <em data-td-fact-id="29258197" style="font-weight: inherit; font-style: normal;">750,000</em> shares of Common Stock. The underwriter&rsquo;s warrants have an exercise price of <em data-td-fact-id="29258198" style="font-weight: inherit; font-style: normal;">$1.00,</em> a term of <em data-td-fact-id="29258199" style="font-weight: inherit; font-style: normal;">five</em> years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company&#39;s Series A convertible preferred stock converted into <em data-td-fact-id="29258200" style="font-weight: inherit; font-style: normal;">20,568,632</em> shares (the &quot;Conversion Shares) of common stock (including accrued dividends paid in kind and the &quot;make-whole&quot; adjustment feature thereof). </font></p>
</div>

<div contenteditable="false" docsect="12" id="10817" sectdesc="Other">&nbsp;</div>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">104</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 9.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 9A.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CONTROLS AND PROCEDURES</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The term &ldquo;disclosure controls and procedures&rdquo; means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time periods specified in the SEC<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&ndash; 15(e) and 15d &ndash; 15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our principal executive officer and principal financial officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s Report on Internal Control Over Financial Reporting</font></b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our Chief Executive Officer and Senior Vice President, Finance, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Internal Control&mdash;Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&nbsp;31, 2017.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">105</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Attestation Report of the Independent Registered Public Accounting Firm</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s report was not subject to attestation by our independent registered public accounting firm pursuant to Section 989G of the Dodd-Frank Wall Street Reform and Consumer Protection Act, which exempts smaller reporting companies from the auditor attestation requirement.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>&nbsp;</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Change in Internal Control Over Financial Reporting</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">There was no change in our internal control over financial reporting that occurred during our fourth quarter ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 9B.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>OTHER INFORMATION</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">106</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PART III</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 10.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information with respect to this item will be set forth in the Proxy Statement for the 2016 Annual Meeting of Stockholders (&ldquo;<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><u>Proxy Statement</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) or an amendment to this Annual Report on Form 10-K (&ldquo;<u>Form 10-K/A</u></font><font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rdquo;) under the headings &ldquo;Election of Directors,&rdquo; &ldquo;Executive Officers,&rdquo; &ldquo;Section 16(a) Beneficial Ownership Reporting Compliance&rdquo; and &ldquo;Corporate Governance&rdquo; and is incorporated herein by reference. The Proxy Statement or Form 10-K/A will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</font></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 11.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXECUTIVE COMPENSATION</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information with respect to this item will be set forth in the Proxy Statement or Form 10-K/A under the headings &ldquo;Executive Compensation&rdquo; and &ldquo;Director Compensation,&rdquo; and is incorporated herein by reference. The Proxy Statement or Form 10-K/A will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 12.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information with respect to this item will be set forth in the Proxy Statement or Form 10-K/A and is incorporated herein by reference. The Proxy Statement or Form 10-K/A will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 13.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information with respect to this item will be set forth in the Proxy Statement or Form 10-K/A under the headings &ldquo;Certain Relationships and Related Party Transactions&rdquo; and &ldquo;Corporate Governance&rdquo; and is incorporated herein by reference. The Proxy Statement or Form 10-K/A will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 14.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Information with respect to this item will be set forth in the Proxy Statement or Form 10-K/A under the heading &ldquo;Ratification of the Selection of Independent Registered Public Accounting Firm,&rdquo; and is incorporated herein by reference. The Proxy Statement or Form 10-K/A will be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">107</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>PART IV</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 15.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Our financial statements are included in Item 8 of Part II of this report.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The exhibits to this report are listed on the Exhibit Index to this report. A copy of any of the exhibits listed will be furnished at a reasonable cost, upon receipt from any person of a written request for any such exhibit. Such request should be sent to Diffusion Pharmaceuticals Inc., 1317 Carlton Avenue, Suite 200, Charlottesville, Virginia 22902, Attention: Stockholder Information. The Exhibit Index indicates each management contract or compensatory plan or arrangement required to be filed as an exhibit to this report.</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>ITEM 16.</b></p>
			</td>
			<td>
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FORM 10-K SUMMARY</b></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">None.</p>

<p style="margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">108</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>SIGNATURES</b></p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 47%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Dated: April 2, 2018</p>
			</td>
			<td colspan="2" style="width: 3%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 47%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</p>
			</td>
			<td style="width: 50%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ David G. Kalergis</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David G. Kalergis</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>Chairman and Chief Executive Officer</i></p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><i>(Principal Executive Officer)</i></p>
			</td>
		</tr>

</table>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: left; text-indent: 51pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>

<p style="margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Name and Signature</b></p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Title</b></p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Date</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ David G. Kalergis</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chairman of the Board and Chief Executive Officer</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">David G. Kalergis</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Principal Executive Officer)</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Ben L. Shealy</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Senior Vice President, Finance</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Ben L. Shealy</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ John L. Gainer, Ph.D.</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">John L. Gainer, Ph.D.</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Isaac Blech</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Vice Chairman</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Isaac Blech</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Robert Adams</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Robert Adams</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Mark T. Giles</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Mark T. Giles</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Alan Levin</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Alan Levin</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: thin; border-bottom-style: solid;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">/s/ Robert Ruffolo</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Director</p>
			</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">April 2, 2018</td>
		</tr>
		<tr>
			<td style="width: 35%; vertical-align: top; text-align: center;">Robert Ruffolo</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 29%; vertical-align: top;">&nbsp;</td>
			<td style="width: 3%; vertical-align: top;">&nbsp;</td>
			<td style="width: 30%; vertical-align: top;">&nbsp;</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">109</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-K</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>FOR THE YEAR ENDED DECEMBER 31, 2016</b></p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 9%; vertical-align: bottom; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Exhibit</b></p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>No.</b></p>
			</td>
			<td style="width: 44%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Description</b></p>
			</td>
			<td style="width: 2%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>Method of Filing</b></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.1</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex2d1.htm" style="-sec-extract: exhibit;">Plan of Conversion, dated June 18, 2015</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 2.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on June 18, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2.2</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774915022289/ex2-1.htm" style="-sec-extract: exhibit;">Agreement and Plan of Merger dated as of December 15, 2015 among the Company, Arco Merger Sub, LLC and Diffusion Pharmaceuticals LLC *</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 2.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on December 15, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.1</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917005713/ex3-1.htm" style="-sec-extract: exhibit;">Certificate of Incorporation of Diffusion Pharmaceuticals Inc., as amended</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 3.1&nbsp;to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.2</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex3-4.htm" style="-sec-extract: exhibit;">Bylaws of Diffusion Pharmaceuticals Inc., as amended</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 3.4 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.3</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917004538/ex3-1.htm" style="-sec-extract: exhibit;">Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock of Diffusion Pharmaceuticals Inc.</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 3.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on March 15, 2017</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">3.5</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex3d2.htm" style="-sec-extract: exhibit;">Certificate of Conversion, as filed with the Secretary of State of the State of Delaware on June 18, 2015</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 3.2 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on June 18, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.1</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916039372/ex4-1.htm" style="-sec-extract: exhibit;">Form of Diffusion Pharmaceuticals Inc. Convertible Note Agreement</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on October 3, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.2</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex4-7.htm" style="-sec-extract: exhibit;">Form of Diffusion Pharmaceuticals LLC Convertible Note Agreement</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.7 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.3</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917004538/ex4-1.htm" style="-sec-extract: exhibit;">Form of Warrant issued to Investors in the 2017 Private Placement by Diffusion Pharmaceuticals Inc.</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on March 15, 2017</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.4</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000101968714001571/restorgenex_8k-ex0401.htm" style="-sec-extract: exhibit;">Form of Warrant issued to Investors in the 2014 Private Placement by the Company</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on April 29, 2014</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.5</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex4d5.htm" style="-sec-extract: exhibit;">Warrant, dated October 21, 2014, issued by the Company to Isaac Blech</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.5 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the fiscal year ended December 31, 2014</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.6</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex4d4.htm" style="-sec-extract: exhibit;">Warrant, dated April 29, 2014, issued by the Company to Sol J. Barer, Ph.D.</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.4 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the fiscal year ended December 31, 2014</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.7</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000800/ex_103239.htm" style="-sec-extract: exhibit;">Form of 2018 Common Stock Warrant</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.1&nbsp;to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on January 19, 2018</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">4.8</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000941/ex_103358.htm" style="-sec-extract: exhibit;">Form of 2018 Underwriters&#39; Warrant</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 4.2 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on January 22, 2018</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.1</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916038465/ex10-1.htm" style="-sec-extract: exhibit;">Employment Agreement, dated as of September 6, 2016, by and between David G. Kalergis and Diffusion Pharmaceuticals Inc.**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K as filed on September 8, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.2</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916039796/ex10-1.htm" style="-sec-extract: exhibit;">Employment Agreement, dated as of October 12, 2016, by and between Ben L. Shealy and Diffusion Pharmaceuticals Inc.**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K as filed on October 13, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.3</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d2.htm" style="-sec-extract: exhibit;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.2 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K as filed on June 18, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.4</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract: exhibit;">Amendment No. 1 to Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Appendix B to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s definitive proxy statement on Schedule 14A filed on June 10, 2016</font></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt;">&nbsp;</p>

<div data-thunderdome-xbrl-exclude="1" id="PGBK" style="width: 100%; margin-right: 0pt; margin-left: 0pt;">
<div id="PGNUM" style="width: 100%; text-align: center;">110</div>

<hr style="border: currentColor; border-image: none; width: 100%; height: 2px; color: rgb(0, 0, 0); page-break-after: always; background-color: rgb(0, 0, 0);">
<div id="PGHDR" style="width: 100%; text-align: left;">&nbsp;</div>
</div>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">

		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.5</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108103.htm" style="-sec-extract: exhibit;">Form of Diffusion Pharmaceuticals Inc. Stock Option Award Agreement**</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.6</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-24.htm" style="-sec-extract: exhibit;">Form of Diffusion Pharmaceuticals LLC Stock Option Award Agreement**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.24&nbsp;to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.7</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d3.htm" style="-sec-extract: exhibit;">Form of 2015 Incentive Stock Option Agreement under the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.3 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on June 18, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.8</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915046210/a15-14238_1ex10d4.htm" style="-sec-extract: exhibit;">Form of 2015 Non-Statutory Stock Option Agreement under the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.4 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on June 18, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.9</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex10d12.htm" style="-sec-extract: exhibit;">Form of Stock Option Agreement between the Company and certain former Executive Officers**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.12 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the fiscal year ended December 31, 2014</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.10</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915025785/a15-2678_1ex10d13.htm" style="-sec-extract: exhibit;">Form of Stock Option Agreement between the Company and certain former Directors**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.13 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the fiscal year ended December 31, 2014</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.11</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-3.htm" style="-sec-extract: exhibit;">Form of Indemnification Agreement between Diffusion Pharmaceuticals Inc. and each of its Directors and Officers**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.3 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.12</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915033236/a15-10474_1ex10d1.htm" style="-sec-extract: exhibit;">Resignation Agreement, dated April 30, 2015, between the Company and Yael Schwartz, Ph.D.**</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.1&nbsp;to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K&nbsp;filed on May 1, 2015</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.13</p>
			</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000110465915033236/a15-10474_1ex10d1.htm" style="-sec-extract: exhibit;">Lease Agreement, dated March 31, 2017, by and between Diffusion Pharmaceuticals Inc. and One Carlton LLC</a></p>
			</td>
			<td style="width: 2%; vertical-align: top;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.4&nbsp;to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s quarterly&nbsp;report on Form 8-K for the quarter ended March 31, 2017</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.14</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916039372/ex10-1.htm" style="-sec-extract: exhibit;">Settlement Agreement, dated September 27, 2016, by and among Diffusion Pharmaceuticals Inc., Diffusion Pharmaceuticals LLC, David Schmidt and the other parties thereto</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.1 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on October 3, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">10.15</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916023394/ex10-2.htm" style="-sec-extract: exhibit;">Contingent Value Rights Agreement, dated as of January 8, 2016, by and between Diffusion Pharmaceuticals Inc. and Computershare, Inc., as Rights Agent</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Incorporated by reference to Exhibit 10.2 to the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s current report on Form 8-K filed on January 8, 2016</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">21.1</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108104.htm" style="-sec-extract: exhibit;">Subsidiaries of Diffusion Pharmaceuticals Inc.</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">23.1</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108150.htm" style="-sec-extract: exhibit;">Consent of KPMG LLP, independent registered public accounting firm</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31.1</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108105.htm" style="-sec-extract: exhibit;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">31.2</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108106.htm" style="-sec-extract: exhibit;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">32.1</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><a href="ex_108107.htm" style="-sec-extract: exhibit;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Furnished herewith</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">101</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following materials from the registrant<font style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&rsquo;s annual report on Form 10-K for the year ended December 31, 2017, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements</font></p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Filed herewith</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">*</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">All exhibits and schedules to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish the omitted exhibits and schedules to the SEC upon request by the SEC.</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="width: 9%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">**</p>
			</td>
			<td style="width: 44%; vertical-align: bottom;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A management contract or compensatory plan or arrangement.</p>

			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="width: 2%; vertical-align: bottom;">&nbsp;</td>
			<td style="width: 44%; vertical-align: top;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>

<p style="margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">111</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>2
<FILENAME>ex_108103.htm
<DESCRIPTION>EXHIBIT 10.5
<TEXT>
<html>
<head>
	<title>ex_108103.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2018 2:52:15 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1.7pt;margin-top:0pt;text-align:right;"><b>Exhibit 10.5</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:1.65pt;margin-top:0pt;text-align:center;"><b>STOCK OPTION AGREEMENT</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">THIS STOCK OPTION AGREEMENT (this &ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Agreement</u>&rdquo;) is entered into and effective as of [</font>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">] (the &ldquo;<u>Grant Date</u>&rdquo;) by and between Diffusion Pharmaceuticals Inc., a Delaware corporation (the &ldquo;<u>Company</u>&rdquo;), and </font>[ <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] (&ldquo;<u>Optionee</u>&rdquo;).</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company has adopted the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan (as such plan may be amended from time to time, the &ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Plan</u>&rdquo;) authorizing the Board of Directors (the &ldquo;<u>Board</u>&rdquo;) of the Company, or a committee as provided for in the Plan (the Board or such a committee to be referred to as the &ldquo;<u>Committee</u>&rdquo;), to grant stock options, among other incentive awards, to certain individuals.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Company desires to grant an option to purchase shares of common stock, p<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ar value $0.001 per share, of the Company (the &ldquo;<u>Common Stock</u>&rdquo;) to Optionee pursuant to the Plan.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">NOW, THER<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">EFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Company and Optionee agree as follows:</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Grant of Option; Exercise Price</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Company hereby grants to Optionee, upon the terms and subject to the conditions set forth in this Agreement and the Plan, and effective as of the Grant Date, an option (the &ldquo;<u>Option</u>&rdquo;) to purchase all or any portion of [</font>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">] shares (the &ldquo;<u>Option Shares</u>&rdquo;) of the Company&rsquo;s Common Stock, at an exercise price of $[</font>&nbsp; &nbsp; &nbsp; &nbsp; <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">] per share, which represents 100% of the Fair Market Value of a share of Common Stock on the Grant Date, as determined in accordance with the Plan (such exercise price, as adjusted from time to time pursuant to <u>Section 5</u> of this Agreement and Section 4.3 of the Plan, the &ldquo;<u>Exercise Price</u>&rdquo;). The Option is not intended to be an &ldquo;incentive stock option,&rdquo; as that term is used in Section 422 of the Internal Revenue Code of 1986, as amended (the &ldquo;<u>Code</u>&rdquo;).</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Vesting</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Option shall vest and become exercisable in [12 quarterly/ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;] equal (or as </font>nearly equal as possible) installments on [the last calendar day of each calendar quarter/&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;] over a [threeyear/&nbsp; &nbsp; &nbsp; ] period, beginning on [&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ]. [Optionee shall receive a full quarter of vestin<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">g for the [</font>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">] calendar quarter of [</font>&nbsp; &nbsp; &nbsp; &nbsp;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">].]</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36.5pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:-0.5pt;">[OR, IN THE CASE OF PERFORMANCE-BASED VESTING]</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:36.5pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:-0.5pt;">[The Option shall vest and become exercisable [&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ]].</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Exercise of Option</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">3.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notice; Payment</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Subject to the terms and conditions set forth in this Agreement, including </font>vesting of the Option in <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Section 2</u> of this Agreement and termination of the Option in <u>Section 4</u> of this Agreement, and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time, by delivery to the Company of written notice of the exercise of the Option, in substantially the form as provided by the Company, stating the number of Option Shares being purchased (the &ldquo;<u>Purchased Shares</u>&rdquo;), and accompanied by payment in full of the total aggregate Exercise Price of the Purchased Shares. The Exercise Price shall be payable in full in any one of the following alternative forms:</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:37pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Full payment in cash, personal check or certified bank or cashier<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s check;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:37pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">An<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">y broker assisted cashless exercise procedure which is acceptable to the Company;&nbsp;</font>or<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;"> </font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:37pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:2.25pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Cashless net exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0px" cellpadding="0pt" cellspacing="0pt" style="width: 91%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt auto 0pt 54pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18.7pt;margin-right:0pt;margin-top:0pt;text-align:center;">X</p>
			</td>
			<td style="vertical-align: top; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">=</p>
			</td>
			<td style="vertical-align: top; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Y &ndash; [<u>(A)(Y</u>B <u>)</u>]</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Where&nbsp; X</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">=</p>
			</td>
			<td style="vertical-align: middle; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">the number of shares of Common Stock to be issued to Optionee.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18.7pt;margin-right:0pt;margin-top:0pt;text-align:center;">Y</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">=</p>
			</td>
			<td style="vertical-align: middle; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">the number of Purchased Shares.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: middle; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18.7pt;margin-right:0pt;margin-top:0pt;text-align:center;">A</p>
			</td>
			<td style="vertical-align: middle; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">=</p>
			</td>
			<td style="vertical-align: middle; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">the Exercise Price.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 7%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:18.75pt;margin-right:0pt;margin-top:0pt;text-align:center;">B</p>
			</td>
			<td style="vertical-align: bottom; width: 3%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">=</p>
			</td>
			<td style="vertical-align: bottom; width: 90%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">the Fair Market Value of one share of Common Stock on the date of exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:2.25pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">3.2.&nbsp;&nbsp;&nbsp; <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Issuance of Purchased Shares; No Fractional Shares</u>. Following receipt of the exercise notice</font> Upon a cashless net exercise, Optionee shall receive the number of shares of Common Stock equal to a number (as determined below) of shares of Common Stock computed using the following formula: and the payment referred to above, the Company shall, as soon<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> as reasonably practicable thereafter, cause certificates (or book-entry notations) representing the Purchased Shares (or such fewer number of Purchased Shares if a cashless net exercise is used) to be delivered to Optionee either at Optionee&rsquo;s address set forth in the records of the Company or at such other address as Optionee may designate in writing to the Company or issue and deposit the Purchased Shares for Optionee&rsquo;s benefit with any broker with which Optionee has an account relationship or the Company has engaged to provide such services under the Plan; <u>provided</u>, <u>however</u>, that the Company shall not be obligated to issue a fraction or fractions of a share otherwise issuable upon exercise of the Option, and may pay to Optionee, in cash or cash equivalent, the Fair Market Value of any such fraction or fractions of a share as of the date of exercise. If requested by the Company in connection with any exercise of the Option, Optionee shall also deliver this Agreement to the Company, which shall endorse hereon a notation of the exercise and, and if the Option is exercised in part, shall return this Agreement to Optionee. The date of exercise of an Option that is validly exercised shall be deemed to be the date on which there shall have been delivered to the Company the notice referred to in <u>Section 3.1</u> of this Agreement and full payment of the Exercise Price of the Purchased Shares. Optionee shall not be deemed to be a holder of any Purchased Shares pursuant to exercise of the Option until the date of issuance of a stock certificate or book-entry notation to Optionee for such shares following payment in full for the Purchased Shares.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">3.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Tax Withholding</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Company is entitled to (a) withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary), or make other arrangements for the collection of, all amounts the Company reasonably determines are necessary to satisfy any and all federal, foreign, state and local withholding and employment related tax requirements attributable to the Option, including, without limitation, the grant, exercise or vesting of, the Option; (b) withhold cash paid or payable or shares of Common Stock from the shares issued or otherwise issuable to Optionee in connection with the Option; or (c) require Optionee promptly to remit the amount of such withholding to the Company before taking any action, including issuing any shares of Common Stock, with respect to the Option. Shares of Common Stock issued or otherwise issuable to Optionee in connection with the Option that gives rise to the tax withholding obligation that are withheld for purposes of satisfying Optionee&rsquo;s withholding or employment-related tax obligation will be valued at their Fair Market Value on the Tax Date.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">3.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Remaining Option Shares</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Option Shares will no longer be outstanding under the Option (and </font>will therefore not thereafter be exercisable) following the exercise of the Option to the extent of (a) shares used to pay the Exercise Price of an Op<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tion under the &ldquo;cashless net exercise&rdquo; method (b) shares actually delivered to Optionee as a result of such exercise and (c) any shares withheld for purposes of tax withholding.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination of Option</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Time of Termination</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Except as provided in this <u>Section 4</u> and <u>Section 5</u> of this Agreement, </font>the Option shall terminate, no longer be exercisable and expire at 5:00 p.m., Eastern Time, on [&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ] (the &ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Time of</u> <u>Termination</u>&rdquo;).</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination for Cause</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. In the event Optionee&rsquo;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated by the Company for Cause, the Option will immediately terminate without notice of any kind, and the Option will no longer be exercisable.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Termination Due to Death, Disability or Retirement </u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. In the event Optionee&rsquo;s employment (in </font>the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsid<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">iaries is terminated by reason of Optionee&rsquo;s death, Disability or Retirement, the Option will remain exercisable, to the extent exercisable as of the date of such termination, for a period of one (1) year after such termination (but in no event after the Time of Termination).</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.4.&nbsp;&nbsp;&nbsp;&nbsp; <u>Termination for Other Reasons</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. In the event Optionee&rsquo;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all </font>Subsidiaries is terminated for any <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">other reason, the Option will, to the extent exercisable as of such termination, remain exercisable for a period of three (3) months after such termination (but in no event after the Time of Termination).</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Effect of Actions Constituting Cause or Adverse Act<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ion</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Notwithstanding anything in this </font>Agreement to the contrary and in addition to the rights of the Committee under <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Sections 13.5 and 13.6</u> of the Plan, if </font>Optionee is determined by the Committee, acting in its sole discretion, to have taken any action that would constitute Cause or an Adverse Action during or after the termination of employment or other service with the Company or a Subsidiary, irrespective<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> of whether such action or the Committee&rsquo;s determination occurs before or after termination of Optionee&rsquo;s employment or other service with the Company or any Subsidiary and irrespective of whether or not Optionee was terminated as a result of such Cause or Adverse Action, (a) all rights of Optionee under the Option and this Agreement will terminate and be forfeited without notice of any kind, and (b) the Committee in its sole discretion will have the authority to rescind the exercise, vesting, settlement or issuance of, or payment in respect of, the Option that was exercised, vested, settled or issued, or as to which such payment was made, and to require Optionee to pay to the Company, within ten (10) days of receipt from the Company of notice of such rescission, any amount received or the amount of any gain realized as a result of such rescinded exercise, vesting, settlement, issuance or payment (including any dividends paid or other distributions made with respect to any shares of Common Stock subject to the Option). The Company may defer the exercise of the Option for a period of up to six (6) months after receipt of Optionee&rsquo;s written notice of exercise or the issuance of Purchased Shares upon the vesting of the Option for a period of up to six (6) months after the date of such vesting in order for the Committee to make any determination as to the existence of Cause or an Adverse Action. The Company will be entitled to withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary) or make other arrangements for the collection of all amounts necessary to satisfy such payment obligations. This <u>Section 4.5</u> will not apply to the Option following a Change in Control.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 54pt;">4.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Clawback/For<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">feiture</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Option and Option Shares issued or issuable pursuant to the Option </font>are subject to forfeiture or clawback by the Company to the extent required and allowed by law, including the DoddFrank Wall Street Reform and Consumer Protection Act of 2010<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> and the Sarbanes Oxley Act of 2002 and any implementing rules and regulations promulgated thereunder, and pursuant to any forfeiture, clawback or similar policy of the Company, as such laws, rules, regulations and policy may be in effect from time to time.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Adjustments</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. In the event of any reorganization, merger, consolidation, recapitalization, liquidation, </font>reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture or extraordinary dividend (including a spin-off), <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">or any other similar change in the corporate structure or shares of the Company, the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), will make appropriate adjustment (which determination will be conclusive) as to the number and kind of securities or other property (including cash) subject to, and the Exercise Price of, the Option in order to prevent dilution or enlargement of the rights of Optionee.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Change in Contr<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ol</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Option shall become immediately vested and exercisable upon completion of a Change in Control and remain exercisable through the Time of Termination regardless of whether Optionee remains in the employment or service of the Company. Notwithstanding any of the foregoing, in connection with a Change in Control, the Committee, in its sole discretion, at any time after the grant of the Option, may take whatever action it deems appropriate pursuant to <u>Section 15.3</u> of the Plan.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Rights as a <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Stockholder</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Optionee will have no rights as a stockholder of the Company unless and until </font>all conditions to the effective exercise of the Option (including, without limitation, the conditions set forth in <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>Section 3</u> of this Agreement) have been satisfied and Optionee has become the holder of record of such shares. No adjustment will be made for dividends or distributions with respect to the Option as to which there is a record date preceding the date Optionee becomes the holder of record of such shares, except as may otherwise be provided in the Plan or determined by the Committee in its sole discretion.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Restrictions on Transfer</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Except pursuant to testamentary will or the laws of descent and distribution or as otherwise expressly permitted by the Plan, no right or interest of Optionee in the Option prior to exercise may be assigned or transferred, or subjected to any lien, during the lifetime of Optionee, either voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise. Optionee, however, will be entitled to designate a beneficiary to receive the Option upon Optionee&rsquo;s death, and, in the event of Optionee&rsquo;s death, exercise of the Option (to the extent permitted pursuant to <u>Sections 2 and 4</u> of this Agreement) may be made by Optionee&rsquo;s legal representatives, heirs and legatees.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Market Stand-off</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Optionee, if so requested by the Company or any representative of the underwriters in connection with a firmly underwritten public offering of securities by the Company pursuant to a registration statement under the Securities Act following the date of this Agreement, shall not sell or otherwise transfer any Option Shares during the 180-day period following the effective date of such registration statement. The Company may impose stoptransfer instructions with respect to securities subject to the foregoing restriction until the end of such 180-day period. This <u>Section 9</u> will not apply to the sale of any Option Shares to an underwriter pursuant to an underwriting agreement and shall only be applicable to Optionee if all then current executive officers and directors of the Company enter into similar agreements.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Employment or Service</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Nothing in this Agreement or the Plan will interfere with or limit in any way the right of the Company or any Subsidiary to terminate the employment or service of Optionee at any time, nor confer upon Optionee any right to continue in the employment or other service with the Company or any Subsidiary.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Option Subject to Plan</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The Option and the Option Shares granted and issued pursuant to this Agreement have been granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and Optionee, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will be interpreted by reference to the Plan. In the event that any provision of this Agreement is inconsistent with the terms of the Plan, the terms of the Plan will prevail. All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.7pt;margin-top:0pt;text-align:left;text-indent:36pt;">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Gene<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ral Provisions</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Governing Law; Venue</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. This Agreement and all rights and obligations under this Agreement </font>will be governed by and construed exclusively in accordance with the laws of the State of Delaware, notwithstanding the conflicts of laws principles <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">of any jurisdictions. By acceptance of the Option, Optionee is deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of the State of Illinois to resolve any and all issues that may arise out of or relate to the Option or this Agreement.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Entire Agreement</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. This Agreement and the Plan set forth the entire agreement and </font>understanding of the parties to this Agreement with respect to the grant and exercise of the Option and the administration of the Plan and supersede all prio<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">r agreements, arrangements, plans and understandings relating to the grant and exercise of the Option and the administration of the Plan.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Failure to Enforce Not a Waiver</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. The failure of the Company or Optionee to enforce at any </font>time any provision of this<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Notices</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. All notices, requests, demands and other communications (collectively, &ldquo;<u>Notices</u>&rdquo;) </font>given pursuant to this Agreement shall be in writing,<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> and shall be delivered by personal service, courier, facsimile transmission, email transmission of a pdf format data file or by United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the signature page of this Agreement. Any Notice, other than a Notice sent by registered or certified mail, shall be effective when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the earlier of when received or the third day following deposit in the United States mails. Any party may from time to time change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Section 12.5.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Suc<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">cessors and Assigns</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Except to the extent specifically limited by the terms and provision </font>of this Agreement, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns, heirs and personal <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">representatives.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Execution</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. This Agreement may be executed in two or more counterparts, all of which when </font>taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delive<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">red to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email delivery of a &ldquo;pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;pdf&rdquo; signature page were an original thereof.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Titles, Captions and Sections</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. Titles and captions contained in this Agreement are inserted for </font>convenience of reference only and do not constitute a part of this Agreement for any other purpose. References to Sections in this Agreement refer to Sections of this Agreement unless otherwise stated.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 63pt;">12.8.&nbsp;&nbsp;&nbsp;&nbsp; <u>Nature of the <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Grant</font></u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">. In accepting the Option and by execution of this Agreement, Optionee </font>acknowledges that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company in i<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ts sole discretion at any time, unless otherwise provided in the Plan.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future Option grants, or benefits in lieu of Option grants, even if Op<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">tion grants have been granted repeatedly in the past.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; All decisions with respect to future Option grants, if any, will be at the sole discretion of the Company.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Optionee is voluntarily participating in the Plan.</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Option grant is not part of normal or e<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">xpected compensation or salary for any </font>purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">in no event shall be considered as compensation for, or relating in any way to, past services for the Company.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In the event that Optionee is not an employee of the Company, the Option will not be interpreted to form an employment contract or relationship <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">with the Company.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The future value of the Common Stock is unknown and cannot be predicted with certainty and if the Option vests and Optionee exercises the Option in accordance with the terms of this Agreement and is issued Purchased Shares, the value of <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">those shares may increase or decrease.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In consideration of the grant of the Option, no claim or entitlement to compensation<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"> or damages shall arise from termination of the Option or diminution in value of the Option or Purchased Shares acquired upon exercise of the Option resulting from termination of Optionee&rsquo;s employment or service by the Company (for any reason whatsoever and whether or not in breach of local labor laws) and Optionee irrevocably releases the Company and its Subsidiaries, and their respective directors, officers, employees and agents, from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by acceptance of the Option and execution of this Agreement, Optionee shall be deemed irrevocably to have waived his or her entitlement to pursue such claim.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&rsquo;s participation in the Plan, or Optionee&rsquo;s purchase or sale of the underlying Option Shares.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 1.75pt 0pt 0pt; text-align: left; text-indent: 90pt;">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Optionee is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking a<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ny action related to the Plan or the Option.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:1.85pt;margin-right:0pt;margin-top:0pt;text-align:center;"><i>[Remainder of page intentionally left blank; signature page follows]</i></p>

<div id="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div id="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div id="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:36pt;">IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement effective as of the Grant Date.</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0px" cellpadding="0pt" cellspacing="0pt" style="width: 100%; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 128px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">OPTIONEE:</p>
			</td>
			<td style="vertical-align: top; width: 508px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 424px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.05pt;margin-right:0pt;margin-top:0pt;text-align:justify;">DIFFUSION PHARMACEUTICALS INC.</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.05pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.05pt;margin-right:0pt;margin-top:0pt;text-align:justify;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.05pt;margin-right:0pt;margin-top:0pt;text-align:left;">By:</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 128px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Name:</p>
			</td>
			<td style="vertical-align: top; width: 508px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 336px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">[Signature]</p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">Name:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>

			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; text-align: right;">Title:&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 128px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 508px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 336px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 128px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">Address:</p>
			</td>
			<td style="vertical-align: bottom; width: 508px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:35.8pt;margin-right:0pt;margin-top:0pt;text-align:left;text-indent:-35.8pt;">Address:</p>
			</td>
			<td style="vertical-align: bottom; width: 336px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">2020 Avon Court, Suite 4</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 128px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 508px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 336px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Charlottesville, Virginia 22902</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 128px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 508px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 336px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 642px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 15px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 90px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 336px; border-bottom: thin solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:230.3pt;margin-top:0pt;text-align:left;text-indent:-0.5pt;">By execution of this Agreement, Optionee acknowledges having received a copy of the Plan.</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex_108104.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
<head>
	<title>ex_108104.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2018 3:23:24 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<table border="0" cellpadding="0" cellspacing="0" style="width:100%;text-indent:0;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="vertical-align: top; width: 33%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>SUBSIDIARIES OF THE REGISTRANT</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;"><b>Exhibit 21.1</b></p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;">&nbsp;</p>

			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.1pt;margin-top:0pt;text-align:right;">&nbsp;</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;"><b>Name of Subsidiary</b></p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>State or Other </b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Jurisdiction of Incorporation or</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Organization</b></p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Direct or Indirect</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>Ownership Interest by</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;"><b>RestorGenex</b></p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Canterbury Laboratories, LLC</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">DE</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.05pt 0pt 0pt; text-align: right;">100%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Hygeia Therapeutics, Inc.</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">DE</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.05pt 0pt 0pt; text-align: right;">100%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Paloma Pharmaceuticals, Inc.</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">DE</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: right;">100%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(255, 255, 255);">
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">VasculoMedics, Inc.</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">DE</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.05pt 0pt 0pt; text-align: right;">100%</p>
			</td>
		</tr>
		<tr style="background-color: rgb(204, 238, 255);">
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Diffusion Pharmaceuticals LLC</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: center;">VA</p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0.05pt 0pt 0pt; text-align: right;">100%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_108150.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
<head>
	<title>ex_108150.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/16/2018 7:29:33 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:center;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">The Board of Directors<br>
<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Diffusion Pharmaceuticals Inc.:</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">We consent to the incorporation by reference in the registration statement<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">s (No. 333-206408, No. 333-206409, and No. 333-218060) on Form S-8, (No. 333-222203) on Form S-1, and (No. 333-218062 and No. 333-222879) on Form S-3 of Diffusion Pharmaceuticals Inc. of our report dated April 2, 2018, with respect to the consolidated balance sheets of Diffusion Pharmaceuticals Inc. as of December&nbsp;31, 2017 and 2016, and the related consolidated statements of operations, changes in stockholders&rsquo; equity, and cash flows for the years then ended, and the related notes, which report appears in the December&nbsp;31, 2017 annual report on Form 10-K of Diffusion Pharmaceuticals Inc.</font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<div style="text-align: center;"><img src="kpmgsig.jpg"></div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">McLean, Virginia</p>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">April 2, 2018</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:justify;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex_108105.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
<head>
	<title>ex_108105.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2018 3:25:00 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 152.45pt; text-indent: 55.5%; text-align: right;"><b>EXHIBIT 31.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>DIFFUSION PHARMACEUTICALS INC.</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>CERTIFICATION OF CEO PURSUANT TO SECTION 302 OF</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>THE SARBANES-OXLEY ACT OF 2002</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:2.5pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>CERTIFICATION</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, David G. Kalergis, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals <font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">Inc.;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading wi<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">th respect to the period covered by this report;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;"> of the registrant as of, and for, the periods presented in this report;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;"> under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Des<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">igned such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Evaluated the effectiveness of the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Disclosed in this report any change in the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s ability to record, process, summarize and report financial information; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s internal control over financial reporting.</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Date: April 2, 2018</font></td>
			<td style="width: 40%; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">/s/ David G. Kalergis</font></td>
			<td style="width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">David G. Kaler<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">gis </font></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Chairman and Chief Executive Officer</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">(Principal Executive Officer)</p>
			</td>
			<td style="width: 10%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex_108106.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
<head>
	<title>ex_108106.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2018 3:26:53 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px; cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt 0pt 0pt 152.45pt; text-indent: 55.5%; text-align: right;"><b>EXHIBIT 31.2</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>&nbsp;</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>DIFFUSION PHARMACEUTICALS INC.</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>CERTIFICATION OF PFO PURSUANT TO SECTION 302 OF</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>THE SARBANES-OXLEY ACT OF 2002</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0.5pt;margin-right:2.5pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><u><b>CERTIFICATION</b></u></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;">I, Ben L. Shealy, certify that:</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals Inc.;</p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with re<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">spect to the period covered by this report;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of th<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">e registrant as of, and for, the periods presented in this report;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;"> our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Designed <font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Evaluated the effectiveness of the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Disclosed in this report any change in the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s ability to record, process, summarize and report financial information; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:15pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">&rsquo;s internal control over financial reporting.</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Date: April 2, 2018</font></td>
			<td style="width: 40%; border-bottom: thin solid rgb(0, 0, 0);"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">/s/ Ben L. Shealy</font></td>
			<td style="width: 10%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="width: 50%;">&nbsp;</td>
			<td style="width: 40%;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Ben L. Shealy</p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;">Senior V<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">ice President &ndash; Finance, Treasurer and Secretary</font></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">(Principal Financial Officer) </font></p>
			</td>
			<td style="width: 10%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex_108107.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
<head>
	<title>ex_108107.htm</title>

	<!-- Created by RDG HTML Converter v1.1.0.0 3/15/2018 3:29:30 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no"/>
</head>
<body style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-left: 10px; margin-right: 10px;">
<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:0.6pt;margin-top:0pt;text-align:right;"><b>EXHIBIT 32.1</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.35pt;margin-right:0.05pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>CERTIFICATION PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.35pt;margin-right:0.1pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>18 U.S.C. SECTION 1350,</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.35pt;margin-right:0pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>AS ADOPTED PURSUANT TO</b></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:2.35pt;margin-right:0.1pt;margin-top:0pt;text-align:center;text-indent:-0.5pt;"><b>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">In connection with the Annual Report on Form 10-K of Diffusion Pharmaceuticals Inc. (the &ldquo;<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">Company&rdquo;) for the period ended December 31, 2017 as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), we, David G. Kalergis and Ben L. Shealy, Chairman and Chief Executive Officer and Senior Vice President &ndash; Finance, Treasurer and Secretary, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge: </font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(1)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;"> Act of 1934; and</font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:'Times New Roman', Times, serif;font-size:10pt;">

		<tr>
			<td style="width:14pt;">&nbsp;</td>
			<td style="width:14pt;vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">(2)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:'Times New Roman', Times, serif;margin-right:0pt;margin-top:0pt;text-align:left;margin-bottom:0pt;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of ope<font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">rations of the Company. </font></p>
			</td>
		</tr>

</table>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><font style="font-size:10pt;font-family:'Times New Roman', Times, serif;">April 2, 2018</font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;"><u>/</u><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>s/ David G. Kalergis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </u></font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">David G. Kalergis</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">Chairman and Chief Executive Offi<font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">cer </font></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">&nbsp;</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;"><font style="font-family:'Times New Roman', Times, serif;font-size:10pt;"><u>/s/ Ben L. Shealy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</u> </font></p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin:0pt;text-align:left;text-indent:-0.5pt;">Ben L. Shealy</p>

<p style="font-family:'Times New Roman', Times, serif;font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-right:61.2%;margin-top:0pt;text-align:left;text-indent:-0.5pt;">Senior Vice President <font style="font-family:'Times New Roman', Times, serif;font-size:10pt;">&ndash; Finance, Treasurer and Secretary </font></p>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>dffn-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:45PM UTC 2018-03-30--><xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:dffn="http://www.diffusionpharma.com/20171231" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="dffn-20171231.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2017-01-01_2017-12-31" id="c-15">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2017-01-01_2017-12-31" id="c-4">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2017-01-01_2017-12-31" id="c-14">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2017-01-01_2017-12-31" id="c-13">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2017-01-01_2017-12-31" id="c-12">2017-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2017-01-01_2017-12-31" id="c-11">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2017-01-01_2017-12-31" id="c-2">0001053691</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2018-03-13" decimals="INF" id="c-9" unitRef="xbrli-shares">50526547</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2017-01-01_2017-12-31" id="c-6">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2017-01-01_2017-12-31" id="c-5">Smaller Reporting Company</dei:EntityFilerCategory>
  <dei:EntityPublicFloat contextRef="i_2017-06-30" decimals="-5" id="c-10" unitRef="iso4217-usd">25300000</dei:EntityPublicFloat>
  <dei:EntityRegistrantName contextRef="d_2017-01-01_2017-12-31" id="c-1">Diffusion Pharmaceuticals Inc.</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2017-01-01_2017-12-31" id="c-7">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2017-01-01_2017-12-31" id="c-8">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:TradingSymbol contextRef="d_2017-01-01_2017-12-31" id="c-3">dffn</dei:TradingSymbol>
  <dffn:AccruedClinicalStudiesExpensesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256685" unitRef="iso4217-usd">63350</dffn:AccruedClinicalStudiesExpensesCurrent>
  <dffn:AccruedClinicalStudiesExpensesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256686" unitRef="iso4217-usd">220978</dffn:AccruedClinicalStudiesExpensesCurrent>
  <dffn:AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256270" unitRef="iso4217-usd">13153524</dffn:AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants>
  <dffn:AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256272" unitRef="iso4217-usd">13153524</dffn:AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants>
  <dffn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256228" unitRef="iso4217-usd">2500000</dffn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt>
  <dffn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256230" unitRef="iso4217-usd">2500000</dffn:AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt>
  <dffn:AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256200" unitRef="iso4217-usd">1321000</dffn:AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed>
  <dffn:AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256202" unitRef="iso4217-usd">1321000</dffn:AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed>
  <dffn:AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256207" unitRef="iso4217-usd">384000</dffn:AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed>
  <dffn:AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256209" unitRef="iso4217-usd">384000</dffn:AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed>
  <dffn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted contextRef="d_2016-01-01_2016-12-31_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29256632" unitRef="iso4217-usd-per-xbrli-shares">-1.60</dffn:BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted>
  <dffn:BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29256407" unitRef="xbrli-shares">0.3652658</dffn:BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest>
  <dffn:BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29256409" unitRef="xbrli-shares">1495615</dffn:BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed>
  <dffn:BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" id="c29256587">P5Y</dffn:BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsideration contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember" decimals="INF" id="c29257541" unitRef="iso4217-usd">21261000</dffn:BusinessCombinationPreliminaryPurchasePriceConsideration>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember" decimals="INF" id="c29257540" unitRef="iso4217-usd">10000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember" decimals="INF" id="c29257538" unitRef="iso4217-usd">1321000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember" decimals="INF" id="c29257539" unitRef="iso4217-usd">384000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember" decimals="INF" id="c29257537" unitRef="iso4217-usd">19546000</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding>
  <dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-19">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,546,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Estimated fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger stock options outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,321,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Estimated fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger warrants outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;384,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;CVRs &lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2013; RES-440 product candidate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total purchase price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,261,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</dffn:BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock>
  <dffn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257547" unitRef="iso4217-usd">377432</dffn:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
  <dffn:ClassOfWarrantOrRightGrantedDuringPeriod contextRef="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember" decimals="INF" id="c29256799" unitRef="xbrli-shares">1179558</dffn:ClassOfWarrantOrRightGrantedDuringPeriod>
  <dffn:ClassOfWarrantOrRightTerm contextRef="d_2018-01-22_2018-01-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" id="c29256421">P5Y</dffn:ClassOfWarrantOrRightTerm>
  <dffn:ClassOfWarrantOrRightTerm contextRef="d_2018-01-22_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember_SubsequentEventTypeAxis-SubsequentEventMember" id="c29256424">P5Y</dffn:ClassOfWarrantOrRightTerm>
  <dffn:ClassOfWarrantOrRightTerm contextRef="d_2017-03-31_2017-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" id="c29256795">P5Y</dffn:ClassOfWarrantOrRightTerm>
  <dffn:ClassOfWarrantOrRightTerm contextRef="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember" id="c29256801">P5Y</dffn:ClassOfWarrantOrRightTerm>
  <dffn:ClassOfWarrantOrRightsExpired contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-WarrantMember" decimals="INF" id="c29256860" unitRef="xbrli-shares">13000</dffn:ClassOfWarrantOrRightsExpired>
  <dffn:ClassOfWarrantOrRightsExpired contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-WarrantMember" decimals="INF" id="c29256861" unitRef="xbrli-shares">17479</dffn:ClassOfWarrantOrRightsExpired>
  <dffn:ConvertiblePreferredStockConversionPrice contextRef="i_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256792" unitRef="xbrli-shares">2.02</dffn:ConvertiblePreferredStockConversionPrice>
  <dffn:ConvertiblePreferredStockConversionPrice contextRef="i_2017-12-31_RangeAxis-MaximumMember" decimals="INF" id="c29256837" unitRef="xbrli-shares">2.02</dffn:ConvertiblePreferredStockConversionPrice>
  <dffn:ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="INF" id="c29256831" unitRef="iso4217-usd-per-xbrli-shares">8</dffn:ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice>
  <dffn:ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="-3" id="c29256836" unitRef="iso4217-usd">10000000</dffn:ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock>
  <dffn:ConvertiblePreferredStockVotesPerShare contextRef="i_2017-03-14_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256828" unitRef="iso4217-usd-per-thunderdome-item">0.84874</dffn:ConvertiblePreferredStockVotesPerShare>
  <dffn:ConvertiblePreferredStockVotesPerShare contextRef="i_2017-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256829" unitRef="iso4217-usd-per-thunderdome-item">0.50627</dffn:ConvertiblePreferredStockVotesPerShare>
  <dffn:CumulativeEffectOfChangeInAccountingPrinciple contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256256" unitRef="iso4217-usd">1134</dffn:CumulativeEffectOfChangeInAccountingPrinciple>
  <dffn:CumulativeEffectOfChangeInAccountingPrinciple contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256257" unitRef="iso4217-usd">-1134</dffn:CumulativeEffectOfChangeInAccountingPrinciple>
  <dffn:DebtConversionConvertedInstrumentRelatedAccruedInterest contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256730" unitRef="iso4217-usd">16000</dffn:DebtConversionConvertedInstrumentRelatedAccruedInterest>
  <dffn:DeferredTaxAssetsCapitalizedCostsAndOther contextRef="i_2017-12-31" decimals="INF" id="c29257100" unitRef="iso4217-usd">5247469</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
  <dffn:DeferredTaxAssetsCapitalizedCostsAndOther contextRef="i_2016-12-31" decimals="INF" id="c29257101" unitRef="iso4217-usd">4690843</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
  <dffn:DeferredTaxAssetsOrphanDrugCredits contextRef="i_2017-12-31" decimals="INF" id="c29257098" unitRef="iso4217-usd">2537039</dffn:DeferredTaxAssetsOrphanDrugCredits>
  <dffn:DeferredTaxAssetsOrphanDrugCredits contextRef="i_2016-12-31" decimals="INF" id="c29257099" unitRef="iso4217-usd">1218069</dffn:DeferredTaxAssetsOrphanDrugCredits>
  <dffn:DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256560" unitRef="iso4217-usd">-22072322</dffn:DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability>
  <dffn:DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability contextRef="d_2016-01-01_2016-12-31" id="c29256561" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent contextRef="d_2017-01-01_2017-12-31" id="c29257121" unitRef="xbrli-pure" xs:nil="true"/>
  <dffn:EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257122" unitRef="xbrli-pure">0.046</dffn:EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent>
  <dffn:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257117" unitRef="xbrli-pure">-1.261</dffn:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent>
  <dffn:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent contextRef="d_2016-01-01_2016-12-31" id="c29257118" unitRef="xbrli-pure" xs:nil="true"/>
  <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257125" unitRef="xbrli-pure">0.36</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
  <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257126" unitRef="xbrli-pure">0.044</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
  <dffn:EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent contextRef="d_2017-01-01_2017-12-31" id="c29257123" unitRef="xbrli-pure" xs:nil="true"/>
  <dffn:EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257124" unitRef="xbrli-pure">0.028</dffn:EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent>
  <dffn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember" decimals="INF" id="c29257738" unitRef="iso4217-usd">13153524</dffn:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic>
  <dffn:FinancingTriggerFromIssuanceOfCommonStock contextRef="i_2017-12-31_RangeAxis-MinimumMember" decimals="-3" id="c29256832" unitRef="iso4217-usd">10000000</dffn:FinancingTriggerFromIssuanceOfCommonStock>
  <dffn:MakewholeProvisionConversionPricePercentage contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29256838" unitRef="xbrli-pure">1.05</dffn:MakewholeProvisionConversionPricePercentage>
  <dffn:NumberOfCommonStockPerUnit contextRef="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256791" unitRef="xbrli-shares">1</dffn:NumberOfCommonStockPerUnit>
  <dffn:NumberOfConvertiblePreferredStockPerUnit contextRef="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256788" unitRef="xbrli-shares">1</dffn:NumberOfConvertiblePreferredStockPerUnit>
  <dffn:OfferingCostsInAccountsPayable contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256396" unitRef="iso4217-usd">146776</dffn:OfferingCostsInAccountsPayable>
  <dffn:OfferingCostsInAccountsPayable contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256397" unitRef="iso4217-usd">126110</dffn:OfferingCostsInAccountsPayable>
  <dffn:OfferingCostsPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258210">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Offering Costs&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Offering costs are either expensed upon completion or abandonment of the related financing or offset against the proceeds of the offering, depending upon the accounting treatment of the offering. Offering costs consist principally of legal and accounting costs incurred through the balance sheet date related to the Company&amp;#x2019;s underwritten public offering, private placement financings and are recognized in other assets on the consolidated balance sheet.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</dffn:OfferingCostsPolicyPolicyTextBlock>
  <dffn:PercentageOfCommonStockOutstandingOwned contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_CounterpartyNameAxis-FormerEquityHoldersOfDiffusionLLCMember" decimals="INF" id="c29256403" unitRef="xbrli-pure">0.841</dffn:PercentageOfCommonStockOutstandingOwned>
  <dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis contextRef="d_2016-07-21_2016-07-21_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember" decimals="2" id="c29256891" unitRef="xbrli-pure">0.04</dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
  <dffn:PreferentialDividendsPayble contextRef="i_2017-12-31" decimals="INF" id="c29256679" unitRef="iso4217-usd">1062314</dffn:PreferentialDividendsPayble>
  <dffn:PreferentialDividendsPayble contextRef="i_2016-12-31" id="c29256680" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="i_2017-12-31" decimals="INF" id="c29256077" unitRef="iso4217-usd">769946</dffn:PrepaidExpensesDepositsAndOtherAssets>
  <dffn:PrepaidExpensesDepositsAndOtherAssets contextRef="i_2016-12-31" decimals="INF" id="c29256078" unitRef="iso4217-usd">50844</dffn:PrepaidExpensesDepositsAndOtherAssets>
  <dffn:PrepaidResearchAndDevelopmentExpense contextRef="i_2017-12-31_TypeOfArrangementAxis-ArrangementWithClinicalResearchOrganizationMember" decimals="INF" id="c29256758" unitRef="iso4217-usd">800000</dffn:PrepaidResearchAndDevelopmentExpense>
  <dffn:ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts contextRef="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="-3" id="c29256797" unitRef="iso4217-usd">22100000</dffn:ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts>
  <dffn:ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256370" unitRef="iso4217-usd">22129774</dffn:ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts>
  <dffn:ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts contextRef="d_2016-01-01_2016-12-31" id="c29256371" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:ProceedsFromReverseMergerTransaction contextRef="d_2017-01-01_2017-12-31" id="c29256365" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:ProceedsFromReverseMergerTransaction contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256366" unitRef="iso4217-usd">8500602</dffn:ProceedsFromReverseMergerTransaction>
  <dffn:QualifiedFinancingMinimumAmountOfGrossProceeds contextRef="d_2017-01-01_2017-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="INF" id="c29256726" unitRef="iso4217-usd">50000000</dffn:QualifiedFinancingMinimumAmountOfGrossProceeds>
  <dffn:ReclassificationOfTheFairMarketValueOfWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256390" unitRef="iso4217-usd">13153524</dffn:ReclassificationOfTheFairMarketValueOfWarrants>
  <dffn:ReclassificationOfTheFairMarketValueOfWarrants contextRef="d_2016-01-01_2016-12-31" id="c29256391" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-26">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Range of exercise &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued prior to Merger&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;447,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$20.00&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$49.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in Series A&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,555,887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.22&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,003,608&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</dffn:ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock>
  <dffn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256985" unitRef="xbrli-shares">301156</dffn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger>
  <dffn:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256986" unitRef="iso4217-usd-per-xbrli-shares">40.13</dffn:SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice>
  <dffn:StockIssuedDuringPeriodSharesMakewholeAdjustment contextRef="d_2018-01-01_2018-01-31_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256840" unitRef="xbrli-shares">11668421</dffn:StockIssuedDuringPeriodSharesMakewholeAdjustment>
  <dffn:StockIssuedDuringPeriodSharesTotal contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256846" unitRef="xbrli-shares">2226698</dffn:StockIssuedDuringPeriodSharesTotal>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="-3" id="c29256827" unitRef="iso4217-usd">1100000</dffn:StockReclassifiedUponConversionOfPreferredStock>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-ConvertiblePreferredStockMember" decimals="INF" id="c29256394" unitRef="iso4217-usd">190080</dffn:StockReclassifiedUponConversionOfPreferredStock>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2016-01-01_2016-12-31_StatementClassOfStockAxis-ConvertiblePreferredStockMember" id="c29256395" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256290" unitRef="iso4217-usd">86</dffn:StockReclassifiedUponConversionOfPreferredStock>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256291" unitRef="iso4217-usd">189994</dffn:StockReclassifiedUponConversionOfPreferredStock>
  <dffn:StockReclassifiedUponConversionOfPreferredStock contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256293" unitRef="iso4217-usd">190080</dffn:StockReclassifiedUponConversionOfPreferredStock>
  <dffn:StockReclassifiedUponConversionOfPreferredStockShares contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="INF" id="c29256826" unitRef="xbrli-shares">86335</dffn:StockReclassifiedUponConversionOfPreferredStockShares>
  <dffn:StockReclassifiedUponConversionOfPreferredStockShares contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256289" unitRef="xbrli-shares">86335</dffn:StockReclassifiedUponConversionOfPreferredStockShares>
  <dffn:TemporaryEquityStockIssuedDuringPeriodNewIssues contextRef="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256796" unitRef="xbrli-shares">12376329</dffn:TemporaryEquityStockIssuedDuringPeriodNewIssues>
  <dffn:WarrantExpense contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="-3" id="c29256813" unitRef="iso4217-usd">10200000</dffn:WarrantExpense>
  <dffn:WarrantExpense contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-WarrantMember" decimals="-3" id="c29256866" unitRef="iso4217-usd">10200000</dffn:WarrantExpense>
  <dffn:WarrantExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256159" unitRef="iso4217-usd">10225846</dffn:WarrantExpense>
  <dffn:WarrantExpense contextRef="d_2016-01-01_2016-12-31" id="c29256160" unitRef="iso4217-usd" xs:nil="true"/>
  <dffn:WarrantExpenseChangeInFairValueAndOtherFinancingExpenses contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256341" unitRef="iso4217-usd">8976250</dffn:WarrantExpenseChangeInFairValueAndOtherFinancingExpenses>
  <dffn:WarrantExpenseChangeInFairValueAndOtherFinancingExpenses contextRef="d_2016-01-01_2016-12-31" id="c29256342" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848484">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Accrued Expenses and Other Current Liabilities&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued interest payable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37,415&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;29,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued Series A dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,062,314&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;312,221&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;399,740&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122,711&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;72,855&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,350&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;220,978&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,840&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;151,332&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,628,851&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;874,264&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
  <us-gaap:AccountsPayableCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256095" unitRef="iso4217-usd">511956</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256096" unitRef="iso4217-usd">1684158</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256683" unitRef="iso4217-usd">122711</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256684" unitRef="iso4217-usd">72855</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256681" unitRef="iso4217-usd">312221</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccruedSalariesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256682" unitRef="iso4217-usd">399740</us-gaap:AccruedSalariesCurrent>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2017-12-31" decimals="INF" id="c29257561" unitRef="iso4217-usd">306818</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="i_2016-12-31" decimals="INF" id="c29257562" unitRef="iso4217-usd">239892</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2017-12-31" decimals="INF" id="c29256138" unitRef="iso4217-usd">82770313</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="i_2016-12-31" decimals="INF" id="c29256139" unitRef="iso4217-usd">69363575</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256305" unitRef="iso4217-usd">28017</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256307" unitRef="iso4217-usd">28017</us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256235" unitRef="iso4217-usd">1391068</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256237" unitRef="iso4217-usd">1391068</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256312" unitRef="iso4217-usd">1240551</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256314" unitRef="iso4217-usd">1240551</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c29256977" unitRef="iso4217-usd">95040</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="INF" id="c29256978" unitRef="iso4217-usd">674643</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c29256979" unitRef="iso4217-usd">1145511</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="INF" id="c29256980" unitRef="iso4217-usd">716425</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256975" unitRef="iso4217-usd">1240551</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256976" unitRef="iso4217-usd">1391068</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256349" unitRef="iso4217-usd">33517</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256350" unitRef="iso4217-usd">38446</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c29256572" unitRef="xbrli-shares">214385</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c29256573" unitRef="xbrli-shares">757909</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c29256574" unitRef="xbrli-shares">447721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="INF" id="c29256575" unitRef="xbrli-shares">460721</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c29256576" unitRef="xbrli-shares">8306278</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember" id="c29256577" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c29256578" unitRef="xbrli-shares">2555989</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" decimals="INF" id="c29256579" unitRef="xbrli-shares">2207409</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" decimals="INF" id="c29256580" unitRef="xbrli-shares">3066</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember" decimals="INF" id="c29256581" unitRef="xbrli-shares">9204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256582" unitRef="xbrli-shares">11527439</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256583" unitRef="xbrli-shares">3435243</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2017-12-31" decimals="INF" id="c29256089" unitRef="iso4217-usd">26145815</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2016-12-31" decimals="INF" id="c29256090" unitRef="iso4217-usd">17484384</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256079" unitRef="iso4217-usd">9666414</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256080" unitRef="iso4217-usd">1603696</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258201">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The accompanying consolidated&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting Standards Updates (&amp;#x201c;ASU&amp;#x201d;) of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessAcquisitionProFormaInformationTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-21">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style="display: inline; font-weight: bold;"&gt;31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,471,398&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic and diluted loss per share&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.60&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
  <us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss contextRef="d_2016-01-01_2016-12-31_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29256631" unitRef="iso4217-usd">-16471398</us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss>
  <us-gaap:BusinessAcquisitionsProFormaRevenue contextRef="d_2016-01-01_2016-12-31" id="c29256630" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="d_2016-01-01_2016-12-31_BusinessAcquisitionAxis-DiffusionLLCMember_NonrecurringAdjustmentAxis-AcquisitionRelatedCostsMember" decimals="-3" id="c29256597" unitRef="iso4217-usd">1600000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
  <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848477">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt; Acquisitions&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Merger with Diffusion Pharmaceuticals LLC&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2015, &lt;/div&gt;the Company entered into a merger agreement (the &amp;#x201c;Merger Agreement&amp;#x201d;) with Diffusion LLC. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 8, 2016, &lt;/div&gt;the Company completed the merger (the &amp;#x201c;Merger&amp;#x201d;), with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the Merger, the Company was renamed &amp;#x201c;Diffusion Pharmaceuticals Inc.&amp;#x201d; and the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s ticker symbol was changed from &amp;#x201c;RESX&amp;#x201d; to &amp;#x201c;DFFN.&amp;#x201d; In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 2016, &lt;/div&gt;the Company&amp;#x2019;s Common Stock was approved for listing on the NASDAQ Capital Market and continues to trade under the ticker symbol &amp;#x201c;DFFN&amp;#x201d;. The Company and Diffusion LLC entered into the Merger Agreement in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Merger was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-transaction owners held an &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;84.1%&lt;/div&gt; economic and voting interest in the combined company immediately following the completion of the Merger, Diffusion LLC is considered to be the acquirer of the Company for accounting purposes.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Each Diffusion Unit was converted into the right to receive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.3652658&lt;/div&gt; shares of Common Stock based on the Exchange Ratio. Additionally, the rights of holders of Diffusion LLC&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s outstanding convertible notes to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the terms of the notes in effect immediately prior to the consummation of the Merger multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise such options for Diffusion Units converted into a right to exercise such options for Common Stock on terms substantially identical to those in effect prior to the Merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In connection with the Merger, the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s former Board of Directors authorized, declared and effected a distribution of contingent value rights (&amp;#x201c;CVRs&amp;#x201d;) to stockholders of the Company as of the close of business on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 7, 2016. &lt;/div&gt;Each CVR is a non-transferable right to potentially receive certain cash payments in the event the Company receives net cash payments during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5&lt;/div&gt;) year period after the Merger as a result of the sale, transfer, license or similar transaction or any other agreement to the extent relating to the development of the Company&amp;#x2019;s product currently known as RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440,&lt;/div&gt; a &amp;#x201c;soft&amp;#x201d; anti-androgen. See below for additional fair value information.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Diffusion LLC, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Diffusion LLC that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger shares outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;19,546,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Estimated fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger stock options outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,321,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Estimated fair value of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-Merger warrants outstanding&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;384,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;CVRs &lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2013; RES-440 product candidate&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total purchase price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,261,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;amp;D was the cost approach.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,500,602&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid expenses and other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;195,200&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;57,531&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,600,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,929,258&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(377,432&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,644,159&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,261,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Qualitative factors supporting the recognition of goodwill due to the Merger include the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the Merger to the Company&amp;#x2019;s later state product portfolio. The goodwill is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; deductible for income tax purposes. The values allocated to IPR&amp;amp;D intangible assets are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.6&lt;/div&gt; million for the RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt; compound and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million for the RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440&lt;/div&gt; compound, each with indefinite useful lives. See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6&lt;/div&gt; for additional information.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Pro Forma Financial Information (Unaudited)&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2016. &lt;/div&gt;The pro forma financial information is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style="display: inline; font-weight: bold;"&gt;31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net revenues&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,471,398&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 79%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic and diluted loss per share&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 18%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.60&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Non-recurring pro forma transaction costs directly attributable to the Merger were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.6&lt;/div&gt; million for the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016 &lt;/div&gt;and have been deducted from the net loss presented above. The costs deducted from the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016 &lt;/div&gt;period included a success fee and other transaction costs&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million and approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;46,000&lt;/div&gt; shares of common stock with a fair market value of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.5&lt;/div&gt; million paid to a financial advisor upon the closing of the Merger on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 8, 2016. &lt;/div&gt;Additionally, RestorGenex incurred approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.0&lt;/div&gt; million in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.7&lt;/div&gt; million in share-based compensation expense as a result of the acceleration of vesting of stock options at the time of Merger. These costs are excluded from the pro forma financial information for the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016. &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; such costs were recorded during the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257542" unitRef="iso4217-usd">8500602</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257543" unitRef="iso4217-usd">195200</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257548" unitRef="iso4217-usd">3644159</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257545" unitRef="iso4217-usd">9600000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257544" unitRef="iso4217-usd">57531</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
  <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257549" unitRef="iso4217-usd">21261000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2016-12-31" decimals="INF" id="c29256382" unitRef="iso4217-usd">1552852</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-12-31" decimals="INF" id="c29256383" unitRef="iso4217-usd">1997192</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2017-12-31" decimals="INF" id="c29256384" unitRef="iso4217-usd">8896468</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" decimals="INF" id="c29257149" unitRef="iso4217-usd">8896468</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257150" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257151" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" decimals="INF" id="c29257727" unitRef="iso4217-usd">1552852</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257728" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257729" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256380" unitRef="iso4217-usd">7343616</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256381" unitRef="iso4217-usd">-444340</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258205">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less to be cash and cash equivalents.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-01-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256420" unitRef="iso4217-usd-per-xbrli-shares">0.80</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256423" unitRef="iso4217-usd-per-xbrli-shares">1</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256794" unitRef="iso4217-usd-per-xbrli-shares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember" decimals="INF" id="c29256800" unitRef="iso4217-usd-per-xbrli-shares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember_RangeAxis-MinimumMember" decimals="INF" id="c29256871" unitRef="iso4217-usd-per-xbrli-shares">20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember_RangeAxis-MaximumMember" decimals="INF" id="c29256873" unitRef="iso4217-usd-per-xbrli-shares">49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c29256876" unitRef="iso4217-usd-per-xbrli-shares">2.22</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2017-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="INF" id="c29256789" unitRef="xbrli-shares">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2018-01-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256416" unitRef="xbrli-shares">15000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2018-01-22_ClassOfWarrantOrRightAxis-AdditionalWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember" decimals="INF" id="c29256417" unitRef="xbrli-shares">1970625</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_RangeAxis-MaximumMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256422" unitRef="xbrli-shares">750000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2016-01-07" decimals="INF" id="c29256843" unitRef="xbrli-shares">478200</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember" decimals="INF" id="c29256870" unitRef="xbrli-shares">447721</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-12-31_ClassOfWarrantOrRightAxis-SeriesAConvertiblePreferredStockMember" decimals="INF" id="c29256874" unitRef="xbrli-shares">13555887</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="i_2017-12-31" decimals="INF" id="c29256878" unitRef="xbrli-shares">14003608</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2017-12-31" id="c29256110" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies contextRef="i_2016-12-31" id="c29256111" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848488">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9.&lt;/div&gt;&amp;nbsp;Commitments and Contingencies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Office Space Lease Commitment&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company leases office and laboratory facilities in Charlottesville, Virginia. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 31, 2017, &lt;/div&gt;the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company capitalized approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.4&lt;/div&gt; million in leasehold improvements as part of the build-out of the new office and laboratory location. Rent expense related to the Company's operating leases for the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.1&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$66,000,&lt;/div&gt; respectively. For the new operating lease, lease payments commenced on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; May 1, 2017 &lt;/div&gt;and expire on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; April 30, 2022. &lt;/div&gt;The Company will continue to recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; yet paid. Future minimum rental payments under the Company's new non-cancelable operating lease at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; was as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;112,354&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;116,464&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;118,519&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,735&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;501,481&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Arrangement with Clinical Research Organization&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; July 5, 2017, &lt;/div&gt;the Company entered into a Master Services Agreement (&amp;quot;MSA&amp;quot;) with a contract research organization (&amp;quot;CRO&amp;quot;) to provide clinical trial services for individual studies and projects by executing individual work orders. The MSA and associated work orders are designed such that quarterly payments are to be made in advance of the work to be performed.&amp;nbsp; The Company recognized research and development expenses related to this MSA of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million during the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017.&amp;nbsp; &lt;/div&gt;As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.8&lt;/div&gt; million of prepaid research and development costs that are estimated to be recognized during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; quarter of fiscal &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Legal Proceedings&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 7, 2014, &lt;/div&gt;a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s former Chief Executive Officer under the caption &lt;div style="display: inline; font-style: italic;"&gt;Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH&lt;/div&gt; (Case &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;BC553996&lt;/div&gt;). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&amp;#x2019; fees and costs. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 30, 2014, &lt;/div&gt;the Company filed a petition to compel arbitration and a motion to stay the action. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; April 1, 2015, &lt;/div&gt;the plaintiff filed a petition in opposition to the Company&amp;#x2019;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; April 14, 2015, &lt;/div&gt;the Court granted the Company&amp;#x2019;s petition to compel arbitration and a motion to stay the action. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 8, 2016, &lt;/div&gt;the plaintiff filed an arbitration demand with the American Arbitration Association. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;have on the Company&amp;#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&amp;#x2019;s financial position.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; September 21, 2015, &lt;/div&gt;David Schmidt, a former member of Diffusion LLC and current stockholder of the Company, filed suit (the &amp;#x201c;Original Complaint&amp;#x201d;) in the Circuit Court for Albemarle County, Virginia (Case. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;CL15&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;791,&lt;/div&gt; David G. Schmidt v. Diffusion Pharmaceuticals LLC), which Complaint was amended on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; April 14, 2016 (&lt;/div&gt;the &amp;#x201c;Amended Complaint&amp;#x201d;). The Original Complaint alleged that a breach of contract with respect to Mr. Schmidt&amp;#x2019;s previously converted convertible note, and requested relief of specific performance requiring Diffusion LLC to issue him additional units, representing the additional number of units he would have received had he converted at the renegotiated conversion price.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; September 27, 2016, &lt;/div&gt;the Company, Diffusion LLC, Mr. Schmidt and the other parties thereto entered into a Settlement Agreement (the &amp;#x201c;Settlement Agreement&amp;#x201d;) pursuant to which, among other things, (i) Mr. Schmidt and Diffusion each agreed to submit a consent order to the Court dismissing all claims set forth in the Amended Complaint with prejudice and without an admission of liability by any party, (ii) Mr. Schmidt and Diffusion each released, on behalf of such party and its heirs, assigns, representatives, affiliates and agents, all claims and causes of action of any nature against the other party existing as of the date of the Settlement Agreement and (iii) as consideration therefor, the Company agreed to issue and sell, to Mr. Schmidt and the other parties to the Settlement Agreement, the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes in an aggregate principal amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.9&lt;/div&gt; million and are convertible into shares of Common Stock at an initial conversion price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.50&lt;/div&gt; per share.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company recognized a litigation settlement charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.5&lt;/div&gt; million which represents the difference between the fair value of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes issued and the cash received from Mr. Schmidt and other parties. The settlement charge was recorded as a component of general and administrative expenses within the Company&amp;#x2019;s consolidated statement of operations for the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c29256130" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c29256131" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="i_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256415" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c29256132" unitRef="xbrli-shares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="i_2016-12-31" decimals="INF" id="c29256133" unitRef="xbrli-shares">1000000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued contextRef="i_2017-12-31" decimals="INF" id="c29256134" unitRef="xbrli-shares">14519629</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="i_2016-12-31" decimals="INF" id="c29256135" unitRef="xbrli-shares">10345637</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c29256136" unitRef="xbrli-shares">14519629</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="i_2016-12-31" decimals="INF" id="c29256137" unitRef="xbrli-shares">10345637</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockValue contextRef="i_2017-12-31" decimals="INF" id="c29256128" unitRef="iso4217-usd">14520</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2016-12-31" decimals="INF" id="c29256129" unitRef="iso4217-usd">10346</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258216">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; items of comprehensive income or loss other than net loss.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2017-01-01_2017-12-31" id="c29258204">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:ConversionOfStockSharesConverted1 contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="INF" id="c29256835" unitRef="xbrli-shares">4070051</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256425" unitRef="xbrli-shares">20568632</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256817" unitRef="xbrli-shares">8306278</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256818" unitRef="xbrli-shares">593933</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConversionOfStockSharesIssued1 contextRef="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256819" unitRef="xbrli-shares">11668421</us-gaap:ConversionOfStockSharesIssued1>
  <us-gaap:ConvertibleDebtCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256093" unitRef="iso4217-usd">550000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256094" unitRef="iso4217-usd">1880000</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="i_2017-12-31_DebtInstrumentAxis-ConvertibleNoteSeriesBMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="INF" id="c29256447" unitRef="iso4217-usd">600000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="i_2016-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="INF" id="c29256455" unitRef="iso4217-usd">2000000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtFairValueDisclosures contextRef="i_2016-12-31_DebtInstrumentAxis-ConvertibleNoteSeriesBMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" decimals="INF" id="c29256457" unitRef="iso4217-usd">600000</us-gaap:ConvertibleDebtFairValueDisclosures>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="i_2017-12-31" id="c29256101" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29256102" unitRef="iso4217-usd">550000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-24">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2016 convertible notes&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,880,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Pre-Merger convertible notes&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,880,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt, net of current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="i_2017-12-31" id="c29256741" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConvertibleLongTermNotesPayable contextRef="i_2016-12-31" decimals="INF" id="c29256742" unitRef="iso4217-usd">550000</us-gaap:ConvertibleLongTermNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="-5" id="c29256408" unitRef="iso4217-usd">1100000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2017-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember" id="c29256733" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2016-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember" decimals="INF" id="c29256734" unitRef="iso4217-usd">1880000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2017-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="INF" id="c29256735" unitRef="iso4217-usd">550000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2016-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="INF" id="c29256736" unitRef="iso4217-usd">550000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2017-12-31" decimals="INF" id="c29256737" unitRef="iso4217-usd">550000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayable contextRef="i_2016-12-31" decimals="INF" id="c29256738" unitRef="iso4217-usd">2430000</us-gaap:ConvertibleNotesPayable>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256739" unitRef="iso4217-usd">550000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:ConvertibleNotesPayableCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256740" unitRef="iso4217-usd">1880000</us-gaap:ConvertibleNotesPayableCurrent>
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="i_2017-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201609Member_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256520" unitRef="iso4217-usd">1000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="i_2017-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201609Member_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember" decimals="INF" id="c29256530" unitRef="iso4217-usd">-1000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="d_2017-01-01_2017-12-31" id="c29256398" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256399" unitRef="iso4217-usd">711495</us-gaap:DebtConversionConvertedInstrumentAmount1>
  <us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="d_2016-01-01_2016-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="INF" id="c29256731" unitRef="xbrli-shares">217122</us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
  <us-gaap:DebtConversionOriginalDebtAmount1 contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256729" unitRef="iso4217-usd">700000</us-gaap:DebtConversionOriginalDebtAmount1>
  <us-gaap:DebtDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848486">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Convertible Debt&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;The components of debt outstanding are as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, &lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2016 convertible notes&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,880,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Pre-Merger convertible notes&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,880,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt, net of current portion&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;550,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;For the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company recognized interest expense of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.1&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$37,000,&lt;/div&gt; respectively in connection with its convertible debt instruments. Accrued interest was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$37,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$29,000&lt;/div&gt; as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; September 27, 2016, &lt;/div&gt;the Company issued and sold convertible promissory notes (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x201c;2016&lt;/div&gt; Convertible Notes&amp;#x201d;) in an aggregate principal amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.9&lt;/div&gt; million. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes were issued to an investor and certain other parties in connection with the settlement of a litigation matter. The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes had a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;) year and bore interest at a rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.0%&lt;/div&gt; per annum with the principal and accrued interest due upon the earlier of the maturity date or conversion date. The Company accounted for the issuance of the convertible promissory notes in accordance with ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;470&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;25&lt;/div&gt; and, at the time of issuance, recorded a litigation settlement expense of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.5&lt;/div&gt; million which represents the difference between the estimated fair value of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes issued and the cash received from the noteholders. Upon maturity of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; Convertible Notes during the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company repaid the outstanding principal and interest of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.9&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.1&lt;/div&gt; million, respectively.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Pre-Merger Convertible Notes&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;From &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 2009 &lt;/div&gt;through &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 2015, &lt;/div&gt;the Company issued unsecured convertible promissory notes (the &amp;#x201c;Pre-Merger Convertible Notes&amp;#x201d;) for aggregate gross proceeds of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22.4&lt;/div&gt; million. The Pre-Merger Convertible Notes bore interest at either &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1%&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5%&lt;/div&gt; per annum, however, all Pre-Merger Convertible Notes outstanding at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;bear interest at a rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1%&lt;/div&gt; per annum. The Pre-Merger Convertible Notes accrue interest beginning on the date of issuance, with the principal and accrued interest due upon the earlier of the maturity date or conversion date. At any time prior to the maturity date, the holders &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;elect to convert, in whole or in part, the Pre-Merger Convertible Notes and any related accrued but unpaid interest into common stock of the Company at a price per share equal to the conversion price. In the event of a Change of Control or a Qualified Financing (each as defined below), the holders of the Pre-Merger Convertible Notes &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;declare the aggregate outstanding amount of the Pre-Merger Convertible Notes to be immediately due and payable or &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;elect to convert the Convertible Notes and any accrued but unpaid interest as if such conversion took place on the maturity date. A Change of Control is defined as: (i) a merger or consolidation in which the owners immediately prior to the transaction do &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; own, directly or indirectly, more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the surviving company; (ii) the acquisition of more than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;50%&lt;/div&gt; of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s outstanding shares by a single person, entity or group or persons or entities acting in concert or (iii) the sale or transfer of all or substantially all of the assets of the Company. A Qualified Financing is defined as a sale of shares or other transaction that results in gross proceeds to the Company of at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$50.0&lt;/div&gt; million, including proceeds received in connection with the conversion of any Pre-Merger Convertible Notes. Through the date the financial statements were available to be issued, there have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; Change of Control or Qualified Financing events. The Company &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;prepay the Pre-Merger Convertible Notes, in full or in part, at any time on a pari passu basis. Upon receipt of notice that the Company intends to prepay the Pre-Merger Convertible Notes, holders will have the option to convert their notes in lieu of payment.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;At the effective time of the Merger, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million in aggregate principal amount of Pre-Merger Convertible Notes were outstanding and&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;the rights of the holders of each such outstanding Pre-Merger Convertible Notes convertible into Diffusion Units were converted into the right to convert such securities into a number of shares of the Company&amp;#x2019;s common stock equal to the number of Diffusion Units such Pre-Merger Convertible Notes would be convertible into pursuant to its terms multiplied by the Exchange Ratio.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016,&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Pre-Merger Convertible Notes&amp;nbsp;of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.7&lt;/div&gt; million&amp;nbsp;and related accrued interest of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$16,000&lt;/div&gt;&amp;nbsp;were converted into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;217,122&lt;/div&gt; shares of common stock.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="i_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember" decimals="INF" id="c29256769" unitRef="iso4217-usd-per-xbrli-shares">3.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentFaceAmount contextRef="i_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember" decimals="INF" id="c29256703" unitRef="iso4217-usd">1900000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="i_2017-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="3" id="c29256722" unitRef="xbrli-pure">0.01</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember" decimals="3" id="c29256708" unitRef="xbrli-pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember_RangeAxis-MinimumMember" decimals="3" id="c29256720" unitRef="xbrli-pure">0.01</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember_RangeAxis-MaximumMember" decimals="3" id="c29256721" unitRef="xbrli-pure">0.015</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentTerm contextRef="d_2016-09-27_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember" id="c29256706">P1Y</us-gaap:DebtInstrumentTerm>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256345" unitRef="iso4217-usd">-1055685</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256346" unitRef="iso4217-usd">-364796</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2017-12-31" id="c29257104" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet contextRef="i_2016-12-31" id="c29257105" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2017-12-31" decimals="INF" id="c29257094" unitRef="iso4217-usd">5310628</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="i_2016-12-31" decimals="INF" id="c29257095" unitRef="iso4217-usd">7547296</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2017-12-31" decimals="INF" id="c29257096" unitRef="iso4217-usd">2141973</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="i_2016-12-31" decimals="INF" id="c29257097" unitRef="iso4217-usd">2720186</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2017-12-31" decimals="INF" id="c29257102" unitRef="iso4217-usd">15237109</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="i_2016-12-31" decimals="INF" id="c29257103" unitRef="iso4217-usd">16176394</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxLiabilities contextRef="i_2016-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentCostsIprdMember" decimals="-3" id="c29257065" unitRef="iso4217-usd">3600000</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="i_2017-12-31" decimals="INF" id="c29257109" unitRef="iso4217-usd">2223678</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilities contextRef="i_2016-12-31" decimals="INF" id="c29257110" unitRef="iso4217-usd">3279363</us-gaap:DeferredTaxLiabilities>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="i_2017-12-31" decimals="INF" id="c29257107" unitRef="iso4217-usd">2223678</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets contextRef="i_2016-12-31" decimals="INF" id="c29257108" unitRef="iso4217-usd">3279363</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29256103" unitRef="iso4217-usd">2223678</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DeferredTaxLiabilitiesNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29256104" unitRef="iso4217-usd">3279363</us-gaap:DeferredTaxLiabilitiesNoncurrent>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257052" unitRef="iso4217-usd">49000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29257053" unitRef="iso4217-usd">28000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29257050" unitRef="xbrli-pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="d_2017-01-01_2017-12-31" decimals="2" id="c29257049" unitRef="xbrli-pure">0.9</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:Depreciation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257876" unitRef="iso4217-usd">67981</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29257877" unitRef="iso4217-usd">25342</us-gaap:Depreciation>
  <us-gaap:DepreciationNonproduction contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256151" unitRef="iso4217-usd">67981</us-gaap:DepreciationNonproduction>
  <us-gaap:DepreciationNonproduction contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256152" unitRef="iso4217-usd">25342</us-gaap:DepreciationNonproduction>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257153" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257154" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257155" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257730" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257731" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember" id="c29257732" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848492">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; Equity Plan&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; Equity Plan, as amended in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; July 2016, &lt;/div&gt;currently allows for the issuance of up to a maximum of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;500,000&lt;/div&gt; shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; including shares subject to awards assumed in connection with certain transactions, including the Merger. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104,291&lt;/div&gt; shares of common stock available for future issuance under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; Equity Plan. In addition, beginning on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2017, &lt;/div&gt;on each &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1&lt;/div&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;st&lt;/div&gt; through the term of the plan, up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.0%&lt;/div&gt; of the total shares of the Company&amp;#x2019;s common stock outstanding as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31&lt;/div&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;st&lt;/div&gt; will be added to the plan reserve, unless a lesser amount is stipulated by the Compensation Committee of the Company&amp;#x2019;s Board of Directors. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2018, &lt;/div&gt;the maximum number of shares of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2015&lt;/div&gt; Equity Plan increased by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;580,785&lt;/div&gt; shares, or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.0%&lt;/div&gt; of the total shares of the Company&amp;#x2019;s common stock outstanding at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95,040&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674,643&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,145,511&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;716,425&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,240,551&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,391,068&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table summarizes the activity related to all stock option grants to employees and non-employees:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;contractual life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(A)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 52%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,495,615&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.92&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;RestorGenex options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;301,156&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(48,190&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;61.30&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;458,828&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.25&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.09&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94,599&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;350,041&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.46&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,461&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.32&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,858,073&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.25&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.49&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.32&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr&gt; &lt;td style="width: 18pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 18pt; vertical-align: top;"&gt; &lt;div style=" text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"&gt;(A)&lt;/div&gt; &lt;/td&gt; &lt;td style="vertical-align: top;"&gt; &lt;div style=" text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;"&gt;The difference, if positive, between the stock option&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s exercise price and the closing price of the Company&amp;#x2019;s common stock at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Generally, the options have a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;) year&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;contractual term and vest in equal monthly installments over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;) years. In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2016, &lt;/div&gt;the Company granted an option to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;204,907&lt;/div&gt; shares of Common Stock to a director in connection with the director&amp;#x2019;s appointment to the board of directors. The options will vest in equal quarterly installments over &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;ten&lt;/div&gt; (&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt;) years and any options exercised are restricted from being sold until &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2021.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Non-employee Stock Options&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,394&lt;/div&gt; stock options granted to non-employees during the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; The total fair value of non-employee stock options vested during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$90,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.8&lt;/div&gt; million, respectively. At &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$14,000&lt;/div&gt; of unrecognized compensation cost related to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,080&lt;/div&gt; unvested stock options and subject to re-measurement until vested. The total unrecognized compensation expense will be recognized as expense over a weighted-average period of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.5&lt;/div&gt; years.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; text-decoration: underline;"&gt;Employee Stock Options&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The weighted average grant date fair value of stock option awards granted to employees was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.10&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$5.55&lt;/div&gt; during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively. The total fair value of options vested during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.6&lt;/div&gt; million, respectively. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; options were exercised during any of the periods presented. At &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.6&lt;/div&gt; million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.37&lt;/div&gt; years.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The grant date fair value of employee stock options is determined using the Black-Scholes model. The following assumptions were used during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016:&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.27&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.76&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.48&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.4%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.2%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.0%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;109.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;136.7%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;106.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125.5%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Restricted Stock Awards&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,066&lt;/div&gt; unvested shares of restricted stock. During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,132&lt;/div&gt; shares vested. The fair value as of the respective vesting dates of the restricted stock awards was both &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12,000&lt;/div&gt;&lt;/div&gt; for &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; The grant date fair value of each restricted stock award granted during the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.97.&lt;/div&gt; There were &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; restricted stock awards granted in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; At &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; there was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6,000&lt;/div&gt; of unrecognized compensation cost related to unvested restricted stock that will be recognized as expense over a weighted average period of less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; year.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:Dividends contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="-3" id="c29256822" unitRef="iso4217-usd">1300000</us-gaap:Dividends>
  <us-gaap:Dividends contextRef="d_2017-01-01_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="-3" id="c29256825" unitRef="iso4217-usd">200000</us-gaap:Dividends>
  <us-gaap:Dividends contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="INF" id="c29256392" unitRef="iso4217-usd">1252394</us-gaap:Dividends>
  <us-gaap:Dividends contextRef="d_2016-01-01_2016-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" id="c29256393" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:Dividends contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256284" unitRef="iso4217-usd">1252394</us-gaap:Dividends>
  <us-gaap:Dividends contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256286" unitRef="iso4217-usd">1252394</us-gaap:Dividends>
  <us-gaap:EarningsPerShareBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256174" unitRef="iso4217-usd-per-xbrli-shares">-0.21</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256175" unitRef="iso4217-usd-per-xbrli-shares">-1.76</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256176" unitRef="iso4217-usd-per-xbrli-shares">-1.94</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256177" unitRef="iso4217-usd-per-xbrli-shares">-1.76</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258215">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the &amp;#x201c;if-converted&amp;#x201d; method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have been incurred if the warrants had been converted into common stock.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,364,518&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Accretion of Series A cumulative preferred dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,252,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,072,322&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(24,689,234&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Common stock equivalents arising from warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;307,675&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,755,316&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common stock, diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.94&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible debt&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;214,385&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;757,909&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;447,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;460,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,306,278&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock awards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,066&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,527,439&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,435,243&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Amounts in the table reflect the common stock equivalents of the noted instruments.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257133" unitRef="xbrli-pure">-0.435</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257134" unitRef="xbrli-pure">-0.02</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2018-01-01_2018-12-31_StatementScenarioAxis-ScenarioForecastMember" decimals="2" id="c29256489" unitRef="xbrli-pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257113" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257114" unitRef="xbrli-pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257127" unitRef="xbrli-pure">-0.388</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257128" unitRef="xbrli-pure">0.272</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257119" unitRef="xbrli-pure">2.055</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="d_2016-01-01_2016-12-31" id="c29257120" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257129" unitRef="xbrli-pure">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257130" unitRef="xbrli-pure">0.042</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257131" unitRef="xbrli-pure">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257132" unitRef="xbrli-pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2017-01-01_2017-12-31" decimals="3" id="c29257115" unitRef="xbrli-pure">0.163</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="d_2016-01-01_2016-12-31" decimals="3" id="c29257116" unitRef="xbrli-pure">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" id="c29256918">P1Y182D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29256933">P5Y135D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember_RangeAxis-MaximumMember" id="c29256954">P1Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="i_2017-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256953" unitRef="iso4217-usd">6000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" decimals="INF" id="c29256916" unitRef="iso4217-usd">14000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256932" unitRef="iso4217-usd">2600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="-3" id="c29256865" unitRef="iso4217-usd">22100000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256157" unitRef="iso4217-usd">-22072322</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="d_2016-01-01_2016-12-31" id="c29256158" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueAssumptionsExercisePrice contextRef="i_2017-11-01" decimals="INF" id="c29257170" unitRef="iso4217-usd-per-xbrli-shares">2.22</us-gaap:FairValueAssumptionsExercisePrice>
  <us-gaap:FairValueAssumptionsExpectedTerm contextRef="d_2017-01-01_2017-11-01" id="c29257171">P4Y138D</us-gaap:FairValueAssumptionsExpectedTerm>
  <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-11-01" decimals="3" id="c29257173" unitRef="xbrli-pure">1.041</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-11-01" decimals="3" id="c29257172" unitRef="xbrli-pure">0.019</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:FairValueAssumptionsWeightedAverageExpectedDividend contextRef="d_2017-01-01_2017-11-01" id="c29257174" unitRef="iso4217-usd-per-xbrli-shares" xs:nil="true"/>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848501">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Fair Value Measurements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; of the following &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; levels of the fair value hierarchy, of which the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;two&lt;/div&gt; are considered observable and the last is considered unobservable:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 36pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;#x25cf;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2014;Quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 36pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;#x25cf;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2014;Observable inputs (other&amp;nbsp;than Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt; quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"&gt;  &lt;tr style="vertical-align: top;"&gt; &lt;td style="width: 36pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;#x25cf;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2014;Unobservable inputs that are supported by little or &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The asset&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s or liability&amp;#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following table presents the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s assets and liabilities that are measured at fair value on a recurring basis:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,896,468&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="width: 21474836.47%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,552,852&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;) is as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Issued in connection with the Series A convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35,225,846&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,072,322&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reclassification of Series A warrants to additional paid in capital&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,153,524&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The common stock warrants issued in connection with the Series A convertible preferred stock were previously classified as liabilities, and were marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&amp;#x2019; equity. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 1, 2017 &lt;/div&gt;the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&amp;#x2019;s Certificate of Incorporation to permit the Company to pay dividends on the Company&amp;#x2019;s Series A Convertible Preferred Stock in either cash or shares of the Company&amp;#x2019;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert there will be sufficient authorized shares available to settle the Series A warrants. Upon this assertion, the Series A warrants were reclassified from liabilities to stockholders&amp;#x2019; equity.&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrant liability as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 1, 2017, &lt;/div&gt;which was the date of the reclassification, were as follows:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.44&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-34">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Warrant Liability&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Issued in connection with the Series A convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35,225,846&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,072,322&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Reclassification of Series A warrants to additional paid in capital&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(13,153,524&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember" decimals="INF" id="c29257737" unitRef="iso4217-usd">22072322</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues contextRef="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember" decimals="INF" id="c29257736" unitRef="iso4217-usd">35225846</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="i_2016-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember" id="c29257735" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="i_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember" id="c29257739" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueOfAssetsAcquired contextRef="d_2017-01-01_2017-12-31" id="c29256400" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:FairValueOfAssetsAcquired contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256401" unitRef="iso4217-usd">21261000</us-gaap:FairValueOfAssetsAcquired>
  <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2017-01-01_2017-12-31" id="c29258203">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The carrying amounts of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the fair value of the Company's outstanding Series B convertible note was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.6&lt;/div&gt; million. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the fair value of the Company&amp;#x2019;s outstanding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; convertible note and Series B convertible note was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.0&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.6&lt;/div&gt; million, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; of the fair value hierarchy.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2017-01-01_2017-12-31" id="c29256335" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:GainLossOnDispositionOfAssets1 contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256336" unitRef="iso4217-usd">-6761</us-gaap:GainLossOnDispositionOfAssets1>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256149" unitRef="iso4217-usd">6191845</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256150" unitRef="iso4217-usd">11094146</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:Goodwill contextRef="i_2017-12-31" decimals="INF" id="c29256651" unitRef="iso4217-usd">6929258</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2016-12-31" decimals="INF" id="c29256675" unitRef="iso4217-usd">6929258</us-gaap:Goodwill>
  <us-gaap:Goodwill contextRef="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="INF" id="c29257546" unitRef="iso4217-usd">6929258</us-gaap:Goodwill>
  <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848483">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Goodwill and Intangible Assets&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company completes its annual impairment test on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at both &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$6.9&lt;/div&gt;&lt;/div&gt; million. There have been &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; changes to the carrying value of goodwill during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In connection with the Merger, the Company acquired indefinite-lived In-Process Research and Development Assets (&amp;#x201c;IPR&amp;amp;D&amp;#x201d;) RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt; and RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440,&lt;/div&gt; with estimated fair values of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.6&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million, respectively. The Company&amp;#x2019;s novel &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;PI3K/Akt/mTOR&lt;/div&gt; pathway inhibitor, RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529,&lt;/div&gt; is in preclinical development for oncology. Through a series of in vitro and in vivo animal models, RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt; has been shown&amp;nbsp;to have activity in several cancer types due to its ability to target and inhibit the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;PI3K/Akt/mTOR&lt;/div&gt; signal transduction pathway. RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt; is a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt;-in-class inhibitor of both &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;TORC1&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;TORC2&lt;/div&gt; that is mechanistically differentiated from other &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;PI3K/Akt/mTOR&lt;/div&gt; pathway inhibitors currently in development. RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;529&lt;/div&gt; has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2016, &lt;/div&gt;the Board of Directors determined that RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440,&lt;/div&gt; a &amp;#x201c;soft&amp;#x201d; anti-androgen compound for the treatment of acne vulgaris, was outside the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s core product focus, and was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; a priority. Therefore, future development efforts were abandoned in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt; In connection with its review of such abandonment, the Company concluded RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440&lt;/div&gt; was impaired in its entirety. The abandonment resulted in a net impairment charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million and was recorded as a component of research and development expenses within the Company&amp;#x2019;s consolidated statement of operations for the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016. &lt;/div&gt;The abandonment also resulted in an income tax benefit of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.4&lt;/div&gt; million.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy contextRef="d_2017-01-01_2017-12-31" id="c29258209">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company performs its annual goodwill impairment test on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s goodwill is less than the carrying value of the reporting unit&amp;#x2019;s goodwill. The Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;/div&gt; recognize any impairment of goodwill during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy contextRef="d_2017-01-01_2017-12-31" id="c29258208">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Assets&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets are comprised of identifiable in-process research and development (IPR&amp;amp;D) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives. In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2016, &lt;/div&gt;the Company abandoned the future development efforts with respect to its RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440&lt;/div&gt; product candidate, and the value of the associated IPR&amp;amp;D asset was written down to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; (See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
  <us-gaap:GoodwillImpairmentLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256478" unitRef="iso4217-usd">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:GoodwillImpairmentLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256529" unitRef="iso4217-usd">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member" decimals="-5" id="c29256673" unitRef="iso4217-usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="d_2016-08-01_2016-08-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member" decimals="-3" id="c29257067" unitRef="iso4217-usd">1000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256470" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256528" unitRef="iso4217-usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
  <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258207">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-Lived Assets&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;/div&gt; recognized any impairment of long-lived assets during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256163" unitRef="iso4217-usd">-2420203</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256164" unitRef="iso4217-usd">-18401415</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848497">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Prior to the Merger, the Company was treated as a partnership for federal income tax purposes.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 2017, &lt;/div&gt;the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act was enacted, which includes a number of changes to previously existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;35%&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%&lt;/div&gt; for tax years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017. &lt;/div&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act also provides for a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt;-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed into service after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; September 27, 2017 &lt;/div&gt;as well as prospective changes beginning in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; including repeal of the domestic manufacturing deduction, acceleration of tax revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company recorded a deferred tax liability of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$3.6&lt;/div&gt; million for the basis differences associated with indefinite-lived in-process R&amp;amp;D assets.&amp;nbsp;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2016, &lt;/div&gt;the Company abandoned future development efforts for the IPR&amp;amp;D asset associated with RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440&lt;/div&gt; and recorded an impairment charge of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.0&lt;/div&gt; million which is equal to its acquired value. Upon recognizing the impairment, the Company recognized an income tax benefit of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.4&lt;/div&gt; million and reduced the carrying value of the related deferred tax liability as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; (See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;). In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; this deferred tax liability was further reduced by &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million as a result of the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act. &lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,310,628&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,547,296&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock option compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,141,973&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,720,186&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,537,039&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,218,069&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,247,469&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,690,843&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,237,109&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,176,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,279,363&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,279,363&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;/div&gt; have unrecognized tax benefits as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; or &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016. &lt;/div&gt;The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company had net operating loss carryforwards (&amp;#x201c;NOL&amp;#x201d;) for federal and state income tax purposes at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;&amp;nbsp;of approximately:&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Combined NOL Carryforwards:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,629,817&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,640,700&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The net operating loss carryforwards begin expiring in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2034&lt;/div&gt; for federal income tax purposes and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2034&lt;/div&gt; for state income tax purposes. In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2016, &lt;/div&gt;the number of outstanding shares of RestorGenex common stock increased in connection with the Merger discussed in note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.&lt;/div&gt; This increase in the number of shares outstanding&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;resulted in&amp;nbsp;a change of ownership, under the provisions of Internal Revenue Code Section &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;382&lt;/div&gt; and similar state provisions, and limits the Company&amp;#x2019;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation.&amp;nbsp;The Company's &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018&lt;/div&gt; financings &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;have also triggered an ownership change, which could further limit the Company's ability to utilize its NOL carryforwards. The Company has yet to determine this potential limitation. The Company recorded a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;100%&lt;/div&gt; valuation allowance of the deferred tax assets as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; because of the uncertainty of their realization.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; is as follows:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rate reconciliation:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16.3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2.3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value of warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(126.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;205.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Litigation settlement charge&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Acquisition costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(36.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4.4&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(38.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(43.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2014&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; tax years remain open and subject to examination.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-12-31_NonmonetaryTransactionTypeAxis-AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" decimals="-5" id="c29256674" unitRef="iso4217-usd">-400000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256165" unitRef="iso4217-usd">-1055685</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256166" unitRef="iso4217-usd">-364796</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256493" unitRef="iso4217-usd">-1100000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258213">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Prior to the Merger, Diffusion LLC was treated as a partnership for federal and state income tax purposes. Diffusion LLC&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s taxable income or loss, as well as certain other tax attributes, were passed through directly to its members and were reported in each member&amp;#x2019;s individual income tax return.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Upon completion of the Merger as discussed in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; the Company converted from a partnership to a corporation for accounting purposes. As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that some portion or all of a deferred tax asset will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be sustained.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 22, 2017 &lt;/div&gt;the President of the United States signed into law the Tax Cuts and Jobs Act (&amp;quot;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act&amp;quot;).&amp;nbsp;This legislation makes significant changes in the U.S. tax laws including, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; limited to, reducing the corporate tax rate to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%&lt;/div&gt; starting in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%.&lt;/div&gt;&amp;nbsp;&amp;nbsp;As a result of the change, the Company recorded a current period tax benefit of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million in its consolidated statement of operations and a corresponding reduction in the deferred tax liability on its consolidated balance sheet.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256354" unitRef="iso4217-usd">-1663789</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256355" unitRef="iso4217-usd">991625</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256352" unitRef="iso4217-usd">664162</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256353" unitRef="iso4217-usd">-319545</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256566" unitRef="xbrli-shares">307675</us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants>
  <us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants contextRef="d_2016-01-01_2016-12-31" id="c29256567" unitRef="xbrli-shares" xs:nil="true"/>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2016-08-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member" decimals="INF" id="c29256475" unitRef="iso4217-usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2017-12-31" decimals="INF" id="c29256083" unitRef="iso4217-usd">8639000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="i_2016-12-31" decimals="INF" id="c29256084" unitRef="iso4217-usd">8639000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES529Member" decimals="-5" id="c29256656" unitRef="iso4217-usd">8600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member" decimals="-5" id="c29256657" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES529Member" decimals="-3" id="c29256591" unitRef="iso4217-usd">8600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member" decimals="-3" id="c29256593" unitRef="iso4217-usd">1000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:InterestExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256695" unitRef="iso4217-usd">100000</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256696" unitRef="iso4217-usd">37000</us-gaap:InterestExpense>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256155" unitRef="iso4217-usd">-48006</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256156" unitRef="iso4217-usd">-29686</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:InterestPaidNet contextRef="d_2017-07-01_2017-09-30_DebtInstrumentAxis-The2016ConvertibleNotesMember" decimals="INF" id="c29256718" unitRef="iso4217-usd">100000</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256387" unitRef="iso4217-usd">112800</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="d_2016-01-01_2016-12-31" id="c29256388" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:InterestPayableCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256677" unitRef="iso4217-usd">37415</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256678" unitRef="iso4217-usd">29359</us-gaap:InterestPayableCurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29256698" unitRef="iso4217-usd">37000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:InterestPayableCurrentAndNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29256699" unitRef="iso4217-usd">29000</us-gaap:InterestPayableCurrentAndNoncurrent>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256339" unitRef="iso4217-usd">50000</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256340" unitRef="iso4217-usd">1409363</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
  <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258212">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:LegalCostsPolicyTextBlock>
  <us-gaap:Liabilities contextRef="i_2017-12-31" decimals="INF" id="c29256107" unitRef="iso4217-usd">4915871</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="i_2016-12-31" decimals="INF" id="c29256108" unitRef="iso4217-usd">8299700</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c29256144" unitRef="iso4217-usd">26145815</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2016-12-31" decimals="INF" id="c29256145" unitRef="iso4217-usd">17484384</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256099" unitRef="iso4217-usd">2690807</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256100" unitRef="iso4217-usd">4438422</us-gaap:LiabilitiesCurrent>
  <us-gaap:LitigationSettlementExpense contextRef="d_2016-09-27_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember" decimals="INF" id="c29256712" unitRef="iso4217-usd">2500000</us-gaap:LitigationSettlementExpense>
  <us-gaap:LitigationSettlementExpense contextRef="d_2017-01-01_2017-12-31" id="c29256347" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:LitigationSettlementExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256348" unitRef="iso4217-usd">2500000</us-gaap:LitigationSettlementExpense>
  <us-gaap:NatureOfOperations contextRef="d_2017-01-01_2017-12-31" id="s848472">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.&lt;/div&gt; Organization and Description of Business&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Diffusion Pharmaceuticals Inc. &amp;#x201c;Diffusion&amp;#x201d; or &amp;#x201c;the Company&amp;#x201d; is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&amp;#x201c;TSC&amp;#x201d;), for use in the many cancer types in which tumor oxygen deprivation (&amp;#x201c;hypoxia&amp;#x201d;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2015, &lt;/div&gt;the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s predecessor for accounting purposes, Diffusion Pharmaceuticals LLC (&amp;#x201c;Diffusion LLC&amp;#x201d;) entered into a definitive merger agreement with the Company, then known as &amp;#x201c;RestorGenex Corporation&amp;#x201d; and traded on the over-the-counter stock exchange under the ticker symbol &amp;#x201c;RESX.&amp;#x201d; On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 8, 2016 &lt;/div&gt;the Company completed the merger with Diffusion LLC under which a newly formed subsidiary of the Company merged with and into Diffusion LLC in an all-stock transaction, with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the merger, the Company was renamed &amp;#x201c;Diffusion Pharmaceuticals Inc.&amp;#x201d; and the Company&amp;#x2019;s ticker symbol was changed to &amp;#x201c;DFFN.&amp;#x201d; On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 9, 2016, &lt;/div&gt;the Company&amp;#x2019;s common stock (&amp;#x201c;Common Stock&amp;#x201d;) began trading on the NASDAQ Capital Market exchange.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The merger transaction was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s pre-transaction owners held an &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;84.1%&lt;/div&gt; economic and voting interest in the combined company immediately following the closing of the merger, Diffusion LLC is considered to be the acquirer of RestorGenex for accounting purposes (See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;). &lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s members&amp;#x2019; capital at &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2016 &lt;/div&gt;has been recast as common stock and additional paid in capital. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 17, 2016, &lt;/div&gt;the Company effected a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1&lt;/div&gt;-for-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; reverse split of its common stock. The accompanying consolidated financial statements and these notes give retroactive effect to this reverse stock split.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Each outstanding unit of membership interest of Diffusion LLC (the &amp;#x201c;Diffusion Units&amp;#x201d;) was converted into the right to receive &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.3652658&lt;/div&gt; shares of Common Stock (the &amp;#x201c;Exchange Ratio&amp;#x201d;). Additionally, the right of holders of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million outstanding convertible notes of Diffusion LLC to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the original terms of the notes multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise converted into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,495,615&lt;/div&gt; options to purchase Common Stock on terms substantially identical to those in effect prior to the merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.&lt;/div&gt;&lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256378" unitRef="iso4217-usd">20123794</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256379" unitRef="iso4217-usd">1825654</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256367" unitRef="iso4217-usd">-447823</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256368" unitRef="iso4217-usd">8498271</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256356" unitRef="iso4217-usd">-12332355</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256357" unitRef="iso4217-usd">-10768265</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256167" unitRef="iso4217-usd">-1364518</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256168" unitRef="iso4217-usd">-18036619</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256243" unitRef="iso4217-usd">-18036619</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256320" unitRef="iso4217-usd">-1364518</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256171" unitRef="iso4217-usd">-2616912</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256172" unitRef="iso4217-usd">-18036619</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256562" unitRef="iso4217-usd">-24689234</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256563" unitRef="iso4217-usd">-18036619</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258217">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; July 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Earnings Per Share (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;); Distinguishing Liabilities from Equity (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480&lt;/div&gt;); Derivatives and Hedging (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. &lt;/div&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; part of this update addresses the complexity of accounting for certain financial instruments with down round features and the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2018 &lt;/div&gt;and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; May 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Modification Accounting for Share-Based Payment Arrangements&lt;/div&gt;, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718.&lt;/div&gt; Specifically, an entity would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2017 &lt;/div&gt;and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this new guidance to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation &amp;#x2013; Improvements to Employee Share-Based Payment Accounting&lt;/div&gt;, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2016 &lt;/div&gt;and interim periods within those years. The Company adopted this standard in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; by electing to account for forfeitures in the period that they occur. Under ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,000&lt;/div&gt;&lt;/div&gt; on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; February 2016, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;)&lt;/div&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. Upon adoption in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the Company will determine the fair of the operating lease and recognize this amount as a lease asset and corresponding liability on its consolidated balance sheet. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this new guidance to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 contextRef="d_2016-01-07_2016-01-07_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="-3" id="c29256842" unitRef="iso4217-usd">400000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
  <us-gaap:OperatingIncomeLoss contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256153" unitRef="iso4217-usd">-11348447</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256154" unitRef="iso4217-usd">-18371729</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="i_2017-12-31" decimals="INF" id="c29256784" unitRef="iso4217-usd">501481</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256779" unitRef="iso4217-usd">112354</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="i_2017-12-31" decimals="INF" id="c29256783" unitRef="iso4217-usd">39735</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="i_2017-12-31" decimals="INF" id="c29256782" unitRef="iso4217-usd">118519</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="i_2017-12-31" decimals="INF" id="c29256781" unitRef="iso4217-usd">116464</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="i_2017-12-31" decimals="INF" id="c29256780" unitRef="iso4217-usd">114409</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2017-01-01_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember" decimals="INF" id="c29256750" unitRef="iso4217-usd">100000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLeasesRentExpenseNet contextRef="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember" decimals="INF" id="c29256751" unitRef="iso4217-usd">66000</us-gaap:OperatingLeasesRentExpenseNet>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2017-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" decimals="INF" id="c29257111" unitRef="iso4217-usd">20629817</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards contextRef="i_2017-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" decimals="INF" id="c29257112" unitRef="iso4217-usd">20640700</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256689" unitRef="iso4217-usd">1628851</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256690" unitRef="iso4217-usd">874264</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29256087" unitRef="iso4217-usd">450491</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29256088" unitRef="iso4217-usd">232675</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-23">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued interest payable&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;37,415&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;29,359&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued Series A dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,062,314&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;312,221&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;399,740&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;122,711&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;72,855&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;63,350&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;220,978&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30,840&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;151,332&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,628,851&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;874,264&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2017-12-31" decimals="INF" id="c29256105" unitRef="iso4217-usd">1386</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="i_2016-12-31" decimals="INF" id="c29256106" unitRef="iso4217-usd">31915</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:OtherNonoperatingExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256161" unitRef="iso4217-usd">2870226</us-gaap:OtherNonoperatingExpense>
  <us-gaap:OtherNonoperatingExpense contextRef="d_2016-01-01_2016-12-31" id="c29256162" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="i_2017-12-31" decimals="INF" id="c29256687" unitRef="iso4217-usd">30840</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="i_2016-12-31" decimals="INF" id="c29256688" unitRef="iso4217-usd">151332</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:PaymentsForFees contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_NatureOfExpenseAxis-SuccessFeeAgreementCostsMember" decimals="-3" id="c29256598" unitRef="iso4217-usd">1100000</us-gaap:PaymentsForFees>
  <us-gaap:PaymentsOfFinancingCosts contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256376" unitRef="iso4217-usd">125980</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfFinancingCosts contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256377" unitRef="iso4217-usd">54346</us-gaap:PaymentsOfFinancingCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2017-03-01_2018-01-07_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="-3" id="c29256798" unitRef="iso4217-usd">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256359" unitRef="iso4217-usd">447823</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256360" unitRef="iso4217-usd">2331</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256361" unitRef="iso4217-usd">10000000</us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit>
  <us-gaap:PaymentsToAcquireRestrictedCertificatesOfDeposit contextRef="d_2016-01-01_2016-12-31" id="c29256362" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848496">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Defined Contribution Retirement Plan&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has established a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k)&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;defined contribution plan (the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan) that covers all employees who qualify under the terms of the plan. Eligible employees &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;elect to contribute to the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;90%&lt;/div&gt; of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4%&lt;/div&gt; of the participant&amp;#x2019;s compensation. The Company made matching contributions under the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;401&lt;/div&gt;(k) Plan of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$49,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$28,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:PreferredStockDividendRatePercentage contextRef="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="2" id="c29256790" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockDividendRatePercentage contextRef="d_2018-01-22_2018-01-22_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="2" id="c29256820" unitRef="xbrli-pure">0.08</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:PreferredStockSharesAuthorized contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="INF" id="c29256786" unitRef="xbrli-shares">13750000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="d_2017-01-01_2017-12-31" id="c29256372" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256373" unitRef="iso4217-usd">1880000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" decimals="-3" id="c29256787" unitRef="iso4217-usd">25000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember" decimals="-3" id="c29256812" unitRef="iso4217-usd">0</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:ProceedsFromIssuanceOfUnsecuredDebt contextRef="d_2009-12-01_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember" decimals="INF" id="c29256719" unitRef="iso4217-usd">22400000</us-gaap:ProceedsFromIssuanceOfUnsecuredDebt>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2018-01-22_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember" decimals="-6" id="c29256419" unitRef="iso4217-usd">12000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256363" unitRef="iso4217-usd">10000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="d_2016-01-01_2016-12-31" id="c29256364" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="d_2017-01-01_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember" decimals="INF" id="c29256746" unitRef="iso4217-usd">400000</us-gaap:PropertyPlantAndEquipmentAdditions>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848550">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Property and Equipment&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Property and equipment consists of the following:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;155,113&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;137,290&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;767,470&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;319,647&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(306,818&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(239,892&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;460,652&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;79,755&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Depreciation expense was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$68,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25,000&lt;/div&gt; for the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; respectively.&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="INF" id="c29257553" unitRef="iso4217-usd">182357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" decimals="INF" id="c29257554" unitRef="iso4217-usd">182357</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="INF" id="c29257555" unitRef="iso4217-usd">155113</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" decimals="INF" id="c29257556" unitRef="iso4217-usd">137290</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" decimals="INF" id="c29257557" unitRef="iso4217-usd">430000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" id="c29257558" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2017-12-31" decimals="INF" id="c29257559" unitRef="iso4217-usd">767470</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross contextRef="i_2016-12-31" decimals="INF" id="c29257560" unitRef="iso4217-usd">319647</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2017-12-31" decimals="INF" id="c29257563" unitRef="iso4217-usd">460652</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2016-12-31" decimals="INF" id="c29257564" unitRef="iso4217-usd">79755</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2017-01-01_2017-12-31" id="c29258206">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-22">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;182,357&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and office equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;155,113&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;137,290&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;430,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;767,470&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;319,647&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: accumulated depreciation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(306,818&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(239,892&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;460,652&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;79,755&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" id="c29256463">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" id="c29256465">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848506">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.&lt;/div&gt; Related Party Transactions&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s Director of Information Technologies is also the son of the Chief Executive Officer and he has held that position since &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 2014.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="d_2017-07-01_2017-09-30_DebtInstrumentAxis-The2016ConvertibleNotesMember" decimals="INF" id="c29256717" unitRef="iso4217-usd">1900000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256374" unitRef="iso4217-usd">1880000</us-gaap:RepaymentsOfConvertibleDebt>
  <us-gaap:RepaymentsOfConvertibleDebt contextRef="d_2016-01-01_2016-12-31" id="c29256375" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31_TypeOfArrangementAxis-ArrangementWithClinicalResearchOrganizationMember" decimals="INF" id="c29256755" unitRef="iso4217-usd">1000000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256147" unitRef="iso4217-usd">5088621</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256148" unitRef="iso4217-usd">7252241</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2017-01-01_2017-12-31" id="c29258211">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s behalf). Costs incurred for research and development are expensed as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;record net prepaid or accrued expenses relating to these costs.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Upfront payments made to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties who perform research and development services on the Company&amp;#x2019;s behalf are expensed as services are rendered.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="d_2017-01-01_2017-12-31" id="c29256343" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256344" unitRef="iso4217-usd">951000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2017-12-31" decimals="INF" id="c29256140" unitRef="iso4217-usd">-61554889</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2016-12-31" decimals="INF" id="c29256141" unitRef="iso4217-usd">-60189237</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible debt&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;214,385&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;757,909&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;447,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;460,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,306,278&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock awards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,066&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,527,439&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,435,243&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-30">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax assets&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,310,628&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7,547,296&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock option compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,141,973&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,720,186&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,537,039&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,218,069&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5,247,469&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,690,843&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(15,237,109&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16,176,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax asset&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Deferred tax liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,279,363&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,223,678&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,279,363&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,364,518&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Accretion of Series A cumulative preferred dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,252,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,072,322&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(24,689,234&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Common stock equivalents arising from warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;307,675&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,755,316&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common stock, diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.94&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-32">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rate reconciliation:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(34.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(16.3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2.3&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in fair value of warrant&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(126.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in tax rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;205.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Litigation settlement charge&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.6&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Acquisition costs&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(36.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(4.4&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(38.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;27.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock compensation&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.2&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Total provision&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(43.5&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2.0&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-27">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;95,040&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;674,643&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,145,511&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;716,425&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,240,551&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,391,068&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-33">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,896,468&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="10" style="width: 21474836.47%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 1)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 2)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Level 3)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Assets&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,552,852&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Liabilities&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 12%; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 55%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-25">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Rental&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Commitments&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2018&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;112,354&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2019&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;114,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2020&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;116,464&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2021&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;118,519&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;39,735&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;501,481&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-20">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,500,602&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Prepaid expenses and other assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;195,200&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;57,531&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,600,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Goodwill&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6,929,258&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued liabilities&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(377,432&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(3,644,159&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net assets acquired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21,261,000&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-28">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Number of&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Options&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;exercise price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;contractual life&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(in years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Aggregate&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Intrinsic&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Value&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(A)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 52%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2016&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,495,615&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.92&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;RestorGenex options outstanding&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;301,156&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cancelled&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(48,190&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;61.30&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;458,828&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.25&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.09&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.8&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;94,599&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;350,041&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.46&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,461&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.32&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,858,073&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.25&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.49&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2017&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.32&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 9%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.13&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,734&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-29">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 72%;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.27&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;6.00&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5.76&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;7.48&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.4%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;1.2%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.0%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;109.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;136.7%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;106.8%&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 2%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;125.5%&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 72%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-35">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.44&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercise price&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.22&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4.38&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1.9&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;104.1&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;%&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:SeveranceCosts1 contextRef="d_2016-01-08_2016-01-08_TitleOfIndividualAxis-ExecutiveOfficersMember" decimals="-3" id="c29256601" unitRef="iso4217-usd">3000000</us-gaap:SeveranceCosts1>
  <us-gaap:SeveranceCosts1 contextRef="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-ExecutiveOfficersMember" decimals="-3" id="c29256603" unitRef="iso4217-usd">0</us-gaap:SeveranceCosts1>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-08_2016-01-08_AwardTypeAxis-EmployeeStockOptionMember_BusinessAcquisitionAxis-DiffusionLLCMember" decimals="-3" id="c29256602" unitRef="iso4217-usd">2700000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256337" unitRef="iso4217-usd">1240551</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256338" unitRef="iso4217-usd">1391068</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" id="c29256899">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-VestMonthlyMember" id="c29256901">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="d_2016-08-01_2016-08-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember_VestingAxis-VestQuarterlyMember" id="c29256904">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256949" unitRef="xbrli-shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256948" unitRef="iso4217-usd-per-xbrli-shares">1.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="i_2017-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256939" unitRef="xbrli-shares">3066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256942" unitRef="xbrli-shares">6132</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256943" unitRef="iso4217-usd">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-RestrictedStockMember" decimals="INF" id="c29256957" unitRef="iso4217-usd">12000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2017-01-01_2017-12-31" id="c29257040" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2016-01-01_2016-12-31" id="c29257043" unitRef="xbrli-pure" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="3" id="c29257033" unitRef="xbrli-pure">1.098</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" decimals="3" id="c29257035" unitRef="xbrli-pure">1.367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" decimals="3" id="c29257036" unitRef="xbrli-pure">1.068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" decimals="3" id="c29257038" unitRef="xbrli-pure">1.255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember" decimals="3" id="c29257027" unitRef="xbrli-pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember" decimals="3" id="c29257029" unitRef="xbrli-pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" decimals="3" id="c29257030" unitRef="xbrli-pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" decimals="3" id="c29257032" unitRef="xbrli-pure">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="d_2018-01-01_2018-01-01_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember" decimals="INF" id="c29256893" unitRef="xbrli-shares">580785</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="i_2016-07-21_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember" decimals="INF" id="c29256885" unitRef="xbrli-shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="i_2017-12-31_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember" decimals="INF" id="c29256889" unitRef="xbrli-shares">104291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="i_2017-12-31" decimals="INF" id="c29257013" unitRef="xbrli-shares">1858073</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="i_2017-12-31" decimals="INF" id="c29257014" unitRef="iso4217-usd-per-xbrli-shares">8.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257005" unitRef="xbrli-shares">1461</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256989" unitRef="xbrli-shares">48190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-08-01_2016-08-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember" decimals="INF" id="c29256903" unitRef="xbrli-shares">204907</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" decimals="INF" id="c29256906" unitRef="xbrli-shares">9394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256993" unitRef="xbrli-shares">458828</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257001" unitRef="xbrli-shares">350041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256919" unitRef="iso4217-usd-per-xbrli-shares">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256920" unitRef="iso4217-usd-per-xbrli-shares">5.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2016-12-31" decimals="INF" id="c29257000" unitRef="iso4217-usd">94599</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="i_2017-12-31" decimals="INF" id="c29257012" unitRef="iso4217-usd">4734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-12-31" decimals="INF" id="c29256981" unitRef="xbrli-shares">1495615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2016-12-31" decimals="INF" id="c29256997" unitRef="xbrli-shares">2207409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2017-12-31" decimals="INF" id="c29257009" unitRef="xbrli-shares">2555989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-12-31" decimals="INF" id="c29256982" unitRef="iso4217-usd-per-xbrli-shares">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2016-12-31" decimals="INF" id="c29256998" unitRef="iso4217-usd-per-xbrli-shares">8.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31" decimals="INF" id="c29257010" unitRef="iso4217-usd-per-xbrli-shares">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="i_2017-12-31" decimals="INF" id="c29257020" unitRef="iso4217-usd">4734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="i_2017-12-31" decimals="INF" id="c29257017" unitRef="xbrli-shares">2555989</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="i_2017-12-31" decimals="INF" id="c29257018" unitRef="iso4217-usd-per-xbrli-shares">7.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257006" unitRef="iso4217-usd-per-xbrli-shares">15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256990" unitRef="iso4217-usd-per-xbrli-shares">61.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256994" unitRef="iso4217-usd-per-xbrli-shares">6.25</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29257002" unitRef="iso4217-usd-per-xbrli-shares">2.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2017-01-01_2017-12-31" id="c29258214">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s common stock, the expected term of the Company&amp;#x2019;s stock options, the expected dividend yield and the fair value of the Company&amp;#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The expected term of stock options was estimated using the &amp;#x201c;simplified method&amp;#x201d; for employee options as the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; dividend yield because dividends are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be paid in the near future, which is consistent with the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s history of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer estimates forfeitures and accounts for forfeitures in the periods they occur.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:SharePrice contextRef="i_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember" decimals="INF" id="c29256418" unitRef="iso4217-usd-per-xbrli-shares">0.80</us-gaap:SharePrice>
  <us-gaap:SharePrice contextRef="i_2017-11-01" decimals="INF" id="c29257169" unitRef="iso4217-usd-per-xbrli-shares">1.44</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2017-01-01_2017-12-31" id="c29257022" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember" id="c29257024">P5Y277D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-12-31" id="c29257025" xs:nil="true"/>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember" id="c29257026">P7Y175D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="i_2017-12-31" decimals="INF" id="c29257016" unitRef="iso4217-usd">4734</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-12-31" id="c29257015">P6Y178D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="i_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" decimals="INF" id="c29256917" unitRef="xbrli-shares">14080</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2016-01-01_2016-12-31" id="c29256999">P7Y292D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2017-01-01_2017-12-31" id="c29257011">P7Y47D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2017-01-01_2017-12-31" id="c29257019">P7Y47D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" decimals="INF" id="c29256912" unitRef="iso4217-usd">90000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember" decimals="INF" id="c29256913" unitRef="iso4217-usd">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256927" unitRef="iso4217-usd">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256928" unitRef="iso4217-usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
  <us-gaap:SharesOutstanding contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256184" unitRef="xbrli-shares">8118939</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256247" unitRef="xbrli-shares">10345637</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29256322" unitRef="xbrli-shares">8306278</us-gaap:SharesOutstanding>
  <us-gaap:SharesOutstanding contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256324" unitRef="xbrli-shares">14519629</us-gaap:SharesOutstanding>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848474">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Basis of Presentation and Summary of Significant Accounting Policies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Basis of Presentation&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The accompanying consolidated&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting Standards Updates (&amp;#x201c;ASU&amp;#x201d;) of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;).&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Fair Value of Financial Instruments&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The carrying amounts of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the fair value of the Company's outstanding Series B convertible note was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.6&lt;/div&gt; million. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the fair value of the Company&amp;#x2019;s outstanding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt; convertible note and Series B convertible note was approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.0&lt;/div&gt; million and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.6&lt;/div&gt; million, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt; of the fair value hierarchy.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Concentration of Credit Risk&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company considers any highly liquid investments, such as money market funds, with an original maturity of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;three&lt;/div&gt; months or less to be cash and cash equivalents.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Property and Equipment&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt; to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15&lt;/div&gt; years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Long-Lived Assets&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;/div&gt; recognized any impairment of long-lived assets during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Intangible Assets&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Intangible assets are comprised of identifiable in-process research and development (IPR&amp;amp;D) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. For those compounds that reach commercialization, the IPR&amp;amp;D assets will be amortized over their estimated useful lives. In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 2016, &lt;/div&gt;the Company abandoned the future development efforts with respect to its RES-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;440&lt;/div&gt; product candidate, and the value of the associated IPR&amp;amp;D asset was written down to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;zero&lt;/div&gt; (See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;).&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Goodwill&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company performs its annual goodwill impairment test on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s goodwill is less than the carrying value of the reporting unit&amp;#x2019;s goodwill. The Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt;&lt;/div&gt; recognize any impairment of goodwill during the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2016.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Offering Costs&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Offering costs are either expensed upon completion or abandonment of the related financing or offset against the proceeds of the offering, depending upon the accounting treatment of the offering. Offering costs consist principally of legal and accounting costs incurred through the balance sheet date related to the Company&amp;#x2019;s underwritten public offering, private placement financings and are recognized in other assets on the consolidated balance sheet.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Research and Development&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s behalf). Costs incurred for research and development are expensed as incurred.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;record net prepaid or accrued expenses relating to these costs.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Upfront payments made to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties who perform research and development services on the Company&amp;#x2019;s behalf are expensed as services are rendered.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Patent Costs&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Income Taxes&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Prior to the Merger, Diffusion LLC was treated as a partnership for federal and state income tax purposes. Diffusion LLC&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s taxable income or loss, as well as certain other tax attributes, were passed through directly to its members and were reported in each member&amp;#x2019;s individual income tax return.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Upon completion of the Merger as discussed in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,&lt;/div&gt; the Company converted from a partnership to a corporation for accounting purposes. As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; that some portion or all of a deferred tax asset will &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; to be sustained.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 22, 2017 &lt;/div&gt;the President of the United States signed into law the Tax Cuts and Jobs Act (&amp;quot;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act&amp;quot;).&amp;nbsp;This legislation makes significant changes in the U.S. tax laws including, but &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; limited to, reducing the corporate tax rate to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%&lt;/div&gt; starting in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018.&lt;/div&gt; The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;21%.&lt;/div&gt;&amp;nbsp;&amp;nbsp;As a result of the change, the Company recorded a current period tax benefit of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million in its consolidated statement of operations and a corresponding reduction in the deferred tax liability on its consolidated balance sheet.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Stock-based Compensation&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s common stock, the expected term of the Company&amp;#x2019;s stock options, the expected dividend yield and the fair value of the Company&amp;#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The expected term of stock options was estimated using the &amp;#x201c;simplified method&amp;#x201d; for employee options as the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; dividend yield because dividends are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expected to be paid in the near future, which is consistent with the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s history of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; longer estimates forfeitures and accounts for forfeitures in the periods they occur.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Net Loss Per Share&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the &amp;#x201c;if-converted&amp;#x201d; method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have been incurred if the warrants had been converted into common stock.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Year ended December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Basic net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,364,518&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Accretion of Series A cumulative preferred dividends&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1,252,394&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(0.21&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss per common share calculation:&lt;/div&gt; &lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss attributable to common stockholders&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(2,616,912&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Change in fair value of warrant liability&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(22,072,322&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Diluted net loss&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(24,689,234&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(18,036,619&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted average common shares outstanding, basic&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,447,641&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Common stock equivalents arising from warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;307,675&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock equivalents&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,755,316&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10,232,791&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net loss per share of common stock, diluted&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.94&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;(1.76&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;)&lt;/div&gt; &lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2016&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible debt&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;214,385&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;757,909&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;447,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;460,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Convertible preferred stock&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,306,278&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;#x2014;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,555,989&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,207,409&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock awards&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,066&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;9,204&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,527,439&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3,435,243&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Amounts in the table reflect the common stock equivalents of the noted instruments.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Comprehensive Loss&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; items of comprehensive income or loss other than net loss.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; July 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Earnings Per Share (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;260&lt;/div&gt;); Distinguishing Liabilities from Equity (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;480&lt;/div&gt;); Derivatives and Hedging (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. &lt;/div&gt;The &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;first&lt;/div&gt; part of this update addresses the complexity of accounting for certain financial instruments with down round features and the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;second&lt;/div&gt; part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2018 &lt;/div&gt;and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;    &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; May 2017, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No.&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Modification Accounting for Share-Based Payment Arrangements&lt;/div&gt;, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;718.&lt;/div&gt; Specifically, an entity would &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2017 &lt;/div&gt;and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this new guidance to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; &lt;div style="display: inline; font-style: italic;"&gt;Compensation &amp;#x2013; Improvements to Employee Share-Based Payment Accounting&lt;/div&gt;, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 15, 2016 &lt;/div&gt;and interim periods within those years. The Company adopted this standard in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; by electing to account for forfeitures in the period that they occur. Under ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;09,&lt;/div&gt; accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1,000&lt;/div&gt;&lt;/div&gt; on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 1, 2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; February 2016, &lt;/div&gt;the FASB issued ASU &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;02,&lt;/div&gt; &lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Leases (Topic &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;842&lt;/div&gt;)&lt;/div&gt;. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. Upon adoption in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2018,&lt;/div&gt; the Company will determine the fair of the operating lease and recognize this amount as a lease asset and corresponding liability on its consolidated balance sheet. The Company does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; expect this new guidance to have a material impact on its consolidated financial statements.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256847" unitRef="xbrli-shares">1861503</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256191" unitRef="xbrli-shares">1861503</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256850" unitRef="xbrli-shares">217122</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256219" unitRef="xbrli-shares">217122</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29256294" unitRef="xbrli-shares">-4070051</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256296" unitRef="xbrli-shares">4070051</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_TitleOfIndividualAxis-FinancialAdviserMember" decimals="INF" id="c29256599" unitRef="xbrli-shares">46000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256848" unitRef="xbrli-shares">45643</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-01_2016-12-31_ProductOrServiceAxis-GeneralFinancialAdvisoryServicesMember" decimals="INF" id="c29256849" unitRef="xbrli-shares">102430</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256853" unitRef="xbrli-shares">17606</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256212" unitRef="xbrli-shares">148073</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256275" unitRef="xbrli-shares">17606</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2018-01-22_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember" decimals="INF" id="c29256414" unitRef="xbrli-shares">15000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember" decimals="INF" id="c29256259" unitRef="xbrli-shares">12376329</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256929" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256955" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="INF" id="c29256956" unitRef="xbrli-shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256192" unitRef="iso4217-usd">1862</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256193" unitRef="iso4217-usd">19544138</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256195" unitRef="iso4217-usd">19546000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256220" unitRef="iso4217-usd">217</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256221" unitRef="iso4217-usd">711278</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256223" unitRef="iso4217-usd">711495</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256297" unitRef="iso4217-usd">4070</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256298" unitRef="iso4217-usd">-4070</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_TitleOfIndividualAxis-FinancialAdviserMember" decimals="-3" id="c29256600" unitRef="iso4217-usd">500000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256213" unitRef="iso4217-usd">148</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256214" unitRef="iso4217-usd">1409215</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256216" unitRef="iso4217-usd">1409363</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256276" unitRef="iso4217-usd">18</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256277" unitRef="iso4217-usd">49982</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256279" unitRef="iso4217-usd">50000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
  <us-gaap:StockholdersEquity contextRef="i_2017-12-31" decimals="INF" id="c29256142" unitRef="iso4217-usd">21229944</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2016-12-31" decimals="INF" id="c29256143" unitRef="iso4217-usd">9184684</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256185" unitRef="iso4217-usd">8119</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256186" unitRef="iso4217-usd">42102876</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256187" unitRef="iso4217-usd">-42152618</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2015-12-31" decimals="INF" id="c29256188" unitRef="iso4217-usd">-41623</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256248" unitRef="iso4217-usd">10346</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256249" unitRef="iso4217-usd">69363575</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256250" unitRef="iso4217-usd">-60189237</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2016-12-31" decimals="INF" id="c29256251" unitRef="iso4217-usd">9184684</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c29256325" unitRef="iso4217-usd">14520</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" decimals="INF" id="c29256326" unitRef="iso4217-usd">82770313</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" decimals="INF" id="c29256327" unitRef="iso4217-usd">-61554889</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="i_2017-12-31" decimals="INF" id="c29256328" unitRef="iso4217-usd">21229944</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848490">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Convertible Preferred Stock and Stockholder&amp;#x2019;s Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In contemplation of completing the private placement described below, the Company amended and restated its articles of incorporation and authorized &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,750,000&lt;/div&gt; shares of Series A convertible preferred stock.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 45pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Series&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;A Convertible Preferred Stock Transaction&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 2017, &lt;/div&gt;the Company completed a &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$25.0&lt;/div&gt; million private placement of its securities in which the Company offered and sold units consisting of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s Series A convertible preferred stock and a warrant to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of common stock for each share of Series A convertible preferred stock purchased in the offering. Each share of Series A convertible preferred stock entitles the holder to an &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0%&lt;/div&gt; cumulative dividend payable in shares of the Company's common stock on a semi-annual basis. The holders &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may, &lt;/div&gt;at their option, convert each share of Series A convertible preferred stock into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of the Company&amp;#x2019;s common stock based on the initial conversion price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.02&lt;/div&gt; per share, subject to adjustment. Each warrant entitles the holder to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;one&lt;/div&gt; share of common stock at an initial exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.22,&lt;/div&gt; subject to adjustment and expires on the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fifth&lt;/div&gt; anniversary of their original issuance date. &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company sold &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;12,376,329&lt;/div&gt; units in the private placement and received approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22.1&lt;/div&gt; million in aggregate net cash proceeds, after deducting commissions and other expenses of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.9&lt;/div&gt; million. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,179,558&lt;/div&gt; shares of common stock at an initial exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.22&lt;/div&gt; per share, which expire on the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fifth&lt;/div&gt; anniversary of their original issuance date.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40,&lt;/div&gt; &lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Derivatives and Hedging, Contracts in an Entity&amp;#x2019;s own Equity&lt;/div&gt; (&amp;#x201c;ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&amp;#x201d;&lt;/div&gt;). The conditions within ASC &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;815&lt;/div&gt;-&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;40&lt;/div&gt; are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; subject to a probability assessment. As the Company was obligated to issue a variable number of shares to settle the cumulative dividends on the Series A convertible preferred stock, the Company could &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; assert that there would be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants were classified as liabilities. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 1, 2017 &lt;/div&gt;the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&amp;#x2019;s Certificate of Incorporation to permit the Company to pay dividends on the Company&amp;#x2019;s Series A Convertible Preferred Stock in either cash or shares of the Company&amp;#x2019;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert that there will be sufficient authorized shares available to settle the Series A warrants, and as a result, the Series A warrants were reclassified from liabilities to stockholders&amp;#x2019; equity in the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;fourth&lt;/div&gt; quarter of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;no&lt;/div&gt; proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.2&lt;/div&gt; million in the aggregate and was recorded as warrant related expenses in the statement of operations for the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017.&lt;/div&gt; &lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As a result of the completion of our common stock offering in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2018, &lt;/div&gt;all outstanding shares of the Company's Series A convertible preferred stock converted into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,568,632&lt;/div&gt; shares (the &amp;quot;Conversion Shares&amp;quot;) of common stock of which (i) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8,306,278&lt;/div&gt; shares were issued for the automatic conversion of Series A convertible preferred stock (ii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;593,933&lt;/div&gt; shares were issued upon settlement of accrued dividends and (iii) &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,668,421&lt;/div&gt; shares were issued for the settlement of the &amp;#x201c;make-whole&amp;#x201d; adjustment feature.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Dividends&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Until the conversion of all outstanding Series A convertible preferred stock in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2018, &lt;/div&gt;the cumulative preferred dividend on the Series A convertible preferred stock was payable at a rate of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.0%&lt;/div&gt; per annum, payable only in shares of common stock, semi-annually in arrears on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; April 1 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1 &lt;/div&gt;of each year commencing on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; October 1, 2017. &lt;/div&gt;This cumulative preferred dividend was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; subject to declaration. The Company recognized approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.3&lt;/div&gt; million in dividends during the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.2&lt;/div&gt; million was settled upon by the issuance of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;86,335&lt;/div&gt; shares of the Company's common stock. As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December 31, 2017, &lt;/div&gt;there were approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.1&lt;/div&gt; million in accrued dividends that were subsequently settled in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2018. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Voting&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &amp;#x201c;Certificate of Designation&amp;#x201d;) or as required by law, the holders of the Series A convertible preferred stock voted together with the holders of common stock as a single class on an adjusted as-converted basis. In accordance with NASDAQ listing rules, in any matter voted on by the holders of the common stock, each share of Series A convertible preferred stock entitled the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance of such shares of Series A convertible preferred stock. Accordingly, shares of Series A convertible preferred stock issued in the initial closing of the private placement on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 14, 2017 &lt;/div&gt;were entitled to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.84874&lt;/div&gt; votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 31, 2017 &lt;/div&gt;were entitled to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;0.50627&lt;/div&gt; votes per share, in each case, subject to adjustment as described in the Certificate of Designation.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Liquidation Preference&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Series A convertible preferred stock was senior to the common stock. In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A convertible preferred stock would be entitled to receive their original investment amount. If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution would be distributed ratably among the holders of the Series A convertible preferred stock in proportion to the full amounts to which they would otherwise be entitled.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Conversion&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Series A convertible preferred stock was convertible, at the holder&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s option, into common stock. The Series A convertible preferred stock was also mandatorily convertible into common stock upon (a) the &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;thirty&lt;/div&gt;-day moving average of the closing price of the Company&amp;#x2019;s common stock exceeding &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$8.00&lt;/div&gt; per share, (b) a financing of at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.0&lt;/div&gt; million in gross proceeds or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock. The conversion price of the Series A convertible preferred stock was subject to adjustment as described in the Certificate of Designation. During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4,070,051&lt;/div&gt; shares of Series A convertible preferred stock were converted into common stock. Upon completion of the Company&amp;#x2019;s public offering of its common stock in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2018, &lt;/div&gt;all remaining shares of Series A convertible preferred stock issued and outstanding were converted into common stock.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Make-Whole Provision&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;Until &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 2020 &lt;/div&gt;and subject to certain exceptions, if the Company issued at least &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.0&lt;/div&gt; million of its common stock or securities convertible into or exercisable for common stock at a per share price less than &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.02&lt;/div&gt; (such lower price, the &amp;#x201c;Make-Whole Price&amp;#x201d;) while any shares of Series A convertible preferred stock remain outstanding, the Company would be required to issue to these holders of Series A convertible preferred stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A convertible preferred stock would be convertible into if the conversion price of such shares was equal to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;105%&lt;/div&gt; of the Make-Whole Price (the &amp;#x201c;Make-Whole Adjustment&amp;#x201d;). The Make-Whole Adjustment was evaluated and was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; required to be bifurcated from the Series A convertible preferred stock.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Make-Whole Adjustment was triggered and settled in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 2018 &lt;/div&gt;in connection with the Company's common stock offering. The Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;11,668,421&lt;/div&gt; shares as part of the Make-Whole Adjustment.&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common Stock&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;In connection with the Merger (See Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;4&lt;/div&gt;) the Company ascribed non-cash consideration of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.4&lt;/div&gt; million to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;478,200&lt;/div&gt; warrants outstanding prior to the Merger. During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; the Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2,226,698&lt;/div&gt; shares of its Common Stock of which &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,861,503&lt;/div&gt; are shares held by the pre-Merger stockholders of the Company, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;45,643&lt;/div&gt; shares were issued for advisory services provided in connection with the Merger, &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;102,430&lt;/div&gt; shares were issued for general financial advisory services provided to the Company and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;217,122&lt;/div&gt; shares were issued pursuant to conversions of convertible debt as discussed in Note &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;8.&lt;/div&gt; In &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company issued &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,606&lt;/div&gt; shares for advisory services. The Company did &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; purchase or retire any shares of its common stock.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Common Stock Warrants&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;As of &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/div&gt;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div&gt; &lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-width: 700px;"&gt;  &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Range of exercise &lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;price per share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued prior to Merger&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;447,721&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; &lt;/div&gt;&lt;div style=" margin: 0pt; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;$20.00&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;-&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$49.00&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in Series A&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,555,887&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$2.22&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="width: 70%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;14,003,608&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 6%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 6%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 3px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt;  &lt;/table&gt; &lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;During the years ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2016,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;13,000&lt;/div&gt; and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;17,479&lt;/div&gt; warrants issued prior to the Merger expired, respectively; these common stock warrants will expire periodically through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2019.&lt;/div&gt; The common stock warrants issued in connection with the &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 2017 &lt;/div&gt;Series A private placement expire in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 2022. &lt;/div&gt;During the year ended &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; the Company recognized a gain of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$22.1&lt;/div&gt; million upon the change in fair value of the warrant until they were reclassified to permanent equity in &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; November 2017 &lt;/div&gt;and &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$10.2&lt;/div&gt; million in warrant related charges associated with the Series A private placement, which consisted primarily of the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. &amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 contextRef="d_2016-08-17_2016-08-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember" decimals="INF" id="c29256406" unitRef="xbrli-pure">10</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <us-gaap:SubsequentEventsTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848507">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;16.&lt;/div&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;Subsequent Event&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 22, 2018, &lt;/div&gt;Diffusion Pharmaceuticals Inc. (the &amp;#x201c;Company&amp;#x201d;) closed its previously announced underwritten public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,000,000&lt;/div&gt; shares of the Company&amp;#x2019;s common stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share (&amp;#x201c;Common Stock&amp;#x201d;), and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,000,000&lt;/div&gt; shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,970,625&lt;/div&gt; shares of Common Stock pursuant to the underwriter&amp;#x2019;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.80&lt;/div&gt; per share and warrant for total gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.0&lt;/div&gt; million. The warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.80&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;750,000&lt;/div&gt; shares of Common Stock. The underwriter&amp;#x2019;s warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.00,&lt;/div&gt; a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,568,632&lt;/div&gt; shares (the &amp;quot;Conversion Shares) of common stock (including accrued dividends paid in kind and the &amp;quot;make-whole&amp;quot; adjustment feature thereof). &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="d_2017-01-01_2017-12-31" id="s848473">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2.&lt;/div&gt; Liquidity&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger) and convertible notes, as well as through the reverse merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;No&lt;/div&gt; assurance can be given that any such financing will be available when needed or that the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s research and development efforts will be successful.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties and other strategic alliances and business transactions. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; January 22, 2018, &lt;/div&gt;the Company closed its previously announced underwritten public offering of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,000,000&lt;/div&gt; shares of the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s common stock, par value &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.001&lt;/div&gt; per share, and warrants to purchase &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;15,000,000&lt;/div&gt; shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;1,970,625&lt;/div&gt; shares of Common Stock pursuant to the underwriter&amp;#x2019;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.80&lt;/div&gt; per share and warrant for total gross proceeds of approximately &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$12.0&lt;/div&gt; million. The warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$0.80&lt;/div&gt; per share and a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;750,000&lt;/div&gt; shares of Common Stock. The underwriter&amp;#x2019;s warrants have an exercise price of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.00,&lt;/div&gt; a term of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;five&lt;/div&gt; years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,568,632&lt;/div&gt; shares (the &amp;quot;Conversion Shares) of common stock (including accrued dividends paid in kind and issuance of shares in respect of the &amp;quot;make-whole&amp;quot; adjustment feature thereof).&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The Company currently does &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; have any commitments to obtain additional funds and &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;be unable to obtain sufficient funding in the future on acceptable terms, if at all. On &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; March 2, 2018, &lt;/div&gt;the Company received a written notice from the NASDAQ Staff indicating the Company was &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; in compliance with Nasdaq Listing Rule &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5550&lt;/div&gt;(a)(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2&lt;/div&gt;) because the bid price for the Company&lt;div style="display: inline; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;#x2019;s common stock had closed below &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.00&lt;/div&gt; per share for the previous &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;30&lt;/div&gt; consecutive business days. In accordance with Nasdaq Listing Rule &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;5810&lt;/div&gt;(c)(&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;3&lt;/div&gt;)(A), the Company has &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;180&lt;/div&gt; calendar days from the date of such notice, or until &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; August 29, 2018, &lt;/div&gt;to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company&amp;#x2019;s common stock must close at &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;$1.00&lt;/div&gt; per share or more for a minimum of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;10&lt;/div&gt; consecutive business days. In the event the Company is unable to regain compliance, it could adversely affect the Company&amp;#x2019;s ability to obtain future funding. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;third&lt;/div&gt; parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it &lt;div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"&gt; may &lt;/div&gt;receive lower consideration upon commercialization of such products than if it had &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;not&lt;/div&gt; entered into such arrangements or if it entered into such arrangements at later stages in the product development process.&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 44pt;"&gt;Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company&lt;div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;"&gt;&amp;#x2019;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&amp;#x2019;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&amp;#x2019;s financial condition and future operations. The Company believes its cash and cash equivalents as of &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; December&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;31,&lt;/div&gt; &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;2017,&lt;/div&gt; together with the proceeds from public underwritten offering received in &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; January 2018, &lt;/div&gt;are sufficient to fund operations through &lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; June &lt;/div&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt; 2019.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="d_2017-01-01_2017-12-31" id="c-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"&gt; &lt;tr style="vertical-align: bottom;"&gt; &lt;td style="width: 85%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Combined NOL Carryforwards:&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"&gt; &lt;div style=" margin: 0pt; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;December 31, 2017&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;/td&gt; &lt;td style="padding-bottom: 1px; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,629,817&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt; &lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt; &lt;div style=" font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/div&gt; &lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&lt;div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"&gt;20,640,700&lt;/div&gt;&lt;/td&gt; &lt;td nowrap="nowrap" style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256169" unitRef="iso4217-usd">1252394</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
  <us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="d_2016-01-01_2016-12-31" id="c29256170" unitRef="iso4217-usd" xs:nil="true"/>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="i_2017-12-31" decimals="INF" id="c29256114" unitRef="iso4217-usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="i_2016-12-31" decimals="INF" id="c29256115" unitRef="iso4217-usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="i_2017-12-31" decimals="INF" id="c29256124" unitRef="iso4217-usd">16778682</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="i_2016-12-31" decimals="INF" id="c29256125" unitRef="iso4217-usd">0</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="i_2017-12-31" decimals="INF" id="c29256116" unitRef="iso4217-usd-per-xbrli-shares">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="i_2016-12-31" decimals="INF" id="c29256117" unitRef="iso4217-usd-per-xbrli-shares">0</us-gaap:TemporaryEquityParOrStatedValuePerShare>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="i_2017-12-31" decimals="INF" id="c29256118" unitRef="xbrli-shares">13750000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="i_2016-12-31" decimals="INF" id="c29256119" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesIssued contextRef="i_2017-12-31" decimals="INF" id="c29256120" unitRef="xbrli-shares">12376329</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesIssued contextRef="i_2016-12-31" decimals="INF" id="c29256121" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="i_2017-12-31" decimals="INF" id="c29256122" unitRef="xbrli-shares">8306278</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="i_2016-12-31" decimals="INF" id="c29256123" unitRef="xbrli-shares">0</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2017-12-31" decimals="-3" id="c29257075" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits contextRef="i_2016-12-31" decimals="-3" id="c29257092" unitRef="iso4217-usd">0</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UseOfEstimates contextRef="d_2017-01-01_2017-12-31" id="c29258202">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" margin: 0pt; text-align: left; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&lt;div style="display: inline; font-style: italic;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;&amp;nbsp;&lt;/div&gt; &lt;div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 10pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256180" unitRef="xbrli-shares">12755316</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256181" unitRef="xbrli-shares">10232791</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2017-01-01_2017-12-31" decimals="INF" id="c29256178" unitRef="xbrli-shares">12447641</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="d_2016-01-01_2016-12-31" decimals="INF" id="c29256179" unitRef="xbrli-shares">10232791</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="#c29257016" xlink:label="c29257016" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29257016" xlink:to="f-35-A" xlink:type="arc"/>
    <link:loc xlink:href="#c29257012" xlink:label="c29257012" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29257012" xlink:to="f-35-A" xlink:type="arc"/>
    <link:loc xlink:href="#c29257000" xlink:label="c29257000" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29257000" xlink:to="f-35-A" xlink:type="arc"/>
    <link:loc xlink:href="#c29257020" xlink:label="c29257020" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29257020" xlink:to="f-35-A" xlink:type="arc"/>
    <link:footnote xlink:label="f-35-A" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The difference, if positive, between the stock option's exercise price and the closing price of the Company's common stock at December 31, 2017.</link:footnote>
    <link:loc xlink:href="#c29256257" xlink:label="c29256257" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29256257" xlink:to="f848470-a" xlink:type="arc"/>
    <link:loc xlink:href="#c29256256" xlink:label="c29256256" xlink:type="locator"/>
    <link:footnoteArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="c29256256" xlink:to="f848470-a" xlink:type="arc"/>
    <link:footnote xlink:label="f848470-a" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of ASU 2016-09.</link:footnote>
  </link:footnoteLink>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-thunderdome-item">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>thunderdome:item</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2009-12-01_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2009-12-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_AwardTypeAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_BusinessAcquisitionAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_BusinessAcquisitionAxis-DiffusionLLCMember_NonrecurringAdjustmentAxis-AcquisitionRelatedCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:AcquisitionRelatedCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_DebtInstrumentAxis-ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_NonmonetaryTransactionTypeAxis-AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">dffn:AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_ProductOrServiceAxis-GeneralFinancialAdvisoryServicesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">dffn:GeneralFinancialAdvisoryServicesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">dffn:CharlottesvilleVirginiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementClassOfStockAxis-ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-01_2016-12-31_StatementEquityComponentsAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-01</xbrli:startDate>
      <xbrli:endDate>2016-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-07_2016-01-07_BusinessAcquisitionAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-07</xbrli:startDate>
      <xbrli:endDate>2016-01-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_AwardTypeAxis-EmployeeStockOptionMember_BusinessAcquisitionAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_NatureOfExpenseAxis-SuccessFeeAgreementCostsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:NatureOfExpenseAxis">dffn:SuccessFeeAgreementCostsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_TitleOfIndividualAxis-FinancialAdviserMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:FinancialAdviserMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_BusinessAcquisitionAxis-RestorGenexMember_LegalEntityAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:RestorGenexMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-01-08_2016-01-08_TitleOfIndividualAxis-ExecutiveOfficersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:ExecutiveOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-01-08</xbrli:startDate>
      <xbrli:endDate>2016-01-08</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-07-21_2016-07-21_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-07-21</xbrli:startDate>
      <xbrli:endDate>2016-07-21</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-08-01_2016-08-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-01</xbrli:startDate>
      <xbrli:endDate>2016-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-08-01_2016-08-31_AwardTypeAxis-EmployeeStockOptionMember_TitleOfIndividualAxis-BoardOfDirectorsChairmanMember_VestingAxis-VestQuarterlyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dffn:VestQuarterlyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-01</xbrli:startDate>
      <xbrli:endDate>2016-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-08-01_2016-08-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-01</xbrli:startDate>
      <xbrli:endDate>2016-08-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-08-17_2016-08-17_NonmonetaryTransactionTypeAxis-ReverseStockSplitMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:NonmonetaryTransactionTypeAxis">dffn:ReverseStockSplitMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-08-17</xbrli:startDate>
      <xbrli:endDate>2016-08-17</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2016-09-27_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">dffn:SettlementAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2016-09-27</xbrli:startDate>
      <xbrli:endDate>2016-09-27</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-11-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-11-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember_VestingAxis-VestMonthlyMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">dffn:VestMonthlyMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_AwardTypeAxis-RestrictedStockMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMember_StatementClassOfStockAxis-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">dffn:ConversionFromSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_DebtInstrumentAxis-ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dffn:ContingentConsiderationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-BuildingMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">dffn:CharlottesvilleVirginiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember_StatementGeographicalAxis-CharlottesvilleVirginiaMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">dffn:CharlottesvilleVirginiaMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MaximumMember_StatementClassOfStockAxis-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-ConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TitleOfIndividualAxis-ExecutiveOfficersMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:ExecutiveOfficersMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-01-01_2017-12-31_TypeOfArrangementAxis-ArrangementWithClinicalResearchOrganizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dffn:ArrangementWithClinicalResearchOrganizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-01-01</xbrli:startDate>
      <xbrli:endDate>2017-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-01_2018-01-07_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-01</xbrli:startDate>
      <xbrli:endDate>2018-01-07</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-31</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-31_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-31</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-03-31_2017-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-03-31</xbrli:startDate>
      <xbrli:endDate>2017-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2017-07-01_2017-09-30_DebtInstrumentAxis-The2016ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2017-07-01</xbrli:startDate>
      <xbrli:endDate>2017-09-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-01-01_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-01</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-01-31_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-01-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-01_2018-12-31_StatementScenarioAxis-ScenarioForecastMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioForecastMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-01</xbrli:startDate>
      <xbrli:endDate>2018-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">dffn:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">dffn:ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">dffn:ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">dffn:ConversionFromSeriesAPreferredStockToCommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_ConversionOfStockByUniqueDescriptionAxis-ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">dffn:ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_StatementClassOfStockAxis-SeriesAConvertiblePreferredStockMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">dffn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2018-01-22_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:January2018OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2018-01-22</xbrli:startDate>
      <xbrli:endDate>2018-01-22</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_DebtInstrumentAxis-ConvertibleNotesMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-07">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-07</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-01-08_BusinessAcquisitionAxis-DiffusionLLCMember_CounterpartyNameAxis-FormerEquityHoldersOfDiffusionLLCMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">dffn:DiffusionLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">dffn:FormerEquityHoldersOfDiffusionLLCMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-01-08</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-07-21_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-07-21</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-08-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-08-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-09-27_DebtInstrumentAxis-The2016ConvertibleNotesMember_LitigationCaseAxis-SettlementAgreementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LitigationCaseAxis">dffn:SettlementAgreementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-09-27</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_DebtInstrumentAxis-ConvertibleNoteSeriesBMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNoteSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_DebtInstrumentAxis-ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dffn:ContingentConsiderationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-InProcessResearchAndDevelopmentCostsIprdMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:InProcessResearchAndDevelopmentCostsIprdMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dffn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2016-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2016-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201609Member_StatementEquityComponentsAxis-AccumulatedOtherComprehensiveIncomeMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-01-01_AdjustmentsForNewAccountingPronouncementsAxis-AccountingStandardsUpdate201609Member_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201609Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-01-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-14_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-14</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_StatementClassOfStockAxis-SeriesBPreferredStockMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember_TitleOfIndividualAxis-PlacementAgentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">dffn:PlacementAgentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-03-31_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-06-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-11-01">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-11-01</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-NonEmployeeStockOptionsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">dffn:NonEmployeeStockOptionsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_AwardTypeAxis-RestrictedStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:ConvertiblePreferredStockIssuedPriorToMergerMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:ConvertiblePreferredStockIssuedPriorToMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ClassOfWarrantOrRightAxis-ConvertiblePreferredStockIssuedPriorToMergerMember_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:ConvertiblePreferredStockIssuedPriorToMergerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_ClassOfWarrantOrRightAxis-SeriesAConvertiblePreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_DebtInstrumentAxis-ConvertibleNoteSeriesBMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNoteSeriesBMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_DebtInstrumentAxis-ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_DebtInstrumentAxis-The2016ConvertibleNotesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">dffn:The2016ConvertibleNotesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByMeasurementFrequencyAxis-FairValueMeasurementsRecurringMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_FairValueByLiabilityClassAxis-ContingentConsiderationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">dffn:ContingentConsiderationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES440Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES440Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_IndefiniteLivedIntangibleAssetsByMajorClassAxis-RES529Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">dffn:RES529Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PlanNameAxis-RestorgenexCorporation2015EquityIncentivePlanMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:RestorgenexCorporation2015EquityIncentivePlanMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">dffn:LaboratoryEquipmentMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_RangeAxis-MaximumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_RangeAxis-MinimumMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementClassOfStockAxis-SeriesAPreferredStockMember_StatementEquityComponentsAxis-PreferredStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2017-12-31_TypeOfArrangementAxis-ArrangementWithClinicalResearchOrganizationMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">dffn:ArrangementWithClinicalResearchOrganizationMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2017-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_ClassOfWarrantOrRightAxis-AdditionalWarrantsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:AdditionalWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:January2018OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">dffn:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_ClassOfWarrantOrRightAxis-UnderwriterWarrantsMember_RangeAxis-MaximumMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-01-22_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-January2018OfferingMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:January2018OfferingMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-01-22</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2018-03-13">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2018-03-13</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dffn-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:45PM UTC 2018-03-30--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:dffn="http://www.diffusionpharma.com/20171231" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20171231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2016-01-31" schemaLocation="http://xbrl.sec.gov/exch/2016/exch-2016-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations" roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity" roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flow" roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flow</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-description-of-business" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Acquisition</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-goodwill-and-intangible-assets" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Goodwill and Intangible Assets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-convertible-debt" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Convertible Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-convertible-preferred-stock-and-stockholders-equity" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-defined-contribution-retirement-plan" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Defined Contribution Retirement Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-fair-value-measurements" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Fair Value Measurements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-related-party-transactions" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Document - Note 15 - Related Party Transactions</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-subsequent-event" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 16 - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 4 - Acquisition (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 5 - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-convertible-debt-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 8 - Convertible Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 9 - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 11 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 13 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-fair-value-measurements-tables" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 14 - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-description-of-business-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 1 - Organization and Description of Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 2 - Liquidity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 4 - Acquisition (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition-purchase-price-consideration-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Note 4 - Acquisition - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 4 - Acquisition - Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-acquisition-pro-forma-financial-information-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 4 - Acquisition - Pro Forma Financial Information (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 5 - Property and Equipment (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-property-and-equipment-property-and-equipment-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-goodwill-and-intangible-assets-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-convertible-debt-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 8 - Convertible Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-convertible-debt-outstanding-convertible-notes-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 8 - Convertible Debt - Outstanding Convertible Notes (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 11 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-stock-option-activity-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 11 - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-stockbased-compensation-fair-value-assumptions-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 11 - Stock-based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-defined-contribution-retirement-plan-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 12 - Defined Contribution Retirement Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 13 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-operating-loss-carryforwards-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 13 - Income Taxes - Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 13 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 14 - Fair Value Measurements - Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 14 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 14 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-subsequent-event-details-textual" roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 16 - Subsequent Event (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" name="AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_AdditionalWarrantsMember" name="AdditionalWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" name="AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" name="AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" name="AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ArrangementWithClinicalResearchOrganizationMember" name="ArrangementWithClinicalResearchOrganizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" name="BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" name="BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" name="BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" name="BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" name="BusinessCombinationPreliminaryPurchasePriceConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" name="BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" name="BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" name="BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" name="BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" name="BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_CharlottesvilleVirginiaMember" name="CharlottesvilleVirginiaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightGrantedDuringPeriod" name="ClassOfWarrantOrRightGrantedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightTerm" name="ClassOfWarrantOrRightTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightsExpired" name="ClassOfWarrantOrRightsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ContingentConsiderationMember" name="ContingentConsiderationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" name="ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" name="ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" name="ConversionFromSeriesAPreferredStockToCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" name="ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConvertibleNoteSeriesBMember" name="ConvertibleNoteSeriesBMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ConvertibleNotesMember" name="ConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ConvertiblePreferredStockConversionPrice" name="ConvertiblePreferredStockConversionPrice" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" name="ConvertiblePreferredStockIssuedPriorToMergerMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" name="ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" name="ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ConvertiblePreferredStockVotesPerShare" name="ConvertiblePreferredStockVotesPerShare" nillable="true" substitutionGroup="xbrli:item" type="us-types:perUnitItemType" xbrli:periodType="instant"/>
  <xsd:element id="dffn_CumulativeEffectOfChangeInAccountingPrinciple" name="CumulativeEffectOfChangeInAccountingPrinciple" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" name="DebtConversionConvertedInstrumentRelatedAccruedInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" name="DeferredTaxAssetsCapitalizedCostsAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsOrphanDrugCredits" name="DeferredTaxAssetsOrphanDrugCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_DiffusionLLCMember" name="DiffusionLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" name="DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" name="EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" name="EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" name="EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ExecutiveOfficersMember" name="ExecutiveOfficersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" name="FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_FinancialAdviserMember" name="FinancialAdviserMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_FinancingTriggerFromIssuanceOfCommonStock" name="FinancingTriggerFromIssuanceOfCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_FormerEquityHoldersOfDiffusionLLCMember" name="FormerEquityHoldersOfDiffusionLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_GeneralFinancialAdvisoryServicesMember" name="GeneralFinancialAdvisoryServicesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_HCWainwrightAndCoLLCMember" name="HCWainwrightAndCoLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_InProcessResearchAndDevelopmentCostsIprdMember" name="InProcessResearchAndDevelopmentCostsIprdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_January2018OfferingMember" name="January2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_MakewholeProvisionConversionPricePercentage" name="MakewholeProvisionConversionPricePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NonEmployeeStockOptionsMember" name="NonEmployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_NumberOfCommonStockPerUnit" name="NumberOfCommonStockPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_NumberOfConvertiblePreferredStockPerUnit" name="NumberOfConvertiblePreferredStockPerUnit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_OfferingCostsInAccountsPayable" name="OfferingCostsInAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_OfferingCostsPolicyPolicyTextBlock" name="OfferingCostsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PercentageOfCommonStockOutstandingOwned" name="PercentageOfCommonStockOutstandingOwned" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_PlacementAgentMember" name="PlacementAgentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PreferentialDividendsPayble" name="PreferentialDividendsPayble" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_PrepaidResearchAndDevelopmentExpense" name="PrepaidResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" name="ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ProceedsFromReverseMergerTransaction" name="ProceedsFromReverseMergerTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" name="QualifiedFinancingMinimumAmountOfGrossProceeds" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_RES440Member" name="RES440Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_RES529Member" name="RES529Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ReclassificationOfTheFairMarketValueOfWarrants" name="ReclassificationOfTheFairMarketValueOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_RestorGenexMember" name="RestorGenexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" name="RestorgenexCorporation2015EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_ReverseStockSplitMember" name="ReverseStockSplitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" name="ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_SettlementAgreementMember" name="SettlementAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" name="SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" name="StockIssuedDuringPeriodSharesMakewholeAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockIssuedDuringPeriodSharesTotal" name="StockIssuedDuringPeriodSharesTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockReclassifiedUponConversionOfPreferredStock" name="StockReclassifiedUponConversionOfPreferredStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockReclassifiedUponConversionOfPreferredStockShares" name="StockReclassifiedUponConversionOfPreferredStockShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_SuccessFeeAgreementCostsMember" name="SuccessFeeAgreementCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" name="TemporaryEquityStockIssuedDuringPeriodNewIssues" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_The2016ConvertibleNotesMember" name="The2016ConvertibleNotesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnderwriterWarrantsMember" name="UnderwriterWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_VestMonthlyMember" name="VestMonthlyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_VestQuarterlyMember" name="VestQuarterlyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_WarrantExpense" name="WarrantExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" name="WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" name="WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" name="statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" name="statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" name="statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-11-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-11-stockbased-compensation-tables" name="statement-statement-note-11-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" name="statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" name="statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-13-income-taxes-tables" name="statement-statement-note-13-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" name="statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" name="statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" name="statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-14-fair-value-measurements-tables" name="statement-statement-note-14-fair-value-measurements-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" name="statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" name="statement-statement-note-4-acquisition-pro-forma-financial-information-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" name="statement-statement-note-4-acquisition-purchase-price-consideration-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-acquisition-tables" name="statement-statement-note-4-acquisition-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" name="statement-statement-note-5-property-and-equipment-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-5-property-and-equipment-tables" name="statement-statement-note-5-property-and-equipment-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" name="statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" name="statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" name="statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-convertible-debt-tables" name="statement-statement-note-8-convertible-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-commitments-and-contingencies-tables" name="statement-statement-note-9-commitments-and-contingencies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" name="statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dffn-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:46PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="dffn_WarrantExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-cash-flow" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="dffn_ProceedsFromReverseMergerTransaction" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="dffn_ProceedsFromReverseMergerTransaction" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PreferentialDividendsPayble" xlink:label="dffn_PreferentialDividendsPayble" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="dffn_PreferentialDividendsPayble" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dffn-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:45PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions" xlink:href="dffn-20171231.xsd#statement-note-15-related-party-transactions" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information" xlink:href="dffn-20171231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20171231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20171231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReverseStockSplitMember" xlink:label="dffn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity" xlink:href="dffn-20171231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="dffn_ConvertibleNoteSeriesBMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_ConvertibleNoteSeriesBMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ExecutiveOfficersMember" xlink:label="dffn_ExecutiveOfficersMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancialAdviserMember" xlink:label="dffn_FinancialAdviserMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="dffn_SuccessFeeAgreementCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="us-gaap_NonrecurringAdjustmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonrecurringAdjustmentDomain" xlink:to="us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="dffn_SuccessFeeAgreementCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_FinancialAdviserMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_ExecutiveOfficersMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets" xlink:href="dffn-20171231.xsd#statement-note-6-goodwill-and-intangible-assets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="dffn_CharlottesvilleVirginiaMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="dffn_CharlottesvilleVirginiaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_GeneralFinancialAdvisoryServicesMember" xlink:label="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PlacementAgentMember" xlink:label="dffn_PlacementAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_PlacementAgentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NonEmployeeStockOptionsMember" xlink:label="dffn_NonEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestMonthlyMember" xlink:label="dffn_VestMonthlyMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestQuarterlyMember" xlink:label="dffn_VestQuarterlyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dffn_VestMonthlyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dffn_VestQuarterlyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dffn_NonEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan" xlink:href="dffn-20171231.xsd#statement-note-12-defined-contribution-retirement-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event" xlink:href="dffn-20171231.xsd#statement-note-16-subsequent-event" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20171231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsPolicyPolicyTextBlock" xlink:label="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:label="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual" xlink:href="dffn-20171231.xsd#statement-note-1-organization-and-description-of-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfCommonStockOutstandingOwned" xlink:label="dffn_PercentageOfCommonStockOutstandingOwned" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReverseStockSplitMember" xlink:label="dffn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfCommonStockOutstandingOwned" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20171231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="dffn_ConvertibleNoteSeriesBMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_ConvertibleNoteSeriesBMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ExecutiveOfficersMember" xlink:label="dffn_ExecutiveOfficersMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancialAdviserMember" xlink:label="dffn_FinancialAdviserMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfCommonStockOutstandingOwned" xlink:label="dffn_PercentageOfCommonStockOutstandingOwned" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="dffn_SuccessFeeAgreementCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="us-gaap_NonrecurringAdjustmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonrecurringAdjustmentDomain" xlink:to="us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="dffn_SuccessFeeAgreementCostsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_FinancialAdviserMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_ExecutiveOfficersMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfCommonStockOutstandingOwned" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForFees" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:href="dffn-20171231.xsd#statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="dffn_CharlottesvilleVirginiaMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidResearchAndDevelopmentExpense" xlink:label="dffn_PrepaidResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="dffn_CharlottesvilleVirginiaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PrepaidResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockConversionPrice" xlink:label="dffn_ConvertiblePreferredStockConversionPrice" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockVotesPerShare" xlink:label="dffn_ConvertiblePreferredStockVotesPerShare" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_GeneralFinancialAdvisoryServicesMember" xlink:label="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_MakewholeProvisionConversionPricePercentage" xlink:label="dffn_MakewholeProvisionConversionPricePercentage" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfCommonStockPerUnit" xlink:label="dffn_NumberOfCommonStockPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PlacementAgentMember" xlink:label="dffn_PlacementAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesTotal" xlink:label="dffn_StockIssuedDuringPeriodSharesTotal" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="dffn_PlacementAgentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_NumberOfCommonStockPerUnit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockConversionPrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_WarrantExpense" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockVotesPerShare" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_MakewholeProvisionConversionPricePercentage" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockIssuedDuringPeriodSharesTotal" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NonEmployeeStockOptionsMember" xlink:label="dffn_NonEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestMonthlyMember" xlink:label="dffn_VestMonthlyMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestQuarterlyMember" xlink:label="dffn_VestQuarterlyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dffn_VestMonthlyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="dffn_VestQuarterlyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="dffn_NonEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:href="dffn-20171231.xsd#statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual" xlink:href="dffn-20171231.xsd#statement-note-16-subsequent-event-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorGenexMember" xlink:label="dffn_RestorGenexMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_RestorGenexMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:label="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:label="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:label="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ContingentConsiderationMember" xlink:label="dffn_ContingentConsiderationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="dffn_ContingentConsiderationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dffn_WarrantExpense" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-cash-flow" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="dffn_ProceedsFromReverseMergerTransaction" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="dffn_ProceedsFromReverseMergerTransaction" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_Dividends" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_OfferingCostsInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="dffn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PreferentialDividendsPayble" xlink:label="dffn_PreferentialDividendsPayble" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PreferentialDividendsPayble" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dffn-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:45PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DocumentAndEntityInformation" xlink:label="dffn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dffn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DocumentAndEntityInformation" xlink:to="dffn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-tables" xlink:label="dffn_statement-statement-note-4-acquisition-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-acquisition-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Acquisition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-acquisition-tables" xlink:to="dffn_statement-statement-note-4-acquisition-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:type="locator"/>
    <link:label xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability</link:label>
    <link:label xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability</link:label>
    <link:label xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the change in fair value of warrant liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:to="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-5-property-and-equipment-tables" xlink:label="dffn_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-property-and-equipment-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-property-and-equipment-tables" xlink:to="dffn_statement-statement-note-5-property-and-equipment-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:to="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockConversionPrice" xlink:label="dffn_ConvertiblePreferredStockConversionPrice" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertiblePreferredStockConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ConvertiblePreferredStockConversionPrice</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockConversionPrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion price related to convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertiblePreferredStockConversionPrice" xlink:to="dffn_ConvertiblePreferredStockConversionPrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-8-convertible-debt-tables" xlink:label="dffn_statement-statement-note-8-convertible-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-convertible-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-convertible-debt-tables" xlink:to="dffn_statement-statement-note-8-convertible-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:to="dffn_statement-statement-note-9-commitments-and-contingencies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidResearchAndDevelopmentExpense" xlink:label="dffn_PrepaidResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="dffn_PrepaidResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PrepaidResearchAndDevelopmentExpense</link:label>
    <link:label xlink:label="dffn_PrepaidResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid Research and Development Expense</link:label>
    <link:label xlink:label="dffn_PrepaidResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PrepaidResearchAndDevelopmentExpense" xlink:to="dffn_PrepaidResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Convertible Preferred Stock and Stockholder's Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:to="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-11-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:to="dffn_statement-statement-note-11-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-tables" xlink:label="dffn_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-13-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-13-income-taxes-tables" xlink:to="dffn_statement-statement-note-13-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-14-fair-value-measurements-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Fair Value Measurements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:to="dffn_statement-statement-note-14-fair-value-measurements-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:label="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock Issued Prior to Merger [Member]</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents common stock warrants that were issued prior to the merger.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:to="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:label="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Acquisition - Purchase Price Consideration (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:to="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:label="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Acquisition - Assets Acquired and Liabilities Assumed (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:to="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:label="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]</link:label>
    <link:label xlink:label="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Table of warrants outstanding to acquire shares of the company's common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:to="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:label="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Acquisition - Pro Forma Financial Information (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:to="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockVotesPerShare" xlink:label="dffn_ConvertiblePreferredStockVotesPerShare" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertiblePreferredStockVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ConvertiblePreferredStockVotesPerShare</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Votes Per Share</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockVotesPerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of votes each share of convertible preferred stock is entitled to.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertiblePreferredStockVotesPerShare" xlink:to="dffn_ConvertiblePreferredStockVotesPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:label="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 5 - Property and Equipment - Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:to="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_MakewholeProvisionConversionPricePercentage" xlink:label="dffn_MakewholeProvisionConversionPricePercentage" xlink:type="locator"/>
    <link:label xlink:label="dffn_MakewholeProvisionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_MakewholeProvisionConversionPricePercentage</link:label>
    <link:label xlink:label="dffn_MakewholeProvisionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Make-Whole Provision Conversion Price, Percentage</link:label>
    <link:label xlink:label="dffn_MakewholeProvisionConversionPricePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the conversion price that would be used when applying the make-whole provision/</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_MakewholeProvisionConversionPricePercentage" xlink:to="dffn_MakewholeProvisionConversionPricePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:label="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Convertible Debt - Outstanding Convertible Notes (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:to="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:to="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangement With Clinical Research Organization [Member]</link:label>
    <link:label xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to a Master Services Agreement ("MSA") with a contract research organization ("CRO") to provide clinical research trial services for individual studies and projects by executing individual work orders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:to="dffn_ArrangementWithClinicalResearchOrganizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Convertible Preferred Stock and Stockholder's Equity - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:to="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 11 - Stock-based Compensation - Fair Value Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:to="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Operating Loss Carryforwards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:to="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 13 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Fair Value Measurements - Fair Value on a Recurring Basis (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:to="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:to="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:to="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatements" xlink:label="dffn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatements" xlink:to="dffn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="dffn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows (used in) provided by investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interim Period, Costs Not Allocable [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfExpenseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Expense [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_NatureOfExpenseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of convertible notes and related accrued interest into common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</link:label>
    <link:label xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of accrued liabilities assumed at the acquisition date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtConversionOriginalDebtAmount1</link:label>
    <link:label xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Original Debt, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</link:label>
    <link:label xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted loss per share (in dollars per share)</link:label>
    <link:label xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:to="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightTerm</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Term</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of the warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightTerm" xlink:to="dffn_ClassOfWarrantOrRightTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant related expenses (Note 10)</link:label>
    <link:label xlink:label="dffn_WarrantExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant Expense</link:label>
    <link:label xlink:label="dffn_WarrantExpense-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expenses recognized resulting from issuance of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantExpense" xlink:to="dffn_WarrantExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial conversion feature for accrued interest of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restorgenex Corporation 2015 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to RestorGenex Corporation 2015 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:to="dffn_RestorgenexCorporation2015EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesIssued1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesIssued1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesIssued1" xlink:to="us-gaap_ConversionOfStockSharesIssued1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConversionOfStockSharesConverted1</link:label>
    <link:label xlink:label="us-gaap_ConversionOfStockSharesConverted1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockNameDomain" xlink:to="us-gaap_ConversionOfStockNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</link:label>
    <link:label xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment</link:label>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Make-whole Adjustment</link:label>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock issued during the period as the part of the make-whole adjustment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:to="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses</link:label>
    <link:label xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Warrant related expense, change in fair value, and other financing expenses</link:label>
    <link:label xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the period in warrant related expense, change in fair value of liabilities, and other financing expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:to="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of accrued dividends related to convertible preferred stock</link:label>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of accrued dividends upon conversion of Series A</link:label>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Reclassified Upon Conversion of Preferred Stock</link:label>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Provides information about the amount of reclassification of accrued dividends upon conversion of convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_StockReclassifiedUponConversionOfPreferredStockShares</link:label>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Reclassified Upon Conversion of Preferred Stock, Shares</link:label>
    <link:label xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the number of shares relating to the reclassification of accrued dividends upon conversion of convertible preferred stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStockShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_FinancingTriggerFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Trigger from Issuance of Common Stock</link:label>
    <link:label xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount that triggers the make-whole provision for convertible preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:to="dffn_FinancingTriggerFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of RestorGenex shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NonEmployeeStockOptionsMember" xlink:label="dffn_NonEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_NonEmployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Stock Options [Member]</link:label>
    <link:label xlink:label="dffn_NonEmployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to non-employee stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NonEmployeeStockOptionsMember" xlink:to="dffn_NonEmployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestIncomeExpenseNonoperatingNet</link:label>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock issued for advisory services</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, convertible preferred stock and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition costs</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to severance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issued in connection with the Series A convertible preferred stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="dffn_SuccessFeeAgreementCostsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_SuccessFeeAgreementCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success Fee Agreement Costs [Member]</link:label>
    <link:label xlink:label="dffn_SuccessFeeAgreementCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding the success fee agreement costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_SuccessFeeAgreementCostsMember" xlink:to="dffn_SuccessFeeAgreementCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_RES529Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RES-529 [Member]</link:label>
    <link:label xlink:label="dffn_RES529Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The reporting entity's product of RES-529, a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and was in preclinical development in oncology.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_RES529Member" xlink:to="dffn_RES529Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExercisePrice</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term (Year)</link:label>
    <link:label xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueAssumptionsExpectedTerm</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ExecutiveOfficersMember" xlink:label="dffn_ExecutiveOfficersMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ExecutiveOfficersMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officers [Member]</link:label>
    <link:label xlink:label="dffn_ExecutiveOfficersMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ranking officers of the entity, appointed to the position by the board of directors.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ExecutiveOfficersMember" xlink:to="dffn_ExecutiveOfficersMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNonoperatingExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other financing expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesRentExpenseNet</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IntangibleAssetsGrossExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 14,519,629 and 10,345,637 shares issued and outstanding at December 31, 2017 and 2016, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant liability (Note 14)</link:label>
    <link:label xlink:label="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</link:label>
    <link:label xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued for advisory services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BoardOfDirectorsChairmanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BoardOfDirectorsChairmanMember" xlink:to="us-gaap_BoardOfDirectorsChairmanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="locator"/>
    <link:label xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of Series A convertible preferred stock and warrants, net</link:label>
    <link:label xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock, Net of Offering Costs</link:label>
    <link:label xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock net of offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the make-whole provision when company reaches a certain amount of proceeds from issuance of common stock or securities convertible into or exercisable for common stock while shares of specified convertible stock remain outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:type="locator"/>
    <link:label xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues</link:label>
    <link:label xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, Stock Issued During Period, New Issues</link:label>
    <link:label xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of new stock classified as temporary equity issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:to="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_PreferredStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price</link:label>
    <link:label xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum share price to trigger the make whole provision.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification of the fair market value of the Series A warrants</link:label>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) to additional paid in capital (APIC) resulting from the reclassification of the fair market value of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ReclassificationOfTheFairMarketValueOfWarrants</link:label>
    <link:label xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of the fair market value of the Series A warrants</link:label>
    <link:label xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The reclassification of the fair market value of warrants in noncash investing or financing activities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:to="dffn_ReclassificationOfTheFairMarketValueOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PreferentialDividendsPayble" xlink:label="dffn_PreferentialDividendsPayble" xlink:type="locator"/>
    <link:label xlink:label="dffn_PreferentialDividendsPayble-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PreferentialDividendsPayble</link:label>
    <link:label xlink:label="dffn_PreferentialDividendsPayble-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Series A dividends</link:label>
    <link:label xlink:label="dffn_PreferentialDividendsPayble-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of preferential dividends not subject to declaration, but unpaid on equity securities issued by the entity and outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PreferentialDividendsPayble" xlink:to="dffn_PreferentialDividendsPayble-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockDividendRatePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PreferredStockDividendRatePercentage</link:label>
    <link:label xlink:label="us-gaap_PreferredStockDividendRatePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsForFees-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsForFees</link:label>
    <link:label xlink:label="us-gaap_PaymentsForFees-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForFees" xlink:to="us-gaap_PaymentsForFees-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsFairValueDisclosure</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityLiquidationPreference-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, liquidation value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquitySharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized, 12,376,329 and 8,306,278 shares issued and outstanding, respectively at December 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $16,778,682 at December 31, 2017)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_January2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">January 2018 Offering [Member]</link:label>
    <link:label xlink:label="dffn_January2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the January 2018 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_January2018OfferingMember" xlink:to="dffn_January2018OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the January 2018 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the January 2018 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion From Series A Preferred Stock to Common Stock, Settlement of Accrued Dividends [Member]</link:label>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the conversion of Series A preferred stock to common stock upon settlement of accrued dividends.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion From Series A Preferred Stock to Common Stock, Make-Whole Adjustment [Member]</link:label>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the conversion of Series A preferred stock to common stock for settlement of the "make-whole" adjustment feature.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion From Series A Preferred Stock to Common Stock Automated Conversion [Member]</link:label>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the conversion of Series A preferred stock to common stock automated conversion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrentAndNoncurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrentAndNoncurrent" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentAdditions</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of warrant</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in fair value of warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueDisclosuresTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:type="locator"/>
    <link:label xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic</link:label>
    <link:label xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification of Series A warrants to additional paid in capital</link:label>
    <link:label xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of reclassification of warrants to additional paid in capital (APIC) classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:to="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">H.C Wainwright &amp; Co., LLC [Member]</link:label>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_HCWainwrightAndCoLLCMember" xlink:to="dffn_HCWainwrightAndCoLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingStandardsUpdate201609Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-09 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201609Member" xlink:to="us-gaap_AccountingStandardsUpdate201609Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BuildingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement of litigation matter upon issuance of convertible debt</link:label>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the issuance of convertible debt to settle a litigation matter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations before income tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abandonmnet of In-Process Research and Development Intangible Asset [Member]</link:label>
    <link:label xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the noncash transaction that disposal the in-process research and development intangible asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_The2016ConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2016 Convertible Notes [Member]</link:label>
    <link:label xlink:label="dffn_The2016ConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the convertible notes issued in 2016, which were issued to an investor and certain other parties in connection with the settlement of a litigation matter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_The2016ConvertibleNotesMember" xlink:to="dffn_The2016ConvertibleNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestQuarterlyMember" xlink:label="dffn_VestQuarterlyMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_VestQuarterlyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Quarterly [Member]</link:label>
    <link:label xlink:label="dffn_VestQuarterlyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to options that vest quarterly.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_VestQuarterlyMember" xlink:to="dffn_VestQuarterlyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfAdoptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_SettlementAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement Agreement [Member]</link:label>
    <link:label xlink:label="dffn_SettlementAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A Settlement Agreement (the &#8220;Settlement Agreement&#8221;) pursuant to which, among other things, (i) Mr. Schmidt and Diffusion each agreed to submit a consent order to the Court dismissing all claims set forth in the Amended Complaint with prejudice and without an admission of liability by any party, (ii) Mr. Schmidt and Diffusion each released, on behalf of such party and its heirs, assigns, representatives, affiliates and agents, all claims and causes of action of any nature against the other party existing as of the date of the Settlement Agreement and (iii) as consideration therefor, the Company agreed to issue and sell, to Mr. Schmidt and the other parties to the Settlement Agreement, the 2016 Convertible Notes in an aggregate principal amount of $1,880,000.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_SettlementAgreementMember" xlink:to="dffn_SettlementAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total principal amount</link:label>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</link:label>
    <link:label xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Warrants [Member]</link:label>
    <link:label xlink:label="dffn_UnderwriterWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued to the underwriter.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterWarrantsMember" xlink:to="dffn_UnderwriterWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion From Series A Preferred Stock to Common Stock [Member]</link:label>
    <link:label xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the conversion of Series A preferred stock to common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:type="locator"/>
    <link:label xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_CumulativeEffectOfChangeInAccountingPrinciple</link:label>
    <link:label xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect of change in accounting principle (a)</link:label>
    <link:label xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of an accounting principle applied during the period of adoption.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:to="dffn_CumulativeEffectOfChangeInAccountingPrinciple-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_AdditionalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Warrants [Member]</link:label>
    <link:label xlink:label="dffn_AdditionalWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the additional warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AdditionalWarrantsMember" xlink:to="dffn_AdditionalWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Common stock equivalents (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net assets acquired</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfConvertibleDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Repayment of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diluted net loss per common share calculation:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDilutedAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share of common, basic (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioForecastMember" xlink:to="us-gaap_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic net loss per common share calculation:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeDomain" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonmonetary Transaction Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertibleDebtFairValueDisclosures</link:label>
    <link:label xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt, Fair Value Disclosures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtFairValueDisclosures" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Unsecured Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationSettlementExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settlement of litigation matter</link:label>
    <link:label xlink:label="us-gaap_LitigationSettlementExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonrecurringAdjustmentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrecurringAdjustmentDomain" xlink:to="us-gaap_NonrecurringAdjustmentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="us-gaap_NonrecurringAdjustmentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonrecurringAdjustmentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrecurring Adjustment [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessAcquisitionsProFormaRevenue</link:label>
    <link:label xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net revenues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentGeographicalDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentGeographicalDomain" xlink:to="us-gaap_SegmentGeographicalDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementGeographicalAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_StatementGeographicalAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in tax rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesBPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeriesAPreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockMember" xlink:to="us-gaap_ConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:type="locator"/>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated fair value of RestorGenex warrants outstanding</link:label>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from stock warrants assumed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:type="locator"/>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated fair value of RestorGenex stock options outstanding</link:label>
    <link:label xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from stock options assumed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="dffn_ProceedsFromReverseMergerTransaction" xlink:type="locator"/>
    <link:label xlink:label="dffn_ProceedsFromReverseMergerTransaction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash received in reverse merger transaction</link:label>
    <link:label xlink:label="dffn_ProceedsFromReverseMergerTransaction-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow associated with a reverse merger transaction.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ProceedsFromReverseMergerTransaction" xlink:to="dffn_ProceedsFromReverseMergerTransaction-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">State tax, net of Federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorGenexMember" xlink:label="dffn_RestorGenexMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_RestorGenexMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RestorGenex [Member]</link:label>
    <link:label xlink:label="dffn_RestorGenexMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to RestorGenex Corporation (RestorGenex).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_RestorGenexMember" xlink:to="dffn_RestorGenexMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible debt, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtNoncurrent" xlink:to="us-gaap_ConvertibleDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_GeneralFinancialAdvisoryServicesMember" xlink:label="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_GeneralFinancialAdvisoryServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General Financial Advisory Services [Member]</link:label>
    <link:label xlink:label="dffn_GeneralFinancialAdvisoryServicesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to general financial advisory services.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_GeneralFinancialAdvisoryServicesMember" xlink:to="dffn_GeneralFinancialAdvisoryServicesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPreliminaryPurchasePriceConsideration</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total purchase price</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of preliminary purchase consideration consisting of the fair value of assets transferable by the acquirer, liabilities obtainable by the acquirer, and equity interest issuable by the acquirer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtTableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Preliminary Purchase Price Consideration [Table Text Block]</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of preliminary purchase price consideration in a business combination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair value of the Company&#8217;s pre-Merger shares outstanding</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair value of shares outstanding in the preliminary purchase price consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated fair value of the Company&#8217;s pre-Merger warrants outstanding</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated fair value of warrants assumed in the preliminary purchase price consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated fair value of the Company&#8217;s pre-Merger stock options outstanding</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated fair value of stock options assumed in the preliminary purchase price consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CVRs &#8211; RES-440 product candidate</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of contingent value rights in the preliminary purchase price consideration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_AccruedClinicalStudiesExpensesCurrent</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReverseStockSplitMember" xlink:label="dffn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reverse Stock Split [Member ]</link:label>
    <link:label xlink:label="dffn_ReverseStockSplitMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The conversion of a reverse stock split where there is a reduction in the shares outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ReverseStockSplitMember" xlink:to="dffn_ReverseStockSplitMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Notes [Member]</link:label>
    <link:label xlink:label="dffn_ConvertibleNotesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to unsecured convertible promissory notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertibleNotesMember" xlink:to="dffn_ConvertibleNotesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DerivativeLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock warrant liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeLiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ContingentConsiderationMember" xlink:label="dffn_ContingentConsiderationMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ContingentConsiderationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Consideration [Member]</link:label>
    <link:label xlink:label="dffn_ContingentConsiderationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to information regarding contingent considerations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ContingentConsiderationMember" xlink:to="dffn_ContingentConsiderationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development Costs (IPR&amp;D) [Member]</link:label>
    <link:label xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:to="dffn_InProcessResearchAndDevelopmentCostsIprdMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseTypeDomain" xlink:to="us-gaap_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:type="locator"/>
    <link:label xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_QualifiedFinancingMinimumAmountOfGrossProceeds</link:label>
    <link:label xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Financing, Minimum Amount of Gross Proceeds</link:label>
    <link:label xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum amount of gross proceeds for qualified financing.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:to="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PlacementAgentMember" xlink:label="dffn_PlacementAgentMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PlacementAgentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Placement Agent [Member]</link:label>
    <link:label xlink:label="dffn_PlacementAgentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the agent of a private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PlacementAgentMember" xlink:to="dffn_PlacementAgentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="dffn_ConvertibleNoteSeriesBMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_ConvertibleNoteSeriesBMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Note, Series B [Member]</link:label>
    <link:label xlink:label="dffn_ConvertibleNoteSeriesBMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to the Series B convertible note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ConvertibleNoteSeriesBMember" xlink:to="dffn_ConvertibleNoteSeriesBMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="dffn_CharlottesvilleVirginiaMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_CharlottesvilleVirginiaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charlottesville, Virginia [Member]</link:label>
    <link:label xlink:label="dffn_CharlottesvilleVirginiaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to the location Charlottesville, Virginia.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_CharlottesvilleVirginiaMember" xlink:to="dffn_CharlottesvilleVirginiaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maturities of certificates of deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:type="locator"/>
    <link:label xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest</link:label>
    <link:label xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Related Accrued Interest</link:label>
    <link:label xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of related accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:to="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ConvertibleNotesPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesTotal" xlink:label="dffn_StockIssuedDuringPeriodSharesTotal" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesTotal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_StockIssuedDuringPeriodSharesTotal</link:label>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesTotal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Total</link:label>
    <link:label xlink:label="dffn_StockIssuedDuringPeriodSharesTotal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate number of shares of stock issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockIssuedDuringPeriodSharesTotal" xlink:to="dffn_StockIssuedDuringPeriodSharesTotal-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightsExpired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Rights, Expired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightsExpired" xlink:to="dffn_ClassOfWarrantOrRightsExpired-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestMonthlyMember" xlink:label="dffn_VestMonthlyMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_VestMonthlyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Monthly [Member]</link:label>
    <link:label xlink:label="dffn_VestMonthlyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to options that vest monthly.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_VestMonthlyMember" xlink:to="dffn_VestMonthlyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current portion of convertible debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtCurrent" xlink:to="us-gaap_ConvertibleDebtCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:label="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:type="locator"/>
    <link:label xlink:label="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RestorGenex options outstanding (in shares)</link:label>
    <link:label xlink:label="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to a merger.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:to="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:label="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RestorGenex options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any of the assumed shares from a merger.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:to="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancialAdviserMember" xlink:label="dffn_FinancialAdviserMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_FinancialAdviserMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Adviser [Member]</link:label>
    <link:label xlink:label="dffn_FinancialAdviserMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about financial adviser.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_FinancialAdviserMember" xlink:to="dffn_FinancialAdviserMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationAcquisitionRelatedCosts</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SeveranceCosts1</link:label>
    <link:label xlink:label="us-gaap_SeveranceCosts1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GoodwillImpairmentLoss</link:label>
    <link:label xlink:label="us-gaap_GoodwillImpairmentLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestPayableCurrent</link:label>
    <link:label xlink:label="us-gaap_InterestPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued interest payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightGrantedDuringPeriod</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Granted During Period</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights granted during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:to="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of certificates of deposit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AcquisitionRelatedCostsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquisition-related Costs [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionRelatedCostsMember" xlink:to="us-gaap_AcquisitionRelatedCostsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cancelled, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedSalariesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and payroll related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock equivalents arising from warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="dffn_OfferingCostsInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering costs in accounts payable and accrued expenses</link:label>
    <link:label xlink:label="dffn_OfferingCostsInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount in Accounts Payable from offering costs in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_OfferingCostsInAccountsPayable" xlink:to="dffn_OfferingCostsInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationNonproduction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to common stockholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsPolicyPolicyTextBlock" xlink:label="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_OfferingCostsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Offering Costs, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="dffn_OfferingCostsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:to="dffn_OfferingCostsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_DiffusionLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diffusion LLC [Member]</link:label>
    <link:label xlink:label="dffn_DiffusionLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name of a company with which the reporting entity has entered into a business combination.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DiffusionLLCMember" xlink:to="dffn_DiffusionLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</link:label>
    <link:label xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of Series A cumulative preferred dividends</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnDispositionOfAssets1</link:label>
    <link:label xlink:label="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale or disposal of assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfCommonStockOutstandingOwned" xlink:label="dffn_PercentageOfCommonStockOutstandingOwned" xlink:type="locator"/>
    <link:label xlink:label="dffn_PercentageOfCommonStockOutstandingOwned-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfCommonStockOutstandingOwned</link:label>
    <link:label xlink:label="dffn_PercentageOfCommonStockOutstandingOwned-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Common Stock Outstanding Owned</link:label>
    <link:label xlink:label="dffn_PercentageOfCommonStockOutstandingOwned-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of all classes of common stock held by shareholders.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PercentageOfCommonStockOutstandingOwned" xlink:to="dffn_PercentageOfCommonStockOutstandingOwned-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Former Equity Holders of Diffusion LLC [Member]</link:label>
    <link:label xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Former holders of equity of Diffusion LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest</link:label>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Shares Called by Each Previously Held Unit of Membership Interest</link:label>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of the reporting entity's common stock into which each previously held unit of membership interest may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="dffn_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tangible personal property used in a laboratory setting.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_LaboratoryEquipmentMember" xlink:to="dffn_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed</link:label>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Number of Shares Called by Share Options Assumed</link:label>
    <link:label xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares of the reporting entity's common stock into which the share options assumed in a business combination may be converted.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentTerm</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VestingAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_RES440Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RES-440 [Member]</link:label>
    <link:label xlink:label="dffn_RES440Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The reporting entity's product of RES-440, a &#8220;soft&#8221; anti-androgen.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_RES440Member" xlink:to="dffn_RES440Member-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:type="locator"/>
    <link:label xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Period Following Merger in Which Receipt of Cash for Discontinued Product Assets Would Trigger Contingent Value Right Payements</link:label>
    <link:label xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period following a merger that, if the reporting entity receives net cash payments for the sale of any of the assets related to a discontinued product line, would trigger a required payment to holders of contingent value rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:to="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IntangibleAssetsNetExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleConversionPrice1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfAssetsAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consideration in connection with RestorGenex Corporation merger transaction</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentInProcess-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abandonment of in-process research and development intangible asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label xlink:label="us-gaap_Goodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized start-up costs and other</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan Drug credits</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Dividends-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Series A cumulative preferred dividends</link:label>
    <link:label xlink:label="us-gaap_Dividends-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Dividends</link:label>
    <link:label xlink:label="us-gaap_Dividends-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends</link:label>
    <link:label xlink:label="us-gaap_Dividends-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Series A cumulative preferred dividend</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Dividends" xlink:to="us-gaap_Dividends-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent</link:label>
    <link:label xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement charge</link:label>
    <link:label xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to litigation settlement charge.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:to="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="dffn_SeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred stock that may be exchanged into common shares or other types of securities at the owner's option and classified as series A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_SeriesAConvertiblePreferredStockMember" xlink:to="dffn_SeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:type="locator"/>
    <link:label xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_NumberOfConvertiblePreferredStockPerUnit</link:label>
    <link:label xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Convertible Preferred Stock Per Unit</link:label>
    <link:label xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Series A convertible preferred stock included in each unit issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:to="dffn_NumberOfConvertiblePreferredStockPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfCommonStockPerUnit" xlink:label="dffn_NumberOfCommonStockPerUnit" xlink:type="locator"/>
    <link:label xlink:label="dffn_NumberOfCommonStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_NumberOfCommonStockPerUnit</link:label>
    <link:label xlink:label="dffn_NumberOfCommonStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Common Stock Per Unit</link:label>
    <link:label xlink:label="dffn_NumberOfCommonStockPerUnit-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of common stock included in each unit issued.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NumberOfCommonStockPerUnit" xlink:to="dffn_NumberOfCommonStockPerUnit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Per share information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dffn-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 11:45PM UTC 2018-03-30--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions" xlink:href="dffn-20171231.xsd#statement-note-15-related-party-transactions" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information" xlink:href="dffn-20171231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20171231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20171231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReverseStockSplitMember" xlink:label="dffn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity" xlink:href="dffn-20171231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="dffn_ConvertibleNoteSeriesBMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_ConvertibleNoteSeriesBMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ExecutiveOfficersMember" xlink:label="dffn_ExecutiveOfficersMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancialAdviserMember" xlink:label="dffn_FinancialAdviserMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="dffn_SuccessFeeAgreementCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="us-gaap_NonrecurringAdjustmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="dffn_SuccessFeeAgreementCostsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_FinancialAdviserMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_ExecutiveOfficersMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets" xlink:href="dffn-20171231.xsd#statement-note-6-goodwill-and-intangible-assets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="dffn_CharlottesvilleVirginiaMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="dffn_CharlottesvilleVirginiaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_GeneralFinancialAdvisoryServicesMember" xlink:label="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PlacementAgentMember" xlink:label="dffn_PlacementAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_PlacementAgentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NonEmployeeStockOptionsMember" xlink:label="dffn_NonEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestMonthlyMember" xlink:label="dffn_VestMonthlyMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestQuarterlyMember" xlink:label="dffn_VestQuarterlyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dffn_VestMonthlyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dffn_VestQuarterlyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dffn_NonEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan" xlink:href="dffn-20171231.xsd#statement-note-12-defined-contribution-retirement-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event" xlink:href="dffn-20171231.xsd#statement-note-16-subsequent-event" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20171231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsPolicyPolicyTextBlock" xlink:label="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="dffn_OfferingCostsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-tables" xlink:label="dffn_statement-statement-note-4-acquisition-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-acquisition-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-5-property-and-equipment-tables" xlink:label="dffn_statement-statement-note-5-property-and-equipment-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-property-and-equipment-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-8-convertible-debt-tables" xlink:label="dffn_statement-statement-note-8-convertible-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-convertible-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ConvertibleDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-commitments-and-contingencies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:label="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-tables" xlink:label="dffn_statement-statement-note-13-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-13-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual" xlink:href="dffn-20171231.xsd#statement-note-1-organization-and-description-of-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfCommonStockOutstandingOwned" xlink:label="dffn_PercentageOfCommonStockOutstandingOwned-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReverseStockSplitMember" xlink:label="dffn_ReverseStockSplitMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_ReverseStockSplitMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfCommonStockOutstandingOwned-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual" xlink:href="dffn-20171231.xsd#statement-note-2-liquidity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNoteSeriesBMember" xlink:label="dffn_ConvertibleNoteSeriesBMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201609Member" xlink:label="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtFairValueDisclosures" xlink:label="us-gaap_ConvertibleDebtFairValueDisclosures-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_ConvertibleNoteSeriesBMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AccountingStandardsUpdate201609Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleDebtFairValueDisclosures-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-n2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest" xlink:label="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements" xlink:label="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ExecutiveOfficersMember" xlink:label="dffn_ExecutiveOfficersMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancialAdviserMember" xlink:label="dffn_FinancialAdviserMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:label="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfCommonStockOutstandingOwned" xlink:label="dffn_PercentageOfCommonStockOutstandingOwned-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SuccessFeeAgreementCostsMember" xlink:label="dffn_SuccessFeeAgreementCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AcquisitionRelatedCostsMember" xlink:label="us-gaap_AcquisitionRelatedCostsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:label="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NatureOfExpenseAxis" xlink:label="us-gaap_NatureOfExpenseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentAxis" xlink:label="us-gaap_NonrecurringAdjustmentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonrecurringAdjustmentDomain" xlink:label="us-gaap_NonrecurringAdjustmentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForFees" xlink:label="us-gaap_PaymentsForFees-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="us-gaap_SeveranceCosts1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="us-gaap_InterimPeriodCostsNotAllocableDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_FormerEquityHoldersOfDiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonrecurringAdjustmentAxis" xlink:to="us-gaap_AcquisitionRelatedCostsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NatureOfExpenseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NatureOfExpenseAxis" xlink:to="dffn_SuccessFeeAgreementCostsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_FinancialAdviserMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_ExecutiveOfficersMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfCommonStockOutstandingOwned-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForFees-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SeveranceCosts1-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:href="dffn-20171231.xsd#statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES529Member" xlink:label="dffn_RES529Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES529Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest" xlink:label="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_QualifiedFinancingMinimumAmountOfGrossProceeds" xlink:label="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentSharesIssued1" xlink:label="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfUnsecuredDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpense-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrentAndNoncurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementExpense-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPaidNet-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfUnsecuredDebt-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_QualifiedFinancingMinimumAmountOfGrossProceeds-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtConversionConvertedInstrumentSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:label="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CharlottesvilleVirginiaMember" xlink:label="dffn_CharlottesvilleVirginiaMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidResearchAndDevelopmentExpense" xlink:label="dffn_PrepaidResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SettlementAgreementMember" xlink:label="dffn_SettlementAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:label="us-gaap_BuildingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseAxis" xlink:label="us-gaap_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationCaseTypeDomain" xlink:label="us-gaap_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAdditions" xlink:label="us-gaap_PropertyPlantAndEquipmentAdditions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="us-gaap_SegmentGeographicalDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="us-gaap_StatementGeographicalAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="us-gaap_SegmentGeographicalDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="us-gaap_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementGeographicalAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementGeographicalAxis" xlink:to="dffn_CharlottesvilleVirginiaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_BuildingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="dffn_ArrangementWithClinicalResearchOrganizationMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationCaseAxis" xlink:to="dffn_SettlementAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentAdditions-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PrepaidResearchAndDevelopmentExpense-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightGrantedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockConversionPrice" xlink:label="dffn_ConvertiblePreferredStockConversionPrice-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock" xlink:label="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockVotesPerShare" xlink:label="dffn_ConvertiblePreferredStockVotesPerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FinancingTriggerFromIssuanceOfCommonStock" xlink:label="dffn_FinancingTriggerFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_GeneralFinancialAdvisoryServicesMember" xlink:label="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_MakewholeProvisionConversionPricePercentage" xlink:label="dffn_MakewholeProvisionConversionPricePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfCommonStockPerUnit" xlink:label="dffn_NumberOfCommonStockPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NumberOfConvertiblePreferredStockPerUnit" xlink:label="dffn_NumberOfConvertiblePreferredStockPerUnit-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PlacementAgentMember" xlink:label="dffn_PlacementAgentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment" xlink:label="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockIssuedDuringPeriodSharesTotal" xlink:label="dffn_StockIssuedDuringPeriodSharesTotal-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues" xlink:label="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:label="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:label="us-gaap_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:label="us-gaap_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesBPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="dffn_PlacementAgentMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="dffn_GeneralFinancialAdvisoryServicesMember" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_NumberOfConvertiblePreferredStockPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_NumberOfCommonStockPerUnit-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockConversionPrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightGrantedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_WarrantExpense-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStockShares-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockVotesPerShare-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_FinancingTriggerFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1-2" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_MakewholeProvisionConversionPricePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment-2" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1-2" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockIssuedDuringPeriodSharesTotal-2" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAdjustmentOfWarrants-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NonEmployeeStockOptionsMember" xlink:label="dffn_NonEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:label="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestMonthlyMember" xlink:label="dffn_VestMonthlyMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_VestQuarterlyMember" xlink:label="dffn_VestQuarterlyMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="us-gaap_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_RestorgenexCorporation2015EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VestingAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dffn_VestMonthlyMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TitleOfIndividualAxis" xlink:to="us-gaap_BoardOfDirectorsChairmanMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="dffn_VestQuarterlyMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="dffn_NonEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:href="dffn-20171231.xsd#statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:label="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:label="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RES440Member" xlink:label="dffn_RES440Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeAxis" xlink:label="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonmonetaryTransactionTypeDomain" xlink:label="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioForecastMember" xlink:label="us-gaap_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="us-gaap_NonmonetaryTransactionTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_InProcessResearchAndDevelopmentCostsIprdMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="dffn_RES440Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_NonmonetaryTransactionTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonmonetaryTransactionTypeAxis" xlink:to="dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability-n2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual" xlink:href="dffn-20171231.xsd#statement-note-16-subsequent-event-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdditionalWarrantsMember" xlink:label="dffn_AdditionalWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ClassOfWarrantOrRightTerm" xlink:label="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:label="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_January2018OfferingMember" xlink:label="dffn_January2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_UnderwriterWarrantsMember" xlink:label="dffn_UnderwriterWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="us-gaap_ConversionOfStockNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="us-gaap_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="us-gaap_ConversionOfStockNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_January2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_AdditionalWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:to="dffn_ConversionFromSeriesAPreferredStockToCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockSharesIssued1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsideration" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-3" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:label="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_RestorGenexMember" xlink:label="dffn_RestorGenexMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:label="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-acquisition-purchase-price-consideration-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_RestorGenexMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationPreliminaryPurchasePriceConsideration-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:label="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-n9" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:label="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities-n9" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExercisePrice-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-fair-value-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details" xlink:href="dffn-20171231.xsd#statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted" xlink:label="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DiffusionLLCMember" xlink:label="dffn_DiffusionLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:label="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaRevenue" xlink:label="us-gaap_BusinessAcquisitionsProFormaRevenue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-acquisition-pro-forma-financial-information-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="dffn_DiffusionLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaRevenue-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:href="dffn-20171231.xsd#statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertibleNotesMember" xlink:label="dffn_ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_The2016ConvertibleNotesMember" xlink:label="dffn_The2016ConvertibleNotesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:label="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleLongTermNotesPayable" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleNotesPayableCurrent" xlink:label="us-gaap_ConvertibleNotesPayableCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-convertible-debt-outstanding-convertible-notes-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_The2016ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="dffn_ConvertibleNotesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:href="dffn-20171231.xsd#statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:label="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20171231.xsd#statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:label="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="us-gaap_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_ConvertiblePreferredStockIssuedPriorToMergerMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:label="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:label="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-13-income-taxes-operating-loss-carryforwards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent" xlink:label="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n9" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n9" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ContingentConsiderationMember" xlink:label="dffn_ContingentConsiderationMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic" xlink:label="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-n8" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="dffn_ContingentConsiderationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-operations" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpense" xlink:label="dffn_WarrantExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-n10" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="dffn_WarrantExpense" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OtherNonoperatingExpense" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-n8" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-cash-flow" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_OfferingCostsInAccountsPayable" xlink:label="dffn_OfferingCostsInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:label="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ProceedsFromReverseMergerTransaction" xlink:label="dffn_ProceedsFromReverseMergerTransaction" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_ReclassificationOfTheFairMarketValueOfWarrants" xlink:label="dffn_ReclassificationOfTheFairMarketValueOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock-1" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses" xlink:label="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="us-gaap_ConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit" xlink:label="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_LitigationSettlementExpense" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="dffn_ProceedsFromReverseMergerTransaction" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfConvertibleDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_ReclassificationOfTheFairMarketValueOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_Dividends-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_OfferingCostsInAccountsPayable" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability" xlink:label="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:label="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasic-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareDilutedAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:href="dffn-20171231.xsd#statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:label="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20171231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_SeriesAConvertiblePreferredStockMember" xlink:label="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dffn_SeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_RestrictedStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:href="dffn-20171231.xsd#statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_LaboratoryEquipmentMember" xlink:label="dffn_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:label="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-5-property-and-equipment-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="dffn_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20171231.xsd#statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PreferentialDividendsPayble" xlink:label="dffn_PreferentialDividendsPayble-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPayableCurrent" xlink:label="us-gaap_InterestPayableCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestPayableCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PreferentialDividendsPayble-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20171231.xsd#statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-11-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20171231.xsd#statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:href="dffn-20171231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="us-gaap_ConvertibleDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="us-gaap_ConvertibleDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Goodwill" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ConvertibleDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:href="dffn-20171231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:label="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_CumulativeEffectOfChangeInAccountingPrinciple" xlink:label="dffn_CumulativeEffectOfChangeInAccountingPrinciple-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20171231.xsd#dffn_StockReclassifiedUponConversionOfPreferredStockShares" xlink:label="dffn_StockReclassifiedUponConversionOfPreferredStockShares-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Dividends" xlink:label="us-gaap_Dividends-n9" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_CumulativeEffectOfChangeInAccountingPrinciple-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Dividends-n9" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStockShares-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockReclassifiedUponConversionOfPreferredStock" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>kpmgsig.jpg
<TEXT>
begin 644 kpmgsig.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  @ ) # 2(  A$! Q$!_\0
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M+R7C1^8(Q'Y>\X4C)"XSQUXJ;2/VQO NM>!;G7H;W4?(M=5.AFS.FS_;Y+X
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J7Q-^W+^WCHG[3GP,?PQHOA;QA97K7T5R)+RVB$6U5<$?)(QS\P[4 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>a6.jpg
<TEXT>
begin 644 a6.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #, :P# 2(  A$! Q$!_\0
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M=%_\B?\ Q5>^+*K?[U24Q'S_ /\ #OW]GO\ Z);H_P#Y$_\ BJ/^'?G[/?\
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MU)+_ +-5OO56H#E9OX:E5FJ+:RT[=5@3[FHHAI^S=2Y0(&H^;^&I&BVT>32
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M\.=4\5ZGX@U :]:RVMC]CC:&.15_UGVBY5O^^HUB:OEOX<_\I>/B7_V(\?\
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M'PZ_Y2\?$O\ [$6/_P!"LJ /NU?NK3J:OW5IU !1110 4444 %%%% !1110
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MJ1K<,S;8MS;MJ_=KD=6^.NFZ;"T=JLDK?,RK]YF;^\W^U_%7)>'-&\<?&GQ
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MNJLK+M967=N6G&H$H<^YY%%\4O#\NL6.GI)>;M0N/LUK>?8V^S32?W5D_P"
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MW;5-JZX_"<,CR*X^#NM6<=G;Z7XJDBL?+M%N%N59I/W,S2?N_P"%=VYE_P"
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M%/+:DZ?-(Z.P\4:;KEPUK'-MN5^62TG5EG7_ +9UG7FL_P#"):Y!>1-M\O\
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MX26R^TKN55V^=YF[;\OW?X:]S_X91^"O_1(_ _\ X3MI_P#&Z/\ AE'X*_\
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M_P!VK?=;^]7I_A']I#X$^$?#6GZ/;_&7P7-!:Q[8Y)O$5IN*[MW_ #TKH/\
MAE'X*?\ 1(_ _P#X3MI_\;H_X91^"G_1(_ __A.VG_QN@"+_ (:X^!__ $5_
MP/\ ^%%:?_'*/^&N/@?_ -%?\#_^%%:?_'*E_P"&4?@I_P!$C\#_ /A.VG_Q
MNF?\,H_!3_HD?@?_ ,)VT_\ C= #?^&N/@?_ -%?\#_^%%:?_'*/^&N/@?\
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M-T?\,H_!3_HD?@?_ ,)VT_\ C= #?^&N/@?_ -%?\#_^%%:?_'*/^&N/@?\
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6%+35^Z*=0 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a5.jpg
<TEXT>
begin 644 a5.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" &) KP# 2(  A$! Q$!_\0
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M +-_C7QIH^@:?K?BXZAKM_!IEJLGAZ:-6EGE6)-Q)P!N89)Z9]*^G_CU\;M
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MV,]1^==;K&JPZ#HUY?7._P"S6,$ES-L7<VQ%+-@=S@'CO0!9S]:-U?$>E_\
M!PE^S#J,]OO\2>++5)R/WTOAFY*#(SD[ S'\%)Q7MGQF_P""B?PE^!_[.6@_
M%C4_$<VJ> _$]_%IVG:GHUG)>BXFDBFE4%.&7"V\@;=@JP (&> #W#/L:,U\
M8^'?^"]O[.?BSQ%IVEV>J>-)+O5;J&SMU;PQ.JF21U1,G/ W,.>U>A?M4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU&:9^T_^PO\ "_\ ;)NO#\WQ%\.R:])X79WTTKJ-Q:^07*EL^2Z!LE%ZYZ4
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M\^,'[8UQX=\.VA\-_%#X16_@OP66U.!&N[F*TD@6%U+!H@/D&]P%]:M^+OV
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MH;BPN-/N[&;&X+)!<(DBY'()7!P?0U\=?&?X*>/OV[_&'[.OB/PY(WC+PO\
M"_XPVWB#49=6GMK>^L-&C>T<O.A""1CY4SK&%,FS:"-QKV3]A3]D_P ;_ O]
MO/\ :H\;>(=)MK#PQ\3M;T^]\/3QW<4C7<<4++(S1H=T;;FYW@9R3BNNG4YX
M\Q\[C,.\/6E0F]5]Y]<T4459RA4&J<Z9<?\ 7)OY&IZ;-&LT;(_"N"IYQUXZ
MU,E=61I1ERU(R?='Y(_\$ZN?^"B_AS_K]U;_ -);JOUP<8;\_P"9KYX^"_\
MP30\!? OXT6OCK1[_P 47&K6,EQ-#'=W<3V^9HY(W+!8E.-LC8&X<A<GL?H<
MMN/;\\Y_ST_ UY^5X6="FXS[W/O/$/B3"9UCX8G!WY8PC%W5M5OW"BBBO2/S
M\**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@#DMU&ZNM^Q0?\\(O^^/_K4?8H/^>$7_ 'Q_]:@#DMU&ZNM^Q0?\\(O^^/\
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M_/"+_OC_ .M1]B@_YX1?]\?_ %J .2W4;JZW[%!_SPB_[X_^M1]B@_YX1?\
M?'_UJ .2W4;JZW[%!_SPB_[X_P#K4?8H/^>$7_?'_P!:@#DMU&ZNM^Q0?\\(
MO^^/_K4?8H/^>$7_ 'Q_]:@#DMU&ZNM^Q0?\\(O^^/\ ZU'V*#_GA%_WQ_\
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M-T,,UM?+&3ZH"Q4^Q ->7_&#_@FEX1\71S7'A=Y?#=\P+)$C&:U8^NQB2/\
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M?]I#X(W7P$^*]]H,V][5\7&GSX_U\#'"D?[2D%3_ +0)[BON']@_X\-\;OA
ML-_()-:T!EL[PY^:90!Y<Q[_ #+P?]I7/>L7_@I#\(5\;_!O_A(+>+_B8>&7
M\\%.IMVVB1??^%AZ%*^9_P!@;XH/\.OVA-/MF=EM?$ _L^89^7<<LC?3<,>O
M->_!?5,7R+X9'X[BI+B7A;VSUKT/OTW^]?B?I4HW+4CC]V?I4!N%B!+-M'K3
M-8UZST/2;J\O)EAM;.%YYY&^[&B+N9B?0 $U]!:Q^'GYU_\ !<[]K633=)T_
MX0Z+<>7)JB1ZCXA>-L-Y.[,%L?0.P\QL]D0="U>5_P#!'+]AN/XX?$&;XD>)
M[-9O"OA.X":=;S)\FIZ@,-N([QPC!/\ >=E'\+"OE[XO?$+5OVKOVCM7UY8Y
M9M2\;:SBRMR-S*DKB."+'^RGEK@=2#7[9^ O#7AW]@_]D6*"\>.WT3P'HCW=
M_..L[HADEDZ=7?.._*T >)_\%9?^"E4/[%'@&/P[X9DAN_B5XJMV:S'#+HMM
MR&NY!_>)RL2D?,02<A"#^'^O>(+[Q;KUYJNJ7EUJ6IZC,UQ=W=RYDFN96.6=
MF/)))[UU'[1OQ\UC]I;XW^(O''B"8G4/$-TTXB9O^/6(?+%"O/1(PB_\!-<:
MOSC(H **,\?X=Z:7V]: '44TO@?2G Y7=QM W9SV]: #%:G@GQQK'PS\8:;X
M@\/ZE=:1K6DS"XM+RV;;) X[C^HZ$9!!!-93-L^]\N.N>U(K[NF#^- '[V?\
M$N_^"AMC^W9\*)O[4^S:?\0?"ZI%K-BAQ'<J?N7L/_3-SD%>J.I!X*,WQG_P
M6)_893X$_$=?B)X9LQ;^$_%UQB]MX1B/3-0/S' 'W8YN6'H^X="HKXO_ &.O
MVG-3_9!_:&\.^.M.\UX=.G$>HVR_\OMG)@318[DK\R_[2CZC]^/CC\--#_;'
M_9EU#0XYK>ZTOQEI*W6FWRD,D;.@DMIU([!BC<=5SZT ?%__  1!_:];4?#F
MH?";7IV<Z+&VI: [-N9H"V)K91_LNVY1_ML.PQ^ALNM>3&NZ":.23 C60#YS
M^!X^AP?:OY_/@Q\3=5_93_:)T7Q(UO/%J/@G6 ;^T;Y9'6*0QW-N?]HJ)$YZ
M-CTK]_H[^/Q#!8W%E/#+9742W,,RKO$J-@HRD\?=(.>M!F[V&VLLU[:Q[9)&
M^T B3>!E 5/(';G P?6O%OV\OCI_PI3X+_9+&0?V]K^;.U"''V=-G[Z8#_9!
M &/XG6O<RK3V>#M60G+#H'P1G\"*_-[]O+XG-\1?VA=2MXY UEX?0:=;C.5!
M'+_^/%OP ]*\[,L1[*E9;O0^XX R&.99K%5E>$%S2^6R^;W,+]DW]G^;]HKX
MKQ:7(K?V38H+O4YUSQ%NQY8)_B=N!_P)N@-?;G[5G[2WAW]B;X%?VE)#&T\:
M"RT;3(VV&[EVD*F.R*!EB.@'TJC^P)\'H?A3\"+6_GB\O4O$'_$PNF9=K;2/
MW2'_ '4Q^+,>]?F9_P %(/VGI?VG/VDM2F@N&D\-^&RVDZ0F?E9%8^9/_O2,
M,YZ[1&#C::\RK56783VF\Y;?UV1^D8'+:G&G$_U23_V:AO;31?K)]>R/*?C#
M\7?$'QW^(.H>)O$^H37^K:DV7=_N0KVC10<(BYQM [9Y.2>98]>/SI/TXZ>E
M:VE^ M<UOPU>ZQ9Z/J5UI.FD"[O(K=GAMO\ ?8# ZY]@<U\/)SJR;>KW9_6F
M'HX/+*$:-.T(*R2V79)?H9=&VFM($."R@^GIVHWX(&5Y..O?TJ.5G;[2'<=B
MFGK5C1M.N?$.K6]A8PR7=]=NL<-O$I:25F.%4+UR3T%17L#Z?>307"F&:VD,
M4J.-IC8=5/N.GUI\KM=HCZU2YN7F5][7UL,4[) P9E8$$%25*D<@@^H//8YK
M]-/^"5W_  40N/B2;7X;^-KYIM=M8R-(U"=OFU&,?\LI#WE4#(;G< <_,.?S
M+*\U=\.^(;[PEKUCJVEW4ECJ6F3I<VMQ']Z&1#N5Q[@]NA QW->AEF85,+4Y
MEMU1\5QYP7A.(<OG0FOWBUA+=Q=MK]GU1^JO_!2#]F(202?$/18=LBLL6L1(
M/O#.U9\>J\!B.HV_4</_ ,$XOV@&\ _$A?"-_,PTGQ/)BU!/RP76/E'MO (/
M^T%KZ@_9;^,.E_MC_LO:3KMU;PO'K5DUEJ]D,E8[A5,5Q'GKM)R5) .PJ>]?
MGK\3? ][\$?BUJ6C>=(MWX>O_P#1K@?*Y56#PR\=#M\MN.C5]9C+4JD,92VD
M?S;POS9E@,3PWF2_>4;\M]U;1?<[?)GZT6<Z7>&4]"1@]01ZU:9MHYKB_@7X
M_A^)7PIT/Q!$JJ-2M4FE49)24@^8OOA\UUDEXKK\I/UQ7T,9<R3[GXC7HRI5
M)4I[Q;3^1P/[5O[0.G_LQ_ ;Q!XTU#;(FCVQ-O"3_P ?-PQ"0Q_\"<@?3/O7
MX:^#_"WB[]LW]HF&QBD?4O%?CC4VDGN)"2D9=BTDK>B(G/T0 5]I_P#!?'X[
MR7_B3P;\-+*9OL]C$?$.J(K AY7)BMD(]55;AB#_ ,]8SVK9_P""#7[.<4'A
MWQ)\5-0MU-S=3MH6CEUX2) KW,R^S.4C!'0Q2CHU,R/K[P=X8\"_\$ZOV4O)
MENH=)\*^#;)KJ_O'7]]>2DY>5N[S2OPH]2JC@"OP]_;Q_;O\5?MV?%B;6-6:
M73?#EB[IH>AK)F'383P"^.'F<8+OTY(!  %?5G_!P%^V/-XO^)FF_!K1KEET
MWPRD6J>(=A_U]]*F^" ^OEQ,)#VS*HZJ<?G&.!0 =J*,?YSTHSB@ HHH)H *
M:W(/_P"KWIP.:* /T4_X(V?\%2+GX8>(=)^$/Q U%IO"^I2+9^'=3N9/^0-,
MQQ';.Q_Y=V)"KGA&( ^4_+]L_P#!4?\ 8A7]K/X+W&J:+9H?'GA."2XTHJ/F
MU&,#<]F3CDO@E,]'P. S8_!"2,2(RE=RL,'V'Y=>_L:_>C_@D!^V%-^UG^R?
M8G6+MKKQ=X-<:-J\CMNDN0J@PW#>K/'C)_B9&/&<4 ?F3^P'^U5=?LB_M':3
MKS23?\(]J+#3/$%MC_6VCL,OC.=\3'S%[_*P_B-?N]I5[#J%K%/;31W%O/&)
M8Y(R"LBL 05(X((((]L5^*W_  5N_9NA_9^_:XU*XT^'RM$\:)_;5JBC"122
M,1.@_P"V@+8_V_I7Z%_\$?\ X]/\:_V-])@O)FEU+P=,^@W)8Y9EC"M"?^_3
M+],$=J /J65L$5X=^W5\?V^"'PBDCL9@FM:X6M+,@_-$,'S)?;8/U(KVRXN,
M%2O3N3VK\W?^"@OQ4;XB?M$WUI&V;'PS&-,BR?D$@.Z5_P 68*?7RQVKAQ^(
M]E2;6^Q]EP'D4<SS6-.HO<@N:7HME\V<M^R[\ KC]H;XK6^CEG33+4?:-3F'
M5(01E<_WF.%&/<U]S_M/_M%^&?V(/@3_ &E<6\>RRC2RTC38"%:ZD"X6-?[J
M@#);LH/?&</_ ()Y?!R/X;_ >TUF>-EU3Q4?M\Q(^9(LD0)_WQ\W^](WH*_-
MS_@I=^U#+^TA^TCJD-I<"3PWX5GDTS30ARD[(V);@=CND!"D=413_$:\F52.
M PGM/MR_K\/S/TC"X&IQEQ-]13:PU#?T3M_Y,U9>1Y)\;?C=XD_:%^(=YXF\
M47SWVH7;$!1_JK>/)VQQKGY44< =>,G)-<GC-!X'KCTHSQ_O<U\/.HZC<Y.[
M\S^NL#@:&#P\,/AXJ,8JR2T20[&*",TFZC-9G987%-[4H;)_6D!W+G\:!J^Z
M$8;A]#D5^E/_  2K_P""A\_C>[M/AGXZOFN-4"%=%U&9_FOMJY^SR,>2ZJ,J
MQY900<D9/YK]N*LZ)J]UX<U>TU"QN)K:^T^=+JVFB;;)#*C!D93V(8 @UZ&6
MXZIA:JE'X7N?"\=<&X/B'+Y4*B_>)-QEU3M^3ZGZG_\ !1[]F=+%&^(&BVP\
MLNL>LQQCD;OE2<#ZX5N^2I[&N'_X)V?'EOAQ\4U\,WTB_P!C^*&"+N/RV]T/
MN$=L.!L/OL/:OIS]E?XP6/[:?[*=EJ.HQPR3:M:2:;J\"< 3*-DN!V#?>'<;
MAZ5^??Q"\)7WPE^)>J:.[NEYH=\T<<N>6VL"KY]QM/'?-?6XKEIU(8NEM(_G
M+AE3S'+\3PQF6E2EHN^C_&TOP9^NEIR"W7=R/IS4U<5^SU\1U^+/P@T'7E^5
M[ZU4RKG.V0##C_OH&NUKZ*,N97/PO$4)4*LJ,U9Q;3^04444S$**** "BBB@
M HHHH **** "H96^<U-4;G$E 'RC_P %5?%,EA\,?#^D*V%U/4'EE&>2L2$C
M_P >;]*\Q_X)=^$5U7XQZOJTD>\Z3IQCBR,J'D8<_4*A^NXUO?\ !6&^9O&'
MA&VSA1;7$N/^!(*W?^"3]I&?#OC.4J#)]L@3=WQL)Q7@R7-F*YNG_#G[1A[8
M7@.4H;S=G\Y?Y*QXW_P7:^*<DFI>"?!<<C"&-9M8N$'W7/\ JHL^ZCS,?[YK
M\]J^LO\ @L]J4EW^V;-:R,[+9:1:*GH-V\G]237R;GFOD\\J.>,G?II]Q_1G
MA#@887AC#.'VDY/YN_\ P /%-GE\F%F^]M!('OZ=>_'Y5VGP9^!&O?'?4-8M
M]#;2H1H5@VIWTVHWJVD$$"NJ%R[<<,P_#)J]XZ_9>\:?#@ZM_:6FIG1KFUMI
M/(8W N6N5W0-"54B574]LG/&,Y%<=/"U)151Q;B?75^)<LHXB6"G7BJNFC>J
MO9K^NQ[!\2OV(?#?@WP]XDTVSF\9ZIXP\+Z%9:W>W4=Q8KI<HG4N1' 56X\M
M%S^]$C#<""HX%=M\1?\ @FSX#\-^(HM-TS7/&%Q+;^)-)T6_SJ6GW9C@O41G
MD:.*W5[5@7 4R[@V00,&OGV7QS\9[KPVO@29OB$]E:6R9TA]/N#,EKOP@<;/
M--N3\JHQ,?R@ #%7_&'Q]^.VIZ6M]K>I>.%L="O%NO/FTHP06EQ;N55Y'\E5
M)CE4KAR=K@J<$8'O1K81+^"_N_X)^.XC*>):DX^SS.&[^WO=)7VZ[J/2^AZI
M^T#_ ,$^/"?P=^"7CSQ99^(/$=W)I,UI<>'8)KBV*WEE-+;PO+<!802PDDF
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M/98)XXQ[15^%XB4-NVKU';DX&.3U_EBOUF_X-MM:DN/AI\5M-9I##:ZK87"
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M]=\5:Y)XBL_#-FEU8Z7_ &-&CW&HZE%;O<!'9HW2.$! C$J&=Y452"<CSO\
M92_8<\5?M<1:DN@ZEHFGWFAZE;6.J6VHM)$^GQ3).QO)"%*B%#!(KG.0V/EY
M%>;?#WXH^)/A/KB:EX;UO4-%OXXIH!-:R;3LEC:*08P5^9&89QD \$5K?!7Q
M)\0M(NO$&F_#MO%$EUX@T>>PU>TT*UENIKS3V($JR)&KL(\D MQC=C<,G(!]
M">'_ /@CE\0=3UB]L]2\4^!O#O\ 95G#>:A)J5U-$ME]HO9K2U1_W?WIF@>1
M>P0H3@NH-:T_X)(>-=-\()KVN>)O!=G;QW4A;38=54W]]90WB6TMQ;,4:)L[
MLJ"2>F1DA6X.V^.G[1O@GQ3<^.(]0^*&G:AX@$/AV;5Y--N%CU!X"4AM-SQ>
M6\T;*P50/,5MV,$MG8\,I^T]J/PU\7>&X6^)EKX=\%QIXAUO3-0M;B"2S$TQ
ME5]DJ>=^\DC:38ORL$D<@X+4 =]\=O\ @D-J?PS_ &C;?P99>,_#^EVOB'^T
MKS04UR=S=S65I((U+O%"L4MQ)E2(HAO 8$JM?+GQD^%>I_ [XK>(/!^LJ!JG
MAV\:SN"(WC5R "&"N P#*589 ."*Z]/VY/B\MZ;C_A/M:DF:]NM1W2+#(//N
M0//8!HR K[02F-I(SC/->?\ C?QQK/Q+\7:AX@\0ZI>ZUK>K2^?>7UW(9)KA
M\ 99CZ   #       H RSTK[I_X-^?C#-X)_;.OO";R;+'QQHLR"(GK<VO[Z
M/_R'Y_/7  Z5\+&O?O\ @E7K4OA[_@HO\([B%F5Y-:>V..ZS6T\+ ^VUVH _
M1K_@X&\#PO\ LV^$?%S1R27'A_7?L#E%'^INH7RQ/;$D,8'NYKY*_P""5W_!
M230/V.-3\:V?B#2]>U72O$45K/!%IZ1,\,\)=2QWNHPR2*"1D_NUK[]_X+@6
M,5Y_P3/^($TBJSVMUH\L1_NL=6M(S_XZ[#\:_#OP8=NM?]LC_,4 ?HM\4?\
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M%?1]P,?[-Q..?QRG:_DDOU=S7\!:;I^L^--(L]7DU*/3+F[CAN3IUN)[LHQ
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M>6G_  33\874>N2'Q'X*C@TF]^P03/J!6/5)/LD=UMB;;_SSD3AL8.<]*O\
MQD_X)XR>!4\%W^G^(K#3])\70V,$<VNW8!2]FB>6;+QQ*D4"A0 7&6/ R<UY
M?X8^//Q6\1W^N:?HVO\ BO4KSQ4[3ZC:V49NIKMO+V.ZHJ,RD1@(2@'RA5Z
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M_P %))/$OBRWO&\/ZE'9W#7TVIVT^H1WRW+7<4220!;B)T^R$0@>5MY!/*X
MK//_  4-M_[=M9%\,?V?:PZOJ.JS6MC=0E)8+J%(G@=)(W1XR$^=2NT@X!7
MK:\!>#_@SXG\._#*&UT6PUKQ%J5_9V&J:38R7-]>7$#PO'<W4FS:T;1-ME9=
MNW]V0C.F7%/X\^'?!W@;X2?%'PQHT=NNG>%;W0;'3+LR,7U+6ER+^=02<%K<
MOG&  H[@5SU*F+474=5:=EY7[>1[F#H\.2KPPL,!4C)M1U;6DFHWT;_F=O*^
MNAX1\<OB7;_%_P")VH^(+71K;0;>\*A+2 #RX@J*O&  ,[<[5 49XKDUX?\
M'_/ZXI&&3_M'UKH/A3\.+[XO?$O0_#&GQR37FN7D=HJQCD!F&YO8!03GMBOF
M??K5DWJVS]YDL-E>77C[M.G'J[V45;=_J?L7_P $Q_"3^#OV'O ,+%E^V:>=
M0Y&#^_=IL$?\#K\V?C7X&B\7?%SQ=K4=\WDZEJ]Y>*/+SPTKM7ZL_%#7;7]G
M?]F2\:&188]!TD6MKC@E@FQ /<G%?F]\'O!<GQ)^+'A_0O+,QU2_CBF [QA@
M9#[?*K<^]?;9M37LZ6'ZZ?Y'\H^'..G"OF.>;)WU^;;_  L>O_$/_@GG>?"/
MX"+XD_MQ]0N+&RM<V,=K\SLYC3:ISDD;^..<5YI^U+^Q#X@\!?L5:]XXUYC8
MWFFW-FZ:>,%X8I)EBW2GLV94^4=,\^WZIV]A'';1IM&%55Z^G3\J\_\ VN/A
M*WQN_9@\?>$[>%9[S6]$NH;,'M<B,O;GZ"94->E3RNC&HII;'P6-\2,XQ%">
M'E4^)N\E9.S^RK;+SW/S+_X(4>*H]&_;,U.QD;YM:\,7447^U+'/;R!?^^%D
M/X5Z!_P<G^#YI/#'PE\1+&WV>VO=1TJ5P.-\L<,L2Y]2()N.^#Z5\A_L/?&5
M/@'^UKX!\673M;VNG:H(KXNF#%;3(]M.2OJL<SG'JH/:OU<_X*X?L[2?M,?L
M)^+-/T^!KS6O#HC\1Z4B+O,LMMN+*H[EX&F08[N#7I:=#X&4G)W9^!MA9MJ5
M_!;QM&LEQ*D*&1PB;F;:,L>%&3R3P ">U=%\0/@UXD^&WB75M+U#3I+B31)9
M(;JZL,WEDK1A=^V>,&-@-RY(.!D9ZC.)X4UM= \2Z5J>V26/3[N&[(#;=XCD
M$FW/\.<8R1P3CV/VSK/_  6-COF\20VOA77K33?$VJZ_J%Y9KK*>3=+J-@+6
M**50N'\F0>9SWZ '!H)/BD>$M8=+-ETC5F744>2S(LY<7B)]YHSM^=5ZL1D*
M <XP:5?!NL3ZE=6*Z-J\EY9P^?<VPLI3-;QE=P>1-N54J0=S #!STYK]"_@U
M_P %BO#/B'XI^%_^$DTS4O"&D07,>H:C=W-_-J.GZ2]OI)LD@TRVBA+VD,K
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M!,[N 0W# CAA[COWZYZFM?P#X U;XI>-=-\.Z#8-J&M:O-Y-I;*0ID;!8]2
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M3,UCC\53I3NFW&.GPVTNC^?+]HWP?-\*/C]XPT$;Y&\.ZO/;IO/+;)."?<@
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M]H@_#OPG-)XL,>B1ZS?ZJUN;6TTR.1Y5 E;) )\EBJYW/S@<&M?]B?X::3\
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MNI2-+\16T'[B=.R3#_EC,!C*DD'!VD@@T >  *1V]J4C-(IW'IR>WI2ALB@
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M,"MG8I_>D;!Z GY1\S9& >WZ_?LO_LR^$_V'/@S)9V]Q&LB(;G6-8NB$DNW
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M#&WS#2-84R1K_P!<[A06 '&%=&/7+GC'CYG\6? ?QGE6UCPKK4!]6MY6 _\
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M^>P_B7^,<C##YOT*J.YA,ZJ =N#GD4 ?@_\ L8_MR>,/V)/',UUI*_;]#O)
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M)_A5XCNBK;=UH8ID/T(?I6IX-_X(^_M%>-[CRX_AS>:8#C+ZE>06JC_OIO\
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M3M?$WB:U:/P[:XFM+60?-JC_ ,+-_P!,1R>V\X'W<U]\6]BUNBH%4*H"@#H
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MI8E0Y=7U['DYW!RP[E?1=.Y\+6PD%V)=WE2$J$,;8((.1R/0\_7!Z@$?K/\
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M_P""8_[07Q)T;1M*\)^-/"?C&^\*W42_V!XB;3II([6%@-D4DFW#0=-C_P
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M%%!F%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % &VBB@
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MC\C5K_@JI^V]>?\ !'#]F+X>_"_X4VEC;^-O%EO/</J<\*RBQCB\H3W3(?\
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MJC[)/_!#7]J$*?\ 1]#^G_"4]O\ .*]W\#_\$XOVJO"_@[2]-3Q%?6RV-M'
M(H/&LZ1Q[5 PH#  ?2OR_P#^'O'[4!_YKE\0/_ I/_B*!_P5U_:@;I\<O'__
M (%)_P#$5O6P>:5HVGR67DR*4,'3UAS+YH_53_A@3]JP?\S5JG_A<7'_ ,71
M_P ,"_M6?]#5JG_A<W'_ ,77Y5_\/=OVH!_S7+X@?^!2?_$4?\/=_P!J#/\
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MWI^3+IRGAZ\)0E>,W:S/V04D+@FI(_N5''R!COUJ8=*^1ZGTX44450PHHHH
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M\2:)'!<);>(K2.U26>"58IXQ"@8"5T; V*& #D8&<!CZ=6,I^U@E&=M?T?\
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M#'_E"[^T)_USUW_TUFNL_P""*/\ R>+JG_8I7O\ Z5V-<G_P0Q_Y0N_M"?\
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M)KXP^N%HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC,1COI-61M1$L7AY-*2XE*21_:6,R"9XG<1RAB'SDY\A\/?L"V?C3]K#X3>
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MFBJ'Z[?\&H/_ !^?M(?]@WP[_P"A:Q6]_P $]/\ D_WPI_V%;O\ ]%RU@?\
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M<>+?^B8V?_@9-_\ $4?\/N/%O_1,;/\ \#)O_B*/[2KWO["/_@2_R'[##_\
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MU.G23Y8=6C[I)R*EC^[4<(WY_P!DXJ9>E?'H^I"BBBJ **** "BBB@ HHHH
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M] ",9V\]B?7'-?P^QZ=;N,?9X_P45<AT6V S]GA)_P!P54:+>P7/[>9K7[1
MT;Y(88)]:((6C!#?,6.2<?2OXBQI%NRX,$(SVV]*4Z#;L?\ 4QCW J_JLB>=
M']N:6BI+YGEKNY)('>E:3<VW:W7KMX_.OX@VT>WC/_'O"#Z[!Q^E0RZ':M\O
MD0\?[(J/8M:A<_MXNYYH)F41NR[/D(C+!CSD'%$*+81M((IMQ7)559FP/X1^
M9K^'Q]*@!V_9XO\ OCJ*<-(A5L_9XAD8.%%9\K'J?V\7#W5_.O\ H\Z0[<GY
MBK>W'3\/>GZ9H#0QJT^V2;;R6&>>_P"-?Q"IID"=88QGK\O:@Z= Q_U,7_?(
MJ];&:HJ]V?W#0:>EN[-'%&C,/F(7EOJ:L!3L;U[5_#UIWA];ZX\NWLA/)GHD
M6X_RKH1\&+^.-7N=-6UC;N\8S_*JCAYRV%+$4H+WG8_M0&BS'RXVD3[*LOFX
M"8?AMP7\\<^@K0VLS?4?E7\8O@K]GFRUZ[VS A>^V,#^E>B6?[)GA>V&Z:/<
M?<@5M]2DOBT.3^TZ?V=3^OA@<#&[\*:59@?O>E?R"ZW^SGX)TRS:62.*$9V[
MBY/-<M_PSKX=\26[3Z9)%-$I*$ANA';#?6FL!-JZ9+S:G%VDF?V)ZI-,Y:&.
M&;&<%]IP>AXQ]?T-5-'TR:>Y^T74.WJ%0H3M_P X_6OXW-6_9H:U'^CM"S8^
MZZ#_ #TKD]<^$VH>&R6N-,5D'/F1H&'\JSG@YQU8Z>*H5I74C^VC[P'RMUZ;
M:CN)FBMS((Y&9> H0DG\*_B#AL+=6XAC7G/W!Q_]>EFL;?R\>3'D<C*YK%TM
M-ST>5[G]MNDZ?<37;W$R[ 6WJ&4AB<$<\]!D\5KQJ59J_AV-A;D\PQ_0K0=.
MA'2WA_[]C_"DJ+0HQY4?W&4TOCL?RK^'E=)ASS;P_P#? _PKJ/"6@VK,H-O#
MU_NUM3PSF[7)J55"/,S^U[?@=_RH\SV;\J_C_P# ?A6S"KFWA_[XS777-G:V
ML'$,/&3_ *L5T2R]IVN>1'.HM-\CMZG]:6_C^+\J-_'\7Y5_(#XBN[?++Y,/
M_? XKSWQ289=W[F$C_=%.66M*_,/#YQ[6?+&#/[02V/7\J7=]?RK^(?4K2W>
M5OW$)^J=*IKI]OG/D0\>BC_"N1T;.USV%*ZN?W"9Q_\ JIN_V;\J_B3T2UB1
MQ^YCQ_NBMQ1;[?\ 4Q>_ K6.#YNIA4Q'+T/[4=WL:-WUK^*[[!;RG_4Q_P#?
M(K5TOPU;R;?W,>?7:*UCE[;LI'/4S!05W$_L]S_G%&?K7\<=CX'MY8_]1"?^
MV8IE[X%MXL[H(?\ O@"M?[)E_,<'^L%+FMRL_L>W?7\J4'-?QAZOX7M8%_U$
M/UVBN3U72K:-S^YBY/9:QJ8%QW9Z.'QRJJZ1_;1FDW?7\J_B,&D6N/\ 4V_X
MH*KMI=NK8\B'_O@5A+#-;,[.=']OA./7\J*_B!;2K5E_X]H_^^!_A6?>:5;1
MR'$,/_? K*5-K<I.Y_<;NYZ-^5&__>_*OXB/#^E6HVGR8_F_V17<>'])M6V_
MN8_^^1731P;GU.3%8SV*NU<_L^\SV;\J7=[-^5?Q_>&?#EI,%W00[?=!703^
M%;%(O^/>+_O@5K++^5V<CRXY\GM#\?\ @']< DR/XORI=W'?\J_CL\3>%;-0
MVVWMP<?\\Q7$ZOX*AN&)-O$5[C8,&B66R2T9OA\YA5>JL?VE9XHS7\35[X%M
M 3_HL.1_L"LV7P1:B0_Z+'_WR*PE@YH]*GB(25S.M(-Y48'K6W!:+&JC'-8%
MO=>4<'JO3%:MIK2[/G^4CO3H3AU-*E^A?\D?W:HZEIJ21$JH#+^M3_VM&!UJ
ME>:L)5*K6\I1:(BI7U,W+-_#[<TX9QT/X5(G7%*RX&:X.0V(6.!T-!+8ZT]S
MA?\ )HCMY)1\J,WX4<KZ 1@<]:=BK,6B74P^6)J>?#EY_P \C5>SGV9//'NB
MJLC*1WQZTY+LH?2I)-(N8AS&U5VB=&^96'?D4FI1W3#F3V98&I,!WI&U-R/O
M5 %8]%II&WKQ^%+VDAV)-[2_>YIQ&:C!(_K3O,'O^5 P*X%3VT.]Q]14&<__
M *JEBGV29P>*TB^X%T0XH>%67E:9'>H_M1)=JG\6:Z.96,W<ANH/)Y' -5E3
MSFXZ4^\N_M'R_P -1)(8VS^?M7-*:N:*YHZ="T>TKQ7J'P!^#$_QRO/$X/B;
MPKX0TSP9H$GB35]6\0&^^QVUHEW:6APME:W4[.9;R$ +$1C<20!SY59ZBL Y
MY#=:]A_94_:LF_9=D^(NH::LHUGQ=X-E\-:=<+!;W$=C.^I:;>>=)'.K(RB.
MRD3&TG=(A'3(Z:=1):,QJ4^;<Z'QO^Q[\6_A!J/B&6;P/XDU?1O"]S';7NO:
M)IMS?Z.3($:(K=)'L D66(J'V-^\4%58[:](\=?LH_$?X%2ZYI?C;PYK^@Z]
MI/\ 9H@TV31;Z7^U4OGD2*2*=(3"!OB= '=2[JZ(':-P,/P1_P %"_"ND_LX
M>--(\1>'?$&M?$[QEHOB/1M0\2$VDRZHVIQJL,\TTJFXB$"@H8(=J.,.3P4?
MH?!G_!5'PI\-/B_K7C;1/!_B*:^\4:AX7UO4+"[N;406]WIJSQ7202(&)1XV
MC:)I$R) 0R[0N[2..E%V>QPXC+*=57ZG,ZW^R'\6-8\:W/AFS^&'Q$F\2VT$
M=U-I">'+LWT,,IVQ2M#LWB-VX5B,$YQD@BN9E_8O^+S?#+1_&%O\//%UYH7B
M#79O#5C);Z5/+))J$3^6UN45-P<R;D48RSQN@&5;':_&7_@HUI?CWX9>,/"N
MAKXM73=;\/6NB:4UY;V&GC3MFK/J,Z&&S54\EBY.,N6E+N=H;:.G\;?\%$O!
M/Q(^*^H>+H]-\<^%]67XH:_XZTN[TA["26&TU8%98)5F4JTJ;4#)RDL<DJ$J
M2'KH>(<]58YL/@50C9ZGCOACX$^(E\;>)_#?B+3=<\*Z[X3T:[UF^T_4-$O6
MNH!;Q+*8Y8HXF> ,K+^]F"1("&=U4@UL^._V=O''PGT?3[[Q7X+\7>%[3524
MLI]7T>XLHKQ@ 2(V= '(W+D*3PPK97]J?P3H?QL^(GB#PQX2NM#\/^+O E_X
M2L]/B:*,PW%S8Q6YNV1<I$C2JTAAC^6-7"J6QD[G[0/[;VG_ !O\/^/+..PU
M:W;Q=XOL/$5NUW,L@MHK?37LGB;U<DH01\NU0.,5O3J2ZV.+&8>^L+D\W_!-
MCXO+<7]K-X-\00:E'X4@\7Z78IIEQ//KUM+?:?9B&V54^>9&U&)W09*A&!^;
M KR_3/V=/B%K%GXDN[7P)XRNK7P;*8=?FBT6X>/0Y "2ET0G[A@ Q(DQ@*<X
MZGU#QA^V7X5U3P)XACTW3=>L/$'BCX66?P]OG\Z'[)%+:ZEIERLZ%<2>5)!8
M3(Z-D[I5&-N37I6M_P#!63P_K&D:S'#H_B/1=2BU?4=7T:\LX-.N)9S?Z=9V
M<\5PTZ,86!L@1+"6+I,RLH**3'M)J6I,*-X=;G@_P^_9(^(GQ"^$%QX]T/PC
MKNL>%[?6HO#YN[*REN-UY(A=5"HI)'W%)[/-$OWG K/\5?LT_%*PM]=W?#7X
M@(OAFTCOM7+>';Q1I5O(F^.:XS&/*1D!8,^ 5YZ5T'[.'[8?A/X-^"+#3?$&
MC:S>W&A_$'0O'=A-IS0;)#8"XCFMI1)\V'CG)1UP04((P<C2^%'_  4NM_!'
MPJ\2:+=6?B2VURY\5ZOXMTK6+"#3[J>2?4;06TL-R]W&[1D!%)DBW,5DF4K\
MX8.KB91T2-L+EO/)5)'C_A+]ASXR?&WQGX#TG2/AOXRC'Q,N4M?#5_?:/<VN
MGZH77>)$N'C\LQ!,R,X)545F/RC-<Y#^Q7\9;C3]1NE^$?Q/^SZ/*UOJ+_\
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M1USC-NOV,_C!8ZAK5I-\)_B5%=>&[--1U>%_#%Z)-*MG#E)IU\O,4;>7)AW
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MU;P^$[JS\0#7D:XNM&CEO+%-<@E@U*.VE)S'YJ2O@G<RX #!6=6K4#KO"_\
MP2=^(GB?QC=:1'JWA2/[+J=Q9K=;KR2&\M+;2EU6XU*%8[=Y9+:*WFM5(6,R
MO)>0HD3'?LT1_P $G?%>G>(]0TG4_'?PVT6XAUVQ\.Z7]LGU$?V_>7MBU_:)
M B6;.BR0C!:X$/EOA9 G%<1I'_!0_P")\FI^ I/MNDZBGP]\/77A2PM)]+6:
MWU'3;E#%<0WJ9_?^9"1$7)5@L<6""JD7=+_:;\?1:G97EMI_A7P[:V/BFU\7
MVMM:Z4(;>WO;:U:UBPF_+1^63D,2S,=S.3G.U*G)['/6Q$([GLWP4_X)^>(1
M\.+(MKWA.W\27VD0>(I/#LD]Q_:-OIDTXACNW=8#; $$2^4)C,(V#>6 03M>
M&?V&->\6^*)M,C\0>$[<V>OZGX;D>9[J0>?80B:9XXHH6DF5E("1QHTK'C8.
M:\]_X;;\;:I\,4\.1ZKIMA>+IR:-_P )!:Z1#'K']GI,9X[+[1@GR$<@ ##[
M J&0HJJ,7XE_M[^-O$&N6LFMZ#\+=2LX]5O-?,,7AB.&WU#4+N-4N+R;RG5_
M/;8IWHR%"/DV#BO1_>11\['#T*\W?<]$^#WP'\/>+O'7Q.T/7/$&E:;'X+\-
MZCJ46LR&YALH9;6[MH?-D3R3<&,K(Y$7D^:3L7RRYV5CZE_P3X\5ZKXIL[#4
M/'/P[TA?$VIV&D>$+J\N+XV_C*ZOK:&YM([0QVK-"KI<0*9+Q;=(W<!RA#!?
M-M%_;4\90?&7QMX]N/\ A']:U[XB07EKK\.JZ3#<6%]#=31RS1?9P%15)B0*
M5PR#&TJP#"ZG_!2WXFZ=XKFU&6'P3?7EGJ=KK&A)>>'+>:'PA>6EO';6DVF1
MXVVY@AB@"*0Z$PQLP=AN,5:T[:,ZL'E]*$KR6IK?&?\ 8ON/"_PR\*^(='N8
MK!;S3/#EKK=OJ$[FY75-7EU5%,856 A0:7(),MN!9<*^3CF?C5^Q!KG[.OPQ
MU#Q-KGB;PS>"UU^^T V5A%?SR2RV=[+:32>?]G%K'EXBZPRS)<-'AQ%MR5I^
M%/\ @H9\0O"EO;VK0^$M?M+/3=,T^.UUS1(M2A\S3I[B>RO"LN=UU')=7'SG
M*N)W5T85C^./VW/&/CSX<>,O#=Q8^$;&#XB:H=5\27^GZ.L-_K+?;3?".27=
MCRUN-KKA0_[M%+LFY6X_:R[GL1HQ.^\*_P#!/?4O$/\ 9/\ :7COP5I>H/::
M3KNN:$/M\NK:#HVH7,$$5])MM&MW(^TV[&&*265!,C-'@,5J^/O@[\)]!_X*
M+77PVAL_$NL^ V\06OA:WF\/>)C8W4=P\T5N]P9]0TN1FV.\F^(VZJ63$<A3
M;(W*Q_MZ^/9_!UEI*KX6CNK>ST_2[C7(M%A76M4L+">.>TLKBYQF2"-X+?@!
M7<6\2NS*N#RH^+6J7GQJ_P"%@S-:#Q'_ &XOB/>L.+=KM9Q<*=F?N>8!\N3Q
MCGO2]Z;*TCHCWP?LB?"GQG-\6X/!^C_%35]>^'FH3Z7:^%U\;Z3+JTT$*WGG
M:T,Z3%]KMT:&W5K&"-94!D<W."H7S#]H;X/_  \_9\TJU\(W1\?7GQ/7P_HV
MN7NI)>60T&.?4;&WU 6"V9A$^(;>[B4W?VMM\J.!;A"'IG@;]L;Q)X"\8>(?
M$>FZ#X'_ .$HUR_NM3CU^ZT&*XU+1KBY1TE>SE8_N\K*V P<(2&7:W-9/CS]
MJKQ-\2/AK8^'=;TSP9?W%CIMIHD?B&308/[?EL+552VMGO,%F6*-$0/CS#'&
MB%RBJHB5.2-.8[CX6_\ !/#QU\3_ ('Z+XX\-WNBZLNLZKIVCPZ1]GU"VNA/
M?WPL;;$\ULEG(&N"BD13NR!U+ 8->S:1^P!IEYX5\,2>'_B5X%U2^C3Q)J&N
M:_'/J":/:VNCK"945'M%N/,4-)@K&PE 4H6RN?$?"_\ P4/^)V@?"S0_">GS
M^'[-/#::;%I^KPZ1&NL0)IU]]OL5^T ](;D[AP"P.&9L+CM--_;B\=>/S-;G
M3? ^@Z;-IVM:?):Z+X?AT^W6+5507SX3^-]@(8DA>0 !@#LPZGT/,S'V?L_>
M/9+[]B.3PSX[TNQE\5>!/%T8U;08-0T[2]1OK2<6FKEA97)EDLL1QR%-K;0\
MT)=-\'S5R>L?L<W3:2FJP^)/!LUQ-8'Q"OAF.^N_[4_LE=3-A)*TQM?(4I*#
MD;_,95+K&P!%>+ZQ^W[XXTWXE:AJVFW&B"28Z%&#)9!D(T9_,LCC/9OO'^/V
MK)3]M?QPVKK>B;1_M$?A^3PP,V(VBRDO7O6'WL^89F/S=EXQWK3V]12M<XHY
M31E!29[WXZ_8"^P^-(;J]\2>'/"_AW5O'DOA"&TC?4=9GT]4OUM&=[B*Q$60
M6RJS>3-(N'$6P@UAR_\ !+WQ9XYU'QU<^"_%WA76/#?A76[_ $+3K^6VU.W.
MNW=G;"YGMX]UH!#)%&Z(SW'DPO(P6.20$,W#-^WKX^U32/$4=O!X3TG4O%6J
MC6-5U:QT6.+4;V5;T7T:M(2RE4N%!4E2X1$CWF-50'BK]N[QCKFG^*K6ZT+X
M=S:?XHU";66LG\/*UKIE_-;+!/>6J%SY4DRHK.&+H756V JI"G*JU>YU4:-&
MF[&AX6_X)J^+/&.M0V-KXV\#O-;^%-)\8:RL4.K7K^'+/5+6VN;%+A+>R=Y)
MY$NT_=VXF*[69L)M=M'P9_P3DU3P;XF\56OQ+\5>%=)OM#T+QQ=:9H%K>W$V
MH:Y/H6CWTZW5O+' UL;874$)VR2H\D0DVJ0"1Y'HW[:?C;PCX]U;5VA\.ZI#
MKGAW2?"NIZ9J6G>?I]_8Z79VMG9AXPX<2QQ6<!\Q'5BV\Y 8K5OP[_P4*\<:
M#X1U/0X[+P&\-_:ZY86UP_ARW^UZ-9ZS;RV]_:V4@P;>&1)6*J@^1L!6",Z/
MY\JE3FLV>HJ<>B/+;?5YI-J@_>]>]=5HFFO,BLQ5L]JX>&X#,K*P/<$'WKHM
M(\0NH56:N_#U%?WCAQE&3A[AW^D:?M<*< UMP:62?O"N*TCQ"L+;B^:U8O&&
M!]ZO3C4TW/D<1A:SEJC2UK3E@7G!KB=?149JVM2\5FY7[W:N8U>_$V<UE6J)
MH]#+\/4B_>,2Z'SXQ5&X3Y:TIY5S56XVN<5YLXGU%/1&+)N\\JN?I5NVTV2?
MEF85/;V2B7=ZUM6ULJ(.._K6-.C?<JI5Y3)7P_N'<TV30M@Z?I71+%QZ4&!7
M7FMO8Q.;ZR[ZG(W6EM'^=5WC$;<[JZF^LE_6L>XL-S9YXKGJ44GH=5.KS(H)
M:[AGH.WK3OLBCNQJT8&.T#I4;(RMBL_9V*N);6 +;O[OKWJ\BJ1]T#'%5(I?
M*_W:<EZH;ALUI#E6XK29:QGM4,T?E\KZTU]12,=?P]*KW6IK*/EJY5(A&,AT
MQ_=_Y]ZIELD_RITL[2^U-/%<=2I=W-#T3PX5.GVBKPNSGZUT$'W/Q]:Y+X;:
MK'?6_P!DD/[Z'E!_>'I73H6&[ [\CT->]AY7IJQ\KCJ?[UQ9S>O:YK#RR%O-
MV[CG!K NO$=TC_O'F_'-?3OB?X4V["3$:\L2.*\Q\7?"WRY6Q&-OTK!Q=17A
M+4WIXJ-*7+6@D>5CQ!)(<^8Q_"K5M/-,WWF7W-=79_#G/\&TCVJZW@%8E^9B
MM$</5^TSH>98=:)'.Z:A##>^<UJ"V0KQ]:+O1X;"3=N^9:KIK<</R[5+>_>M
M.7EW,I-U-8%?5].\Q,C<*YF^9XSCYJ[+^T5N>R].E03V%K=C#*O\JSJ4^;9G
M10Q#IZ21QPWG'6K,$# !LUT/_"&M*_\ H\<K9[!":O0?#?4Y8LBPN?Q3%8QP
M[ZG5+'4NH[P-KLVF7<:[FVYKZ!^'OB(7,"$MVKPFQ\$:CI\RL]K,H7U%=GX<
M\7-HD.)$D7_@)/\ *NQTG.GRGS^(Q$8UU4I?,]WDNXY8><'BN*\<6<5S$WRK
M[5S%Q\8HX;<_O!P.^<US%]\9OM=[MW*R^YK"GA7"5[FF(Q7UB/+&)7UCX>#4
M;HMY:M^%8>K?!O,181[6Z\#I7K7@K4(=85=P&X_G^76NN_X1J&Y@SL7\JUJU
M8+2:,<*\0U[DCY!\0^ +C22Q7.U:Y^2,Q/M9=K>E?4GCWP/$5;:B\^U>%_$+
MPJ+*9F5>_I7'B,+'EYZ9[&!S&4Y^QJZ,X^BF[O\ Z]*#S7F>1[ ^$Y+?E5I"
M#GWJHL189Z59MT9QSZUM3O;0"[8.$7EA]3[=:^N/V7?V4_#?Q _9XL?&MOH_
MBC4/%>CZY:WFI/=SFRTFVTX:M96@DAC>U9+[+3F.3;=Q/&[J!%( 17R %\D;
MO[O7G'Z_UKI-*^)&M67AZ/1X=;U:+25N%O%L([V5+5;A>DPB#!!(,\/@-UP<
MFNN$CGJ1;6A]_?$3]BWX8?%?XK^)_$WA_1?'4.GZ;XE\>V6I>&[6_MI+[7KC
M1(=/O(UT_9:XMA*NHE3'LG:-;8L"_P!U>;^)_P"Q[\*/@C\/]6\7:UX?^(MT
MLEWX16R\.7&O6^GW.A?VOIM]?7%M?SM9.SR1?8U*D0Q%EE!95S\OQOIOQ3UJ
MSO8;F'6]6AGL[I]0AFCOI=]O<OLWW"L&^65MD>Z0$,0B DA0*VGNO%6H^$KC
MQ7?R:U=>&=2UHV5S?W$[R6]WJ:PF4H[,?FN!%*6).6VR'^]ST12VN>=4C-7:
M1][_ !9_9 ^&NN>+_BOX A\&ZUX!TVZ^,4?AS0-]VDLT-T^GZN+$QRR6R%+&
M>X6W'D@$A2I\U\!J\D_9E_8O\.^"/^"DOACX?-I>KZ[<:7X1U"S\6631Q7DG
M]NOX9OI;RUM(S& &MKB18$5][">V+;N0!X[\/?BKKY\;>']8FOIM<FT74+2_
MAM=9N)KNTEDM7#1++$SC<B_=V@@A"R@@-7JGA+P-XV^*/B3Q#KVBZ+XP\4Z_
M*USK.N7FD:=<WD\1G9VN)YFA1BJN7?<S<$,0>.*JI1C'<XH9A5?NQ1]&?"7_
M ()I?"F/P_;^)M3T_P =Z+IMQH^EWTGAB>],^LZ2UW<74+2R31V+-)'LMP\8
M-M%O,B@LO!;IO$/P(\!W7[.-CH]AX7\7:S;>"=-U7Q!+8Z5/;VNK>*Y4UV/2
MED938// (TF$L@/FB-4\LQ\LX^2;5OBU=Z#J7Q+TG3?B=<Z3"&CU#QA9VVHM
M;*HVJRS:@H*X'R##/C[N:YBUA^)&A^!+#QU8Z5X^L?"]C*UI9>)+6SO8M.MY
M)"5:&&\4>6KMN8%%<,VXC!YRXX><_M'++&0CJH7\SZI\9_L,_#+PSX@\-Z#<
M7'BRUU3QQX['A>UN+C4((8O#EN;+2[I_M,7D%IKB-K]HRH,8)VL=K*$?P;]M
MGX3^!OV>OB3X2C\.P>*Y--U!9SJ^GZQYL4L#0W;PGRKF:S@#*\:\XA81.K*2
M^ :\2D\8ZMXGU"UTN.YOM2N+R\WP6WGM)YUS,54NHSCS)"$!;J<+D\<9/Q=\
M9Z]?>*KRQ\57FL76M:6[6$\>J74EQ<6IB8HT1+L6 0AA@' (]1QO&+AO(SA%
MU9? ?H%XN^$OPML?B-\5/!=[\/\ Q;X9T&\^,'A+PMI,-KJL*W5J;V/6XQ=1
M336>?LA"HZP!&WF #SL$,O*Z/^Q[X)\&?"/P7K%YK/BR[\6ZXZ:C:7ME:O<Z
M8K1^(I=,:T:(V4D*LD=ON:62XP)'"&$H5W_G_J7Q3U_5)(GG\0:Y<?9F@:)I
M-2F;R#!N$!4[^&BWL$.?W>XA<;B*KP_$_P 06^A2:;#X@UR/3+B[&H26B7\R
MVTESE2+AH]VUI<@'>1N!4<Y QSN<NYZT<OI/5Q/L3]N;PIX3^#=HL]G%XHOO
M&'B;Q1XF:?4+B]M;?3[>"QUNZM%"6D%K&OF.$5CM9(T*D+'L8*GLOP7^'>E?
M'72_A%--X/M/#GAZSNM,T;5="U3PHFD7_B/5YM-N[BS>#6%1+B]MM2GBA#1F
M;,2W,0BVKL8_#$G[,7QZ\5^#K#Q+-\+/C/J?AN^@2^LM:G\+:I+ILT-R1*MP
METT7DF.5I _FA]LF\-DYS7'^+_&WB2WG;P[XDOM:D;PO/)8C3[^ZDE3298V*
MR1)&Y*QLKJ00N.GTH=1221/]GN#O%'Z*?LXZ7-\;=,\(7GQ6^&NA^&O$5QXX
MGTO0M-A\*0>$E\4"/1K^[.EO;P10+,@OX-/MO,V^:#>M&92Q7;Y#X>^*>K>*
M_P!HSX:0_%3X;V?AJUUC4X+:>QM?#<?A)=6@-YY<FZ%(5B&QMT1<0AB$*N68
M%J^/?%?Q(UCQS?17VN:YJFK75O&(XI]1OWNGA1>0H>1B549&%SP.P/(M:KXA
MU_QM=KK6K7^LZM+(ZVZZC?3RW#LZ+N6/SG))95Y"ALA3Z&B,8O=!4P[MO8_1
MZX^!7PU\5>.=)T6^T/QAX1U3QK\5-;\$V<%WJ<9M]$M;%-,D\QD:T62620WY
M6-/D&UH_F;:?-+K_ ()@?"GXJ_&:&TL='\>3Z&NF1/JUJU[-9WFGW,FJ&QC>
M*5M+9[F-QM.U;=520.K2?+N/Y^S>+=8UMDN-4UW4]3\N5KA9+J^DGVNRQAI
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M4&YL]:KWGF%?E]*WJ5FUJ*E0C!6@-O;M8W^6IK'5%/!;\ZS-C2R;?XJT]/\
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M_G4\5T<]N?>LXU$]$=<J>FA;N8?.MY%#;=RD9QGJ/2OMW1O^"J/A7P!\2_\
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M+_A1_8MN/^7.W_[\K_A7C5M]W\3_ #JR.E8>]W.[V6%_Y\Q^Y?Y'KG]CV_\
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:\*G[FD;K6GMIWO<Y/[,P:VI1_P# 5_D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>a4.jpg
<TEXT>
begin 644 a4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $= 1H# 2(  A$! Q$!_\0
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M\3Q*]Q')YEW_ &UYC1[MORJRLL>[:S;5_O;:U?AY^Q?^SSKEX\&J>&,H\?\
MHUVNL3+ S;O]6W_QS=_L_*M7R@?17_#86DEBG_"R/A*&4?-_Q/9N/E9_[O\
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MC*YV_P!W[5_Z%][_ ,=KTNO-+5HS^T->JGE?\BVOF;6^;=]H_B7_ '=M>ET
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M=TGRJJ_,K*R_Q+M7YO\ 9I<L>4/A+W@7P_9Z#K&U)&@_?>6VZ3=]UF5E5?\
MOK_/WOH"XNKK2=!E6>^\J*2-I]LB^9NA^[][[WW55?\ @7_?/PKX*^-D4EYI
MVD:M)<+<"5HVNIEVKNV[59E_VOXO]Y?[M?4E]XHAUOP+<PSM'.T,BJL<;?>C
M^\VW_9^7[K?_ !5:A+^\97V__A(-8EF\F.Y6-O+AC;:ORK]U=S?*W^UN_AKH
M=#LY%:VD@M9&GLY/WRLNZ*.3[K3,N[=_P)OE_P!G;7GOAS_0[.??(NUF^;:K
M2>3_ +/_ *"OS?WJ]'T'4K.SU#3)+"\:V:-F59%^;^%6VM_L_P"S_P#$UG]D
M@GN/#,UXVJMH>ZYN?[-D\E;&XW2S*K>6RR+\NYMK-_LK_P "^6:XU*W\03:'
M'IT<DMC:Z:OF1SLJLTW_ "TD5?E^96V_+6!K_P 3X?A_X^\$:JC6FF(=<M8I
M&2-6MI(V^7;\W_+-5_O?^@UD_'K6%\$?M.>)O"[0R:7!:+'Y,EO_ ,>_DS1[
ME:/=\RKN_P!K^*F!UC6&FK;^3%,T\"M)Y<D^UOF;YOW?\3+)MV[?O?-_L[JX
M7QOI+6=YI]Q;R?;/,C_TBV7]RUJW]UE^ZWW?\[:[BWU*'1KQ6LE74[:UF\MF
M@7]TJMYFY?\ :^9MVY?NU3\56ZRZ//'/9M%+8JS23K&OF[F_YZ?[OW?^^OXJ
M7V0,:WUS=X9U#3?[4DBVM^YM+E=JK\S;MS?P_P!W_P")6L?5/ W_  D'@.^U
M1=%N-0T&S9?M$\EOYD']WYO[VUO[O]VO2/@E\%=4^)^L+Y\,UCX<5EDNM0GM
M=K2*NW]W'\VYE;Y6:ON+3]'L=/T5-(M;&&WTB.+RULU3=$(V^5EV_=9?E;YF
M_B_\=_/\^XNHY15CAZ,?:3^UY?\ !_(]G"Y?4Q,>:7NQ/QC\._!^XT]9CJ^N
MRV>DQW#,NEV<[+NC9OEVS?Q?PUW3>)M/T:UL]+T%K.QMEC:#:LS?>V_+\W\2
MLR_=_P!VOT&\4?L@_"[Q5:SI<:)<6,LB[H_L-Z84A;^\L?\ WS7@'Q._94^$
M'P=L_.US3_B%>:1#&N[4M)A6:/:K?-^\_A^7;_\ %56#XUR_&/D49<TNEO\
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M=;;\RU\NK;JLGF.OF[5_B^]MW+_G_P#:^8:+S5B565E95V_P^9_M?-_GYO\
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MRO-K?;_PT)=XSN_X1I<Y_P"OFO2: "BBB@ HHHH **** /Q;_P""F4>[X?\
MP:+A7;[1X@&Y0S8_XF#?Q?=4_P!Y=W;HNVO2O^"-?CZQDT_QUX NY=QOW-W#
M&PW;U\M5*[>5'R^8W_?7WJ\T_P""F3!?AW\&\R;_ -_X@^]'U_XF#?=;YO\
M@7S?-\O_  'P[]@/XIWWPL_:8\*7EI/Y<%]-]CN86/RRQMV_WOO58,J_$+X=
MZA\-?BQX]ATU[>VU;2=<:!+.0LN;>XD_=LK?+N56^7=_\4M=-X3^)FFLT^EW
M&ZVU2&9HIM.^5F:1F_>1JWS*RJV[;_N[J]W_ ."FO@N;X2_M%1^+K:T_XD7C
M;0V@:Y_U<<=U#(&;YU^7=M5/^ M7B#6L>M:DVH2M;VT^M1_:9(%MUW;=K+N;
M;_J_O;O^^O\ @5&<CJHKJWO(5D$=PJM_JUG7;+(NW[RLM=';V]Q:K^]FA\CR
M_P!Y(T;;5C5=J_[7W67_ +ZKS7Q-X^T_PO-]CECN/,\GS-T<.[=M;YO]G;\W
M_CU='H/C*W\1[&M[.9I89%58_,_B_A^[_P!]?+_M?-_%1_B%+^:1UT2R-#/)
M<;95:-E9I-OS+\TC?=_AW*WS;EJ?5]0FTGP_<ZHOG3VUNK>3N;Y8]OR_>7[T
MFW;_ +W_  &MCP_H<-U(K3R-MO)/(DVLO^CJVWYF;[NW:O\ X\NVL[QEX7CN
M-)U.QO)&;1;C=_I*PM'!)\WW57^%?O?_ &5+W2#Y9T_XX7&EZQ)XRO;&SUW5
MM02>TBAU7]]'86^W;(L>W[LS*P59&7Y=U<_\.?"O_"U/'DC+8)'I5NH>2V\Q
MMJK]U8]WWOF;^+_OJJ.E_!+Q1K'BJ71;739F$<[1M=[/W*JI_P!9N_B6OJ;X
M9_#K3OA=H;6=I=1WE])M:\OHX]V[[W_ E7YO]G_>^[NGXC8ZZWEM;"S_ -)9
MEGW>1_K/+\MO][^+[K?+_>6M/P7IT.N>"?BQK6HLUM<Z#)IVI:;'=Q[;9E:3
M;(R[69MS?W?N_=^9:S+B+[5)$LMJUY/#NDW,S,OS?\M&;^)OEW*R_P!U?]VM
MSX6^,/*\2>);."SMVL[[39E6VN9-WF-]YF;^[_P'_P =JR/B((M.CUE6NE9E
MN9+5IYHX]J[E^[_>^[]W;]VOCKXT?#Y?A3XXM];T6-9="N)?.A6&1CY+?Q0L
MWXU]D6NJ?9V6:)MUG<,L=Q']GV_=7Y6_W?F^7[W_ ++7(?$;P)IWB?2[G3=9
M:&+[8JMY\&[=&WS;6V_=_AW?+N_O?WMQR\P?#(^Q_P!D/5O!VL?">U?PJJ_V
MBR1SZRK!8YY;AE^5F_A\O;\JM_#\U>?_ !9M[VW^)FM2W^YC/+YT<B[O+:-F
M55;_ '=OR_\ [-<I^QXLW@GXI0:(VH1W,&HZ3]G9HO\ ELT?S*S?[7R_=^9O
MF^7^%J^C_C=X#N?%&B6VI:9$UQJ^GR;O+CV[IX_O,NW^]N;_ +YW?W?F_GS.
M*+RK.ZD:DN:-36[\S]8X3S"-&I%U-G[I\T+M7R]C;?+_ 'C,NWY?E_O+_P"S
M?=_[ZKO_ (=?";5?$NJ6EY/;2VFD1RQO/<3+M:3YONQ_Q?P_^.[JZ+X;_ ^]
MN+BRU/Q KV5C'MFM[!MK32?=95D7_EFORK][^]7NVL3+;Z7?3%E7RX9BNY]V
M&VMMV_W57=]W[ORUY6,S2*E["C[Q]GG&?1HQE1POO?WOZ_I'CG[1GQ"L]0\*
MZSX+L1#J&HWB-;7?V@LT%JRM_JV7[S-_Z#N7_@7Y_P#Q8^&^M77@_5HXM-N+
MFZV,UNNCKYD3JK?-\NW<S-]YO[O\/WJ^C%E\UFD>3S'DVLLF[[WWFW?W?^6:
M_P#CO^TM5M9EOETN^DL%FEU#R]L+0*S2^8S?+_O,VW[O^ZOWOO?HV1N644EA
MZ7VG[WJ?S1B,RK5ZW.PUS]HGQIX7_8E@\&WT$/\ :5UIC65KK6GW"-##$L>[
MRVW;OF_AW9_A_O5\N?\ !.G4I;_]MCX?7-[//>7<MQ/B66X^9F^SR?>9F^;Y
M?X?FK?\ A3\'?&/C3XD^))_B,;G1-&DT>_EMY;]&^S27#1JL:1JK;59MZM]W
M_@/S5K?L2_!7Q5\*/VS?AS/K-DS:?))*T=]9R$V[[H77[_RY^9A\M?HRKT92
MY8M<QV1KQ_A\Q^V5YX=TK4;];ZZTZUN+M;>2T6:6)6;R9-N^/_=;:/EK!T'X
M/^"_#6GRV.E^&=-L[2;S5DBBMU 82+MD_P"^E^7_ ':Q]>_:"\'>&_%L^@:A
M?7%O=6]Q;VT\[6K?9X9)O]6KS?=7=_G[RY[6;Q3I$%O<S2:G9I';R>5,WVA?
MW;?W6_VO]FMS4R-6^%'@[7+JVN+_ ,-Z;<RVMQ]JA:2W7Y9?E^;_ ,=6M*3P
M;H<V@W&B2:3:R:/<;O-L&C!@;<VYOE^[][YJH'XD>'HM!N-5DU&.&WAM6O9(
M9/EG2%?O,T?WOQJ_I_C+0]2T>SU2UU:RDT^\*BWN!<+LDW?=53_>_P!F@#%M
M?@OX'LVTLQ>%=+4Z7"T%INMU;RXV^\O/WA_O5:F^&OA6?5M&U-]#LFU#1XQ'
M83^7\UNJC:H7_='_ 'S6S'XATQKNZM5U&T:YM=OGPK.NZ'=]W<O\-:$4JRQK
M)&RNC#<K+WH \[A_Y.&N,_>_X1E/^^?M;8_]FKTFO-8<?\-"7>T$_P#%-+N;
MW^T_=_S_ 'J]*H **** "BBB@ HHHH _%S_@IFPD^'/P9V?+'Y_B#&X[_P#E
M_;[K9;_@7S?+\M? ^G:A-I.I6E];MLFM95FC;_:5MRU][?\ !30_\6[^#3,P
MW>?X@^5HO^HBWW6^;_@7S?-\IK\_* /VN\?>#[C]MK_@GS;7>F1I-XBLD_M/
M2VD*^9NA^;R_XMNY?EV_+_#7YLV,<LGA.#Q;9VEU)X<A/V'5[=2S?V5?,NUI
M&_B6&1F9MM?9O_!(+XZN+'4? >HZFD4=M)NA@N<*OEMN92K?WMVY=O\ M+4/
MQ\\.Z?\ L3_M4:O?ZOITE]\#/BU#+;:Y81Q!HX)I&;S-JM\NZ-F\Q?\ 9>J^
MT2?&,6MZQXRN(/\ A&]-FURYCC9OLVGPMYDC1M\NU=OS*J[O[U==X9\:6<6G
MO'+#MU*/]PT$7WMV[_[)MVYE^[6G\2-(N/@'\3+KP=+=7%BEO&LFCZI8[E_M
M"PD56@96^;Y?+^]_#\OS4:;:Z786\MY!I:VT6[SY+F!?F9OXMW\7\.YMU60>
MJ6NL27EG!:Q-Y'^C[6CV[5DW+MW,W_?/_ =M:<4NZ&#^U+J2\O(V^9I&_P!&
MCVLVV-E^[MW+_"NVO)&^*4-UK/V![+4H+;:NZX@7='(RKM955OF^7^+YJ[BS
MUF/5-'^V,T+6+;I(59=TK?[3-][YF;^+^\WW6H_NAS&E>77E?NX)F5E96CD\
MO;MV_+\VW[K?,J[6_AI\NJ+8^0KM&K2-NW+Y<:^7]YEC_P!GYEW?^RU@7'F1
M:;*UA9^5/Y:K#&S?,WS+_P!]?=5MW^U7-:;X?D35&U;Q!JW]JZG#;_9H[N1?
M^/5?XECCW?>_VO\ :_W5JR#L_%5K'K.BRV?F7%M]H9H_N_-N7[RKM;YMW_H5
M>?73>*-#L?,MY(?-63YE9=NZW9OFV_[.W_V7^*NC\3:M<>'X;/RI+>)O.6"2
M/RVVR;OE;_@6W_@7WOEK0N+=M9M_L=M_I,LDDBM/Y:K\OE_,O^SM5JS^T6;%
ME<-<-*SW"VT$D/S>7"S;MO\ >55^[\R_]\_[M:'S76Z2SDDBM%N/+D;[LK2,
MWWI&;=N_A_[Z_P!FN.\'ZXMY9_Z1?3>5_JU9E;<S*WW?]G;_ )W?=KL]-O&M
M[IMLVVY_U;>?\S1KM^\N[^+YF7_:9MW\2K5#^R$OB:^^'VM:5KVB21Q7.FW$
MGER,S213?WE;=M^]MVM_LU[,W[>&F-^YB\(R27/R_:)Y+K;$K;?E^]]Y57_:
M^[_X[XE+%;W4*QQ6?FRJJM)Y[-YK?\!7^[\WS*O\3?[58VI>%]T<3126\2R;
M66#YMTFYOF_VOO?+N;;][_OGY_,LBP&:SC4QE/FE'U_0Z,/B:N']VG(^C+W]
MO71+.SDFG\(ZAYY7>5^UKM?=_M?W5_\ LO\ 9KRKQY^V!XZ\:201_P!EV.A^
M&ONWUC#,OGS+N_BDV_+_  M][_XFO*8O"ZV]FJV4;01-)\JS?-Y>W;][=_#\
MRTVPTF/3[.*U\S;Y+2;H]VZ5MWS*K?[*_=^:N##<)9/AY<U.C[WF[_J:U,97
MK1]G4E[I[+I.O6.LZ>MUIUQY]LO[MF5E_<R+]Z-E_A957YO_ &;Y5KBOCQJU
MSIOP]N=-TJ1HM9UB;[%8^2S1M\NWS&5F^ZJQQ[O[WS;:\Z_X6<WPJMYYFDC\
MUF\RXMHX]T5Q,OW5_P!YO_9?FKSWXU?%J[\97$+11OI]Q;VZVMC$C/YA:;Y9
MV9ONLSJW^U\K55/*ITL5%OX3Y^.%E&I_=/J+]A32[Y?V<?CK\3=3FN/$ATZQ
MGM-).J2M<>7Y<?F;E5ONM]SYMO\ P)?FKQK]A7XH^(_B)^VO\/9]>U.2\7[3
M-LAW^7#'^ZE;Y8U95_B/]ZOO:\^#ME^SM_P3$\3>'KJV\F^E\.27.I[2S>9<
MS;=WW=WR_,J_A7YO_P#!-/S/^&TOAWY?7SKC<<;OE^S25]'[.GS<W*>KRQYN
M8_:"?]G32]:^)WBOQ5K4\]W%J4EE-9V*7$B00R0Q-'YDD:[5D;=M;YMWW%KS
M'X?_ +%5QX;NM/36]2LM7M+&^CFVRM))]L6-9]LLT>U5\[=(K;OF^ZWS?=V_
M6M%:%'QQ8_LD^)=4U;5]/OKC3;&RMUMEM]>VR2WEVRVS*R_-]V%FE^9?XFCJ
M]XN_8JN;ZZMO[&U+3['38V5?[*@5K2"'_18HO.7:K?O/,C9E^7^*OKFB@#Y-
M\2?LNW&GWOAVPTI'DU'5O$%Q<:]KEO"%1M,9=TD,V[[S-\JJW][=7U7;V\=K
M;QPP(L<4:A45>RU/10!YM O_ !D+=MMQ_P 4TO;[W^DUZ37FL.?^&AKC?M_Y
M%E=NWKM^U=_^!;J]*H **** "BBB@ HHHH _%K_@IM)M^'?P85?E43>(/E8[
MC_Q_MT;_ -"7_=K\_*_03_@IG&!\.?@N2V_=/X@^9H_^G_\ AY;_ -"^;:M?
MGW0!Z3\ ?BE-\'?BMH?B:(MY$,GEW*KU:%OE?_XK_@-?N9XT^'7A_P#;D_93
M33=2OK2\FU2U^U:?K%NJ_P"CW*LWDW 7^'=CYD_NNRU_/41BOTO_ ."5/[3$
M.DZI+X(U^\\J&SA9[.5Y)&9H>\:QK][:S;ON_=JB=CS&/7-2\3?"FX^'WBJT
MNF^,7P@NKA+"&2+=)>Z1]VXA5F_>,T.-T>W;\NW[WW:X:+4K76(8+B#4H8(%
MA9K5OMGS2;?E^]][[R_-_P !VM_>^X/^"F'[-^I6\VG_ +0WPV;[/X@TA%.K
MBQ3=]IM]ORW/'#!5^5L_>4CTK\X]!UBU\0WMQ<:?#';:7+,LEUILG[S:S?>5
M?X5CW-_NM_=6GS$':27D^O7D&G^%/L2^7<?:;J_NVW>2R_,J_P"U_P!]?=_X
M$U>IV\EPT+*[?ZS_ )9KN7Y?E^9?]EE^;_QZN T/R=)L[.&ST^-8K?; K?+Y
MJLWR_P"\K?WEW?[/]W=UDNH,T+2)'_M-!&WF-\JK\RM_X[\M4!OQ:I#<7$6Z
MZW;8VW,N[RF;YE7[WWOO;O\ :_\ 0HFU22ZCEN'MXV6%OEDDC7RHU7^%?_B?
M]EO[S5SVC:\TNH2VO^HEA^99+F%?FC9MOW?[J_[/_CU7KBSD:.>W>S96C7:S
M>6WFK_M;F^7YMU _>,/Q?827%K]N69OMENRM'''\JLWR_>7^]_L_\!J?PS?Z
MAJ'V:3^R[JSN8YHX/(@C:3S%;[WR_P!UOF_^R^[6);Z.=8\2>=-<7%Y!;W#2
M1K;R[8/,7[OF?=W;?]GY?X6W?Q=NNK6/A.XBU274+C0[:WN(V:>23_5JS;=R
M_-_M*W^U_LTO>%_B.AT.UFL[>>W15@BDD:!HE5OW;+NW;E_B;[VY=M<UX\FN
M/$"KI-I<M::A]N\RXN8VV^7'\OR_[7RK_=^[N_V:;<?%2'Q%XLUG^R;5EU"&
MZ99O,D\N"%F^](O\3?+_ .@U0O\ 7+'0=<TZQU+SIY]4D;RV9F^;Y=WS-]W^
M*F0=HMU]GT]6M9KBQLXUVQ_>W+\WWOO?Y^;^[\V@NJ1V\;3/=+$K+'N:1EG5
MMOW6_P#0?N[65EKB=4US^P;=6LUM]LDRP6_E_-N;S/\ 6;?[WWOEK:BU*&+:
ML_F-/''M5?O*R_+_ !?WMN[Y?E_B^[5EC=4NML;3-'&RM(K1QPR?>_O-(V[=
M_EJS)?+O+CS%_P!)G^]M5=JK_%N_]E_[ZHU>*XN+Q56SABN8_FVJO\/WMW\/
MS+NKGKS5)/\ 0['RYI=5O)/(CL;1?,EW?[*[=K*VWYMW_H50!Q/CKP[J/Q$\
M?Z3X0TZP9IM0:, VTB_ZI9%7<N[[W^[N^7;7N/[+O[/MC\=_VR(],CT?RO 7
MP]59+V.9A*MQ<1[5^8_Q-)(OS?>^[7%>+/BQ'\ _$>GW^D6ZS_$QU;[.NY6C
MTU6V^4K?WF_BVM_>K]/OV#?V<;C]G?X,)'K3%_%_B.;^U]<9]O[NX9?]7\OR
M_+_,M4_9+B>:?\%>/B%)X-_9931H#ME\1:I#8LW_ $S56D;_ -!%?FS_ ,$W
M-G_#9WP[61]NZ>?;AL9;[-*W]Y:]2_X*V_'F/XE?'B#P;IUSYFD^$XO(FVGY
M3>-_K.V?E^[7E_\ P3;95_;.^'(\SRCY\W1F7=^XD^7[R_Y[&H*/Z"**** "
MBBB@ HHHH \UMUV_M"77S,=WAI6^8\+_ *3_ )_\>KTJO-+=-O[0UVWE[=WA
MM?F5/O?Z1_>KTN@ HHHH **** "BBB@#\6/^"FBQ'X;_  5= KC[1XBQ)_%_
MR$>G\7_H7_ ?[OY_5^@?_!3#%Q\./@S,Q4G[1X@3<S;G_P"0@W^S]WY?[WR_
MW?NU^?E !70^!_&>K?#OQAI'B70[I[/5]+G6YMYU."K+_G%<]10!_1%^R;\>
M]#_:2^$=C?PHMY'<P-%J%K<1JRP3_P#+2W92S;E^9MO_ $S45^;7[='[#^K_
M ++/BR?XC> ;-KWX>W,A:Y@*K)_9S2,VZ%EV_P"I^ZJM_#7)?\$P?VD(_@?\
M<?[&UB_BL_#'B9?LL\EQ)MCBG7F-OF957=]W<U?MQJ,.C^,M'N=%U..TO;>\
MM?\ 3-.D=9 T;KT8?W?]JJ)/P"\"^++;Q#"TFG7-O9ZA]V:.^9?/;<WS;?\
MGI_#][;]W_:KO)98]2MX+6X\R#4)H?E5E^:-67;ND7YEW?Y^:O9_VJO^"3.O
M>#[R\\7?!FYEURQCF:X'AQO^/NV^;<%@;_EH%_N_>KYP\/\ Q<M=2O6\.?$8
M3>$O$EGMM/[4DL=RQ[=O_'S'_K-W][;]ZF'*7O!_B"XU*\U".63[9<PLWF1J
MRK\RM\W^[\M=C<:E]OC6.\O)(O,5H[62/Y6DC_B5F_N_,R_+6(WPRD^'^KWT
MEMXAL?'=CJFW4;;5-!D\_P"5ONJRK\JR?P_=7;_P):HWGQ$1=6_LJXCAMIF_
M=36-Q'Y<OD_-]W^ZWR_,J[FIQYB="K>WMU\-]26.*WAET&X_?QPV7WK-?O,R
MM]U5_P#0:Z>XN/\ A+=#::5K=F;YE7S/E5E_AVM]U?E7_OEJ@TF\DUSS]B^1
M%#(RPW-S\NUF_B_A_BW?W?O5;\(?",?'[XD:3X1\(ZS;WNJ><L^I3:6VUH;/
M=^^;:W[N23^ZK?=_]"G^\+[7,::Z#IOA7Q L;W3-?:E"NI+]KA55NH_O;EVM
MM^7YOE_WJAU9H]MI<7EO;V=RS;5EC_>*S,W\+?PK_#5S]I#]G/PE^SK\4CX/
M\0^+M4U71DTY;FRDUZ-A)MD7:WV:1?O+NW*R_P#V58NDZCIE]I<MGIOB*QFT
MNWM5@5I]RP1PKN;_ %C+MD;:K?\ ?6VKY@,Q=R^,F_M'4)/*F7S;>TME^6%5
MV[FD9?XO[M=_YLD5O!LNI+967<TBKMVQ_P 3?WF;Y?\ 9_X%\M<[9_ 7X@76
MM:)XHTG0)(/#'V62[74K_5(X;:^A;Y6:'<VZ1E9MVUOO?^/5] K^SKX2\->'
M;KQ-\0_'4>G:?''YBVEA'Y;3-\VY5NIONR?=^;:WWEH(/G9KK5-<O/L/AI;C
M5=9^]#;01M(T*_>^;R_NK\N[_+5F:]X\L?@AI<\'G3:]\8;M5AM?L4.R#1U9
MFW0;?O,W\.W_ "NQJOQZ\5_%C49_AY^SKX'NM CFFW3R:,/].O57[K7$S?Q?
M>^;Y?_0MWU_^QU_P3\T']F=[7XC?%F\L=4\;862SLV/G1:?(WWMO_/:?YOO?
M-M_A_O4%F#^PG_P3UO\ 2=:MOC!\: +GQ%*S7MEH=VJLL+-\WVBY_P"FG^S_
M  _Q>E?4O[4W[57A[]G_ .#NH^*I[U99Y]]IHT<9.Z^N]K853_=1MK,WW?E9
M:\F_:T_;\\/? O3VL;NPN;OQ?N9[/PN]POS+D^7->[?]7']UEC^\W\6:_'[X
MV?'SQI^T!XH&M>,=6:_EB7R[2U15CMK2/_GG%&ORJM27RG&>)/$%_P"+/$&I
M:UJ<K7.H:A<27-Q*W\4C-N8U]$?\$U\?\-E_#[+;?](D_P#1;5\Q5]/_ /!-
MSR_^&S/AVK2+$S7$VS.[+-Y$OR_*P_\ 'J@H_H)HHHH **** "BBB@#S.!7_
M .&AKO=U_P"$:7;_ +OVGZ?WMU>F5YI"KK^T%>-MX;PTI5AW_P!)_P!W_P"*
MKTN@ HHHH **** "BBB@#\6O^"FV'^'/P5E(R?.U]59OO;?M_3^+Y?\ @7_
M?[OY^5^@/_!318C\-_@JZ!7'VCQ%B3^+_D(]/XO_ $+_ (#_ '?S^H ***]#
MN/AM-K6BZ%>>'UM;KSK-?M<?VR-9(YO-D7YE9OEXVT >?JS(RLIVE>AKZK^"
M/[?WB;X<76CIXETJ'Q=:Z=\D-V\\D-]%'_=656^;_@5>(V_P=\0W&EW=VWV&
M!H'C5;>2_A#3;E9OE^?^$+_%_>%)I'P7\3ZIJ=M:O;VMHLTJQM-+?0;8MW\3
M?O*K6),N61^QWP#_ ."A7A#XF6:FQU"2>Y7;GP_JDBC5(_N;MLGRQS(N6;=]
M[^&NF^.O[.OP+_;"M?M.OA= \41A8XM6@=;.]5F56VLK?+-V7^+_ &6K\27^
M$/BR"8^7:6S,DFU3'J%ON/?Y?WFZOH3P9\6/C9\,+;1-+FNM)^(&C6J0W<>E
MZ[>1W26#+^\\M9/,5HV^9ONM_%1]HGFC_,>D_$K_ ()@_'#X%ZE>ZU\+]:C\
M5Z5#^\5;.3R+YE]&A;Y7_P" LU<[X1_:YUOX3:$/#/QA^!%GX@@MY69[W5[&
M:TO/,S_$TB_[/_Q-?2'P;_;2\0Z?I\$FH7,VB7,<C1MHNL7UO=6GW?E\N16\
MR.%=NW[OR_\  J]TA_:JT?Q/X=N;?Q3_ ,('=W=O%YZR0:S#=02-\K>4L,GS
M+)GY=N[Y?O?PTQ<W\Q^>D?[57[.OB#<WB/X1ZT@V^2MIINK>3;-'M_BC^:NH
MUC]M#]G[P!X=T:Y^$WPHN-#\3VMS]H6[:^FBDM)-I7S5^\LGR_PM\OS?=_B7
MZS\4>#?V6?BAH$\VI_#*WT^2^D^:;2;*&.9I-R[ECDA;Y?N_>7;\M,M_V,_V
M2_$D:Q2>&VT:4_N(X9+Z2.27Y5^==KM_>'S4O\1?-$^%-)_;J\-^';G5K^'X
M6Z?XQU?4E\J76_'FI-J,J*V[Y%AV[5C_ -E?^!?>K(\4?MXZUXS\-W7AZ?PC
MX#TW2+-Q)HMO;:*RP:>WR[FC^\Q9MK?>_O-]ZON=OV#?V23JD4:Q:@R,_P!J
M-W'K#- @Z^6W/W?^ _\  J</V??V2_ $SRZ=\.9O$$]F9)0M]/(\$B_=;YII
M-K;55F56_N[F_O4?:#W?A/SN\,>.?BI\>=;T;3-&T/5O&VI6,GGV%BCM]DLK
MC^]&J[5C7:5^7=MK[.\&?\$U_'?Q:DB\9?M*_$:XCCA2-O[+CN@WDQ<?(\AV
MQP]=NU!\M>]ZO^U!HW@O2[S3M N/"7@72+?;'9S:3/#J-RZ_W?LZ[5W*OS?,
MVW_:KY;^,/[8/C2]NKR'0=%;Q5>VKRQQZWXCU.W-I&=W^NALE98V_AV^9NV[
M?^!4?X@YN4^U/"^I_"7]E'X<3V_@:QTOPMX7M'_TO7-5FD6&1E^\VYMTUQ)_
MLK_XZM?!7[3W_!42[U[5+BP^%CRM(L/D_P#"8:E;K'<C^]]DM_NP_P"S(VZ3
M_=KYV^,$?Q,^,UCI^M>*]2_M_P 0-/(LD3ZE;JD4.W]WY<:MY:K\K_,OWJ\P
MD^$^LV.DZEJ6I26FGVEG;^</],AD:5F;:JJJM_%_2@#E-8U:]U_4)]0U*\GO
M[Z=M\UQ<R-))(W]YF;K6?114E!7U!_P39.W]L[X=8;;_ *1-N.=O_+"7_:7_
M #_"U?+]?3__  395F_;,^'@3<I^T3993M^7R7H _H)HHHH **** "BBB@#S
M.U54_:&O66'RBWAQ-S>7MWM]H^]N_BXVK_P&O3*\S@5_^&AKO=U_X1I=O^[]
MI^G][=7IE !1110 4444 %%%% 'YZ?'K]D.X_: \/^&-)\3:1XRL+OPM<:BJ
M7.CVME<Q74=Q=-)N5I)%;Y5V_+\O_?2UXM_PZ;TH8RWQ'7[JM_Q+=,;:WK_Q
M]_,OWO\ OG_:6OU5\:ZA<:/X-UZ^M'6.[M;"XGB9H_,PZQLR_+_%T^[7RQ#^
MT/\ $O6+?08K9;6.^73;6RU-8+-=SZO)=VT<GEM(WEK'Y<R[=S*K,_\ L[:
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M[_@/S?:?E_S_ ,"1?^"4>B/@+)\1Y?E_ATO3DR<-_>N?E^Z/^^MO\-?:UO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>a3.jpg
<TEXT>
begin 644 a3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W 8H# 2(  A$! Q$!_\0
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M_LS4 >IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MW23W-Q&J_P#H-<U\.='\::]XFM/$%QXQU[2_!%LVZ&'7&C6YU3_:9=O[N/\
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M9ZE\-_$6G^,/"MTVGZOILRW-O/'\OW?X6_V6_NUZC\0OVW/C+\=_+BT;4/\
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M#_&FE>$=2\5:?%XCU2;R+?3UF5I5;_:_N_\  J[%O%>BR+\FL:?_ ,!NH_\
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M=TD\C;5C7^]NKR__ (2/Q%\8)I;/P<TF@^%=VV;Q)/'^]N%_B6T5O_1C5?\
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M-MB\MF9O[M9&DV^H:]I]M-?LUG!Y?_'M&WS2?[3-_M42HTR?;5)?%(XSPO\
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MB@ HHHH K7W_ !XW7_7-O_0:\N_9=_Y(#X,_Z\?_ &9J]1OO^/&Z_P"N;?\
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M9+FG_-_D>R2V=FNFM9O&L5C''M6-?^6:JM9'A?2YI;6"\U*3[3+_ ,NJLO\
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M*=:)9LT?A;PW>:F=WRSW3>6E?GYINDW.HS+'86-Q>/N^[;0LS-_WS7K/@_\
M9)^*_C_;]C\,7%G WW9M0_=K_P"/5@L?BZDO=B?0/@OA[*Z3ECL1S2]3]2?@
M3KP\46?BC6-GEG4-3@N=J_P[M-LJ]0KQW]F?PY?>$_"FKZ+JAC;4=/O;>VG\
MIMR[ETZSKV*OI8WY?>/Y_P 3&$:THTOA'T4451S!1110!6OO^/&Z_P"N;?\
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MN8X[X=_\C!\0O^Q@7_TW65=O7$?#O_D8/B%_V,"_^FZRKMZLR"BBB@ HHHH
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M ,#+C_XY7K"\T^CX=!RE*<N:1Y)_PRG\+?\ H55_\#+C_P".5ROQ-^"GP?\
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M^FR6L>U?(CC7:W]Y?F7;0!WFA_!GX$>*-4U#3='L]-U6^L6VWEK;:M-(\/\
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A** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>a2.jpg
<TEXT>
begin 644 a2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %2 B8# 2(  A$! Q$!_\0
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M)(1\Q"Y"*SR,%#2.6]FHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\,_$;4M4USPG\5M>\*:CH<VGK]ID\,Z1KD&D7FM0[,[GMVO;&69&VHL<SMN
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M .%4?_D.C_A^Y=?]$FA_\*H__(=? =%=_P#J3DO_ #Y_\FG_ /)'%_K?F_\
MS^_\EC_\B??G_#]RZ_Z)-#_X51_^0ZYGQ]_P<0W7@B[M8O\ A34%U]H1GS_P
MF!CVX('_ #XGUKXIKS/X]*1J>F-CY6BD /J05_Q%?!^)61X+*N'ZV.P$.2I%
MPL[R>\XIZ2;6S?0_=?HW1CQ3Q_@\DS[][AZD:KE'X+N-*<H^]#EDK-)Z-7MK
MH?H)_P 1+%U_T0^W_P#"U/\ \@4?\1+%U_T0^W_\+4__ "!7Y?@YHK^8/]:,
MS_Y^_P#DL?\ (_TS_P")>_#_ /Z%_P#Y5K__ "T_3J?_ (.:6M9-LGP7L8V]
M&\<;3_Z05(G_  <MW4B[E^"-NRGH1XU//_DA5/\ 88O/B?I/_!*+0Y_A'XD\
M'^$?$<WQ%N(]0U#Q'):Q6,EAY#F2.1IXWR-XB)$8\S:C;2.:\]_;%_9;\(_M
ME?&OX[>+/@1;G7;CP)#X=1=,\+622V.OWUY+<1WLT.PXVQQPJY:/(=Q*Q))+
M'VYX[-O8QJ4ZUY22=N2*O[KD[;WLEKHMU8_(L+PGX;/-\1E^-RI4Z5&<J;J+
M$8B7*U5ITHNK&\535251<KYY:1DY62N>H?\ $2Q=?]$/M_\ PM3_ /(%'_$2
MQ=?]$/M__"U/_P @5\SC_@G5I7A?]I./P?XP\5:EX5\/:-X!L_&GBC4[JT19
M]'><1QFU"$[=PN9HXQN.2-_IFH_A%_P3K@\0^/?C-H_B&^\::G=?"#4QIS:'
MX-TF"_U[6(FGEC%[%!/-'F *D;$('<B=>%Q\W+_:6><W+SZW:VAT5WT\GZV=
MMCZ*7 ?@_&DZWU7W5"$[J>)UC4E&$;/VEF[RC=7]U3BY633/IS_B)8NO^B'V
M_P#X6I_^0*;)_P '+MQ$NYO@C;*OJ?&Q_P#D"OES2/V%=%O?V+[/XKH/BQK3
M:E%K\JIHN@6L^GZ*FG3/'')J,KSJ\"2* [%%D*B.; .T;O/OV0OCKXJ^#_C.
MYTWP-X'\&^-/&'BZ2VL=+&LZ"NK7=I(K2$K:!F C,@;$A.5VQ@G&W<,WG>:P
ME!5JME))JT8O1JZTMU.^GX3^&^+PV)JY7ERJ3P\G"2E7KTTI1DXSO*4WRJ-I
M-NST6E[H^Y$_X.6[J1<K\$;=AZCQJ?\ Y IW_$2Q=?\ 1#[?_P +4_\ R!7S
M7_P6(TGPAH'[4VEV7A_3?#6D^)H/#=G_ ,)M:^'HQ'ID&M,7:58U[/L*%NY!
M3=\^^OE.L\7Q!FE"M*BZU^5VORQ_R^\[^&/!?P]SG*J&:1RMTU5BI<KK5[J_
MG[35/>+TO%IV5S]0/^(EBZ_Z(?;_ /A:G_Y H_XB6+K_ *(?;_\ A:G_ .0*
M_+^BN;_6C,_^?O\ Y+'_ "/=_P")>_#_ /Z%_P#Y5K__ "T_3]O^#EFZ5<_\
M*/M__"U/_P @5Z#9?\%Y+J[LX9O^%2PKYT:OC_A*R<9 ./\ CRK\?9/]6WTK
MZ!T;_D#6?_7"/_T$5^S>#M..>5\5#-/WB@H./V;7<K_#RWO9;G\<_2]X.R?@
MK!Y95X8H^PE6E54WS3GS**IN/\24[6YGM:]]>A^@O_#]RZ_Z)-#_ .%4?_D.
MHE_X+V,TFP?"VS+YQM_X2WG\OL=? ER?]&D_W3_*OU:U#Q#K/AC7/AK_ &_X
MC\ Z7\#U\"VS>)-*UXVFZ]G,$H7RXW0R,2?(&-VPA7&&;@_K&=9'DV Y$L,I
M<W-]N:^%)V7Q7;O9+37J?QME.=9MC>>^(Y>6WV(/=VN]K);MZZ=#R7_A^Y=?
M]$FA_P#"J/\ \AT?\/W+K_HDT/\ X51_^0Z\5\,_L&S_ !BM_AOXB\&VOB2Z
M\)?$'7M4@O9(K/S%\,V$.IFVMW=B<EC &<[^AC/7FL7X??L:VGC;P7X\OI/$
M$UMJNBZIJFD^&=.$"M)XAGT^VDNK@$9RO[I8P"N?F<CH#C7^Q^&;-NGL[-<T
M[I\SB[KFTLT[^2OMJ9_VMQ%=)3WU3M"S5D]-.J:^;MOH?0G_  _<NO\ HDT/
M_A5'_P"0Z/\ A^Y=?]$FA_\ "J/_ ,AU\R7O[-NEZ/\ L@V?Q*DNO%VL7&K)
M<E&T738+C2=$EBE\M8=0F,HEB:0;6#",*-X'S<%M?]KO]D?3_P!FC286M5^(
M%ZTEQ:PKJNH:3;P:)=>=;&<I!.LID>1>5VF,#,<G/ SI'(>&Y5515+WFY16L
M]XV3^UTNOTT,Y9UQ!&FZKJ:))[0VE=KIUL?03?\ !>*9& ;X4VZD] ?%AY_\
MDZ=_P_<NO^B30_\ A5'_ .0ZX/\ X)E^,1XCU33_  G?2?!VWT2.[ECN]-UC
M2HI->\4^:CN(HG<A9"K81=Q&T8!#  5\R_&C38M&^,OBZTM]$NO#5M;ZU>)!
MI%SCSM,C\Y]D#;2RY1<+\K,O'#,,$F&X;R:IC*F$EAK.*3OSSU3;6UUVZ76N
M]] Q'$&;4\+#%1Q%U)M6Y(Z-)/L_QL_*Q]K?\/W+K_HDT/\ X51_^0Z/^'[E
MU_T2:'_PJC_\AU\!T5ZG^I.2_P#/G_R:?_R1YW^M^;_\_O\ R6/_ ,B??G_#
M]RZ_Z)-#_P"%4?\ Y#H_X?N77_1)H?\ PJC_ /(=? =%'^I.2_\ /G_R:?\
M\D'^M^;_ //[_P EC_\ (GZ 0?\ !=:YF?;_ ,*GA7C/_(U'_P"0Z*^!;+_7
M_P# ?\**E\%Y-_SY_P#)I_\ R1<>+LV:_B_^2Q_^1/D7-&:_I<_X=Y_ '_HA
MOP?_ /",T[_XS1_P[S^ /_1#?@__ .$9IW_QFOY9_P!7JG\Z/]'O^)BLM_Z
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M)O'/[%'A/X(ZM:V-YI'@O68]4TW5W+?;U@CANHX[)ST:)#>3%,\J"J !17]
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MJ7Q$^ >E>'=%\->,&\0ZM%<):Z/?K>1QO:).+5O-/GHS-&S 7!((V)MTH?\
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M_P#7"/\ ]!%?MQ_PP)\"?^B*_"7_ ,)#3_\ XS6E'^QK\((D55^%/PW55
M\,V0 'I_JZ_3?#6JN&:N(J5_WGM%%*VEN5OOZG\U?2.\0\-XDX; 4,#2E0>'
ME4;YVG?G4$K6[<NOJ?A[(!)&R_WABO0/VB?V@[S]HS6_#=]J&F6.FR>&= MO
M#\(MW9_.CA9R)&+=&/F'@<<5^P7_  QS\(?^B5_#?_PF;+_XW1_PQS\(?^B5
M_#?_ ,)FR_\ C=?J4_$+!3J1JRH2YHWL[K2^_P!Y_+4>!<9&$J:K1M*UU9ZV
MV/R,\/?M1ZIX<T[X26T6FV;1_"+4+O4+,^<Z_P!I-<7J7;++C@!67:-O8FNO
M\&_\%%_''PYNO#:^'X[72=+T34[_ %2^T^*0F+7I+RY:>07!(SA0^Q,<J #S
M7ZB?\,<_"'_HE?PW_P#"9LO_ (W1_P ,<_"'_HE?PW_\)FR_^-UQU>,LIJJU
M3"MK7=K=N3?XRD_*^G0ZZ?">9T_X>)2VV3Z62_"*];:]3\C_  W^TE9> /AG
MXHT/PSX'T;0]4\8:5=Z#J.KKJ5[,TFGW#DM$+9I/($BH0BR[=P X ).3]H7]
MH[3?VA+R;5+CP)I.C^*+LVPN-8MM5O97F2&%853R'D,"Y1$&50'Y>N22?UP_
MX8Y^$/\ T2OX;_\ A,V7_P ;H_X8Y^$/_1*_AO\ ^$S9?_&ZN/&V6QJ^V5"?
M-J[\[OK;1ZZK1:/338B7!^82I^Q=:/+VY5;2^NVCU>JUUW/RG^!G[7NF_ W0
M='\GX5?#_6O$WAUY)=.\07L4OVI9&D>19)E4XE="^%;*E55 I&T&O+/'GCG4
MOB9XWU;Q%K5P+K5M;NY+R[E"A5:1SDX4?=4= .P %?M7_P ,<_"'_HE?PW_\
M)FR_^-T?\,<_"'_HE?PW_P#"9LO_ (W6E'CK+Z565:&'ES2W?-?K>RNW97UL
MK(BKP7CJE.-&=>/+'96MTM?1*[MI=W9^'^ZC=7[@?\,<_"'_ *)7\-__  F;
M+_XW1_PQS\(?^B5_#?\ \)FR_P#C==?_ !$G#?\ /F7WHY?^(?XC_G['[F?A
M]NI=U?N!_P ,<_"'_HE?PW_\)FR_^-T?\,<_"'_HE?PW_P#"9LO_ (W1_P 1
M)PW_ #YE]Z#_ (A_B/\ G['[F?B)9']]_P !_P **_;U?V._A&IX^%?PY'T\
M-67_ ,;HJ7XD8;_GS+[T:1X!Q"_Y>Q^YGHU%%%?D1^H!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 44UYEB^\RK]33;NY%K;M)@M
MCH!_$3T'XT 24F\!L9Y]*J275S:VK2R1QMM7)5"<C_']/QJ&&V:5)M\8\R5B
M5DQR?0Y[8H)YBT]Z1*RJFY5."<XR?0?_ %\4V]?[9IS;%9LD94=6&02/Q'\Z
MDAAC+M\RN^<MST.,=.W2H9E9II?FD5E \H+TZ?KSV/M4@.N(B@C:-47RV '&
M,+W%4X9)=9GE?S9([>,[56,[6;MG-:C;BG;=6;8R_P!C.UO*K>6"2C@<8)SS
M0PD-N(FM9HU\R9H68 ;SED8]"#Z9X(/J*M7"_8X&GDD;Y8RN .F::]PVJ21K
M&K>2KAF<C&[!S@9_G4VJ(TUC(JX+[=P7UQS2\QE&TM[B:)9/W%K_ '4$18_\
M".:DMY9;Z3:QPT;8E0/@$=B.^#UY[\=JL0:I"\.YV6%OXE<[2M-M#YUU/<!2
MJ[0B9XW 9.?U_2@8UM3CT_>DCHK;\1J\@W$<<]SC.:L6]\DZ9W+TSD'*D>H-
M5]$M$2T696W23J&=O4GK^M1E%L=2D!VB%H_.?C&U@>OX_KCZT)NP&E16:+F4
MQAO)NEA7)/*AS[XZ_@.?:K4%\HA#2.#D_(W]\'IT[GVIJ0%BBFQRK*N5^G3&
M*=5 %<]X)\(1>$=8\1NMY'<S:UJ/]J/'L"M;JT4<2J>22,PL0W&<D8XK:N+E
MHY&553Y4WDLVWC_/?MQ7"?"_7KSQ1\8/'EQ<6JPVVG&RTFWD4'$OEB>8YR?O
M#[2,XXP5JHWL[?,#T*BBBI **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTZ8 ))+CLVMD!Z914-E<?:(<[E;!(R.X['\:FI@%%%% !1110 4444 %%%%
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M^?\ R)7*U>\-WL>GZNLDREDVD9 SM/8_Y]:'7J);O[R*N58&,')4(.W]V/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M,?QCIIU/39(_[PK\@?CI_P $0_BCXV^,7B_7+77/ _V'Q!KM]J=O%+-=^9'%
M/<R2HK@6Y&X*P!P2,@X)ZU^RKH'&#4#Z7"YY1?RKS\PRNAC8J-=.RVL['W'
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M6_\ SS7\J/\ 5'+OY7][#_B9GCK_ )_0_P#!<3\1/^'#7Q5_Z"_@'_O[=_\
MR/2_\.&OBK_T%_ /_?V[_P#D>OVZ_LBW_P">:_E1_9%O_P \U_*C_5'+OY7]
M[#_B9GCK_G]#_P %Q/Q%_P"'#7Q5_P"@OX!_[^W?_P CT?\ #AKXJ_\ 07\
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M_@T@_P#BZ_G1^QQ_\\U_[Y%'V./_ )YK_P!\BC_7>I_SY7_@7_ #_B47!_\
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M&D:21@!DC  '8"IJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*W#G_0PPG_A3'_Y ^1<T9KZZ_P"'=?[2'_0D_#__ ,$WAW_Y'H_X=U_M(?\
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MH_X=U_M(?]"3\/\ _P $WAW_ .1Z/[%Q?_/J?_@##_B*W#G_ $,,)_X4Q_\
MD#Y%S1FOKK_AW7^TA_T)/P^_\$WAW_Y'H_X=U_M(?]"3\/\ _P $WAW_ .1Z
M/[%Q?_/J?_@##_B*W#G_ $,,)_X4Q_\ D#Y$XS2DYKZZ_P"'=?[2'_0D_#__
M ,$WAW_Y'H_X=U_M(?\ 0D_#_P#\$WAW_P"1Z/[%Q?\ SZG_ . ,/^(K<.?]
M##"?^%,?_D#Y)LV19E\SS"JG^#[R^X_'%3:K=7<_EK=,[*HS'GN/6OK#_AW7
M^TA_T)/P^_\ !-X>_P#D>KL7_!/C]HZ^79=>"_ +%4VQ.=)\/?N_S@Y)Z?E3
M_L7%O_EU/_P!_P"9RS\4^'(S]I]?PC_[F8W7I[I\FZ=-=>']&:Z46\D-]F,
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MZLY_#TRLL*3+G8&YD)[<^G:OH*R_X)#?':[NDC;PSIT*L>6.L6W'_C]7(/\
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M>^.G4BK[7JJ?NOMW;=V. >GU_&D):ZLFHI$=9%RI# ]".]+3+"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $-W9K=J,EE*Y
MP1Z$8(JF)WTDK#Y>_<3M;.,CKZ?I^-:5->-95VLJLOH1FG<EQ[&?'>7$T9FC
MME;D]).#C@_7IUIKZK='++" J@GE6Y/8=/\ ZU:@&T8' HH#E?<S1=7DD7F+
M;Q]\;@<_EU_R.HIPN;X9_=C;GJ5SCCT!SU_K]:T**0<IFO;WTJ[O]'4LH!!S
MGZ'MWI)_[0C(4,K9.=RJ#^'4?7T[5IT4!RE:QMR,R2I^]).&8#=C\*LT44%!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>a1.jpg
<TEXT>
begin 644 a1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" %4 B8# 2(  A$! Q$!_\0
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M9^*=SH_@D7=W->#1H7#FXTN*65F;R[:1%&TDG=*[,2SDGY>_X+\^&?''C/\
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MC+1_A#\:%TWPA9:/XQC^/7PQDTN35DGEN(4$MQ=75VCSO=-,K;&A>!5ND\O
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M#)-RZVMM/=P+#)))!G9*ZJBM&S F-EW*02<^H44 >,?';]@+X7_M(?';PO\
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MR:C^SSI>J:1X,N+[6[FZ:T@U!2EP)=S?O<(SJ@;Y8U?"J J!</X?_P#!%?\
M9\^&EM\"8=,\)WOE_LXWVI:AX($^ISS&REO[AKJ;SBS9G"W#"6/>249!@X+!
MOJZB@#YE^#O_  2)^!_P*\6?"O6O#_A_5(KSX+WOB'4/"@N-6N)X["?7')O7
M9&8B0[3L3?G:H!Y8!ATO[0G_  3?^$O[3_QD?Q[XNT&\NO$UQX)U3X>75S:Z
ME/9_;=%U!66>VE$3+OVB6<QD_<:=V'S!&7W6B@#YU^*'_!*[X-?&+]BKP?\
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MNVE*Z25.3>FUGLTW].?\10-Y_P!$(M__  N&_P#E=1_Q% WG_1"+?_PN&_\
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M^!8\3_%74_@;HUMK(\9>(X+NS@>VLH@8TN;@FYF)<_.$^SQ,08RD>APG6?\
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M%?M,OA?2-<@TF]UF'8#F2W:]LI9E;:BQRNV0$PP!];?\1SG_ %:[_P"9(_\
MO71_Q'.?]6N_^9(_^]=?&.G_ /! /2_'OQ#C\.Z%\1[G2%B^,WC;X?:EJVKV
M EM=)T3PY ;F;4VCBP\D[1*P$0*JTC(NZ-27'C?PK_8Y_9Z_;#_;0^&7PU^#
M/C;XM6OAO4OM]WXXU_QSHVG:>NE:?8V[7EQ=V@MKB8%?LT%RVV;:581#YMQ
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M?-P6V?VOOV1--_9HT>%[./XAWC27%K"NK:AIEM#H=UYUL9RD$R2F5I%Y7!C
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MJ?:W_#]RZ_Z)-#_X51_^0Z/^'[ES_P!$FA_\*H__ "'7P'17J?ZDY+_SY_\
M)I__ "1YW^N&;_\ /[_R6/\ \B??G_#]RZ_Z)-#_ .%4?_D.C_A^Y=?]$FA_
M\*H__(=? =%'^I.2_P#/G_R:?_R0?ZX9O_S^_P#)8_\ R)^@$'_!=>XE?;_P
MJB%>,_\ (U'_ .0Z*^ [7_6_A14O@O)O^?/_ )-/_P"2*CQ=FW_/W_R6/_R)
M\C[J-U?TN?\ #O;X!_\ 1#_@_P#^$;IW_P 9H_X=[? /_HA_P?\ _"-T[_XS
M7\L_ZNU/YU]Q_H__ ,3%9;_T!S_\"B?S1[J]8_9L_:\U?]F7P#\5?#^EZ3IF
MI6_Q8\-2^&+^6Z=UDL89(YXS)%M."X$['#9&5'O7] G_  [V^ ?_ $0_X/\
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M=9TJ]DG'@#2T\RUM]0M[BZ@RMOG]];Q2Q8/!\S#?*373?\.G?V6?^C:?V?\
M_P -YI'_ ,CT ?Q!U[Y_P3!_Y/G\"_6^_P#2"YK^P#_AT[^RS_T;3^S_ /\
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ME0DGLWS-WU;UN]7=O5W>IG6X-Q]6'LZE>+7^';1+2RTT2T5EH?DDGQ_U"/\
M9GD^&'V"R_LN3Q /$)O=[?:!+Y(B\O'W=N!G/6N$W5^X/_#'7PC_ .B5_#C_
M ,)JR_\ C='_  QU\(_^B5_#C_PFK+_XW711\0L%2OR4)+F=WJM6]V85.!,7
M4MSUD[)):/9=#\/MU&ZOW!_X8Z^$?_1*_AQ_X35E_P#&Z/\ ACKX1_\ 1*_A
MQ_X35E_\;K7_ (B3AO\ GS+[T9_\0_Q'_/V/W,_#[=7(?$**UEUNS\[RVD6!
MM@?&"-W./TK]\/\ ACKX1_\ 1*_AQ_X35E_\;JM?_L/_  5U5U:Z^$'PON60
M84R^%;%RH]!F*OC^/.)*>?Y-4RNC%PE-Q=W9KW9*73T/U+P97^I?%=#B'%?O
M84XU$XQT;YX2@K-Z:-W?D?SF>)%MXM8D%N5\OOM^Z#WQ^-4=PK^CC_A@CX%_
M]$7^$W_A(:?_ /&J3_A@?X%_]$6^$O\ X2&G_P#QJOPJ/ ]=*WM5]S/[GI?2
MRRB$%'ZA5=O[T3\%=6_:CU/6/V.M,^#,NDZ;_8NE^)V\41ZAN?[4\S12Q>65
M^[LQ*3D#/ K)\#?'>_\  7P*^(W@*VLK.:P^)#Z2]Y=NSK-9_P!G7$D\?E@'
M!WM*0V[/ XYK^@'_ (8(^!?_ $1;X3?^$AI__P :H_X8(^!?_1%OA-_X2&G_
M /QJNC_5+%W4O;*Z7+MTM:WW-H\R/TE^&%2E165U.6515FN=:U%.-13WWYXQ
ME;:ZVMH?B@?^"FGCS1M!U>/PU#:>$]<UC0-!\-MKNG32"^MK325<((F;.PS%
M_P!X1U  ]Z&_X*#QZQ^T,WQ6U[X8^%=>\?1G3;NTU1]5U&S-M?V4*PK=%+>9
M%D$BI'OA<%&V8Z$BOVN_X8'^!?\ T1;X2_\ A(:?_P#&J7_A@CX%_P#1%OA-
M_P"$AI__ ,:K?_5O,':]=.SOJKJ^NMFK7U>NYXT?';@B/,Z>3U(N2<9.-1QD
MXM03BY1DI.+5."Y6^6RVU=_P\\:?MP1_%SX76OA_QU\.?"_B[4M.U#7=6LM:
MDU"_L9[.[U>Z-W<RK%;S)$V)=A575E C QRV4_89_;LOOV$]>UW5]&\&^%_$
MFM:U!':IJ&J>:MQI\*[B\<+QD%!(2I;&,^6GH,?N)_PP1\"_^B+?";_PD-/_
M /C5)_PP/\"_^B+?"7_PD-/_ /C53'AC'*I&LJRYH[/EUVMVUT[W-ZGT@.#J
MF K97/*JKH5G>4/:OE;<N=V7-:"<FVU#E3;U3/P/_:1^/NE_'[Q!IVH:;\._
M!OP]:SCE6YC\/Q.JZE)(X;S9BY)9Q@\]3N.<UYQN%?T<?\,$? O_ *(M\)O_
M  D-/_\ C5'_  P1\"_^B+?";_PD-/\ _C5<]7@W$U).<ZL;ORM^1[N7_2FR
M' X:.$PN755".R=12>]]Y-MZOJWVV/YQ]PHW"OZ-_P#A@?X%_P#1%OA+_P"$
MAI__ ,:I?^&"/@7_ -$6^$W_ (2&G_\ QJL_]2:__/Q?<SL_XFVRC_H J?\
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M/^?L?N9^(5IS+^%%?M\O['GPC4\?"WX<CZ>&K+_XW14_\1(PW_/F7WH:\/\
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MP3X9\5:DI E2RT>[,5KGH9IFNQ%"I_O2NH]ZZ']HO]NG]KO]DBUTF;XC>!/
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MXXX_PJ;^W;?_ )Z+^=?C1IG_  6O\70--]HO=/F7HK+X)<8Z_P#4:[TNB?\
M!9KQEJ5XT<FKZ7$H4L-W@MDS^)UHBD^+, M6W^'^9$OH\\813;IQLO\ '_\
M('[)7&N0M"VR1=WLW;O^E$>MVZN-LB[,=SSFOQEE_P""T?C87$BQZII<BJQ
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M+=_&HJR_8? 2D@C(TV\W+^=WU^M0V7_!;;XU6=E#"T'@>Y>&-4,TVG77F3$
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M^C)QO_)2_P#!B_R/W&_MVW_YZ+^=']NV_P#ST7\Z_#G_ (?>?&K_ )\? /\
MX+;O_P"2Z/\ A]Y\:O\ GQ\ _P#@MN__ )+I_P"MV7]W]P_^)8^-OY*7_@Q?
MY'[C?V[;_P#/1?SH_MVW_P">B_G7X<_\/O/C5_SX^ ?_  6W?_R71_P^\^-7
M_/CX!_\ !;=__)='^MV7]W]P?\2Q\;?R4O\ P8O\C]QO[=M_^>B_G1_;MO\
M\]%_.OPY_P"'WGQJ_P"?'P#_ ."V[_\ DNC_ (?>?&K_ )\? /\ X+;O_P"2
MZ/\ 6[+^[^X/^)8^-OY*7_@Q?Y'[C?V[;_\ /1?SH_MVW_YZ+^=?AS_P^\^-
M7_/CX!_\%MW_ /)='_#[SXU?\^/@'_P6W?\ \ET?ZW9?W?W!_P 2Q\;?R4O_
M  8O\C]QO[=M_P#GHOYT?V[;_P#/1?SK\.?^'WGQJ_Y\? /_ (+;O_Y+H_X?
M>?&K_GQ\ _\ @MN__DNC_6[+^[^X/^)8^-OY*7_@Q?Y'[CIK5O(ZJ)%RQQUK
ME/@9XYF\3_!'P;JFJ70NM2U+0K&[NYB%4RRR6\;NQ"@ 99B<  <\ 5^,8_X+
M??&I6R+'P",=QIMYQ_Y-U%9?\%K_ (QZ;90VUMI?P[MK:VC6*&&+2KI(XD48
M55476%4   #@ 8J?];<OYKWE]W_!-8_1GXU5)P]G2NVG?VBV2=UMUNON/W+_
M +=M_P#GHOYT?V[;_P#/1?SK\-W_ ."X'QHC7<UEX 4#KG3;O_Y+K]./V"8?
MBUK7PN3QE\;+?0M%U75$6;2M L;*:WGTV C(DO/-FD_?/D$1  Q ?.3(Q2+T
M<OSS#8VI[.@F[;Z:+U9\1QIX0Y[PK@XXS.94HJ3M&*G>4GUY8I:I+5O1+2[N
MTG]&:IJ\>GP&61MJKSSVK /C^1K,WBVETU@I.;@(2F!U/T]^GO6=86$WQ2U-
MI)2\>AV[E6(.#>,.J*?[H_B;\!SDKWT,*6\*QQJJ1Q@*JJ,*H'0 5[!^6G%Z
M_HR^,(H]3TF9(=4B7@YPERO]Q_Z-V^E6/!'CD:H&M[A6M[RW;RYH9!AXV]"/
M\Y'M5/Q#X9N/ UX^I:2C2:>QW7%H@R8/5D']WU7MVXX#=2TNW\>VL.IZ9-';
MZM"H\N7/R3KU$;X[>AZK[C((!W:.'7(I:X_P1XY^WL]I=H]M?6S>7-#)PR-[
M_P P1P001D5UR.)%R* '4444 %%%% !1110!E>+_ /D#R_[IK\9?BW^S]:_M
M2_\ !;Q? ^I*6T?5M0L9]37)'F6EOI45S-&2.5\Q(C'D<@R C!K]FO%__('E
M_P!TU^6_P:URWT;_ (.&98YRJMJ5F]I"3_ST_L))/U6)A^-?/<14XU(4*<]G
M4BG^)^V>"&88C XG.,9A&U4IX#$2BUNFI4VFO3?Y'M?_  6;_;U\5?L0>$?
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M_;.H\?\ DQ7VOL'H/RJ"_0!8VV[MCYP.IX/\NOX4_P"RL%_SYA_X"O\ (/\
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MJ?PC/88JK_9MK]LEN0D:W<\:123*H#LB%RBD]PI=R >FX^M1_9>"_P"?,/\
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M_P#0CI_X.-1_^2*^U]@]!^5&P>@_*C^R\%_SYA_X"O\ (/\ B(O%G_0TQ/\
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MT'?\-E>!_P#H:O#O_@S@_P#BJ</VN?!MXFY/%&@;5S\PU*#@_P#?5?SW_9/
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M5MFOS]3[+->&<NR+ASAK/LLARXFK./M))N]15%>49:ZJUX6_E;3W/D[XM_\
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MOIEXDT?WE_6KVN>*Y-7M_*5/+3J?>LNBAQ3=V5/"TYS522U044451T!1110
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M1]?/,+3MRR4_\,J>GKS3C^%SS4JI':C"UZ5_PC&I?]$8O?\ P&UO_P".T?\
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MH84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6>%:7J_QTT.?+_!?@''8U9?A.(8SJR=DE&/O/HHOFY9-]$F[]+G[&_\ #?\
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M5? FGQHSG &J7F%]OOT+C2I_)'[Y?_(A_P 2JX:]GB:WE[E'_P"7'[P>*_\
M@HY\,O"FGQW#>,/#%\SW]G8F*UUFUD=/M%U%;>:1YG^KC\WS'/\ #'&YYQBK
M_P#PW_\ #'_H?/!G_@\M?_CE?SYO9+>V<<ABM[-8XF"OMP+@KU'U_G5$0IC[
MJ_E6:XXJ_P#/I?>_\CT*?T2\MDO^1C/_ ,%Q_P#DC^AK_AO_ .&/_0^>#/\
MP>6O_P <H_X;_P#AC_T/G@S_ ,'EK_\ '*_GF6W1O[BJ.,D4?9U!P57BC_7>
MK_SZ7WO_ "+_ .)2<MO;^T9_^"X__)']#/\ PW_\,?\ H?/!G_@\M?\ XY1_
MPW_\,?\ H?/!G_@\M?\ XY7\\WD)_=7\JO>%_"&H>.?$^GZ)HFFW6K:SJUPE
MK965K'YDUU*QPJ*OJ?R R20 337&U9NRI+[W_D34^B7E=.#J5,SFHI7;=.*2
M2W;?-HEU9_0QX<_;;\!^,M?L])T?Q9X9U;5M0D\FULK/5K>>XN7P3M1%<DG
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!S/Q/_Y%V?\
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MP:?WZF>%X5\*(8FE6QF=/$PI.\*=7$QE37ERJ,7;RO9K1IH^6(8E@B5%X50
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M(SS_ #_2LR1F$"C<Q1?N@MD?@*^T;W_@E]^T';.HCT/X4S;ER2-'TD;3Z?\
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M(WRVMGI]K,N"&&)(K9'7)&#AAD9!R"168O\ P1X^-5GIU]9G1_#5P920DO\
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M=O\ JVZ]O/\ X3_"_P :>#OBMX;UK4/A_P"-GT_3=8L[R\5/#MXV88KA'D
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MSORIRMRW23;22=O9?^&Z?VJ,?\C1)_X+='_^-4A_;G_:H)_Y&R8>W]FZ-_\
M&J\EO_V2]5'P[T/7--:^UJZUS1M-U2/3K31Y9)5EOM6O],BM0R,V9#)8[ER
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MX4TZPTRSNFNKNUN&CM=0O[[9(\$J%X97U"02P,?+D\BW+*VPJW<_#O\ 9O\
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MUO\ P3*_:X\$_ ;6;[X0:UI<WAN_FU=HH=9NT>%M3OCMA:*YC<!K9]R!8E(
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MKX-_\J'_ ,B5^I'_ !#]?#G_ *#GC[_P8VO_ ,C4?\0_7PY_Z#GC[_P8VO\
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M?KX<_P#0<\??^#&U_P#D:I_U3QW\L?O9M_Q,IPC_ -!-?_P5 _+?_A7&G_\
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:BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784613088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 13, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Diffusion Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">dffn<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,526,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784831632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,896,468<span></span>
</td>
<td class="nump">$ 1,552,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses, deposits and other current assets</a></td>
<td class="nump">769,946<span></span>
</td>
<td class="nump">50,844<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,666,414<span></span>
</td>
<td class="nump">1,603,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">460,652<span></span>
</td>
<td class="nump">79,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,929,258<span></span>
</td>
<td class="nump">6,929,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">450,491<span></span>
</td>
<td class="nump">232,675<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,145,815<span></span>
</td>
<td class="nump">17,484,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Current portion of convertible debt</a></td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">511,956<span></span>
</td>
<td class="nump">1,684,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,628,851<span></span>
</td>
<td class="nump">874,264<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,690,807<span></span>
</td>
<td class="nump">4,438,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible debt, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNoncurrent', window );">Deferred income taxes</a></td>
<td class="nump">2,223,678<span></span>
</td>
<td class="nump">3,279,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">31,915<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,915,871<span></span>
</td>
<td class="nump">8,299,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Convertible preferred stock, $0.001 par value: Series A - 13,750,000 shares authorized, 12,376,329 and 8,306,278 shares issued and outstanding, respectively at December 31, 2017; No shares authorized, issued or outstanding at December 31, 2016 (liquidation value of $16,778,682 at December 31, 2017)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 14,519,629 and 10,345,637 shares issued and outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">14,520<span></span>
</td>
<td class="nump">10,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">82,770,313<span></span>
</td>
<td class="nump">69,363,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(61,554,889)<span></span>
</td>
<td class="num">(60,189,237)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">21,229,944<span></span>
</td>
<td class="nump">9,184,684<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock and stockholders' equity</a></td>
<td class="nump">$ 26,145,815<span></span>
</td>
<td class="nump">$ 17,484,384<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences, with jurisdictional netting and classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31958-109318<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936373248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">13,750,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">12,376,329<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">8,306,278<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Preferred stock, liquidation value</a></td>
<td class="nump">$ 16,778,682<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">14,519,629<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">14,519,629<span></span>
</td>
<td class="nump">10,345,637<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784907552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 5,088,621<span></span>
</td>
<td class="nump">$ 7,252,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">6,191,845<span></span>
</td>
<td class="nump">11,094,146<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">67,981<span></span>
</td>
<td class="nump">25,342<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="nump">11,348,447<span></span>
</td>
<td class="nump">18,371,729<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest expense, net</a></td>
<td class="nump">48,006<span></span>
</td>
<td class="nump">29,686<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liability (Note 14)</a></td>
<td class="num">(22,072,322)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpense', window );">Warrant related expenses (Note 10)</a></td>
<td class="nump">10,225,846<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other financing expenses</a></td>
<td class="nump">2,870,226<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from operations before income tax benefit</a></td>
<td class="num">(2,420,203)<span></span>
</td>
<td class="num">(18,401,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(1,055,685)<span></span>
</td>
<td class="num">(364,796)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(1,364,518)<span></span>
</td>
<td class="num">(18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A cumulative preferred dividends</a></td>
<td class="num">(1,252,394)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,616,912)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Per share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">12,447,641<span></span>
</td>
<td class="nump">10,232,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted (in shares)</a></td>
<td class="nump">12,755,316<span></span>
</td>
<td class="nump">10,232,791<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785625376">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Series A Preferred Stock [Member]</div>
</th>
<th class="th"><div>Series A Preferred Stock [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,118,939<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2015</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,119<span></span>
</td>
<td class="nump">$ 42,102,876<span></span>
</td>
<td class="num">$ (42,152,618)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (41,623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,861,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Fair value of RestorGenex shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,862<span></span>
</td>
<td class="nump">19,544,138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,546,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed', window );">Estimated fair value of RestorGenex stock options outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,321,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed', window );">Estimated fair value of RestorGenex warrants outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">384,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">148,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for advisory services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 148<span></span>
</td>
<td class="nump">1,409,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,409,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">217,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">711,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt', window );">Settlement of litigation matter upon issuance of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,391,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,036,619)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,036,619)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Series A cumulative preferred dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,345,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2016</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 10,346<span></span>
</td>
<td class="nump">69,363,575<span></span>
</td>
<td class="num">(60,189,237)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,184,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,606<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Common stock issued for advisory services</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">49,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,070,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,070,051)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,070<span></span>
</td>
<td class="num">(4,070)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,364,518)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,364,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_CumulativeEffectOfChangeInAccountingPrinciple', window );">Cumulative effect of change in accounting principle (a)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants', window );">Reclassification of the fair market value of the Series A warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,153,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,153,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Series A cumulative preferred dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,252,394)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,252,394)<span></span>
</td>
<td class="num">(1,252,394)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStockShares', window );">Stock Reclassified Upon Conversion of Preferred Stock, Shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Reclassification of accrued dividends upon conversion of Series A</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 86<span></span>
</td>
<td class="nump">189,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">190,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature', window );">Beneficial conversion feature for accrued interest of convertible debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,017<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,519,629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,306,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2017</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 14,520<span></span>
</td>
<td class="nump">$ 82,770,313<span></span>
</td>
<td class="num">$ (61,554,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,229,944<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In 2017, the Company adopted provisions of ASU 2016-09, Improvements to Employee Share Based Payment Accounting, resulting in a cumulative effect adjustment to Accumulated Deficit and Additional Paid-in Capital for previously unrecognized stock-based compensation expense. See Note 3 for further discussion of the impacts of ASU 2016-09.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from the reclassification of the fair market value of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AdjustmentsToAdditionalPaidInCapitalFairValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of convertible debt to settle a litigation matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AdjustmentsToAdditionalPaidInCapitalSettlementOfLitigationIssuanceOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from stock options assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AdjustmentsToAdditionalPaidInCapitalStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from stock warrants assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AdjustmentsToAdditionalPaidInCapitalStockWarrantsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_CumulativeEffectOfChangeInAccountingPrinciple">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of an accounting principle applied during the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_CumulativeEffectOfChangeInAccountingPrinciple</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockReclassifiedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provides information about the amount of reclassification of accrued dividends upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockReclassifiedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockReclassifiedUponConversionOfPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about the number of shares relating to the reclassification of accrued dividends upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockReclassifiedUponConversionOfPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e34017-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=84234705&amp;loc=SL4590271-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568740-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784786128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flow - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,364,518)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">67,981<span></span>
</td>
<td class="nump">25,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sale or disposal of assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">1,240,551<span></span>
</td>
<td class="nump">1,391,068<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Common stock issued for advisory services</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">1,409,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses', window );">Warrant related expense, change in fair value, and other financing expenses</a></td>
<td class="num">(8,976,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Abandonment of in-process research and development intangible asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">951,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Change in deferred income taxes</a></td>
<td class="num">(1,055,685)<span></span>
</td>
<td class="num">(364,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement of litigation matter</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense, net</a></td>
<td class="nump">33,517<span></span>
</td>
<td class="nump">38,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="num">(664,162)<span></span>
</td>
<td class="nump">319,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="num">(1,663,789)<span></span>
</td>
<td class="nump">991,625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(12,332,355)<span></span>
</td>
<td class="num">(10,768,265)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows (used in) provided by investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(447,823)<span></span>
</td>
<td class="num">(2,331)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit', window );">Purchases of certificates of deposit</a></td>
<td class="num">(10,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of certificates of deposit</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromReverseMergerTransaction', window );">Cash received in reverse merger transaction</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">8,500,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(447,823)<span></span>
</td>
<td class="nump">8,498,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts', window );">Proceeds from the sale of Series A convertible preferred stock and warrants, net</a></td>
<td class="nump">22,129,774<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from the issuance of convertible debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of convertible debt</a></td>
<td class="num">(1,880,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of offering costs</a></td>
<td class="num">(125,980)<span></span>
</td>
<td class="num">(54,346)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,123,794<span></span>
</td>
<td class="nump">1,825,654<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">7,343,616<span></span>
</td>
<td class="num">(444,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">1,552,852<span></span>
</td>
<td class="nump">1,997,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">8,896,468<span></span>
</td>
<td class="nump">1,552,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">112,800<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ReclassificationOfTheFairMarketValueOfWarrants', window );">Reclassification of the fair market value of the Series A warrants</a></td>
<td class="nump">13,153,524<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Series A cumulative preferred dividends</a></td>
<td class="nump">1,252,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Conversion of accrued dividends related to convertible preferred stock</a></td>
<td class="nump">190,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_OfferingCostsInAccountsPayable', window );">Offering costs in accounts payable and accrued expenses</a></td>
<td class="nump">146,776<span></span>
</td>
<td class="nump">126,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of convertible notes and related accrued interest into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">711,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Consideration in connection with RestorGenex Corporation merger transaction</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,261,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Series A cumulative preferred dividends</a></td>
<td class="nump">1,252,394<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Conversion of accrued dividends related to convertible preferred stock</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Conversion of accrued dividends related to convertible preferred stock</a></td>
<td class="nump">$ 190,080<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_OfferingCostsInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount in Accounts Payable from offering costs in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_OfferingCostsInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromReverseMergerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with a reverse merger transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromReverseMergerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ReclassificationOfTheFairMarketValueOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reclassification of the fair market value of warrants in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ReclassificationOfTheFairMarketValueOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockReclassifiedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provides information about the amount of reclassification of accrued dividends upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockReclassifiedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in warrant related expense, change in fair value of liabilities, and other financing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantExpenseChangeInFairValueAndOtherFinancingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2443-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from temporary investment with specific maturity and interest rate that are prohibited for current use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRestrictedCertificatesOfDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775727808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.</div> Organization and Description of Business</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Diffusion Pharmaceuticals Inc. &#x201c;Diffusion&#x201d; or &#x201c;the Company&#x201d; is a clinical stage biotechnology company focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy. The Company is developing its lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (&#x201c;TSC&#x201d;), for use in the many cancer types in which tumor oxygen deprivation (&#x201c;hypoxia&#x201d;) is known to diminish the effectiveness of current treatments. TSC is designed to target the cancer<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s hypoxic micro-environment, re-oxygenating treatment-resistant tissue and making the cancer cells more susceptible to the therapeutic effects of standard-of-care radiation therapy and chemotherapy.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2015, </div>the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s predecessor for accounting purposes, Diffusion Pharmaceuticals LLC (&#x201c;Diffusion LLC&#x201d;) entered into a definitive merger agreement with the Company, then known as &#x201c;RestorGenex Corporation&#x201d; and traded on the over-the-counter stock exchange under the ticker symbol &#x201c;RESX.&#x201d; On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 8, 2016 </div>the Company completed the merger with Diffusion LLC under which a newly formed subsidiary of the Company merged with and into Diffusion LLC in an all-stock transaction, with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the merger, the Company was renamed &#x201c;Diffusion Pharmaceuticals Inc.&#x201d; and the Company&#x2019;s ticker symbol was changed to &#x201c;DFFN.&#x201d; On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 9, 2016, </div>the Company&#x2019;s common stock (&#x201c;Common Stock&#x201d;) began trading on the NASDAQ Capital Market exchange.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The merger transaction was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-transaction owners held an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84.1%</div> economic and voting interest in the combined company immediately following the closing of the merger, Diffusion LLC is considered to be the acquirer of RestorGenex for accounting purposes (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>). </div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s members&#x2019; capital at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2016 </div>has been recast as common stock and additional paid in capital. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 17, 2016, </div>the Company effected a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>-for-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> reverse split of its common stock. The accompanying consolidated financial statements and these notes give retroactive effect to this reverse stock split.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Each outstanding unit of membership interest of Diffusion LLC (the &#x201c;Diffusion Units&#x201d;) was converted into the right to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3652658</div> shares of Common Stock (the &#x201c;Exchange Ratio&#x201d;). Additionally, the right of holders of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million outstanding convertible notes of Diffusion LLC to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the original terms of the notes multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495,615</div> options to purchase Common Stock on terms substantially identical to those in effect prior to the merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941171968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Substantial Doubt about Going Concern [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.</div> Liquidity</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> generated any revenues from product sales and has funded operations primarily from the proceeds of private placements of its membership units (prior to the Merger) and convertible notes, as well as through the reverse merger. Substantial additional financing will be required by the Company to continue to fund its research and development activities. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> assurance can be given that any such financing will be available when needed or that the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s research and development efforts will be successful.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties and other strategic alliances and business transactions. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 22, 2018, </div>the Company closed its previously announced underwritten public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000,000</div> shares of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share, and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000,000</div> shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,970,625</div> shares of Common Stock pursuant to the underwriter&#x2019;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div> per share and warrant for total gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.0</div> million. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div> per share and a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of Common Stock. The underwriter&#x2019;s warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00,</div> a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,568,632</div> shares (the &quot;Conversion Shares) of common stock (including accrued dividends paid in kind and issuance of shares in respect of the &quot;make-whole&quot; adjustment feature thereof).</div></div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company currently does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have any commitments to obtain additional funds and <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>be unable to obtain sufficient funding in the future on acceptable terms, if at all. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 2, 2018, </div>the Company received a written notice from the NASDAQ Staff indicating the Company was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> in compliance with Nasdaq Listing Rule <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5550</div>(a)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div>) because the bid price for the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s common stock had closed below <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share for the previous <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30</div> consecutive business days. In accordance with Nasdaq Listing Rule <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5810</div>(c)(<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>)(A), the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">180</div> calendar days from the date of such notice, or until <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 29, 2018, </div>to regain compliance with the minimum bid price requirement. To regain compliance, the bid price for the Company&#x2019;s common stock must close at <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00</div> per share or more for a minimum of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div> consecutive business days. In the event the Company is unable to regain compliance, it could adversely affect the Company&#x2019;s ability to obtain future funding. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties to: commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>receive lower consideration upon commercialization of such products than if it had <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> entered into such arrangements or if it entered into such arrangements at later stages in the product development process.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: justify; text-indent: 44pt;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company<div style="display: inline; font-family:'Times New Roman', Times, serif;font-size:10pt;">&#x2019;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#x2019;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#x2019;s financial condition and future operations. The Company believes its cash and cash equivalents as of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> together with the proceeds from public underwritten offering received in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> January 2018, </div>are sufficient to fund operations through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> June </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> 2019.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775744000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Basis of Presentation and Summary of Significant Accounting Policies</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>    <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The carrying amounts of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the fair value of the Company's outstanding Series B convertible note was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the fair value of the Company&#x2019;s outstanding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> convertible note and Series B convertible note was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> of the fair value hierarchy.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash and cash equivalents.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> recognized any impairment of long-lived assets during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets are comprised of identifiable in-process research and development (IPR&amp;D) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2016, </div>the Company abandoned the future development efforts with respect to its RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440</div> product candidate, and the value of the associated IPR&amp;D asset was written down to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>).</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Goodwill</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>    <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company performs its annual goodwill impairment test on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s goodwill is less than the carrying value of the reporting unit&#x2019;s goodwill. The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> recognize any impairment of goodwill during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016.</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Offering Costs</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Offering costs are either expensed upon completion or abandonment of the related financing or offset against the proceeds of the offering, depending upon the accounting treatment of the offering. Offering costs consist principally of legal and accounting costs incurred through the balance sheet date related to the Company&#x2019;s underwritten public offering, private placement financings and are recognized in other assets on the consolidated balance sheet.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Research and Development</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the end of the reporting period, the Company compares payments made to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>record net prepaid or accrued expenses relating to these costs.</div> <div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upfront payments made to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Patent Costs</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Income Taxes</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prior to the Merger, Diffusion LLC was treated as a partnership for federal and state income tax purposes. Diffusion LLC<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s taxable income or loss, as well as certain other tax attributes, were passed through directly to its members and were reported in each member&#x2019;s individual income tax return.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon completion of the Merger as discussed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> the Company converted from a partnership to a corporation for accounting purposes. As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that some portion or all of a deferred tax asset will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be sustained.</div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>    <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 22, 2017 </div>the President of the United States signed into law the Tax Cuts and Jobs Act (&quot;The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act&quot;).&nbsp;This legislation makes significant changes in the U.S. tax laws including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, reducing the corporate tax rate to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> starting in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%.</div>&nbsp;&nbsp;As a result of the change, the Company recorded a current period tax benefit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million in its consolidated statement of operations and a corresponding reduction in the deferred tax liability on its consolidated balance sheet.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Stock-based Compensation</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The expected term of stock options was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> dividend yield because dividends are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be paid in the near future, which is consistent with the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s history of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer estimates forfeitures and accounts for forfeitures in the periods they occur.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the &#x201c;if-converted&#x201d; method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have been incurred if the warrants had been converted into common stock.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div>    <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,364,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accretion of Series A cumulative preferred dividends</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,252,394</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,072,322</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24,689,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock equivalents arising from warrants</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">307,675</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,755,316</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.94</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214,385</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">757,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">460,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,306,278</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock awards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,066</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,204</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,527,439</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,435,243</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amounts in the table reflect the common stock equivalents of the noted instruments.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Comprehensive Loss</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> items of comprehensive income or loss other than net loss.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> July 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Earnings Per Share (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>); Distinguishing Liabilities from Equity (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480</div>); Derivatives and Hedging (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> part of this update addresses the complexity of accounting for certain financial instruments with down round features and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2018 </div>and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div>    <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Modification Accounting for Share-Based Payment Arrangements</div>, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> Specifically, an entity would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2017 </div>and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this new guidance to have a material impact on its consolidated financial statements.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Compensation &#x2013; Improvements to Employee Share-Based Payment Accounting</div>, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2016 </div>and interim periods within those years. The Company adopted this standard in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> by electing to account for forfeitures in the period that they occur. Under ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div></div> on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2017.</div></div></div> <div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>)</div>. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. Upon adoption in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company will determine the fair of the operating lease and recognize this amount as a lease asset and corresponding liability on its consolidated balance sheet. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this new guidance to have a material impact on its consolidated financial statements.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941232592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Acquisition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div> Acquisitions</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Merger with Diffusion Pharmaceuticals LLC</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2015, </div>the Company entered into a merger agreement (the &#x201c;Merger Agreement&#x201d;) with Diffusion LLC. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 8, 2016, </div>the Company completed the merger (the &#x201c;Merger&#x201d;), with Diffusion LLC surviving as a wholly-owned subsidiary of the Company. Subsequent to the Merger, the Company was renamed &#x201c;Diffusion Pharmaceuticals Inc.&#x201d; and the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s ticker symbol was changed from &#x201c;RESX&#x201d; to &#x201c;DFFN.&#x201d; In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 2016, </div>the Company&#x2019;s Common Stock was approved for listing on the NASDAQ Capital Market and continues to trade under the ticker symbol &#x201c;DFFN&#x201d;. The Company and Diffusion LLC entered into the Merger Agreement in an effort to provide improved access to the capital markets in order to obtain the resources necessary to accelerate development of TSC in multiple clinical programs and continue to build an oncology-focused company.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Merger was accounted for as a reverse acquisition under the acquisition method of accounting. Because Diffusion LLC<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-transaction owners held an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">84.1%</div> economic and voting interest in the combined company immediately following the completion of the Merger, Diffusion LLC is considered to be the acquirer of the Company for accounting purposes.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Each Diffusion Unit was converted into the right to receive <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.3652658</div> shares of Common Stock based on the Exchange Ratio. Additionally, the rights of holders of Diffusion LLC<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s outstanding convertible notes to convert such notes into Diffusion Units was converted into the right to convert such notes into a number of shares of Common Stock equal to the number of Diffusion Units into which such notes would have been convertible under the terms of the notes in effect immediately prior to the consummation of the Merger multiplied by the Exchange Ratio. In addition, all outstanding options to purchase Diffusion Units were assumed by the Company and the right to exercise such options for Diffusion Units converted into a right to exercise such options for Common Stock on terms substantially identical to those in effect prior to the Merger transaction, except for adjustments to the underlying number of shares and the exercise price based on the Exchange Ratio.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger, the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s former Board of Directors authorized, declared and effected a distribution of contingent value rights (&#x201c;CVRs&#x201d;) to stockholders of the Company as of the close of business on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 7, 2016. </div>Each CVR is a non-transferable right to potentially receive certain cash payments in the event the Company receives net cash payments during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5</div>) year period after the Merger as a result of the sale, transfer, license or similar transaction or any other agreement to the extent relating to the development of the Company&#x2019;s product currently known as RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440,</div> a &#x201c;soft&#x201d; anti-androgen. See below for additional fair value information.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The purchase consideration in a reverse acquisition is determined with reference to the value of equity that the accounting acquirer, in this case, Diffusion LLC, would have had to issue to the owners of the accounting acquiree, the Company, to give the pre-acquisition equity holders of the Company the same percentage interest in Diffusion LLC that such pre-acquisition equity holders held in the Company immediately following the Merger. The purchase price was calculated as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger shares outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,546,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger stock options outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,321,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger warrants outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">384,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">CVRs <div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2013; RES-440 product candidate</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total purchase price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,261,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Merger transaction has been accounted for using the acquisition method of accounting, which requires that assets acquired and liabilities assumed be recognized at their fair values as of the acquisition date. The valuation technique utilized to value the IPR&amp;D was the cost approach.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,500,602</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,600,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,929,258</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(377,432</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,644,159</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,261,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Qualitative factors supporting the recognition of goodwill due to the Merger include the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s anticipated enhanced ability to secure additional capital and gain access to capital market opportunities as a public company and the potential value created by having a more well-rounded clinical development portfolio by adding the earlier stage products acquired in the Merger to the Company&#x2019;s later state product portfolio. The goodwill is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> deductible for income tax purposes. The values allocated to IPR&amp;D intangible assets are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.6</div> million for the RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div> compound and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million for the RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440</div> compound, each with indefinite useful lives. See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6</div> for additional information.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pro Forma Financial Information (Unaudited)</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following pro forma financial information reflects the consolidated results of operations of the Company as if the Merger had taken place on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2016. </div>The pro forma financial information is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> necessarily indicative of the results of operations as they would have been had the transactions been effected on the assumed date.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style="display: inline; font-weight: bold;">31, 2016</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,471,398</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted loss per share</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-recurring pro forma transaction costs directly attributable to the Merger were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.6</div> million for the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016 </div>and have been deducted from the net loss presented above. The costs deducted from the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016 </div>period included a success fee and other transaction costs<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">46,000</div> shares of common stock with a fair market value of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.5</div> million paid to a financial advisor upon the closing of the Merger on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 8, 2016. </div>Additionally, RestorGenex incurred approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.0</div> million in severance costs as a result of resignations of executive officers immediately prior to the Merger and approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.7</div> million in share-based compensation expense as a result of the acceleration of vesting of stock options at the time of Merger. These costs are excluded from the pro forma financial information for the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016. </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> such costs were recorded during the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017. </div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775710080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Property and Equipment</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Property and equipment consists of the following:</div> <div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155,113</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,290</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">767,470</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">319,647</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(306,818</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(239,892</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">460,652</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79,755</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Depreciation expense was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$68,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25,000</div> for the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941301616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Goodwill and Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Goodwill and Intangible Assets</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company completes its annual impairment test on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>each year, or more frequently if triggering events indicate a possible impairment. The Company continually evaluates financial performance, economic conditions and other relevant developments in assessing if an interim period impairment test is necessary. The Company's goodwill balance at both <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6.9</div></div> million. There have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> changes to the carrying value of goodwill during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger, the Company acquired indefinite-lived In-Process Research and Development Assets (&#x201c;IPR&amp;D&#x201d;) RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div> and RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440,</div> with estimated fair values of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.6</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million, respectively. The Company&#x2019;s novel <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</div> pathway inhibitor, RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529,</div> is in preclinical development for oncology. Through a series of in vitro and in vivo animal models, RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div> has been shown&nbsp;to have activity in several cancer types due to its ability to target and inhibit the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</div> signal transduction pathway. RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div> is a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div>-in-class inhibitor of both <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">TORC1</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">TORC2</div> that is mechanistically differentiated from other <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">PI3K/Akt/mTOR</div> pathway inhibitors currently in development. RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">529</div> has shown activity in both in vitro and in vivo glioblastoma animal models and has been demonstrated to be orally bioavailable and can cross the blood brain barrier.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2016, </div>the Board of Directors determined that RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440,</div> a &#x201c;soft&#x201d; anti-androgen compound for the treatment of acne vulgaris, was outside the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s core product focus, and was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> a priority. Therefore, future development efforts were abandoned in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> In connection with its review of such abandonment, the Company concluded RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440</div> was impaired in its entirety. The abandonment resulted in a net impairment charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million and was recorded as a component of research and development expenses within the Company&#x2019;s consolidated statement of operations for the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016. </div>The abandonment also resulted in an income tax benefit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final.  May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775875872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Accrued Expenses and Other Current Liabilities</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Accrued expenses and other current liabilities consist of the following:</div> <div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued interest payable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37,415</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued Series A dividends</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,062,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">312,221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">399,740</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122,711</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,855</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,350</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,840</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151,332</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,628,851</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">874,264</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941321712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Convertible Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Convertible Debt</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;The components of debt outstanding are as follows:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016 convertible notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,880,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pre-Merger convertible notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,880,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">For the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company recognized interest expense of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37,000,</div> respectively in connection with its convertible debt instruments. Accrued interest was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$37,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$29,000</div> as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> September 27, 2016, </div>the Company issued and sold convertible promissory notes (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x201c;2016</div> Convertible Notes&#x201d;) in an aggregate principal amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes were issued to an investor and certain other parties in connection with the settlement of a litigation matter. The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes had a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div>) year and bore interest at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.0%</div> per annum with the principal and accrued interest due upon the earlier of the maturity date or conversion date. The Company accounted for the issuance of the convertible promissory notes in accordance with ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">470</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">25</div> and, at the time of issuance, recorded a litigation settlement expense of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.5</div> million which represents the difference between the estimated fair value of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes issued and the cash received from the noteholders. Upon maturity of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company repaid the outstanding principal and interest of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million, respectively.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Pre-Merger Convertible Notes</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">From <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 2009 </div>through <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 2015, </div>the Company issued unsecured convertible promissory notes (the &#x201c;Pre-Merger Convertible Notes&#x201d;) for aggregate gross proceeds of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.4</div> million. The Pre-Merger Convertible Notes bore interest at either <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5%</div> per annum, however, all Pre-Merger Convertible Notes outstanding at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>bear interest at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1%</div> per annum. The Pre-Merger Convertible Notes accrue interest beginning on the date of issuance, with the principal and accrued interest due upon the earlier of the maturity date or conversion date. At any time prior to the maturity date, the holders <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>elect to convert, in whole or in part, the Pre-Merger Convertible Notes and any related accrued but unpaid interest into common stock of the Company at a price per share equal to the conversion price. In the event of a Change of Control or a Qualified Financing (each as defined below), the holders of the Pre-Merger Convertible Notes <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>declare the aggregate outstanding amount of the Pre-Merger Convertible Notes to be immediately due and payable or <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>elect to convert the Convertible Notes and any accrued but unpaid interest as if such conversion took place on the maturity date. A Change of Control is defined as: (i) a merger or consolidation in which the owners immediately prior to the transaction do <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> own, directly or indirectly, more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the surviving company; (ii) the acquisition of more than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">50%</div> of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s outstanding shares by a single person, entity or group or persons or entities acting in concert or (iii) the sale or transfer of all or substantially all of the assets of the Company. A Qualified Financing is defined as a sale of shares or other transaction that results in gross proceeds to the Company of at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$50.0</div> million, including proceeds received in connection with the conversion of any Pre-Merger Convertible Notes. Through the date the financial statements were available to be issued, there have been <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> Change of Control or Qualified Financing events. The Company <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>prepay the Pre-Merger Convertible Notes, in full or in part, at any time on a pari passu basis. Upon receipt of notice that the Company intends to prepay the Pre-Merger Convertible Notes, holders will have the option to convert their notes in lieu of payment.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the effective time of the Merger, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million in aggregate principal amount of Pre-Merger Convertible Notes were outstanding and<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;the rights of the holders of each such outstanding Pre-Merger Convertible Notes convertible into Diffusion Units were converted into the right to convert such securities into a number of shares of the Company&#x2019;s common stock equal to the number of Diffusion Units such Pre-Merger Convertible Notes would be convertible into pursuant to its terms multiplied by the Exchange Ratio.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016,</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Pre-Merger Convertible Notes&nbsp;of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.7</div> million&nbsp;and related accrued interest of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$16,000</div>&nbsp;were converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">217,122</div> shares of common stock.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775882992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9.</div>&nbsp;Commitments and Contingencies</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Office Space Lease Commitment</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company leases office and laboratory facilities in Charlottesville, Virginia. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 31, 2017, </div>the Company entered into a lease for its office and laboratory facilities at a new location in Charlottesville, Virginia. During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company capitalized approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million in leasehold improvements as part of the build-out of the new office and laboratory location. Rent expense related to the Company's operating leases for the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.1</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$66,000,</div> respectively. For the new operating lease, lease payments commenced on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 1, 2017 </div>and expire on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 30, 2022. </div>The Company will continue to recognize rent expense on a straight-line basis over the lease period and will accrue for rent expense incurred but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> yet paid. Future minimum rental payments under the Company's new non-cancelable operating lease at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> was as follows:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Rental</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Commitments</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112,354</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">116,464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,735</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501,481</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Arrangement with Clinical Research Organization</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> July 5, 2017, </div>the Company entered into a Master Services Agreement (&quot;MSA&quot;) with a contract research organization (&quot;CRO&quot;) to provide clinical trial services for individual studies and projects by executing individual work orders. The MSA and associated work orders are designed such that quarterly payments are to be made in advance of the work to be performed.&nbsp; The Company recognized research and development expenses related to this MSA of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million during the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017.&nbsp; </div>As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.8</div> million of prepaid research and development costs that are estimated to be recognized during the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> quarter of fiscal <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 26pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Legal Proceedings</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 7, 2014, </div>a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s former Chief Executive Officer under the caption <div style="display: inline; font-style: italic;">Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH</div> (Case <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">BC553996</div>). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 30, 2014, </div>the Company filed a petition to compel arbitration and a motion to stay the action. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 1, 2015, </div>the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a hearing for the petition and motion on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 14, 2015, </div>the Court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 8, 2016, </div>the plaintiff filed an arbitration demand with the American Arbitration Association. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div> arbitration hearing has yet been scheduled. The Company believes this matter is without merit and intends to defend the arbitration vigorously. Because this matter is in an early stage, the Company is unable to predict its outcome and the possible loss or range of loss, if any, associated with its resolution or any potential effect the matter <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#x2019;s financial position.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> September 21, 2015, </div>David Schmidt, a former member of Diffusion LLC and current stockholder of the Company, filed suit (the &#x201c;Original Complaint&#x201d;) in the Circuit Court for Albemarle County, Virginia (Case. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">CL15</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">791,</div> David G. Schmidt v. Diffusion Pharmaceuticals LLC), which Complaint was amended on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 14, 2016 (</div>the &#x201c;Amended Complaint&#x201d;). The Original Complaint alleged that a breach of contract with respect to Mr. Schmidt&#x2019;s previously converted convertible note, and requested relief of specific performance requiring Diffusion LLC to issue him additional units, representing the additional number of units he would have received had he converted at the renegotiated conversion price.</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> September 27, 2016, </div>the Company, Diffusion LLC, Mr. Schmidt and the other parties thereto entered into a Settlement Agreement (the &#x201c;Settlement Agreement&#x201d;) pursuant to which, among other things, (i) Mr. Schmidt and Diffusion each agreed to submit a consent order to the Court dismissing all claims set forth in the Amended Complaint with prejudice and without an admission of liability by any party, (ii) Mr. Schmidt and Diffusion each released, on behalf of such party and its heirs, assigns, representatives, affiliates and agents, all claims and causes of action of any nature against the other party existing as of the date of the Settlement Agreement and (iii) as consideration therefor, the Company agreed to issue and sell, to Mr. Schmidt and the other parties to the Settlement Agreement, the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes in an aggregate principal amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.9</div> million and are convertible into shares of Common Stock at an initial conversion price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.50</div> per share.</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company recognized a litigation settlement charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.5</div> million which represents the difference between the fair value of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> Convertible Notes issued and the cash received from Mr. Schmidt and other parties. The settlement charge was recorded as a component of general and administrative expenses within the Company&#x2019;s consolidated statement of operations for the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941167008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Convertible Preferred Stock and Stockholder's Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Convertible Preferred Stock and Stockholder&#x2019;s Equity</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In contemplation of completing the private placement described below, the Company amended and restated its articles of incorporation and authorized <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,750,000</div> shares of Series A convertible preferred stock.</div> <div style=" margin: 0pt; text-align: justify; text-indent: 45pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"></div> <div style=" margin: 0pt 0pt 0pt 10pt; text-align: justify; text-indent: -10pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Series<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;A Convertible Preferred Stock Transaction</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 2017, </div>the Company completed a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$25.0</div> million private placement of its securities in which the Company offered and sold units consisting of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s Series A convertible preferred stock and a warrant to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock for each share of Series A convertible preferred stock purchased in the offering. Each share of Series A convertible preferred stock entitles the holder to an <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0%</div> cumulative dividend payable in shares of the Company's common stock on a semi-annual basis. The holders <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may, </div>at their option, convert each share of Series A convertible preferred stock into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of the Company&#x2019;s common stock based on the initial conversion price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.02</div> per share, subject to adjustment. Each warrant entitles the holder to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> share of common stock at an initial exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22,</div> subject to adjustment and expires on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fifth</div> anniversary of their original issuance date. </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company sold <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,376,329</div> units in the private placement and received approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.1</div> million in aggregate net cash proceeds, after deducting commissions and other expenses of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.9</div> million. In addition, as compensation for its services, the Company granted to its placement agent in the offering warrants to purchase an aggregate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,179,558</div> shares of common stock at an initial exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div> per share, which expire on the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fifth</div> anniversary of their original issuance date.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During its evaluation of equity classification for the common stock warrants, the Company considered the conditions as prescribed within ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40,</div> <div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Derivatives and Hedging, Contracts in an Entity&#x2019;s own Equity</div> (&#x201c;ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40&#x201d;</div>). The conditions within ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40</div> are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> subject to a probability assessment. As the Company was obligated to issue a variable number of shares to settle the cumulative dividends on the Series A convertible preferred stock, the Company could <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> assert that there would be sufficient authorized shares available to settle the warrants issued in connection with the Series A offering. Accordingly, these warrants were classified as liabilities. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 1, 2017 </div>the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&#x2019;s Certificate of Incorporation to permit the Company to pay dividends on the Company&#x2019;s Series A Convertible Preferred Stock in either cash or shares of the Company&#x2019;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert that there will be sufficient authorized shares available to settle the Series A warrants, and as a result, the Series A warrants were reclassified from liabilities to stockholders&#x2019; equity in the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">fourth</div> quarter of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As the fair value of the warrants upon issuance was in excess of the proceeds of the Series A offering, there are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> proceeds allocated to the Series A convertible preferred stock. The excess fair value of the warrants over the gross proceeds of the Series A offering and the fair value of the warrants granted to its placement agent was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million in the aggregate and was recorded as warrant related expenses in the statement of operations for the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> </div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As a result of the completion of our common stock offering in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2018, </div>all outstanding shares of the Company's Series A convertible preferred stock converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,568,632</div> shares (the &quot;Conversion Shares&quot;) of common stock of which (i) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,306,278</div> shares were issued for the automatic conversion of Series A convertible preferred stock (ii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">593,933</div> shares were issued upon settlement of accrued dividends and (iii) <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,668,421</div> shares were issued for the settlement of the &#x201c;make-whole&#x201d; adjustment feature.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Dividends</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 36pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Until the conversion of all outstanding Series A convertible preferred stock in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2018, </div>the cumulative preferred dividend on the Series A convertible preferred stock was payable at a rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.0%</div> per annum, payable only in shares of common stock, semi-annually in arrears on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> April 1 </div>and <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>of each year commencing on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1, 2017. </div>This cumulative preferred dividend was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> subject to declaration. The Company recognized approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.3</div> million in dividends during the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.2</div> million was settled upon by the issuance of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">86,335</div> shares of the Company's common stock. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017, </div>there were approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million in accrued dividends that were subsequently settled in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2018. </div></div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div><div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"></div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Voting</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Subject to certain preferred stock class votes specified in the Certificate of Designation of Preferences, Rights and Limitations of the Series A Convertible Preferred Stock (the &#x201c;Certificate of Designation&#x201d;) or as required by law, the holders of the Series A convertible preferred stock voted together with the holders of common stock as a single class on an adjusted as-converted basis. In accordance with NASDAQ listing rules, in any matter voted on by the holders of the common stock, each share of Series A convertible preferred stock entitled the holder thereof to a number of votes based upon the closing price of our common stock on the NASDAQ Capital Market on the date of issuance of such shares of Series A convertible preferred stock. Accordingly, shares of Series A convertible preferred stock issued in the initial closing of the private placement on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 14, 2017 </div>were entitled to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.84874</div> votes per share and shares of Series A Preferred Stock issued in the final closing of the private placement on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 31, 2017 </div>were entitled to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">0.50627</div> votes per share, in each case, subject to adjustment as described in the Certificate of Designation.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Liquidation Preference</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Series A convertible preferred stock was senior to the common stock. In the event of a liquidation, dissolution or winding up of the Company, either voluntary or involuntary, or in the event of a deemed liquidation event, which includes a sale of the Company as defined in the Certificate of Designation, the holders of the Series A convertible preferred stock would be entitled to receive their original investment amount. If upon the occurrence of such event, the assets and funds available for distribution are insufficient to pay such holders the full amount to which they are entitled, then the entire remaining assets and funds legally available for distribution would be distributed ratably among the holders of the Series A convertible preferred stock in proportion to the full amounts to which they would otherwise be entitled.</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Conversion</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Series A convertible preferred stock was convertible, at the holder<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s option, into common stock. The Series A convertible preferred stock was also mandatorily convertible into common stock upon (a) the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">thirty</div>-day moving average of the closing price of the Company&#x2019;s common stock exceeding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$8.00</div> per share, (b) a financing of at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.0</div> million in gross proceeds or (c) upon the majority vote of the voting power of the then outstanding shares of Series A convertible preferred stock. The conversion price of the Series A convertible preferred stock was subject to adjustment as described in the Certificate of Designation. During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,070,051</div> shares of Series A convertible preferred stock were converted into common stock. Upon completion of the Company&#x2019;s public offering of its common stock in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2018, </div>all remaining shares of Series A convertible preferred stock issued and outstanding were converted into common stock.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Make-Whole Provision</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Until <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 2020 </div>and subject to certain exceptions, if the Company issued at least <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.0</div> million of its common stock or securities convertible into or exercisable for common stock at a per share price less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.02</div> (such lower price, the &#x201c;Make-Whole Price&#x201d;) while any shares of Series A convertible preferred stock remain outstanding, the Company would be required to issue to these holders of Series A convertible preferred stock a number of shares of common stock equal to the additional number of shares of common stock that such shares of Series A convertible preferred stock would be convertible into if the conversion price of such shares was equal to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">105%</div> of the Make-Whole Price (the &#x201c;Make-Whole Adjustment&#x201d;). The Make-Whole Adjustment was evaluated and was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> required to be bifurcated from the Series A convertible preferred stock.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Make-Whole Adjustment was triggered and settled in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2018 </div>in connection with the Company's common stock offering. The Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,668,421</div> shares as part of the Make-Whole Adjustment.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Common Stock</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 15pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In connection with the Merger (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>) the Company ascribed non-cash consideration of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">478,200</div> warrants outstanding prior to the Merger. During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,226,698</div> shares of its Common Stock of which <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,861,503</div> are shares held by the pre-Merger stockholders of the Company, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">45,643</div> shares were issued for advisory services provided in connection with the Merger, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">102,430</div> shares were issued for general financial advisory services provided to the Company and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">217,122</div> shares were issued pursuant to conversions of convertible debt as discussed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.</div> In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company issued <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,606</div> shares for advisory services. The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> purchase or retire any shares of its common stock.</div></div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Common Stock Warrants</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company had the following warrants outstanding to acquire shares of its common stock:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price per share</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to Merger</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$20.00</div> </td> <td style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49.00</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in Series A</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,555,887</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div></div></div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,003,608</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">During the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">17,479</div> warrants issued prior to the Merger expired, respectively; these common stock warrants will expire periodically through <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2019.</div> The common stock warrants issued in connection with the <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 2017 </div>Series A private placement expire in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March 2022. </div>During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the Company recognized a gain of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$22.1</div> million upon the change in fair value of the warrant until they were reclassified to permanent equity in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$10.2</div> million in warrant related charges associated with the Series A private placement, which consisted primarily of the excess fair value of the common stock warrants over the gross cash proceeds of the Series A offering. &nbsp;</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6669105776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Stock-Based Compensation</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Equity Plan</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Equity Plan, as amended in <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> July 2016, </div>currently allows for the issuance of up to a maximum of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">500,000</div> shares of common stock in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> including shares subject to awards assumed in connection with certain transactions, including the Merger. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104,291</div> shares of common stock available for future issuance under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Equity Plan. In addition, beginning on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2017, </div>on each <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">st</div> through the term of the plan, up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.0%</div> of the total shares of the Company&#x2019;s common stock outstanding as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31</div><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;">st</div> will be added to the plan reserve, unless a lesser amount is stipulated by the Compensation Committee of the Company&#x2019;s Board of Directors. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2018, </div>the maximum number of shares of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2015</div> Equity Plan increased by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">580,785</div> shares, or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.0%</div> of the total shares of the Company&#x2019;s common stock outstanding at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95,040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674,643</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,145,511</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">716,425</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,240,551</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,391,068</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table summarizes the activity related to all stock option grants to employees and non-employees:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise price</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">remaining</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">contractual life</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in years)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intrinsic</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"><div style="display: inline; font-weight: bold;">(A)</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">RestorGenex options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">301,156</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(48,190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">458,828</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94,599</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350,041</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,461</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2017</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.32</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,858,073</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.25</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.32</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr> <td style="width: 18pt;">&nbsp;</td> <td style="width: 18pt; vertical-align: top;"> <div style=" text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">(A)</div> </td> <td style="vertical-align: top;"> <div style=" text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-right: 0pt; margin-bottom: 0pt;">The difference, if positive, between the stock option<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s exercise price and the closing price of the Company&#x2019;s common stock at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div></div></div> </td> </tr>  </table> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Generally, the options have a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>) year<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;contractual term and vest in equal monthly installments over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) years. In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2016, </div>the Company granted an option to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">204,907</div> shares of Common Stock to a director in connection with the director&#x2019;s appointment to the board of directors. The options will vest in equal quarterly installments over <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">ten</div> (<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10</div>) years and any options exercised are restricted from being sold until <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2021.</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Non-employee Stock Options</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Non-employee options are remeasured to fair value each period through operations using a Black-Scholes option-pricing model until the options vest. There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,394</div> stock options granted to non-employees during the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> The total fair value of non-employee stock options vested during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$90,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.8</div> million, respectively. At <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$14,000</div> of unrecognized compensation cost related to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,080</div> unvested stock options and subject to re-measurement until vested. The total unrecognized compensation expense will be recognized as expense over a weighted-average period of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.5</div> years.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Employee Stock Options</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The weighted average grant date fair value of stock option awards granted to employees was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.10</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$5.55</div> during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively. The total fair value of options vested during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million, respectively. <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No</div></div></div> options were exercised during any of the periods presented. At <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.6</div> million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.37</div> years.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The grant date fair value of employee stock options is determined using the Black-Scholes model. The following assumptions were used during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016:</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 72%;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.27</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.76</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.4%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.2%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;109.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">136.7%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;106.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125.5%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Restricted Stock Awards</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,066</div> unvested shares of restricted stock. During the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,132</div> shares vested. The fair value as of the respective vesting dates of the restricted stock awards was both <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12,000</div></div> for <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div> The grant date fair value of each restricted stock award granted during the year ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.97.</div> There were <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> restricted stock awards granted in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017.</div> At <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> there was <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$6,000</div> of unrecognized compensation cost related to unvested restricted stock that will be recognized as expense over a weighted average period of less than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> year.</div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941318880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Defined Contribution Retirement Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Other Postretirement Benefits Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Defined Contribution Retirement Plan</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has established a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k)<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;defined contribution plan (the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan) that covers all employees who qualify under the terms of the plan. Eligible employees <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>elect to contribute to the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">90%</div> of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4%</div> of the participant&#x2019;s compensation. The Company made matching contributions under the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">401</div>(k) Plan of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49,000</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$28,000</div> for the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> respectively.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941288480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Income Taxes</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prior to the Merger, the Company was treated as a partnership for federal income tax purposes.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 2017, </div>the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act was enacted, which includes a number of changes to previously existing U.S. tax laws that impact the Company, most notably a reduction of the U.S. corporate income tax rate from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35%</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> for tax years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act also provides for a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div>-time transition tax on certain foreign earnings and the acceleration of depreciation for certain assets placed into service after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> September 27, 2017 </div>as well as prospective changes beginning in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> including repeal of the domestic manufacturing deduction, acceleration of tax revenue recognition, capitalization of research and development expenditures, additional limitations on executive compensation and limitations on the deductibility of interest.</div></div> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse.<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp; In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the Company recorded a deferred tax liability of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$3.6</div> million for the basis differences associated with indefinite-lived in-process R&amp;D assets.&nbsp;In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2016, </div>the Company abandoned future development efforts for the IPR&amp;D asset associated with RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440</div> and recorded an impairment charge of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.0</div> million which is equal to its acquired value. Upon recognizing the impairment, the Company recognized an income tax benefit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.4</div> million and reduced the carrying value of the related deferred tax liability as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>). In <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> this deferred tax liability was further reduced by <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million as a result of the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act. </div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Deferred tax assets</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,310,628</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,547,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,141,973</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,720,186</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,537,039</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,218,069</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,247,469</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,690,843</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,237,109</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,176,394</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax liabilities</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,279,363</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,279,363</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> have unrecognized tax benefits as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> or <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016. </div>The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company had net operating loss carryforwards (&#x201c;NOL&#x201d;) for federal and state income tax purposes at <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>&nbsp;of approximately:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Combined NOL Carryforwards:</div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,629,817</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,640,700</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The net operating loss carryforwards begin expiring in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2034</div> for federal income tax purposes and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2034</div> for state income tax purposes. In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 2016, </div>the number of outstanding shares of RestorGenex common stock increased in connection with the Merger discussed in note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.</div> This increase in the number of shares outstanding<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;resulted in&nbsp;a change of ownership, under the provisions of Internal Revenue Code Section <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">382</div> and similar state provisions, and limits the Company&#x2019;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation.&nbsp;The Company's <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018</div> financings <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>have also triggered an ownership change, which could further limit the Company's ability to utilize its NOL carryforwards. The Company has yet to determine this potential limitation. The Company recorded a <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">100%</div> valuation allowance of the deferred tax assets as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> because of the uncertainty of their realization.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the financial statements as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> is as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Rate reconciliation:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of warrant</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(126.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Litigation settlement charge</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisition costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(36.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(38.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total provision</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(43.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.0</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2014</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> tax years remain open and subject to examination.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775708480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Disclosures [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Fair Value Measurements</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair value are to be classified and disclosed in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">one</div> of the following <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> levels of the fair value hierarchy, of which the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">two</div> are considered observable and the last is considered unobservable:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&#x25cf;</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2014;Quoted prices in active markets for identical assets or liabilities.</div></div> </td> </tr>  </table> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&#x25cf;</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2014;Observable inputs (other&nbsp;than Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1</div> quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div></div> </td> </tr>  </table> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;">  <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&#x25cf;</div></div> </td> <td> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2014;Unobservable inputs that are supported by little or <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</div></div> </td> </tr>  </table> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The asset<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s or liability&#x2019;s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following table presents the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s assets and liabilities that are measured at fair value on a recurring basis:</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Assets</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,896,468</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="width: 21474836.47%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,552,852</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The reconciliation of the contingent consideration liability measured at fair value on a recurring basis using significant unobservable inputs (Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div>) is as follows:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common Stock </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant Liability</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issued in connection with the Series A convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,225,846</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,072,322</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Reclassification of Series A warrants to additional paid in capital</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,153,524</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The common stock warrants issued in connection with the Series A convertible preferred stock were previously classified as liabilities, and were marked-to-market each reporting period with the change in fair value recorded as either income or expense in the accompanying statements of operations until the warrants are exercised, expire or other facts and circumstances lead the liability to be reclassified to stockholders&#x2019; equity. On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 1, 2017 </div>the Company held a Special Stockholders meeting, requesting stockholders, both common and Series A, to approve a proposed amendment to the Company&#x2019;s Certificate of Incorporation to permit the Company to pay dividends on the Company&#x2019;s Series A Convertible Preferred Stock in either cash or shares of the Company&#x2019;s Common, which was approved by the stockholders. As a result of this amendment, the Company is able to assert there will be sufficient authorized shares available to settle the Series A warrants. Upon this assertion, the Series A warrants were reclassified from liabilities to stockholders&#x2019; equity.</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The fair value of the warrant liability is estimated using the Black-Scholes model and assumptions used to value the warrant liability as of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> November 1, 2017, </div>which was the date of the reclassification, were as follows:</div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;">  <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr>  </table> </div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941235616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions Disclosure [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.</div> Related Party Transactions</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s Director of Information Technologies is also the son of the Chief Executive Officer and he has held that position since <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 2014.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775741872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">16.</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;Subsequent Event</div></div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 22, 2018, </div>Diffusion Pharmaceuticals Inc. (the &#x201c;Company&#x201d;) closed its previously announced underwritten public offering of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000,000</div> shares of the Company&#x2019;s common stock, par value <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.001</div> per share (&#x201c;Common Stock&#x201d;), and warrants to purchase <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,000,000</div> shares of Common Stock. At the closing, the Company also issued warrants to purchase an additional <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,970,625</div> shares of Common Stock pursuant to the underwriter&#x2019;s partial exercise of its overallotment option. The shares of Common Stock and warrants were sold at a combined public offering price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div> per share and warrant for total gross proceeds of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$12.0</div> million. The warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.80</div> per share and a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date of issuance. In addition, at the closing, the Company issued to designees of the underwriter of the offering warrants to purchase up to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">750,000</div> shares of Common Stock. The underwriter&#x2019;s warrants have an exercise price of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.00,</div> a term of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">five</div> years from the date of issuance and otherwise substantially similar terms to the form of investor warrant. As a result of the offering, all outstanding shares of the Company's Series A convertible preferred stock converted into <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,568,632</div> shares (the &quot;Conversion Shares) of common stock (including accrued dividends paid in kind and the &quot;make-whole&quot; adjustment feature thereof). </div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936346000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Basis of Presentation</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The accompanying consolidated<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;financial statements of the Company have been prepared in accordance with US GAAP. Any reference in these notes to applicable guidance is meant to refer to US GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;).</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The preparation of financial statements in conformity with US GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation, the fair value of the warrants, the fair value of the convertible notes, allocation of the purchase price and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The carrying amounts of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s financial instruments, including cash equivalents, accounts payable, and accrued expenses approximate fair value due to the short-term nature of those instruments. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017,</div> the fair value of the Company's outstanding Series B convertible note was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million. As of <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the fair value of the Company&#x2019;s outstanding <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div> convertible note and Series B convertible note was approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.0</div> million and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$0.6</div> million, respectively. The fair value of the convertible notes is determined using a binomial lattice model that utilizes certain unobservable inputs that fall within Level <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3</div> of the fair value hierarchy.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Concentration of Credit Risk</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company considers any highly liquid investments, such as money market funds, with an original maturity of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">three</div> months or less to be cash and cash equivalents.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2</div> to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15</div> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Long-Lived Assets</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Long-lived assets are reviewed for potential impairment whenever events indicate that the carrying amount of such assets <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be recoverable. The Company does this by comparing the carrying value of the long-lived assets with the estimated future undiscounted cash flows expected to result from the use of the assets, including cash flows from disposition. If it is determined an impairment exists, the asset is written down to its estimated fair value. The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> recognized any impairment of long-lived assets during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2017 </div>and <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Intangible assets are comprised of identifiable in-process research and development (IPR&amp;D) assets and are considered indefinite-lived intangible assets and are assessed for impairment annually on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>or more frequently if impairment indicators exist. If the associated research and development effort is abandoned, the related assets will be written-off and the Company will record a non-cash impairment loss. For those compounds that reach commercialization, the IPR&amp;D assets will be amortized over their estimated useful lives. In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> August 2016, </div>the Company abandoned the future development efforts with respect to its RES-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">440</div> product candidate, and the value of the associated IPR&amp;D asset was written down to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">zero</div> (See Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4</div>).</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Goodwill</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: left; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Goodwill is the excess of the cost of an acquired entity over the net amounts assigned to tangible and intangible assets acquired and liabilities assumed. Goodwill is <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> amortized, but is subject to an annual impairment test. The Company has a single reporting unit and all goodwill relates to that reporting unit.</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company performs its annual goodwill impairment test on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> October 1 </div>of each fiscal year or more frequently if changes in circumstances or the occurrence of events suggest that an impairment exists. If the fair value of the reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the reporting unit<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s goodwill is less than the carrying value of the reporting unit&#x2019;s goodwill. The Company did <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div></div> recognize any impairment of goodwill during the years ended <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">31,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> and <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 31, 2016.</div></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_OfferingCostsPolicyPolicyTextBlock', window );">Offering Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Offering Costs</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Offering costs are either expensed upon completion or abandonment of the related financing or offset against the proceeds of the offering, depending upon the accounting treatment of the offering. Offering costs consist principally of legal and accounting costs incurred through the balance sheet date related to the Company&#x2019;s underwritten public offering, private placement financings and are recognized in other assets on the consolidated balance sheet.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Research and Development</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">At the end of the reporting period, the Company compares payments made to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> may </div>record net prepaid or accrued expenses relating to these costs.</div> <div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upfront payments made to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">third</div> parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Patent Costs</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the statements of operations.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Income Taxes</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Prior to the Merger, Diffusion LLC was treated as a partnership for federal and state income tax purposes. Diffusion LLC<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s taxable income or loss, as well as certain other tax attributes, were passed through directly to its members and were reported in each member&#x2019;s individual income tax return.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Upon completion of the Merger as discussed in Note <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,</div> the Company converted from a partnership to a corporation for accounting purposes. As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> that some portion or all of a deferred tax asset will <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> to be sustained.</div> <div style=" margin: 0pt; text-align: justify; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">On <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 22, 2017 </div>the President of the United States signed into law the Tax Cuts and Jobs Act (&quot;The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act&quot;).&nbsp;This legislation makes significant changes in the U.S. tax laws including, but <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> limited to, reducing the corporate tax rate to <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%</div> starting in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018.</div> The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> Tax Act required the Company to revalue its deferred tax assets and liabilities to the new rate of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21%.</div>&nbsp;&nbsp;As a result of the change, the Company recorded a current period tax benefit of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1.1</div> million in its consolidated statement of operations and a corresponding reduction in the deferred tax liability on its consolidated balance sheet.</div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Stock-based Compensation</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company measures employee and nonemployee stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. Stock-based awards issued to non-employees are revalued until the award vests. The Company uses the Black-Scholes option pricing model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The expected term of stock options was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. For options granted to non-employees, the Company uses the remaining contractual life. For stock price volatility, the Company uses comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> dividend yield because dividends are <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expected to be paid in the near future, which is consistent with the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s history of <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the option. The Company <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> longer estimates forfeitures and accounts for forfeitures in the periods they occur.</div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Net Loss Per Share</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. For purposes of calculating diluted loss per common share, the denominator includes both the weighted average common shares outstanding and the number of common stock equivalents if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and restricted stock awards using the treasury stock method and convertible debt using the &#x201c;if-converted&#x201d; method. The diluted loss per common share calculation is further affected by an add-back of change in fair value of warrant liability to the numerator under the assumption that the change in fair value of warrant liability would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> have been incurred if the warrants had been converted into common stock.</div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,364,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accretion of Series A cumulative preferred dividends</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,252,394</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,072,322</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24,689,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock equivalents arising from warrants</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">307,675</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,755,316</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.94</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214,385</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">757,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">460,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,306,278</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock awards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,066</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,204</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,527,439</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,435,243</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Amounts in the table reflect the common stock equivalents of the noted instruments.</div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Comprehensive Loss</div></div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">The Company has <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">no</div> items of comprehensive income or loss other than net loss.</div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements</div></div> <div style=" margin: 0pt; text-align: left; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> July 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,</div> <div style="display: inline; font-style: italic;">Earnings Per Share (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">260</div>); Distinguishing Liabilities from Equity (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">480</div>); Derivatives and Hedging (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">815</div>): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. </div>The <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">first</div> part of this update addresses the complexity of accounting for certain financial instruments with down round features and the <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">second</div> part addresses the complexity of distinguishing liabilities from equity. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2018 </div>and interim periods within those years. The Company is currently evaluating the potential impact of the adoption of this standard on its consolidated results of operations, financial position and cash flows and related disclosures.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div><div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> May 2017, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">No.</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Modification Accounting for Share-Based Payment Arrangements</div>, which amends the scope of modification accounting for share-based payment arrangements. The ASU provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">718.</div> Specifically, an entity would <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> apply modification accounting if the fair value, vesting conditions, and classification of the awards are the same immediately before and after the modification. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2017 </div>and interim periods within those years. Early adoption is permitted, including adoption in any interim period. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this new guidance to have a material impact on its consolidated financial statements.</div></div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> March</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016,</div> the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> <div style="display: inline; font-style: italic;">Compensation &#x2013; Improvements to Employee Share-Based Payment Accounting</div>, which simplifies several aspects of the accounting for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification in the statement of cash flows. The guidance is applicable to public business entities for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December 15, 2016 </div>and interim periods within those years. The Company adopted this standard in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2017</div> by electing to account for forfeitures in the period that they occur. Under ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">09,</div> accounting changes adopted using the modified retrospective method must be calculated as of the beginning of the period adopted and reported as a cumulative-effect adjustment. As a result, the Company recognized cumulative-effect adjustment of approximately <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$1,000</div></div> on <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> January 1, 2017.</div></div></div> <div style=" margin: 0pt; text-align: center; text-indent: 8pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; text-align: justify; text-indent: 44pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">In <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> February 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2016</div>-<div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">02,</div> <div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic;">Leases (Topic <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">842</div>)</div>. The FASB issued the update to require the recognition of lease assets and liabilities on the balance sheet of lessees. The standard will be effective for fiscal years beginning after <div style="display: inline; font-style: italic; font-style: normal; font-weight: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15,</div> <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> including interim periods within such fiscal years. The ASU requires a modified retrospective transition method with the option to elect a package of practical expedients. Early adoption is permitted. Upon adoption in <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2018,</div> the Company will determine the fair of the operating lease and recognize this amount as a lease asset and corresponding liability on its consolidated balance sheet. The Company does <div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">not</div> expect this new guidance to have a material impact on its consolidated financial statements.</div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_OfferingCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_OfferingCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939386608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,364,518</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Accretion of Series A cumulative preferred dividends</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,252,394</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.21</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss per common share calculation:</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss attributable to common stockholders</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,616,912</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Change in fair value of warrant liability</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,072,322</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Diluted net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(24,689,234</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(18,036,619</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Weighted average common shares outstanding, basic</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,447,641</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Common stock equivalents arising from warrants</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">307,675</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">12,755,316</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,232,791</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, diluted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.94</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.76</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible debt</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">214,385</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">757,909</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">460,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,306,278</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock options</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock awards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,066</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,204</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">11,527,439</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3,435,243</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775744000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Acquisition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock', window );">Business Combination, Preliminary Purchase Price Consideration [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger shares outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">19,546,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger stock options outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,321,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Estimated fair value of the Company<div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2019;s pre-Merger warrants outstanding</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">384,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">CVRs <div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#x2013; RES-440 product candidate</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total purchase price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,261,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,500,602</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses and other assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">195,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">57,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">9,600,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Goodwill</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6,929,258</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued liabilities</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(377,432</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,644,159</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net assets acquired</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">21,261,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Business Acquisition, Pro Forma Information [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended December</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style="display: inline; font-weight: bold;">31, 2016</div></div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net revenues</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,471,398</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 79%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted loss per share</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 18%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of preliminary purchase price consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775690176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">182,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Furniture and office equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">155,113</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">137,290</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">430,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total property and equipment</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">767,470</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">319,647</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less: accumulated depreciation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(306,818</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(239,892</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">460,652</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">79,755</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941073152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued interest payable</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">37,415</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">29,359</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued Series A dividends</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,062,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">312,221</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">399,740</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">122,711</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">72,855</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">63,350</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">220,978</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">30,840</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">151,332</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,628,851</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">874,264</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6609270288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Convertible Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Convertible Debt [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, </div></div></td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2016 convertible notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,880,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Pre-Merger convertible notes</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,430,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,880,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">550,000</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6608577152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Rental</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Commitments</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2018</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">112,354</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2019</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">114,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2020</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">116,464</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">118,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">39,735</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">501,481</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775728896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Convertible Preferred Stock and Stockholder's Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock', window );">Schedule of Warrants Outstanding to Acquire Shares of Common Stock [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Range of exercise </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">price per share</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued prior to Merger</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">447,721</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"> </div><div style=" margin: 0pt; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">$20.00</div> </td> <td style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">-</div></td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$49.00</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in Series A</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">13,555,887</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 61%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">$2.22</div></div></div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">14,003,608</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 6%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Table of warrants outstanding to acquire shares of the company's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ScheduleOfWarrantsOutstandingToAcquireSharesOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941159088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Year ended</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">95,040</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">674,643</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,145,511</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">716,425</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,240,551</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,391,068</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Number of</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">exercise price</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">per share</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">remaining</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">contractual life</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(in years)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intrinsic</div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Value</div><div style="display: inline; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline;"><div style="display: inline; font-weight: bold;">(A)</div></div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,495,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">3.92</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">RestorGenex options outstanding</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">301,156</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">40.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cancelled</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(48,190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">61.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">458,828</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.25</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,207,409</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.09</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">94,599</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">350,041</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.46</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expired</div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(1,461</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">15.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2017</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.32</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,858,073</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8.25</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,555,989</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.32</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,734</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 72%;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2017</div></div></td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> <td colspan="3" style="width: 52%; text-align: center; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2016</div></div></td> <td style="width: 1%; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Expected term (in years)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.27</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">6.00</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5.76</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7.48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.4%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;1.2%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.0%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;109.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">136.7%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;106.8%</div></td> <td style="width: 2%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">125.5%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 72%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="3" rowspan="1" style="width: 52%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></div></div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775714832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">&nbsp;</div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Deferred tax assets</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,310,628</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">7,547,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,141,973</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,720,186</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2,537,039</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,218,069</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">5,247,469</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4,690,843</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(15,237,109</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16,176,394</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax asset</div> </td> <td style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&nbsp;</div></td> <td style="padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Deferred tax liabilities</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,279,363</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2,223,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(3,279,363</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Combined NOL Carryforwards:</div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,629,817</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">20,640,700</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 70%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Rate reconciliation:</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(34.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: none;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(16.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.3</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value of warrant</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(126.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in tax rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">205.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Litigation settlement charge</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Acquisition costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(36.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(4.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(38.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">27.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock compensation</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(0.1</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Total provision</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(43.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(2.0</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)%</div> </td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775814432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2017</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Assets</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">8,896,468</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="width: 21474836.47%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2016</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 1)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 2)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="width: 1%; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Level 3)</div></div></div> </td> <td style="width: 1%; padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Assets</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1,552,852</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">Liabilities</div></div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 12%; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 55%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrant liability</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 1px; border-bottom-style: solid;"> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Common Stock </div></div></div> <div style=" margin: 0pt; text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Warrant Liability</div></div></div> </td> <td style="padding-bottom: 1px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2016</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Issued in connection with the Series A convertible preferred stock</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">35,225,846</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Change in fair value</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(22,072,322</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Reclassification of Series A warrants to additional paid in capital</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">(13,153,524</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2017</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom-color: rgb(0, 0, 0); border-bottom-width: 3px; border-bottom-style: double;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; padding-bottom: 3px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="width: 85%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Stock price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Exercise price</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">2.22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">4.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">1.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">104.1</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">%</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font-weight: inherit; font-style: normal;">&#x2014;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785757584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 1 - Organization and Description of Business (Details Textual)<br></strong></div></th>
<th class="th"><div>Aug. 17, 2016</div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 08, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="nump">$ 2,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_ReverseStockSplitMember', window );">Reverse Stock Split [Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest', window );">Business Combination, Number of Shares Called by Each Previously Held Unit of Membership Interest | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3652658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed', window );">Business Combination, Number of Shares Called by Share Options Assumed | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,495,615<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Former Equity Holders of Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfCommonStockOutstandingOwned', window );">Percentage of Common Stock Outstanding Owned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">84.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of the reporting entity's common stock into which each previously held unit of membership interest may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of the reporting entity's common stock into which the share options assumed in a business combination may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationNumberOfSharesCalledByShareOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfCommonStockOutstandingOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of all classes of common stock held by shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfCommonStockOutstandingOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_ReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=dffn_ReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=dffn_FormerEquityHoldersOfDiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=dffn_FormerEquityHoldersOfDiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785772848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Liquidity (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 22, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 07, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Conversion From Series A Preferred Stock to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">20,568,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrants Issued in Connection with the January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriter Warrants [Member] | H.C Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriter Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | January 2018 Offering [Member] | Additional Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,970,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_January2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_January2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_AdditionalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_AdditionalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785571056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 01, 2017</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of Long-Lived Assets to be Disposed of</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill, Impairment Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member', window );">Accounting Standards Update 2016-09 [Member] | AOCI Attributable to Parent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-Lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Convertible Note, Series B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | The 2016 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtFairValueDisclosures', window );">Convertible Debt, Fair Value Disclosures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtFairValueDisclosures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtFairValueDisclosures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201609Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNoteSeriesBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_ConvertibleNoteSeriesBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936442704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,364,518)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of Series A cumulative preferred dividends</a></td>
<td class="num">(1,252,394)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,616,912)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">12,447,641<span></span>
</td>
<td class="nump">10,232,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common, basic (in dollars per share)</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per common share calculation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (2,616,912)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability', window );">Change in fair value of warrant liability</a></td>
<td class="num">(22,072,322)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Diluted net loss</a></td>
<td class="num">$ (24,689,234)<span></span>
</td>
<td class="num">$ (18,036,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic (in shares)</a></td>
<td class="nump">12,447,641<span></span>
</td>
<td class="nump">10,232,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants', window );">Common stock equivalents arising from warrants (in shares)</a></td>
<td class="nump">307,675<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Common stock equivalents (in shares)</a></td>
<td class="nump">12,755,316<span></span>
</td>
<td class="nump">10,232,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock, diluted (in dollars per share)</a></td>
<td class="num">$ (1.94)<span></span>
</td>
<td class="num">$ (1.76)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the change in fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of call options and warrants using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1757-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToCallOptionsAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785385904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">11,527,439<span></span>
</td>
<td class="nump">3,435,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">214,385<span></span>
</td>
<td class="nump">757,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">447,721<span></span>
</td>
<td class="nump">460,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">8,306,278<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">2,555,989<span></span>
</td>
<td class="nump">2,207,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">3,066<span></span>
</td>
<td class="nump">9,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773606224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Acquisition (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 08, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,606<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="nump">$ 1,409,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,240,551<span></span>
</td>
<td class="nump">1,391,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember', window );">Executive Officers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member', window );">RES-529 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest', window );">Business Combination, Number of Shares Called by Each Previously Held Unit of Membership Interest</a></td>
<td class="nump">0.3652658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements', window );">Business Combination, Period Following Merger in Which Receipt of Cash for Discontinued Product Assets Would Trigger Contingent Value Right Payements</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based Compensation</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Financial Adviser [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="nump">46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock Issued During Period, Value, Issued for Services</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Success Fee Agreement Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Payments for Other Fees</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Acquisition-related Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Business Combination, Acquisition Related Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member] | Former Equity Holders of Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfCommonStockOutstandingOwned', window );">Percentage of Common Stock Outstanding Owned</a></td>
<td class="nump">84.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of the reporting entity's common stock into which each previously held unit of membership interest may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationNumberOfSharesCalledByEachPreviouslyHeldUnitOfMembershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period following a merger that, if the reporting entity receives net cash payments for the sale of any of the assets related to a discontinued product line, would trigger a required payment to holders of contingent value rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPeriodFollowingMergerInWhichReceiptOfCashForDiscontinuedProductAssetsWouldTriggerContingentValueRightPayements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfCommonStockOutstandingOwned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of all classes of common stock held by shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfCommonStockOutstandingOwned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=84229725&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dffn_ExecutiveOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dffn_FinancialAdviserMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dffn_FinancialAdviserMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfExpenseAxis=dffn_SuccessFeeAgreementCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfExpenseAxis=dffn_SuccessFeeAgreementCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_AcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=dffn_FormerEquityHoldersOfDiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=dffn_FormerEquityHoldersOfDiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784428992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Acquisition - Purchase Price Consideration (Details) - RestorGenex [Member] - Diffusion LLC [Member]<br></strong></div></th>
<th class="th">
<div>Jan. 08, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding', window );">Fair value of the Company&#8217;s pre-Merger shares outstanding</a></td>
<td class="nump">$ 19,546,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed', window );">Estimated fair value of the Company&#8217;s pre-Merger stock options outstanding</a></td>
<td class="nump">1,321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed', window );">Estimated fair value of the Company&#8217;s pre-Merger warrants outstanding</a></td>
<td class="nump">384,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights', window );">CVRs &#8211; RES-440 product candidate</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration', window );">Total purchase price</a></td>
<td class="nump">$ 21,261,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preliminary purchase consideration consisting of the fair value of assets transferable by the acquirer, liabilities obtainable by the acquirer, and equity interest issuable by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent value rights in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationContingentValueRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of stock options assumed in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfStockOptionsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of warrants assumed in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationEstimatedFairValueOfWarrantsAssumed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares outstanding in the preliminary purchase price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationPreliminaryPurchasePriceConsiderationFairValueOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_RestorGenexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_RestorGenexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773836720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Acquisition - Assets Acquired and Liabilities Assumed (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,531<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,929,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(377,432)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,644,159)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,261,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31917-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939328752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Acquisition - Pro Forma Financial Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaRevenue', window );">Net revenues</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (16,471,398)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted', window );">Basic and diluted loss per share (in dollars per share) | $ / shares</a></td>
<td class="num">$ (1.60)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma basic and diluted net income per share for a period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionsProFormaRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)-(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionsProFormaRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775700320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Property and Equipment (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 67,981<span></span>
</td>
<td class="nump">$ 25,342<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773571280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 767,470<span></span>
</td>
<td class="nump">$ 319,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(306,818)<span></span>
</td>
<td class="num">(239,892)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">460,652<span></span>
</td>
<td class="nump">79,755<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">182,357<span></span>
</td>
<td class="nump">182,357<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">155,113<span></span>
</td>
<td class="nump">137,290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=dffn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773910336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Goodwill and Intangible Assets (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,929,258<span></span>
</td>
<td class="nump">$ 6,929,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,685)<span></span>
</td>
<td class="num">(364,796)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember', window );">Abandonmnet of In-Process Research and Development Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member', window );">RES-529 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross (Excluding Goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440 [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES529Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785056912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest payable</a></td>
<td class="nump">$ 37,415<span></span>
</td>
<td class="nump">$ 29,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PreferentialDividendsPayble', window );">Accrued Series A dividends</a></td>
<td class="nump">1,062,314<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and payroll related expenses</a></td>
<td class="nump">312,221<span></span>
</td>
<td class="nump">399,740<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">122,711<span></span>
</td>
<td class="nump">72,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AccruedClinicalStudiesExpensesCurrent', window );">Accrued clinical studies expenses</a></td>
<td class="nump">63,350<span></span>
</td>
<td class="nump">220,978<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">30,840<span></span>
</td>
<td class="nump">151,332<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,628,851<span></span>
</td>
<td class="nump">$ 874,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PreferentialDividendsPayble">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of preferential dividends not subject to declaration, but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PreferentialDividendsPayble</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786408736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Convertible Debt (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">73 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jan. 08, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrentAndNoncurrent', window );">Interest Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112,800<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550,000<span></span>
</td>
<td class="nump">2,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Debt Conversion, Original Debt, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest', window );">Debt Conversion, Converted Instrument, Related Accrued Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember', window );">The 2016 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayments of Convertible Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest Paid, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember', window );">The 2016 Convertible Notes [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt Instrument, Term</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt', window );">Proceeds from Issuance of Unsecured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_QualifiedFinancingMinimumAmountOfGrossProceeds', window );">Qualified Financing, Minimum Amount of Gross Proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible Notes Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1', window );">Debt Conversion, Converted Instrument, Shares Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember', window );">Convertible Notes [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember', window );">Convertible Notes [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of related accrued interest being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DebtConversionConvertedInstrumentRelatedAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_QualifiedFinancingMinimumAmountOfGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum amount of gross proceeds for qualified financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_QualifiedFinancingMinimumAmountOfGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid, after deduction of cash paid for capitalized interest, for interest. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest payable on debt, including, but not limited to, trade payables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfUnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of long-term debt that is not secured by collateral. Excludes proceeds from tax exempt unsecured debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfUnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=dffn_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=dffn_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941478592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Convertible Debt - Outstanding Convertible Notes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="nump">$ 2,430,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Less current portion</a></td>
<td class="num">(550,000)<span></span>
</td>
<td class="num">(1,880,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Long-term debt, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">550,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember', window );">The 2016 Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,880,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Total principal amount</a></td>
<td class="nump">$ 550,000<span></span>
</td>
<td class="nump">$ 550,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785183680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,088,621<span></span>
</td>
<td class="nump">$ 7,252,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember', window );">The 2016 Convertible Notes [Member] | Settlement Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Debt Instrument, Convertible, Conversion Price</a></td>
<td class="nump">$ 3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation Settlement, Expense</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=dffn_ArrangementWithClinicalResearchOrganizationMember', window );">Arrangement With Clinical Research Organization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PrepaidResearchAndDevelopmentExpense', window );">Prepaid Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember', window );">Charlottesville, Virginia [Member] | Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, Plant and Equipment, Additions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember', window );">Charlottesville, Virginia [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating Leases, Rent Expense, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for research and development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6928298&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=dffn_The2016ConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationCaseAxis=dffn_SettlementAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationCaseAxis=dffn_SettlementAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=dffn_ArrangementWithClinicalResearchOrganizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=dffn_ArrangementWithClinicalResearchOrganizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=dffn_CharlottesvilleVirginiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941227552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 112,354<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">114,409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">116,464<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">118,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">39,735<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 501,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6790113920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Convertible Preferred Stock and Stockholder's Equity (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">10 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 22, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>$ / shares </div>
<div>$ / item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 07, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>$ / item </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 07, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2017 </div>
<div>$ / item</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts', window );">Proceeds from Issuance of Convertible Preferred Stock, Net of Offering Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,129,774<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpense', window );">Warrant Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,225,846<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,252,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Stock Reclassified Upon Conversion of Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_MakewholeProvisionConversionPricePercentage', window );">Make-Whole Provision Conversion Price, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockIssuedDuringPeriodSharesTotal', window );">Stock Issued During Period, Shares, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,226,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,861,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,606<span></span>
</td>
<td class="nump">45,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Stock Issued During Period, Shares, Conversion of Convertible Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (22,072,322)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=dffn_GeneralFinancialAdvisoryServicesMember', window );">General Financial Advisory Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock Issued During Period, Shares, Issued for Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,430<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember', window );">Diffusion LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Noncash or Part Noncash Divestiture, Amount of Consideration Received | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockConversionPrice', window );">Convertible Preferred Stock, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_FinancingTriggerFromIssuanceOfCommonStock', window );">Financing Trigger from Issuance of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock', window );">Convertible Preferred Stock, Make-Whole Provision, Proceeds from Issue of Common Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment', window );">Stock Issued During Period, Shares, Make-whole Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,668,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember', window );">Conversion From Series A Preferred Stock to Common Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">20,568,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember', window );">Conversion From Series A Preferred Stock to Common Stock Automated Conversion [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">8,306,278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember', window );">Conversion From Series A Preferred Stock to Common Stock, Settlement of Accrued Dividends [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">593,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember', window );">Conversion From Series A Preferred Stock to Common Stock, Make-Whole Adjustment [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">11,668,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpense', window );">Warrant Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightsExpired', window );">Class of Warrant or Rights, Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="nump">17,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockVotesPerShare', window );">Convertible Preferred Stock, Votes Per Share | $ / item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.84874<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_WarrantExpense', window );">Warrant Expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,252,394<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStockShares', window );">Stock Reclassified Upon Conversion of Preferred Stock, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockReclassifiedUponConversionOfPreferredStock', window );">Stock Reclassified Upon Conversion of Preferred Stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,070,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice', window );">Convertible Preferred Stock, Make-Whole Provision, Minimum Share Price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Conversion From Series A Preferred Stock to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from Issuance of Private Placement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_NumberOfConvertiblePreferredStockPerUnit', window );">Number of Convertible Preferred Stock Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_NumberOfCommonStockPerUnit', window );">Number of Common Stock Per Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ConvertiblePreferredStockConversionPrice', window );">Convertible Preferred Stock, Conversion Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues', window );">Temporary Equity, Stock Issued During Period, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,376,329<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts', window );">Proceeds from Issuance of Convertible Preferred Stock, Net of Offering Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock [Member] | Private Placement [Member] | Placement Agent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightGrantedDuringPeriod', window );">Class of Warrant or Right, Granted During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,179,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=dffn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightGrantedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights granted during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightGrantedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion price related to convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum share price to trigger the make whole provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockMakewholeProvisionMinimumSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the make-whole provision when company reaches a certain amount of proceeds from issuance of common stock or securities convertible into or exercisable for common stock while shares of specified convertible stock remain outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockMakewholeProvisionProceedsFromIssueOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ConvertiblePreferredStockVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of votes each share of convertible preferred stock is entitled to.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ConvertiblePreferredStockVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:perUnitItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_FinancingTriggerFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount that triggers the make-whole provision for convertible preferred stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_FinancingTriggerFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_MakewholeProvisionConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the conversion price that would be used when applying the make-whole provision/</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_MakewholeProvisionConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_NumberOfCommonStockPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common stock included in each unit issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_NumberOfCommonStockPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_NumberOfConvertiblePreferredStockPerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series A convertible preferred stock included in each unit issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_NumberOfConvertiblePreferredStockPerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromIssuanceOfConvertiblePreferredStockNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period as the part of the make-whole adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockIssuedDuringPeriodSharesMakewholeAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockIssuedDuringPeriodSharesTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of shares of stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockIssuedDuringPeriodSharesTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockReclassifiedUponConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Provides information about the amount of reclassification of accrued dividends upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockReclassifiedUponConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockReclassifiedUponConversionOfPreferredStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about the number of shares relating to the reclassification of accrued dividends upon conversion of convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockReclassifiedUponConversionOfPreferredStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_TemporaryEquityStockIssuedDuringPeriodNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_WarrantExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from issuance of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_WarrantExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=dffn_GeneralFinancialAdvisoryServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=dffn_GeneralFinancialAdvisoryServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=dffn_DiffusionLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockAutomatedConversionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockSettlementOfAccruedDividendsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMakeWholeAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=dffn_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=dffn_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=dffn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=dffn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941289584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 10 - Convertible Preferred Stock and Stockholder's Equity - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares) | shares</a></td>
<td class="nump">14,003,608<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_ConvertiblePreferredStockIssuedPriorToMergerMember', window );">Convertible Preferred Stock Issued Prior to Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares) | shares</a></td>
<td class="nump">447,721<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_ConvertiblePreferredStockIssuedPriorToMergerMember', window );">Convertible Preferred Stock Issued Prior to Merger [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_ConvertiblePreferredStockIssuedPriorToMergerMember', window );">Convertible Preferred Stock Issued Prior to Merger [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares) | shares</a></td>
<td class="nump">13,555,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_ConvertiblePreferredStockIssuedPriorToMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_ConvertiblePreferredStockIssuedPriorToMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786513488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2018</div></th>
<th class="th"><div>Jul. 21, 2016</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,041<span></span>
</td>
<td class="nump">458,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 135 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 5.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Vest Monthly [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option [Member] | Vest Quarterly [Member] | Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=dffn_NonEmployeeStockOptionsMember', window );">Non-employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 182 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember', window );">Restorgenex Corporation 2015 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember', window );">Restorgenex Corporation 2015 Equity Incentive Plan [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</a></td>
<td class="nump">580,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based awards, other than options, awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under an established share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dffn_VestMonthlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dffn_VestMonthlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=dffn_VestQuarterlyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=dffn_VestQuarterlyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=dffn_NonEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=dffn_NonEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_RestorgenexCorporation2015EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941219392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,240,551<span></span>
</td>
<td class="nump">$ 1,391,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">95,040<span></span>
</td>
<td class="nump">674,643<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,145,511<span></span>
</td>
<td class="nump">$ 716,425<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773908112">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,207,409<span></span>
</td>
<td class="nump">1,495,615<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.09<span></span>
</td>
<td class="nump">$ 3.92<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger', window );">RestorGenex options outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">301,156<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice', window );">RestorGenex options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Cancelled (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,190)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">350,041<span></span>
</td>
<td class="nump">458,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2.46<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted-average remaining contractual life (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 47 days<span></span>
</td>
<td class="text">7 years 292 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,734<span></span>
</td>
<td class="nump">$ 94,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,461)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,555,989<span></span>
</td>
<td class="nump">2,207,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="nump">$ 8.09<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,858,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual life (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">6 years 178 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,555,989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted-average remaining contractual life (Year)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">7 years 47 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 4,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The difference, if positive, between the stock option's exercise price and the closing price of the Company's common stock at December 31, 2017.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could acquire or could have acquired the underlying shares with respect to any of the assumed shares from a merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_SharebasedCompensationArrangementsBySharebasedPaymentAwardOptionsAssumedInPeriodDueToAMergerWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6941134752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Stock-based Compensation - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 277 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">109.80%<span></span>
</td>
<td class="nump">106.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 175 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">136.70%<span></span>
</td>
<td class="nump">125.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775700320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Defined Contribution Retirement Plan (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774176112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,223,678<span></span>
</td>
<td class="nump">$ 3,279,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,055,685)<span></span>
</td>
<td class="num">(364,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized Tax Benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember', window );">Abandonmnet of In-Process Research and Development Intangible Asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InProcessResearchAndDevelopmentCostsIprdMember', window );">In Process Research and Development Costs (IPR&amp;D) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Deferred Tax Liabilities, Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member', window );">RES-440 [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember', window );">Scenario, Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonmonetaryTransactionTypeAxis=dffn_AbandonmnetOfInprocessResearchAndDevelopmentIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InProcessResearchAndDevelopmentCostsIprdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_InProcessResearchAndDevelopmentCostsIprdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=dffn_RES440Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784956144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 5,310,628<span></span>
</td>
<td class="nump">$ 7,547,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option compensation</a></td>
<td class="nump">2,141,973<span></span>
</td>
<td class="nump">2,720,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsOrphanDrugCredits', window );">Orphan Drug credits</a></td>
<td class="nump">2,537,039<span></span>
</td>
<td class="nump">1,218,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther', window );">Capitalized start-up costs and other</a></td>
<td class="nump">5,247,469<span></span>
</td>
<td class="nump">4,690,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(15,237,109)<span></span>
</td>
<td class="num">(16,176,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(2,223,678)<span></span>
</td>
<td class="num">(3,279,363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (2,223,678)<span></span>
</td>
<td class="num">$ (3,279,363)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsCapitalizedCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6597616688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Operating Loss Carryforwards (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 20,629,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 20,640,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774914688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Income Taxes - Reconciliation of Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(34.00%)<span></span>
</td>
<td class="num">(34.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of Federal benefit</a></td>
<td class="num">(16.30%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent', window );">Change in fair value of warrant</a></td>
<td class="num">(126.10%)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Change in tax rate</a></td>
<td class="nump">205.50%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent', window );">Litigation settlement charge</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent', window );">Acquisition costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent', window );">Orphan drug credit</a></td>
<td class="num">(36.00%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(38.80%)<span></span>
</td>
<td class="nump">27.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="num">(43.50%)<span></span>
</td>
<td class="num">(2.00%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to litigation settlement charge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectIncomeTaxRateReconciliationLitigationSettlementChargePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to the change in fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfWarrantPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to severance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectiveIncomeTaxRateReconciliationSeveranceCostsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774872592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 14 - Fair Value Measurements - Fair Value on a Recurring Basis (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 8,896,468<span></span>
</td>
<td class="nump">$ 1,552,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Common stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41228-113958<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6945355&amp;loc=d3e41271-113958<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13433-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13495-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774719920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details) - Contingent Consideration [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues', window );">Issued in connection with the Series A convertible preferred stock</a></td>
<td class="nump">35,225,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(22,072,322)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic', window );">Reclassification of Series A warrants to additional paid in capital</a></td>
<td class="num">(13,153,524)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of warrants to additional paid in capital (APIC) classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityReclassificationOfWarrantsToApic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=dffn_ContingentConsiderationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=dffn_ContingentConsiderationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6668739104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="1">10 Months Ended</th>
</tr>
<tr><th class="th">
<div>Nov. 01, 2017 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term (Year)</a></td>
<td class="text">4 years 138 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">104.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend', window );">Dividend yield (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774663040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 16 - Subsequent Event (Details Textual) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th"><div>Jan. 22, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 01, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jan. 07, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Conversion From Series A Preferred Stock to Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of Stock, Shares Issued</a></td>
<td class="nump">20,568,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Warrants Issued in Connection with the January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriter Warrants [Member] | H.C Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightTerm', window );">Class of Warrant or Right, Term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Underwriter Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | January 2018 Offering [Member] | Additional Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
<td class="nump">1,970,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the warrants, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=dffn_ConversionFromSeriesAPreferredStockToCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_January2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_January2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_AdditionalWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_AdditionalWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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MUQ]^-V'?6K=W_]CX*JAJ^'47Z@M02P,$%     @ =H""3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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MJ6_>ER5]0[+.EES14/>M_P%02P,$%     @ =H""3&&,W=O; P  U1   !@
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M8=?UNS;N-]>%]O6@J\_C1X3\]B5C]1]02P,$%     @ =H""3-IZD358 @
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M&Z]R6F<<9JPS1ZJL$-D4 ANB8=."UX4AM7-;"(Q5$6<KH2RUI0KMCI &)9N
M$FB35-,!=,@)(0=$JK\G<2FE([X$ B5'*0'K?DQ%O0D8GQP <SI=A<8BSASX
M2\I;=@_@]@&*4>(&@E8I/D'. *:D9*L![C6@:,D-H%0=BCCH;*!. U-2LD$
M=PC/%@U<^B?@E7:.VN#L+&C*2S8*D)R"9+L70.98]V5=!T'8@2V]!,56.JJ2
MSH\DDS4;!-$&H,FX''?)'*T3+NZN4QR;6_KU.'+B5%PHH<[IU^.Y"_#&>7.D
MG[(9P#EN ((=Y(Z*R^PD+"4D^P&<8P@@J#B;G=P13%'0"3,3FK+'Y0)E.\!S
M[ "YS!N5*V5)6=T)P E%IJQD1\!S' &YB'>YR& BMX1) DOY'-DG2$I//QMR
M 0<TRM)1FIT!3$G)2H]<Z9FH(M?O"6AG+-L'G(-,6<E2CUSJHP.GR6Y$D*;C
M*>P%0!O:0\D+#F$I:=D'4/ !,+2XA=U 5#>G\8CIH.P&*+F!I9V7UN]@M45#
M/]P9R)26[!LH+?;I!A0%F0>TJ-GN';G*R\C9.6VF'9 - 05# "8:7.F]T]I2
M]J=@*2'9$% P!+IDG2)7<4]M&(4M@B\*/N:"N8"TUI0:+)3R1U11R]ZA!>]@
M9J:%+8)7=!AF)V$I(=DVM& ;=/$XU=P0(*I<X9 @[P2DU\H=;B=25K)Y:,$\
MD*[^!E"ZN[,4=BO /.:YTE0]OPK(B0-KC?=T.2U ,>[A8GT=F8":&E+Z5C8&
M?8;FWT@@I+:8'1QXKD/]W!^(-Z-Y];IINQ.X@Z?[0_>;_HB</M?ZXEYKX4TD
M$M_TI[+91XK=*?^?9?V\W#2CQZIMJW5_H/I456V(_-676"POH5SL;U;AJ>TN
M\WA=[T[7=S=MM1W^<Y#M_WUQ_3]02P,$%     @ =H""3/51?15!!0  @1H
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M?NR'KV7ZWAY>BAQ^],U^>N&S.+YUNOD/4$L#!!0    ( ': @DS=%RL,M@$
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M/YMQS$;#83?](#9_X^(O4$L#!!0    ( ': @DS[K:)MM@$  -(#   9
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M]Q$D#CG=T&O@532M"P%69!UOX!NX[]W)>(_-*I50H*U 30S4.7W<'(Z[@(^
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M=',O<VAE970Q-"YX;6QM4]MNG# 0_17+'Q"#V:2K%2!E$T6IU$BK5&V?O3"
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M@LZ_;.Q_C>C IY+<^!%J_0>;#0FU"\<[?S;CF(V&PV[Z06S^QL4?4$L#!!0
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MOVSL?XWHP*>27/D1:OT'FPT)M0O'[_YLQC$;#8?=](/8_(V+?U!+ P04
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M^]\@.O"I)#=^A#K_P59#0N/"\8,_FWG,9L/AL/P@MG[C\B]02P,$%     @
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ML>SZFFZB1=OW;,G0.*[_ E!+ P04    " !V@(),_)(.1<$!   W!   &0
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M9EJN++IHYU\V]K_1VH&7DMSX$>K\!UL, 8T+QR_^;*8QFPRG^_D'D>4;E_\
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M\7BS<?Z5,1ZPE,T=KE"##VQV%%0^F ]HVW'-1L>;;GI!;'[&^1]02P,$%
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M$1WX4I([OT*M?V"+HZ!VP7STMIG6;'(<]O,+8LLS+OX"4$L#!!0    ( ':
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MDFJE++A2D@?7<.N>BB404%L_/;BYGB[,%%C5SV\!61ZDX@]02P,$%     @
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M>2:K7V=[DHKG#8N6DM/W^IH6U?72\%_#X #<!. V $4W X(F(/@((#<#2!-
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M A3#C2%^O^@#Y@-5AY"WRXZN]"L$I-G3A?R;@7&<Z:)ZPGR^:W<#@>WM'F%
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M)V6ZB>Z+_BWH!XJWPSL'QL>V^ =02P,$%     @ =X""3-EP&G'C 0  HP0
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MX_W6#_S7B:?Z7"DS 8J\(V?ZC:KOW:/0(S"Y'.N&MK+FK2?H:>N_#S9E $V
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ME=E,FO2A#$PRA'WH;2!7$68A01828,D\%K)@P1 A!#V4@*PL<Y*$<=(@3AK
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M*!Q!Q]/@5/</Q )JH06Y< 1\ "'0@A+D:1V+(*V/U^@GA58H4 +-I< ZX,,
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M92&.FM<MK*6GCDW#Y+\5<-$O_= _)][J0Z5M@I1%QP[P"_3O;BU-1":67=U
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M1R#F$1."U80 J6 >J2!8*P@2"V9/+ +YXF -($ $F*?;"68W0=2U-P,#FO=
MSG)?KICA!%'<%E #FBM6#O03P+(KND8PTPF@NB.A!K30=.Z-1#%7*>*J'<F
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MLS&UG7#]^]J&< C<ZEZPO9Z=G;'QYCT7K[(&4-X;HZTL_%JI;AL$LJJ!$?G
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M9LM>0%LE$%ZIL%>2H(6$.&V!G+! A>[FE@#YUWP"+5[SN1K: 3GA6PK_/YM
MGQWW.1=M<)PP.(6OU@1:/,5S(MJ4.&%*"E\7"I0N'!E.6Q(G+$EE>"M]$+&5
MOF]]LI78N>:CM(5PWT(\&5L")!7>Y/CAKW^MV]-05G7!WEP;V\<^]-Y+MRWO
M2P?4OW,E'1#]SUP^[5R2_H@3Z$:&*C#^GWJL(7\OVE/9=,&;L:Z8&4J.HS%6
MN[Q8Y%;L[,K6>Z/21]N_*O?>CK7;V+#F,M6E\;TXWOP'4$L#!!0    ( '>
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M]4I9<*39G6,=W&"N@8#>^NW.[77\/6-@U;1,'EG'O_D#4$L#!!0    ( '>
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MNP)!(.L>[4!0.B-FIAHB@,(IARXH76:V&(AIYJH@L&YN4>1>!*>:0*#$KJ\
M*(MGOA\$EU@$U,;8$0. $KNV@2"[N 5W_:LA_&):O?".[-I*W2GNK-,XL8UT
M_[/LI1XS3%_\H!EFE)^87^I6> <F57<U/?#,F"1*8_BDZEZEQJ)I0\E9ZN5"
MK?DP&PP;R;IQ[@FFX:OX#U!+ P04    " !W@(),J.Q)GD,"  "5"   &0
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MD>MT[K_2"V4:;I3H;^PYD_;7V9^EXF7'HJ64Y*U]%I5]-AW_M0PN\+L"OR_
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ME1DN]%BT!V4[4;SN+@&HOXED?P%02P,$%     @ =X""3%*^N2WY 0  -@4
M !D   !X;"]W;W)K<VAE971S+W-H965T-C,N>&ULC53;CILP$/T5Y/>NP5R2
MC0!IL]6JE5HIVJKMLT,F :V-6=N$[=_7-H2BX(>^8'LX<\X97R8?A'Q3-8 .
M/CAK58%JK;L=QJJJ@5/U(#IHS9^SD)QJLY07K#H)].22.,,D##/,:=.B,G>Q
M@RQST6O6M'"0@>HYI_+/'I@8"A2A6^"UN=3:!G"9=_0"/T#_[ [2K/#,<FHX
MM*H1;2#A7*"G:+??6+P#_&I@4(MY8"LY"O%F%U]/!0JM(6!0:<M S7"%9V#,
M$AD;[Q,GFB5MXG)^8W]QM9M:CE3!LV"_FY.N"[1%P0G.M&?Z50Q?8*HG1<%4
M_#>X C-PZ\1H5((I]PVJ7FG!)Q9CA=./<6Q:-PX3_RW-GT"F!#(GD+&64<@Y
M_TPU+7,IAD".>]]1>\31CIB]J6S0;87[9\PK$[V66?*8XZLEFC#[$4,6F&A&
M8,,^2Q"?Q)ZLTLECZB>(O1YC1Y L/:;AG<<U)MGZ-1*O1N+1B.XT1DSJ,*W#
MQ"DAZ3;)_$JI5RGU*)$[I72E](F0<$-B0OQ2F5<J\TC%=U+96BJ*H]14EOBE
M-EZIS7^<T1JS.B.\N+<<Y,6]6!54HF]=MUA$YZ;P1-R]_P<?.\IW*B]-JX*C
MT.;UN#M^%D*#<1(^F'IKT\3F!8.SMM.-F<OQ*8\++;JI2^&Y599_ 5!+ P04
M    " !W@(),<Y";]_T!  "/!0  &0   'AL+W=O<FMS:&5E=',O<VAE970V
M-"YX;6QME.UNFS 4AF\%<0$QN$!H!$A-IVJ3-BGJM.VW X</U<;4=D)W][,-
M82GX#[8/[WF?8UL^V<C%FVP!E/?!:"]SOU5J." DRQ88D3L^0*__U%PPHO12
M-$@. DAEDQA%. @2Q$C7^T5F8R=19/RB:-?#27CRPA@1?X] ^9C[H7\+O'9-
MJTP %=E &O@)ZM=P$GJ%%I>J8]#+CO>>@#KWG\+#,35Z*_C=P2COYI[9R9GS
M-[/X5N5^8 H""J4R#D0/5W@&2HV1+N-]]O07I$F\G]_<7^S>]5[.1,(SIW^Z
M2K6YG_I>!36Y4/7*QZ\P[R?VO7GSW^$*5,M-)9I1<BKMURLO4G$VN^A2&/F8
MQJZWXSC[W]+<"7A.P$L"CNQ>)I"M_ M1I,@$'STQG?U S!6'!ZS/IC1!>Q3V
MGRY>ZNBU2.(H0U=C-&N.DP9_TL2+!FG_!8)=D"-V&"1N@P=GE0_6(/IDL%]5
M.6D>K::WFG 716Y*Y*1$#DJZHD0;"MYA[*;$3DJ\H<1IN*)L-4G\Z(8D3DCB
M@*RO=:M)DL -V3LA>P=D?2M;39*$;DCJA*0. [R";#51NF*@NP?!0#2V%4BO
MY)?>MJ&[Z-)MGK!]4/_E4ZOZ0433]=([<Z6?I7T\-><*="7!3M]<J[OCLJ!0
M*S/=Z[F8>L2T4'R8VQ]:>G#Q#U!+ P04    " !W@(),XE&@\^0"   ?#
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MA94X32R.]I?(Y@PMMOQ#>L]/6!M[E<Y625EF8'0D4J:"_.=CL$Z*7T'LJ-.
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MAP$J[[,R 0B[L%K!LG$0-B!K92D<-((+9,5<$5D<,X8U1 XFX2!JK6:>F+K
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M=JL;QR1/+%J8<QQXX%?+[X,W/A=D53J)D^GP]9P$T30<#D:DX/CJVQQLUU=
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MO3'/UY6R. 9['W;CL4*LC)"]#3&W7WXS[@XF5%.WL\ SHG!7!:6J="<OU)/
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MR[Y?/ZKMXS;K4M9E(-C76W4M/)Q%<6<X\[ZG&P$\<*9U+6OVWQ@6Z^>532J
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M+RYR96QS4$L! A0#%     @ =H""3&;S"V""    L0   !
M ( !Z0   &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !V@(),\L_2">\
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M=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ =H""3-IZD358 @
M P@  !@              ( !Z0\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM
M;%!+ 0(4 Q0    ( ': @DS5JMOK=@,  ,<-   8              "  7<2
M  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !V@(),/CP;
M)B<%  #*&   &               @ $C%@  >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&UL4$L! A0#%     @ =H""3/51?15!!0  @1H  !@
M ( !@!L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ':
M@DS=%RL,M@$  -(#   8              "  ?<@  !X;"]W;W)K<VAE971S
M+W-H965T-RYX;6Q02P$"% ,4    " !V@(),%LL")[8!  #2 P  &
M        @ 'C(@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%
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M+GAM;%!+ 0(4 Q0    ( ': @DR*]H,NLP$  -(#   9              "
M 8(L  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ =H""
M3/(FK$*U 0  T@,  !D              ( !;"X  'AL+W=O<FMS:&5E=',O
M<VAE970Q-"YX;6Q02P$"% ,4    " !V@(),;C))+[8!  #2 P  &0
M        @ %8,   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0
M   ( ': @DP?,8[WMP$  -(#   9              "  44R  !X;"]W;W)K
M<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ =H""3+0-/QNV 0  T@,
M !D              ( !,S0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q0
M2P$"% ,4    " !V@(),]=J O+<!  #2 P  &0              @ $@-@
M>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( ': @DPDNV'I
MMP$  -(#   9              "  0XX  !X;"]W;W)K<VAE971S+W-H965T
M,3DN>&UL4$L! A0#%     @ =H""3-\'MANV 0  T@,  !D
M ( !_#D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !V
M@(),@1#"++8!  #2 P  &0              @ 'I.P  >&PO=V]R:W-H965T
M<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ': @DRZC1&>MP$  -(#   9
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M970R-BYX;6Q02P$"% ,4    " !V@(),$G3F@[<!  #2 P  &0
M    @ %M2   >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    (
M ': @DQT#/7FM@$  -(#   9              "  5M*  !X;"]W;W)K<VAE
M971S+W-H965T,C@N>&UL4$L! A0#%     @ =H""3.6\+Q*S 0  T@,  !D
M             ( !2$P  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"
M% ,4    " !V@(),-&JE +,!  #2 P  &0              @ $R3@  >&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( ': @DS!0^D_S@$
M )P$   9              "  1Q0  !X;"]W;W)K<VAE971S+W-H965T,S$N
M>&UL4$L! A0#%     @ =H""3 *4Z[K1 0  G 0  !D              ( !
M(5(  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !V@(),
MD)MYZ,\!  "<!   &0              @ $I5   >&PO=V]R:W-H965T<R]S
M:&5E=#,S+GAM;%!+ 0(4 Q0    ( ': @DR/4V5-/@(  !$'   9
M      "  2]6  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%
M  @ =X""3*]F<[7C @  'PP  !D              ( !I%@  'AL+W=O<FMS
M:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !W@(),U/1'^ $#  "I#
M&0              @ &^6P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+
M 0(4 Q0    ( '> @DS;[/9^Z0(  /H*   9              "  ?9>  !X
M;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ =X""3)->\+5Z
M @  0@@  !D              ( !%F(  'AL+W=O<FMS:&5E=',O<VAE970S
M."YX;6Q02P$"% ,4    " !W@(),:CJ>6?<"   6#   &0
M@ ''9   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( '>
M@DQ+K[G,UP$  , $   9              "  ?5G  !X;"]W;W)K<VAE971S
M+W-H965T-# N>&UL4$L! A0#%     @ =X""3%C\&X-/ @  > <  !D
M         ( ! VH  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M    " !W@(),V7 :<>,!  "C!   &0              @ &);   >&PO=V]R
M:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( '> @DS1X$1/U $  "0$
M   9              "  :-N  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL
M4$L! A0#%     @ =X""3)J"(PE" @  ) <  !D              ( !KG
M 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !W@(),&H84
M0' "   -"   &0              @ $G<P  >&PO=V]R:W-H965T<R]S:&5E
M=#0U+GAM;%!+ 0(4 Q0    ( '> @DQ]> ?*/P(  .<&   9
M  "  <YU  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @
M=X""3&1*,LUY P  E1   !D              ( !1'@  'AL+W=O<FMS:&5E
M=',O<VAE970T-RYX;6Q02P$"% ,4    " !W@(),T'?MR L"  !0!@  &0
M            @ 'T>P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4
M Q0    ( '> @DR _4$L:P(  (D(   9              "  39^  !X;"]W
M;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ =X""3 Y/7BWO 0
M)P4  !D              ( !V(   'AL+W=O<FMS:&5E=',O<VAE970U,"YX
M;6Q02P$"% ,4    " !W@(),OH)F*?D%  #F(   &0              @ '^
M@@  >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( '> @DSJ
M4. A"P(  "D&   9              "  2Z)  !X;"]W;W)K<VAE971S+W-H
M965T-3(N>&UL4$L! A0#%     @ =X""3&]07X/- P  51(  !D
M     ( !<(L  'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( '> @DQQH;EFP (  -X)   9              "
M 3::  !X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ =X""
M3(-,X,A8 @  C <  !D              ( !+9T  'AL+W=O<FMS:&5E=',O
M<VAE970U.2YX;6Q02P$"% ,4    " !W@(),,Q'ZB+D!   *!   &0
M        @ &\GP  >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0
M   ( '> @DR4;<CGB (  (@)   9              "  :RA  !X;"]W;W)K
M<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ =X""3*CL29Y# @  E0@
M !D              ( !:Z0  'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q0
M2P$"% ,4    " !W@(),4KZY+?D!   V!0  &0              @ 'EI@
M>&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( '> @DQSD)OW
M_0$  (\%   9              "  16I  !X;"]W;W)K<VAE971S+W-H965T
M-C0N>&UL4$L! A0#%     @ =X""3.)1H//D @  'PP  !D
M ( !2:L  'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " !W
M@(),KN-IX8M"  "L3 $ %               @ %DK@  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    " !W@(),  _F+6@"  !.#0  #0
M    @ $A\0  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( '> @DR M>"YV00
M  <K   /              "  ;3S  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " !W@(),VKGW5R\"   X)P  &@              @ &Z^   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " !W@(),,&^I3/4!  "/
M)@  $P              @ $A^P  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    2@!* #@4  !'_0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>167</ContextCount>
  <ElementCount>335</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-operations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-changes-in-stockholders-equity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flow</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-consolidated-statements-of-cash-flow</Role>
      <ShortName>Consolidated Statements of Cash Flow</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business</Role>
      <ShortName>Note 1 - Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity</Role>
      <ShortName>Note 2 - Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Acquisition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition</Role>
      <ShortName>Note 4 - Acquisition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment</Role>
      <ShortName>Note 5 - Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Goodwill and Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets</Role>
      <ShortName>Note 6 - Goodwill and Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Convertible Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt</Role>
      <ShortName>Note 8 - Convertible Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-</Role>
      <ShortName>Note 9 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity</Role>
      <ShortName>Note 10 - Convertible Preferred Stock and Stockholder's Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation</Role>
      <ShortName>Note 11 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Defined Contribution Retirement Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan</Role>
      <ShortName>Note 12 - Defined Contribution Retirement Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes</Role>
      <ShortName>Note 13 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements</Role>
      <ShortName>Note 14 - Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Document - Note 15 - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-15-related-party-transactions</Role>
      <ShortName>Note 15 - Related Party Transactions</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 16 - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event</Role>
      <ShortName>Note 16 - Subsequent Event</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 4 - Acquisition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-tables</Role>
      <ShortName>Note 4 - Acquisition (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 5 - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-tables</Role>
      <ShortName>Note 5 - Property and Equipment (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-tables</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 8 - Convertible Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-tables</Role>
      <ShortName>Note 8 - Convertible Debt (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 9 - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-tables</Role>
      <ShortName>Note 9 - Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-tables</Role>
      <ShortName>Note 10 - Convertible Preferred Stock and Stockholder's Equity (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 11 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-tables</Role>
      <ShortName>Note 11 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 13 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-tables</Role>
      <ShortName>Note 13 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 14 - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-tables</Role>
      <ShortName>Note 14 - Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 1 - Organization and Description of Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-1-organization-and-description-of-business-details-textual</Role>
      <ShortName>Note 1 - Organization and Description of Business (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 2 - Liquidity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-2-liquidity-details-textual</Role>
      <ShortName>Note 2 - Liquidity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-basic-and-diluted-earnings-per-share-details</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 4 - Acquisition (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-details-textual</Role>
      <ShortName>Note 4 - Acquisition (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Note 4 - Acquisition - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-purchase-price-consideration-details</Role>
      <ShortName>Note 4 - Acquisition - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 4 - Acquisition - Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-assets-acquired-and-liabilities-assumed-details</Role>
      <ShortName>Note 4 - Acquisition - Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 4 - Acquisition - Pro Forma Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-4-acquisition-pro-forma-financial-information-details</Role>
      <ShortName>Note 4 - Acquisition - Pro Forma Financial Information (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 5 - Property and Equipment (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-details-textual</Role>
      <ShortName>Note 5 - Property and Equipment (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-5-property-and-equipment-property-and-equipment-details</Role>
      <ShortName>Note 5 - Property and Equipment - Property and Equipment (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 6 - Goodwill and Intangible Assets (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-6-goodwill-and-intangible-assets-details-textual</Role>
      <ShortName>Note 6 - Goodwill and Intangible Assets (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-7-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 7 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 8 - Convertible Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-details-textual</Role>
      <ShortName>Note 8 - Convertible Debt (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 8 - Convertible Debt - Outstanding Convertible Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-8-convertible-debt-outstanding-convertible-notes-details</Role>
      <ShortName>Note 8 - Convertible Debt - Outstanding Convertible Notes (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 9 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 9 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-9-commitments-and-contingencies-total-future-operating-lease-obligations-details</Role>
      <ShortName>Note 9 - Commitments and Contingencies - Total Future Operating Lease Obligations (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-details-textual</Role>
      <ShortName>Note 10 - Convertible Preferred Stock and Stockholder's Equity (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 10 - Convertible Preferred Stock and Stockholder's Equity - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-10-convertible-preferred-stock-and-stockholders-equity-warrants-outstanding-to-acquire-shares-of-its-common-stock-details</Role>
      <ShortName>Note 10 - Convertible Preferred Stock and Stockholder's Equity - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 11 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-details-textual</Role>
      <ShortName>Note 11 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 11 - Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 11 - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 11 - Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 11 - Stock-based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-11-stockbased-compensation-fair-value-assumptions-details</Role>
      <ShortName>Note 11 - Stock-based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 12 - Defined Contribution Retirement Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-12-defined-contribution-retirement-plan-details-textual</Role>
      <ShortName>Note 12 - Defined Contribution Retirement Plan (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 13 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-details-textual</Role>
      <ShortName>Note 13 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 13 - Income Taxes - Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-operating-loss-carryforwards-details</Role>
      <ShortName>Note 13 - Income Taxes - Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 13 - Income Taxes - Reconciliation of Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-13-income-taxes-reconciliation-of-income-tax-rate-details</Role>
      <ShortName>Note 13 - Income Taxes - Reconciliation of Income Tax Rate (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 14 - Fair Value Measurements - Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-fair-value-on-a-recurring-basis-details</Role>
      <ShortName>Note 14 - Fair Value Measurements - Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 14 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-reconciliation-of-common-stock-warrant-liability-details</Role>
      <ShortName>Note 14 - Fair Value Measurements - Reconciliation of Common Stock Warrant Liability (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 14 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-14-fair-value-measurements-blackscholes-model-and-assumptions-details</Role>
      <ShortName>Note 14 - Fair Value Measurements - Black-Scholes Model and Assumptions (Details)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="dffn-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 16 - Subsequent Event (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20171231/role/statement-note-16-subsequent-event-details-textual</Role>
      <ShortName>Note 16 - Subsequent Event (Details Textual)</ShortName>
      <MenuCategory>Uncategorized</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>dffn-20171231.xml</File>
    <File>dffn-20171231.xsd</File>
    <File>dffn-20171231_cal.xml</File>
    <File>dffn-20171231_def.xml</File>
    <File>dffn-20171231_lab.xml</File>
    <File>dffn-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>92
<FILENAME>0001437749-18-006050-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-18-006050-xbrl.zip
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M(.I7M/6.0_EJAN,!R;$'HF=7=>TAPM&I7>J(*$-#-W>G]SI*[('0]^3!H?=
MS8\.",]6P?CAQ8?_=,)?;/8H!>'<H7 '"V8.F;^3F.L -+]((WA<=T2FS($O
M@6]H(+GT2?*]*7'C7P/V/_2=I,BS\.(_Q^$O^,0089(>/!^ ?'\!*MNBCC,C
MMD@2B?\.9L1*_HY?_XN$L'>9:X,*?B?)L^<E"/Z33&>__!5YX2_W')8? ,LM
MPK+XH2/QGSI2 .;*: 7&7R0@:%?\\XG9X>2=U)?Q11QXB4/O)_#P:(M%G"YQ
MV-A]!QB%H3?]17H@UI]CWXM<NVMYCN>_D_SQPQM5UCN2J@W@'X;Q<_:!=O+
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MJ+14]8_"Q_%M,7G(5_#I,3)UY;DNY6D"O\,:P<+'AZKXL.O1B"XVRS_NHH>
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M'SYQUJ9 +(3VD7G.8L(HE[2%('[#VEM@-EN4XL;S:RV4V-B7$@1BHY$$7DA
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M6&I K'<G=6H8^U&FS9RPU$IB*XFM)#9!$D]YN&.K7TY(#9R8M!Y=,)O)/DV
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M)$Z4,F4C%&C&6N""0@)$S:+@'P#,("K\:Q24"1@3(((]Z;>9V F$A#8)&1M
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M2W-*_.,I,LXL%OSL$RN,B ,K[T^Y&N.A7>9*]"_\&G14.''F\$4 6#M38(Q
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MD/T7F39##D_9'6^UR\&+-,]:O32E4%51.H8*/HZVNX]SS&K55AQ;<3P'<=1
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MT<[AS2:G6$%,XC$[DSLG.W@)K,82^\W!-$V<*^.+<3,"/C^T<?*L\@CTZR-
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M%,)5T5<,@1K;E4VH?JI+D4H;;.BC,5"','IM]E]R<EMV4G+R)>U_DX-:-7*
M?*:!@A.91)=8V\6&C\3SEE/7JTFB36WD2_.YJ97C\^I1'MY7>UI7'>A-J$)I
M-4>U>6U26K1$6@S5OC%4]?'QF7]-1[5,I*ZNAB@SBN7\BET=1&ISC,S*2C$T
M0U/'P^,3(\Z> U%/ JH##.TGXJ'>5;51$XY7Z>:HXAB\]Q8SXBCOO?!1,3UJ
M,=E32<J.HH+:WE#MEI"G>W;944\"J@,,;2=B3=6UD=H=M("(I1U83E\ELN"D
M]!]>2$N\X#I<1(- <::6&P!%R1-1"I-<U[9N#%6C#<*DG@14!QC:3L2&.AAW
MU5$)!1]G)V)I$I9R(OZ#V"'WA/(QU,_$,:D\ .N1]'UVH=3T:O8W&AS:8,9J
MC6BI4Y=\=#$,_20L_?;\HJ4^;-WJQ4F9=;#,&JC:<*#VQLWNP]$ >2-]*J7E
M3EH;E23[2_I*2L@;+:5EZX3ZM$[@BV].J^(:T%P+V:B%2ZI"&K2"]S?:)13C
MM XGVXG=9:^1UV7_+C7-<MJ4[,+9KY0YVZM&.QO,6\>^)R=]\6'XW%?\563L
M5;0:";LDWP:OIGFPRT!?*8?GG1,0YY%/%-ML]2'#?-)EWER7N:[J>D\=-&+V
MF8SR7197MWIQ4F0=*K)ZJCX<J[U!^9UW99!/NEXJ"/+%?I3E^85]HV6RC.G5
MQZ]_&8KD;MAN@&B_-,9N]^JDV*JA,EGE&(<&2)S#YDGL->^A:&C$^I2)=\1G
M)CSH/0ZJP&<?.C1"&\JA$:4-C3B;:EN'3MGIYNX#V=R];<W=_T6)IU!@2DM)
M]WDOBJ+OJ+K5@7#W\A'4BNW/R.%R?$/K.+R$T2MU8&?)'I(]3L0>[1UH4KI'
M_)+FIW%C#$RB0+0.7X!F9+KSN>LH/MIJ"N#5#&U>9OW#CI1R03*SXCRK.N/@
M\EY\N;LN\]J.E;U9K6><CE6B'#Y_\* 6+OY\;VN=VYI75FJM]@:&VM>:$.YK
MBHM<\I7D*VRZV!NH ZT);5>:PE@RD>E$ZL*-:7J4=\!RI\H#/!] N%',<,XM
MMB>J++PX\0F6P"SJ'#(/J@Z6?[U3"F1V:FVR4S55[^NR!<V9M"4I*J2H:(JH
MX&LOJPW*.86%]--4D$'.O>,D"#PV"45V4. FGG(<T31S;2!HZ;DY3ZIBG6W7
MYF=IZF 0#]2QII<N)V66IA004D T7D"4Z#:3$N*<OK371,-E_R[UZ5+TZ7]R
MN4(MA0#JR",5J2:^XH:!'Q 'V5\%[/G,E(>E=#:TPMF@Z:IA#-6!H;74U2"9
M43)C8YBQJ^H]71V.V\J,,N!:KM\/LV)%.JP[C9Q^4D&1UGQ;K?EN1R]?,DH[
M7LH&*1L:+QNTSG"SDDC*AOKY^*2;*>HO(8N;9)F+?+'<]9H5F;9=^LJDF9/#
MT/IJC/+R3J1R66]2K@,,K6<G6=PDC;4:J@L%Q4VW,^(\4B!K94J8ISP1.^3^
M]V?B><0)CFGC+,L49+"R*<'*-[JN=H>ZVM/+S[Z5)4U25DA9T1Y9P=<N2YJD
M=V9OW_CY3<83\)[C.@WO55_VVMHD65,8J$ ),]3!:*SJO>/KRAN.[*;J<:WE
MZ3:O3<JK2W#U7;J\DB[$TY05I7,]9'61C)-47ZMS=G.YGA14!QA:3\7E%;F<
MG8JET^=4,;94+HY"_PS9$[&I$_@*\9@/!Z4R]=QY''&3K0.E\[S%SO->%\[\
M8;^E?G/)GI(]&\V>,K8E_0"[^0&*E!II[DM1V I1J(%9!QS>RYGIU0Y!*)E1
M,F-CF%$V$Y'.ER.;B0A=154LD94C%962185L'%"'Q@$GF,D@&P=(V2!E0PMD
M@VPJ4F62R?>\&#O!='3+W[X/_>M'0A8_/)@S:H4VO9]^()X#2/6_4.\!=18^
M+OC&L:+\X6_XG&^PO'<V*# ___=_*<K?<AXRG5(3YU'=.:#OT&_DY2L)Z%=J
MNH[);,;[;V2?!'J1@UC[2J= <;_C=/?KK@;_B(^:?MW3KA1F_71E7O?TJY]W
MHM$8WP''L@-8]A#+&]A,J%Z4K L&^>FJ>Z68U+8C,DO^]A?$C/^.7A_M.',L
MZG J.0DA A6*?T<\,.SBBU*J]6NZ>IX6GCSK D9?[T0TF[/4D785+T.\/VP(
MKSHVDH&# 8C5^>E*3RBUBG'W59O\N\OB4ZWX&.JJ]K;WU*3S"1BD/0U,<Q"M
M181< P(_OZ^L12N2LD#*@E=DP:9&?K@LJ$.B@?1CEJ(U?:3 <<16 O*B3*A#
MIRQ02 " D2 ,7&^I>* ?G=]+49L2EC:OK7DNCYJ4Y_2,3O=HAT?#T;S];#Z-
MA^0[*9@N8FU2,$G!U"+!)!,#2U%='P)TW8'BJO*^%^Y4B9792)$]_^E0!RG>
M'&E;67QJT.DU0"K65'K5DVCK $/K&4>7?'/F4U\ZK%[I(RI%EQ1=N6>^/N@T
MIG2Z?L*KGE1;!QC:SCD<Q+(*]=K+/]+BK_3LQW!5/2)34FC54&CIW7[G^-+_
M2Y56]:39.L#0=KZ1AWU=#GMIZ']B 7OD^;CPK""PZ9PZ@6+.X')Y[$OQ)<67
M//TE^Y3*/D;G^+*M2^4::>&7<NC?F'^&S&?\U#==7W;YD:)*GO3RI)?L4[)_
MK#.27"/-^W.>]/?>8D8<Q?+"1\7TJ"73]:2L*DAB'C0BB5E&[B7CU(MQC$X3
MQIO5E&^D05]RR!XS]80[G]BV^TP<4[KQI>#*/_%'TCZ1)[YDG+W-^F'G^*GR
M[>4;:==7<. _!*+AVWQ!'9^?]U)826&5(ZPT*:NDYUYRS=XQ>LDU,D9_7L]]
M #0JQ1/'T=F;&)Y=[C5^X$<C@@OG[*O85OVF/LS;ZL5)R72H&[1;0L7R.8<0
MU<\U*GT\I6B .]'^9DO:;R[P@;+PW"?FK_F%SG\:-%IH[SCZH]52NS;C3XQ>
M(VI/3XSH^@G_2V/A=J]."J@CVG@=;_+6=SS3N?7*/:8Q[3U(J7 DTWQANTM*
M'ZCWQ$P:SW:BUFTJ#G=CPR/XI_LION31@45:7V#5+ESG!_Y!\YKTH9S75-J\
MIK,IM768Z)">8S*0<TS:-L?D7Y1X"@6FM#8.GR(C\-)0E)[9LC.2ZLO0>WE;
MI#C<(@[E6*?6\?JNX]EJSN.U@T;R3*MY9J<Q9C7GF8JB$)<T_/4K]4&]-&<*
M<2S%HD_4=A?8+ZK!#L$F# BJ=I)+*Z>VUV-2T+BO=HT+382I#SNU>6U25+1$
M5 R&ACHPFC (Y$S\)-.,2U'I?J$.'^:%&AVQYLQA?N 1#)><7ZFKA425&7Y-
MS_#35,WHJWVMV6E^9^:#.L @>;'QO#C4!JJA'Y^X54].E(FOI>@D(H/5QQ+G
MZPGF5V0*G17Z@I^E?G*>S*E6VGQU21K35-WHJOU^^:I*E9EC4E61;-DRMNR-
M-;4[.+Y=4CW9\L#$RG+3(8NR+C\2YOT#YX_>^#X-_!O'^L3(A-DL8-3_E1(_
M]*AU[\##0\\#W ((S,\F=.Z3:=GKR4Q+F6E9=IJ$UI5Y$FW+DTCG$2HM2322
MR80R,4HR?,%M;SYARHNBO6T!H]<.&LDXK6<<73*.9!S)./LS3J\-C%-M/FZ_
M?P'YN =2E7"D'$!&9Q.UM6+E++S%WD )>PMAE\0J86\,[))8)>REP2X3;LL9
MU4-\43]EX@?Z9\B>B T6BYS!*P/GK0N<C]31>* :K0V<2[:4;-E MN2++VNN
MM^1,R9F2,R5GRB3Y)OA^4[EST@$L37T)NR16"7MK89?$*F&7#N!Z*6ZW[GSN
M.J*\47DFGD><0+$CM6PIO<#2J)5&;>.,6LF9DC,E9TK.E)PI.5-R9EE5QSNA
M.5Y"P &7=;AG28K>4_;5(1^]H#PW@E+7C*$QZ@TZQO"[:LH+9$'%&6IVCVUT
M7C.:/KI\MVZ"XHPR0<\[2:4@:(D@**N6MV8"0#*19*+FU?5*)I),=.E,='2-
M;\V82);[UB7EZ^!RWY8[3*N,]A<Y1%&RMF-E+=D@2>N2UB]E@R2M2UIOYP95
ME*IV2<JGK%NN5PA:1M]/&'W7U'Y?5T=]O:6A=\F6DBT;R)9_;7]2C.1,R9F2
M,^O(F=*A71>']G$US"V7J]+[<?'>#TGKDM;K1"0M68:D=4GKTJO=+@U4%F/7
MT%R5EKJTU*4/K8[D*3E3<J;DS#J2I^1,R9FG+<;.&P%=PFSFPK'/80 W_\H<
M-@_G7ZD#&_>%+.>8<?+1]>X7U",!//$3O(0>,>Y9[\MQSW+<\^DJ=F293DO*
M=(0(*HHW;7@*+@T]Z$AAP7P](?" ^%P=>+G:6._H$CQM</2.=J2 B[,-:J_!
M5Y5VJ>EJKV\<K6+72IN6K5*/D1EC*3,.@J']HL)0C>Y8B@HY#B,2%7I7B@HI
M*G)%!8Z@DUJ%U"H24:%)42%%1:ZH&*E]36H54JM(1(4N1<7I/<J-D$$G1L')
MA5MOK Y[_=+CER?QSTK=Z#P"[YN[%N2X8(DG4SA:E,+1[VJJ,=)*EWZ-SMXX
M/,6B*&OC*S7=1P=68MUA^@*;,FI%N2'FGR'SX*],C@C\%LZI=43^1E?F;QR4
MOR&CEK+KC0QEGNR\&:G];E<==(_O(%.KPT6JU@>+DB\>71!F*?1E01TX4+E8
M<0.@(X5L=&B]7)'2''] 53[)<5_5NUTI1Z1/,I(C+FCFP9++#]1(%JBQ2^$A
MA4>>V3M4^[WCK=YVR ZI@]R!C>\\,C1LI<XAQ4:AV!B#Y=)5NU+KD%I'!,HO
MKFL],UO&!J3 R!,8 W6LCU6]/Y("0ZH:')0;T_1":B7-5-::]4G9(65')#O>
M](9#U>@UQE.Z>WW?"?MEO=W*3%+I*46&O:=3ZGD@Q +R(KM"R82PEB6$O>FI
M \-0M?[Q":_G3 J[%'DL=<K/-(C\5@J)TDFD,):Y:FW+5=,U51]HI;C?VI2N
M5DIN65'BVL.,>/0=\:EUZ\XQ0$\"YCH/V!?T?H$?X24!>P+U[XA<M9',56M^
MKZ'J7RS;"@6M[9OS.9Q/J*>XTPU1+SL+B=LB\;LS?NK;54C*$"E#3L$A_^3?
M9&TA*4)2MQ'0*\@CE?@IN(V^4,]D/E46'C,EFHIN6\!![:.=(,\B>1;)LTB>
M1?(L*A\_'IT3YH!XE!@JN T]3AXQ@Y#8BLVFDI2*;GO#'&5)B>>_W1E%\L"6
M!_9E,<G-XZ-''TD@Q4C1;7<@;IGC,U-BJ. V/@)B'2,[1SFJ6G,DO3N]'IUG
M'C'"4.7"]1DZ&D&<4)L$[ GNV A'$)_R9QUU*MWL=!PU])BJ>$JV?@$]"-X1
MFS@F54B@_)TX(?&6B@:HZ6J#'>FB65E@CILP6.LRW Y:V[AQB10[(6 7Z7E4
M&H6F&N.^.M".;WG6=%1+/FK)3KZ>=B6%Q8'-$3OC)A0@G)V76B<<6K>@*KB_
MV;R^AL5BCF\KB<@%U7U!DHDE$\OJY-/Y5+Y2/W"]7ZA#7Q17)!@J;ACX 7&L
MM=CCY5:5-,91496-T-54K3]X1=[4P4QH(O74JC]IVTG9Z':T7IL(^8*B\=6I
MB!>BRM5_KR61M9W(9,>.DOJU.UCJ*.O"I0:?V_'"&*G:N#%=#1O0V:*69"Q-
MB0IY:J!U>HWAJ%HK6U++:[N6=\DOED36)%-"A@A^\8@3'&)(U"$-MZF)78>U
M &Q3TE.E'0"-_D@=Z<<W;:[G3-@+Y\Z*J;7&EE#3V730T=LZM[D&BJG4B-NN
M$5_RBR61-<GLDA&<PFJWX?G]T&=/"[V M;5)2:PR'U97]>Y0-;K']W)O.JHE
M'[5D)R_+HJQ26(PZ4DZ<F9>:",,ZNU77^*<BOAAV6C# KI:D(U,R*B3CL:'V
MQTT0\#*26>M(9AN%1F/LT:J*FOI=M6NT8$1\+:FG#C"TG8+UCM&JFCP9HY Q
MBO;NM22RMA.9#(25HK5_>%D<-N#R<C*<9/YAPQ.;WFBJ,3C>]I#3AZ5M+RVC
M3?;2^IT29LA*TTAJK>W76B_YQ9+(FF0:R8#&_:I3&^8)OJ<FY5-T>P=G"E8R
M)[T.*M+!%D.OT&*PW'!B7T*BWXXH.+W#6^T#^X]'QT=X*R'[T]1MM9=#JR;8
M&N=+-)Y5AYW>\6WE&\2E;61(F26W0=3MZAU9(]J1:7(5TK&A#GM&\PE9QMM*
MBK=1SV0^ >V@)*.RE<)$VH^-5THU==0?J=WA\8>XU$QK=K)+4[&Q7#DZ19,/
MR9"UAJ'UIN*@8[2@#J66M"--16DJRH*JLYB*_Z!^0"V%.)9"7Q;4Q#\"5WF"
MKZ7I*$W'%BNI%QEZ;"4S2M.Q/5PIHXS-9TAI.LHH8Y/I5YJ.EV,Z?A]@E"Q9
M2[2NOWT?^M>/A"Q^>#!GU IM>C]]F!&/OB,^M6[=^8(Z/L%9NP^!:_YQ+\;N
MWI@!>V+!\AL^\AO0P3L;?OSYO_]+4?ZV[7E?R'(.(N_FF7A6^GG_(';(7W+C
M^^%<?)=]MF("+N"/KW0*&_X[&FC770W^$1\U_;JG72G,^NG*O-;'5S_O1"+Q
MU@1\0QS8$ \W9 /Q"=%Q%$;*PT]7W2L%YY9%9W#RM[\@9OQW]/J(69ACP>IQ
MYTYR2@-EB']')#CLXHM2MOYKSH,\MT#\+/V[@R167I77Z\\!;0ZPZ/QTU5MG
MJ[Y><(2>OZ@N%BX3US[NMG7OPRMRJ"RDR\TK:?,V&UN<>//R/80')XVD6/XT
M6L^'Q/]&O;GRACG*DA+/?]L(/:Q?C>I3D:+3[^B;LF;;\HM8N#6J'P?Q_[P
M'QO[,6^_0HVO@AA@NXI0I0 YF0 9OM;(20J0"Q0@PX[1@K:L%<5>3ZYQU2@.
M^Y7Y?UQ//4J!AH#Q,?SJD8 V+]S:+CF^6KC6&7TG);J4Z#DM&U^CBP9(="E*
M*A4ENA0E4I3DB))N"T1)135<EZ0<)I[!)]<F ;-9L)2*86VD>7<L54,ISW.P
MH/4&G6$+)+H4)Y6*DX$4)U*<Y(D3O=_IMT"<2.]AZ0KB>_;$+.I8RI)1NQ'3
M<=+I$)[[+#YK.Z=&-%7,M^$-VX3Q;ND=#1!2DDTDFT@V.7DJ[>&IKX5IM?B4
MF6M;U/,__!FR8/G9#>@_B8>3X_Q[[RONGW]0!FVO+S-H#\J@/=K+-SJ%(E\W
M)8Y3KK+PF-G L&^MZC"T]?.P;8486L=H61V&+.$_(CK N[U1*3JDZ-@ER*@?
M7V#;#M$A&T5N+3FX>"&R-PQMEQU&IR>S5Z7:\6.[,E9K 4/;18?6:4SSO T>
MRXQ!/ FE?+>5:Z2R([.H:@5#ZX55U^@</\I5BBNI7UU43+^&,+1=4OUU]\RH
MV@BLW2RS/:*)^T7\U@*'% 03<4QZZ_J!KVV& P<\'#A*?_S& GSOG6,ABX;$
MOGEA_O6'%VJ& 7N"7Z;,!%A^Y9U3KQ2+F@PVS/_IZKH7A1+UL=X?#+K:E1(Z
M3+R,^:ZA:\/KT+>N?NYU^?]2J\V"N><:-D.:Y:VA5[2&G:'/[:NTTT;PL/&W
MY8(*X.<+VUU2FHHC"_!_?Q?ZP&^^?V,">?B,QY7QCO=L.H6?7.?3I]O75ZH7
MK50?KN]6[I(.6W9>.'H%X]WGCVD@>[UA$9":;G3[?>TT0 Y60 YV ')4"&1O
MK'4'HS* O$'V?Z287?!NF9]PP/^%#9"9\_@%1)AK[<8[.Y)=>LVC\?CJYR]:
M]U^O+>TPL)N!D-^C1_.K\/.O\.R9O=Q$UQA$X\]?>BW %G#&*.$,^+@'MO)%
M]#L7[KZ?OF<>&+.NY]_." -]H C%_QL2+Z!>/I*-!M"D.-'O'#_P0OS2OP]
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MSEP;OG&Y5.$]H!&JN6M1&U\FULL"7^ GODX U5$^P"+FA"\$GYE"$2PHYPX
M]<^0X3[ =A(A/O$U9+&PET AUB/_!O$[)W]0A8KGXTXSQ[1#*W[3J@E;C+IH
M@7N)GE)9@_?1&?_(*6(.*^;+5SEL--,H=PW@S+UIG/EK-UN9EDX<29M(+WQR
M&BJD3[PPX@J.<Z3QCG(#% 6;Y(=V "B?PL-Y(H-BSO"TBS8FV3E.3!:;3JG'
MMVV5Q:IF^"F71TPWA%5,  IXL\>(#12P>M;4]91IB#I?3&Q27)Y>7&X0:H8>
ME6?B)RP)TL:/N7%%:>://@/9Q*8,+IC38.9:JQ^M'_FV)B(W?BSQTV2KS.#O
MT_>^<MS,OLP8IGEBBSFX=8K7<6(%V631)VJ["^ *XKL.'[4BT$0BZ"=N&,2T
M2I-N^B0 '.+/P#(+UP\2B2^6+R0?8)DYXDT3.B-/#*D>_G]#X/)S*!+E&QB&
MPT$1C!;Q-1&Z92P/XC?#>>28,^HGH@.U10\X/(15PQ/Y#928,_&ZC@*&5[))
M_*N<$TC-[%URO(!4(<S!MZZ_1#S67XTK20GSG(>A[" >1_LBG,!&BV\<1CGA
MD.A@C;%&-]MT(LBPKV9HXS&^*3)S4!Q#P"4:/0,YKLGZ"34)8"/Y6IS[54 5
M9,!:R0<7)?>"," ^07,.);'$5I7G&0,J8CP?!W8G0&)_9L&L9B>U8'JN0E2/
MRP59(GLD6RHHS\OOBYUA\=\Z#W"QQP_O);P#]".!72+D-FA3GON25LR2?8NY
M'+\4=)\E^,H)W79!K_!6BAXR<NSLX7**F* H &,*C2#U8T1W0H'F0@<VTC1#
MKU!3*/K\FJV_U>3.L=D+W,>\?D;7]RM_X5<SBQ%O^4"2?H7\^K\3)X2O\<GW
MJ#;!9K^:\6/LX:#N=D;K7KPB+T6QPQR=#UO<,MI@]W0P'%NT(SR3UQWIDUV*
ML1)G.K#53LW,LM$J?8<^ A6!ND]Q87H)V.2K_R]].'R_AOJ3P%TG_&3QT&_*
M5F8K&]-+&,!6#O^E#?M-VLK-^I-LP%4[+$Q7$#'*C2.?!.R3H6?-O_PUUL-O
M5VKX8=),ZP/]#(!^1F70S^& EXNYM7Y?<='<KBW.#JY2V!)]UXSNQL%;_@K+
M16-QG+EH'_7_O[TO;6X;N1;]?JON?T#I)3=V%:7A3LK)3!4MVXGRY.5:=J;>
MIRD0:)*8 0$&BV3FU[]S3G<##1#@)A($2*0F,Q2)I?OTV=<=>7#_EIJ@#OX?
M_'% !-QCX26$W";2;1'DN@<1XF4!W,X9#P=DA;>'A^?AMG,,,,OH923V]VGM
MNS^SS$TBO\TH13_"9D\%THU5'_N#-+<+X3"KO/^,8'J<LJ9V?CO!UID#]$BE
M2;EMWONG@Z<J]7(3UG][#/2 7LP[1."J7 <310@:=Q2(VZY+96O8S543AZW6
M\+:33M)45[CS!OH'WT"[NT;/;7:ZO7XG7=K\HAT,TCNXLW7?5[UFCW#*S!]]
M\=B$>5ZB7>B&?6?=LFY003N_P^ZPT^RW!^EBV\/N_,5GUVGG(U^KVVO=]ML[
M8)\U=:R)9>A >]RCB[W>T8,*IQ%-5]E>$_.'W6%W4$3V4GESC:3/?>S:9E$C
M@SHKWO73Q' HLOZ6Y]1,-"!-'W"<1U(Q:O 8SN'8*+*C8)X6HYXF<6^; ,&9
MIAB<&G\S<N4R3_3"CN4DF1\89J,0H! N/I 'I@29)R;QB>7HCF'I-BQ "#8_
ME>>DS?0GIHT9P_PUM@ Q1$%IW)%GXMPH'AS]_JC]?33Z<J.-X!82Y0Q_XV%$
MGXDXJDA& W:!&0?3T.)/ *2<,YTGJ]&]^$$\$=,0)CB"4(8D%2[SB,*0,M_N
M7).X$+&H5VK&S.CQ3LV1>4T,+/,9WQ<FQ4A3MW]/WBZ@\R&"7.:SJ%=-\DD?
M1H]O$X^ZM)RK$C+$[S[%Z]_+^/B%G<A)>"'G(IQ2 ?:9+,BB.6:8*(891BJ#
MB7-<51X%["*9T<J3&^+@&5RM!YH^F3 C$!E4"]?#G U]SA,@8"EP/0OXK;:E
MCS&]R1*/ HPR;!?3.?%"U*.!WD569N8]_"V4VBPX1N9&9:Y8UG)$*J>OF:$G
M4TWX=7%J\TV-I8=?\&?4<C77F;H(:,J 2Z;.448XH1DEQ45(QW,VE61'/$(P
MB%'&X4F[.*)"9OVFDZZ-T*/<7 ;8Y<XM0V/.D^6Y#B+*34+/M@![?,T/Q[\3
M-KOPT9BIN(]IO0KNAYC9A D^B]!;N(A1@%TFX_F1^/J\;.)&3@KTLYC?F?>[
M@4$Q0%,4\B3X&YIN@P4:$3VE%H6>,=,QF9/26Y1L)%P2+A>55!TNXA3($T5Y
M!KL16$]$:#?:QSAA>LQL"ZY*GPK/IE,23$&9$'4"AN49X1QM:@.?->)YE#Q#
MVQ<YU#QK6O/C ["7V@0L7'@" #-^485I$?Y7%C%^%GH%NCFU?TF2B'5%95Q-
MK6H<7]4P@$^1R:5(U7+ER,9*@16CABH9#-T'U@XJ#S!8_EN4LKG0E\C.&I)U
M>EBD%"D-<9IJ@D.;\']@B @%?P:JQ#7EM#IZ(%0;SM.4Q5#5RDM2>)-NKFR'
M&)_O_HX9Y#7-QK4"O&^MQCKD/L(;T>^:?.?:FJ._P$DH7FKN;-?>KLA;*B51
M$, N(O7X3\V;?F(K0#<VI4#7"'1,!.KO@$!)YJ/B4C%+3:QT!6O)M5PNG&[?
M-+-PFI9Z.I)JH(J*>2P6Z,1+7F.PA1:.?C:I]D<59KHVMM#>P/HA/0A0%1?U
MJ6@QAUCD\Q_,V(,GZ6"6AXX[!O'V1(JTY2P A?B5$]#PR5*'BQY05R\ /IT$
M<*2='0-B9C$/#8AEY5QMA06HUBAWAX)9J33S.Y>J3&+_TYW'3"O0<#!,U9"D
M:BKYARQEEW./A8M5;+Q,&518U$%3_CU#/3A2* Q^<EC3)2OAT)< ;UC0<_ 2
MU)[AG$T&C[1$E=P<C'MK8;.4\FT%H5(7/M9M<@K@4WB]W<3CY4.T0H.A2X69
MP%_P57!_Z%$!V-P*JNP(J#1IXV&C8*8/[V.;J:;KXEJ!$"$"6:!K>PD">#H#
M\K M. P,X&&JO#!QR6<)*MW<==@2-_,'PSIOQX3?>+DEL&?/@BT"?<[1/A7M
M*(ZO5@0SC[&DW@57SH 7>( )OO0H&A+?TC9Z3?\GH?\OGKL +75)9X+D3\[B
MFOB+(W[9M6>AG@23)X%!,0-[-1 -Z881SJEI /KV%W"K%2<8Z7.,<OU'YR74
M=W 3"6*/.>Q9MWG8S)K#:YZ8HD3 CIF(IX4^FX38$>&)15X_&:KSD'07A#G_
M829&$+ 8W-%EE ;CDY;'+Q3N-(PEHE,.0S1PQSMUO99/^YXZ-$YN<V\BM<5'
MWB)EC3\.1N,:!J7;\K!# :9ZTJ/@%O#*5B_QSB73O72W"(X3 "J;Z3Z;@=63
MQ($(PN38A,\"I!D C\OT"=[(V/$/M8&0QSANTLMNM.\+.%F/!99HZ -W(!10
MJQ2&A#PY;GK[(K@K'[,UNHN>4W/8C2G#3"QV^D9]'GB0"BWX*> OETTN+,&G
MSD( ,'023&S>F,!RHJ 6M>1@0HVN)=5))-6#ZTRO'RP\X1%A32VDCBND". V
M 5R1 AY[LMBSC(U+"Q29"@X6HZXJ,V# R%;8D\A+,3')C'%Y$ZR&F*BK$]=L
MZ34%.+WG.O>$%N?F3O=:H>BZ@>P7O8))KFVZE*J##5:6HMM0E/ @09?P6MHK
M1Q6QO)B1BWY08"U8/C%&)K3PB>T^^XE&.ISOQ9PT]%E:UJ:B;?P9=(/"XF^T
M^PG *^5#!2-%01?VP_*E".""!:Y^!E@":@$DGJGCE9J<8"K>RB3<BFG353BN
M)/!&49MPRPH@X8!6\4!)@R+U0 -EC[W #;][7$GKM!H:QNP2!%=,+ ##)Y5S
M8Y^?Z+YW M#$*:92B^XB1+<"<-6  S;I6=2Q"[@R+L*:6"(F=0TV@8$F9F[^
MV*O[+U]I&?C_=Z_5)$[^<.[#(L799!/+L0(F>)&UNAQQ%_[IRTP[A9?ICA-R
M?[13!*_Z; 0NLJI6@D?!DL#&8*H3&ZP$995"L\%NI"3%2-P).>:BK<+,?'BR
M">R9A)T^AM]<D(R-A!$527+;1FU!B,1K=S*),F"EX*-KN",!+&ELADA"65DJ
MFCF\S2%/5D%<P (!X07PJ,<B-F3%YB=HY"NYC(F#3R]+6IAF9$I:7HZY#N I
MY#1'X10(3J,P?^) 59!%0.?Q3ZX;K9Z/T*1$Z%BJ(E_?/UX?7WIUN\DX.I"H
M&<(B#$P_P"SI1H0("6U0P;Z,HZ.<@+1^=?S-_(=YR39[KQX9TSYADD(!D%3?
M_+HVX$^B!?S==4WD&A<F_#,6>T3)+X&,<H6WV22I'F6W^&0GZ%B+1B4AIH9J
M  :)I"/0 18A4S^!8< >N$T8BW G4Z++YZU4=5##6O-&4Y=6O+T=R:F&-@Y)
M["JU  @/TCA4D1DPE.AI^U+7, /(5JM*L""=:S2PN:G<)1?C/D\<)1&K7E]A
M'E3IO/>3AGH6S,/R+%YK(1 NPI<4YIU6\Q5-MR>6CQ4YZ#G0LK5AWH6?%Y^I
M=2$R.D#M;WE9*SZ4>P3]<#K%+?+ZL@QO4*1(KR;HI<C.\D5T>8;/P?J3A(.L
MD7H\JL$R^.29@K$1FZ2&T)&'DOJ9)SQ-V>\O03;\5&&K,2CR?86I#60^*^6.
MM(KPU93$K9;A58L@?'IGVD4E:0^2 OPE'L/]W9;Y_L/J2O"RB.]]K C95YPG
M.%S8>12NO9Q$OD5'+#(",*7$HBK@*+,DQ,P"]&'9C*<2>-*A(YFVZDD3.:OP
M1)P>,IF@%T2G#  N[<GWR<S(3'+% AJ8=<!XK0>]4<DJX--+F!ZH+Y0WWFBI
M/>2DVMIL"NI5JHJ7WR$39^"YGAM.9VJ"K>;/&./SD:(]"D4FLV:%:G>ERT>,
M+(GW"&MZPB?!R1H\3R."5^RH5<).H.KQFFQA^0FXJ!U:D@L]3@3FF%A_?FSS
MJ^J&?A>[.6L&>EQ4^JC_[GK<V^[(1D&Y(8&(\NW0%--6'%Y:GQ.2D?G /I";
M)]MN2(X0#;4:,X=-+(RQ,VK E]FTP ^QQY!L L(;#Y !9/")1;0VW@A(CD^"
MG[&JR4)S[]46?0>D_1M/A2I/33'.NK(GKV7>9,1]U[=4R$MVK*GJN%0UXG(;
M$U=7K%K>XR79>X3GT# J_^9YCW/=9,4$/H*9Y9DJ7*]A*4!0@G10^7CBR?_2
M%Q$%S^"GJ<=SYVEXIJKPR&T+U,342@4S77)M\J#;XVJC$\7U*<<HP@^F24D[
MJ7ES8Y#\>%;ZDV[9/%?I7:05"3J&9]-?DQC LEY^99<R9!5O3CI=HDXQT5K1
MX4I=U.BX]'@2I-Q_Q'_$\U/G?H),,A&%12\Z-6VR3%).TYT&B$F3#NF*9F_$
M8/=T"V.1%_-*7VFYL6*RQ"SG)#+J^V+BP?>E8%L:LBV4XL\S5TKR?-$8$69*
MTF<(W14Q&MW+#0^'LDHN3:8>TX9(+*UXQ6M/$^:+3C[ZM7Z?"T",PCF?@#O)
M)S7O-R[V0">&^#E/)4XX$BCR(MH>B&H=_KN)O=5\JE=^8K&P%$U,D^U6ZX*,
MDV=UHF*H?=-_U#U CTZ#'LYA%CKU1^9-F=?0WEF32>BCCO[P<$=I7>20Y(2G
MD[P&VO)GUH+,6%%Y3Y1&I(3$B2<8Z#^B+H<WR:>6P#*'U8D<55JL*-EJX!Z?
MF6WC?V6?%>Z6Q.WH0>!9XY"Z*#Z#^@# H#13Z4PU+>!#&,(6"7USBOEPXX2N
MCWJ+PF,I%#Z/XV_1TC#_$ZP.RAN)0>FQ(/2< ^@KQ>NX52.+[^DPP$0A$,0,
M+'4)Z>3A' M*-FRM]I92"OVQNY L4DS2*.8AP15 AZ+1RH0;CC(N$)/HR$]>
MF3/PG*=[JOE82SF>'7/ DGU#8P0F)B#FBG!BRFG7FPP+3-QTJ:Y(JL5'8'"
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M!HU#'[8"6B23J(1PFUB^ <!:,MWSM3$#:D6&I^D3P)DB)%74KZ>%$85F:YA
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M%>2^177PRNDW*KFVX/G(MPO@OW]J]VZ2K!?@:J,H6!4V*"T"[/ 4I5-8CF@
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MT0)P!F:-;2M\U[#HJXB!Y;,1V76;*M5IJ@A< EH?MD$5AX1=K7P_X_2R62G
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M<!TRQI^OI/FXNL&K7\S)Q'F3O4V^F)4GKQQ.<DGRVP14Q.*Y]W9E2X'N!>]
ME/P2GTOT[.BWU$U@AHI;Y/G%+S:5&^2WRJOE5P(GUJ$)/#LRYB6:C# _+!J]
M*04LM57\3(IIM9$DL;VK7^37N?L\!9;(8RD+EF2X?(H__1>"M+\[2/N%@O2W
M$6S,1+<D:*6/45_W]S\PG,#,#Z#QHZ(<!J0Y?IZ\USUT\_LRA>?M,OL!:4:/
M7#+^M>+$?#R0Q:QA ^Q.PB N&YO/3R@5@<?E$G&7C<%?&:BIEH$1*#R-&GLW
M8F\FQ&K,+1QS>=OMD2(4O\B>VS4JKT=ELD6W@U^-V(4C]J\\_:7&WXVL. &I
M&E.S,;7VHM0JYHY8\LEU,@!8=1,]B2DD ]=NM$:5+5#EO.R';&92:_S;8\=;
MT4YY9/P[M'P*41.>O+,FDQ"A_?!P5VTDR=FAX"BK^ZP1Y86(\AMP:0\U0"Q3
MB.OAZ6KE[J^,LB3N7#^HN*0Z-(;M\NY\6,?\<"W0:W3/1/<ZYGWZF'<%T.3>
MP4;+C[*"ZT$4M1"^_)WFQ]LCQQR96%E#+>7!.G[/4[>JC3YK-AXSGJT@4&/6
MSICU551" 6#?Q750EX-76^R_QJIC8!7<;[()4#(FA3XQ\]X)=&>*HF)$A:]O
MEQ_UWUWOSM9]$:YZ_]CM-FN4/+3:M^,Y"-&NGD9-()D$ OKTW'48+&SYS=,=
M'VM+72=RGXS&NF/")7#%Y\F](T8*9!]^ZE"J303KX2+PZ\70J9$R$RF_\"D8
MG[U'YCU9!E/5RP^RC\#(?+)\UUN*:RINGF1M66#9=ANO42D/E>!AP?*+K8/5
MYYC8Y(?H\>TR8G)O0\O&:EDA\R/)]W>&X\06,^QEP"WBF>[9;@!&XI-EV^Q?
M%K9LL/3*8]XF",5B/PFJ0TKX7*A+,WT=[&ODST3^KSC;BS#WH_X#IQE6&U.C
M[<3XF-A7C06;L(#/M#P_+%#W56-!)A9$_)6,I,\3"A6F_;SGE*&6N^',A/4Z
MM^P F"12]BX,B];LNL:@]1@DVDV[\P78VD[ ?6AQZ3A6CM\[HF[\3/ H:\M*
MZ'+=WFMLV@.;[JC)QSEQHO48M++?&FOVP)JO#"?G,E/F_5X$ZF1ONL:?/?#G
M+'+DMT2;.LL]$UL&ZL<Z[;!$:8>#W1 E<<L1$&6H?MRR'.("$.K0E1-GBLS#
MW9%Y6!0RGS^2UHA2,*+\]DD/0@];1_-4$^YW"@T,O']@;#3U&'?7U&G6+TJS
M7H6R+,M="^L:OU^*W]^LP&:834+-S$(1>4X&_YE78_:^F)T)7_'F;"C7.+T3
M3F,UFNMATLH/@=(/;*K;[PD.%R7^5R!Q"#PVF?4F!=!:V]@-<[-9[/L?S*!J
M_L^3B64PK^+:PSH^E[/5&EWHV8/K=DO]B(E1G_0Y4[C;%&GZSO5P<!P2/5S=
MXTZR>\= 0#PQO*O:&*3N.\'1=MK]J9 *CVY'I%)O.312#2/W,7S<ONU%#J]Z
MZ\+=.)O%8S1,Z6ZF6]Z\Z@AW2H]/#KN,!/U:@)\*QX<[.[T)^<X!QW_[%PZ>
M<J9T*7[^WQ#VSSQ[6=- *6E@EX4H9RL$3\8)UT27271UQ=ON^%97O)TU@;0&
MZL<-%6]?X6P]GS/:1X!;Q6/X6]6QY>SY= C4VC5$J]YR: 2ZO6X/U(\9K3*^
MS1A>D-U*XK<'*["FQ%'N=!FQ8 '(6KI?>M&KC6>Y[376@N:0#',5RE$CT1Q8
MGPJ_$8MVQ&_UEH/B=W+R)GZLWL2"P>[I/V*O!8"TFD,@]@/IT3*J5D%:#X'8
MG4->[!"(R\;F\^NI6P0>EZM#[V5C\'DU<2T">\O3$O:R,;<> G&V0R N&['/
MHL#E0H9 5 !3ZR$0M8IY*"Q9"0U_A&?/ZL#PH>.Q";#6*+L%RM9S2VI4V1)5
MSLOD+?O<DK/ CG-K]W9(K-GEO:5L,U=^#.4VND^6$IW,V^5WQ_IWR-XQW_"L
M192%%%^(%E9F]Z1O[DH;D\MJ.[4M,!,S+'8%Z2&)IH)]LLI/4O50EA(,92D_
MFGS0+>]?NAVRM\L'2Q];-C9KB1(T 91HO"%I@@H.Y\B+-JJ-.&NW'.-0_L9K
M5,I$I7J^3S7G^U0;L^KY/N6<[U-^K*K;^]?M_6OD7X/\#TSWV<RUS?OYPG.?
MZ C\FA(V4L(:N-5D46ZR.#,W:.V./"067)8;\:6X4WL RX/%]>R6B\6">G9+
M-6:W5!F3SE#ZU1*I+!BTH5M^C71'#<FN;]]?X_ZQ<3\<^Y9IZ=[R4<?^.O%=
M7SSK"9[XQ=:-,V@!4"+,SX.XBO59H*_Q?CW>U_.Z2C^OJ^K85,_KJK%F=ZRI
MYW6==EY7U?'G+,H9*S.OZZRPY?+T^P.B5ZW5GP['ZS;X)6J#7P%T62X 4",D
M[BF+\M&5OW^U@MF=;3F8PB SVCY[4]VQ_G,&&<>9VQ>(M#,0:A2CY70B%(./
MM7^M]J\="^\[.^,](619\/[M0? ^1^!'5XVFET,BF1"M!(D<2OG).O::/!/D
M.;SFPYMKL52+I5+@O4#(X^%]IU;':KPO N\[Y>+WN^%]K8[5ZMAYJV/5(,_:
M-U_[YL\$QP>Q1^#VNM/<><9,5?'V.&-CCH4T@]WM5#S-HR#-,/;0RX\O'51+
MW)+].T0V\@3_BHI(4]]7&^6*&6N[*_/, +NB)&7!_R1$,-P]AI"ZY:A$@-K!
M)>#P!6#,D61M F-2N1Z/0.4Z/)7CB_CC@^LQ0_>KCC!9>U30)7.SU<&7XT4I
M:3GMMOI1&+-"E_[L?;6F,ZZB?7=,YCU[5L \\:MLM7#GAO!@;P&;648B^A]W
MO^J6 ]?C_8YYYSX\W%V2),X%I!#+N> \I/#-.AGQ_OSSN63IWV[OS,OC6TY'
MFQ*#[GT_Q'&Z8%DXC(:A8LH&F!O_U)T0[%=\V.?)!%84=PRJB=%YLS_\:F(I
M*[$<JV/O* S<.:S<C&^\*%(Z;O/>7.C6A'9IA/91_X/].G-M-C)_#_U "2[5
MA': +MEYT*T)[>((K::J$O>>KTFH B3TR(+ )A_4Y\G(,#RP(MYA'!PVY-?D
M=3#RV@SFFO1*2GH;\^TV]+RZ#/I9DU1TP)&Q-1&<B@AVP>$U^3VY[JC*XOU1
ML&S7%>0D^1#E[>T!/'-4MQ"_>SQ(=0+LVQV.E@/0@G.(EQT]7/QR2)!L/^;H
MW%H['WC\T2ZO+DM7Z2J@VCETWBT9JIVBZ6_!J%8W32MUT[1284/=].P23[UN
M6E9XT[*"SK_/"S6KINSWD_6E1P#)\+>WH0_'[_LC ]#$MR)W\CMK,@D1HZ(D
MJZH20LX.A;ZUNL\3X+XXC)(<='9VY ?7FS./,Y-_N+;)//_SI,:2(^<\;@GU
M\\/9P77[Y14T547&8FIBCH,4>'#'0HHAGUQJL@D8K %[@.V"O0*OF**]//)]
M%OAOEQ_UWUTO'KC\]?UCM]NL-D+LN&>),\K.3X,,PR-J=+?7[<'.A9F_/0!K
MGQ+MW.F^"&5$(=K1U&-G4'U\G"K.75:P"N4H&I@#Z]/@)^+0D?"SDN&%_E&-
ML&U]OJ()A:!89;9\]/$?L%]LY;A\P/G,7#^5O]T[BS#PZ8?.F=+Q.G@=DHRW
M WWL3%AS!B>A[S(@<\7=2 <.5)S/,=?]'^I#3^F6M:0ZG<99BZI-Z/P"[&RM
M(OA'IONA1PK\!X_2G(QE\G[E"O\K,T*O^CE?AT"RUE%Q/^]8,M:TYGQJ"DB?
M6KNF@(-10+NF@ I20*>F@*(5C9H"CDH!#Y8^MFS,C8AB!:"G!@ !6#U\\@&!
MO#,8E;)VR[$UG[_Q,T6%70-)]\X7SS68[\M!,B/'?(?D["ZH_L7U _]^X9G5
MQI;]0DV[P>9,$0I  $\(EAB"Q0Y%&)FE[;]=1G4S'T(/8 L\%W[_8/W 3Q7W
M&6VQ:T7RY&[_@G'B01]C/-_UEM&O%X 2Q#=RMW[)Z !*&9NYMGD_7WCN$]?.
M+@ AHN!Q_O[/%"OJVH2JU":<'AOJVH1+//6Z-N&4M0G'/'\YVC5N:N5_<+U/
M['ED&)@7#!L'Z>G 1SZG0<B$Z$> I6/JGNE_7Y@ 55QM\U;XZC;(%<,(YZ&-
MK>L^!S/FX<\>F^%A/;%[QW#GK-IHMA-(%9FS#6P/Z;O;5A9N>UXGH)#4,-MS
MH9!SU+S.C2I*IB$>F1(ZUZWNY8Q1*OL8H^2YX]D<[]SK"9#[=Z*J)T"NQ]OC
MZ;;U!,>3H'@]P?&4$QQ/15[U!,9Z F-9<?12\*X^=WGN_>M.LVH%<&+91P))
M"RW#ZH&D=42#MI)EDH.C^H-Y/&#TK'MF%!-^/U_8[I(Q8B>?%]5/2DML+^:-
MN?L\"7LL^I0_N4X& "H>[$F=-"GG:S=Z$4>-_3P\RP@2!MJ9''$<O\O8XYF>
M;OZDN]S.YWQT&VB#KO?-_<B\*?.JC0:;9M;M#HD:63:"Z-R:,!>/1+NLKH1]
MFJN,L.?0RKEZ"'OB;L^G1=CMYI&<*S(>9AI+19&B[CRT+1K5G8?. )DK[C<H
M?^>A$QUSW7GHW ^];M7R8GRJ6[5<*@74K5KJ5BV730%UJY:Z5<MY44#=JJ6\
MK5J*0 5>W?1-_S$*@YGKP2+Y[!+XT@\L@P9H>,MJGWWV'F-.D+G9RSIO2NH<
M.>:#:^CV/T//\DW+J#[5;SKY#=L^6QRHYWQ48LY'29&AU[Z]4&2(=GZFR%"/
MA:K86*A"D*)NOE:IYFMEP8FZ^5HIFJ^5!AWJYFLE:KY6!%:<6?[DA68HGEE2
MX86F[>W5X**J9WS<?A67A $;*N!KI#E*!XCM*NPO$7<OIYE899MTG1H;ZC:N
MEWCJ=1O74[9Q+>+\T:+^/!EA^<6412F[RM^_6L'LS@9=WM!M.2SCLS?5'>L_
M9Y# D+E]X6[:&0AGAB)#[ S9;J^I38K%I/A13A;%KC*4'A2\?X)_1=ZJU/?*
MU=F]=OZI.R%\C8OY/ &UK/(I7IOJG?(@>E!%./MP%(4\ZY0.O8*<ID,$A=QC
M/P&%"2HX$85]=TSF/7M6P+P4B5%:#?,6NA<LH^#B/^Y^!=$%U^/]CGGG/CS<
M[4.2YTI>N> \)'9GG8QX?_[YE)_ +XBV<ESL-0T51D,OC0K4Y')P<I&'S=L
MW#MWKN,P2NM#[?C;C.5*[9IND&[VAU^-[$="]HO R_K$]SWQ2S),:Z.P1*C:
MN6YUJM9C5"S[!2"1W^"_X<__#U!+ P04    " !W@(),\T> :.07  "K)0$
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M^>KLN$'DWQ0"2>R#0-9]+M !],IE],V$&LTT3$%*G6)?6K,_#/P-M@D3[LQ
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M@*KV^T)*SW'FC09/.$?G(4\"&H;7^HR8PEE-[KSI9I/*&SQ&B!"43*8'#0^
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M]E;6?\"@P":,NGDZ--WT=3''V.=F NQ%429E)O7*M?HF?^U ='=]__KU<74
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MR6/ZJ82E6221^V2T ;YNZ[NJQY 'MK@>S)YD1T]M5EP8UE%_^JWNK-[2#YV
MJ,RAF$<O[MOOJC2])G=58YH.KJ;2[DA]CNB'YB%X1K=!LVLAZA[K@J5[NR]
M=YK@::^_.[KX%0=N*.MFV7:9*@UP#=YVY+>^*X-2:?A?JJD+L@T1?<%:UT1F
M]W9W1W=O*\O)+AW'E8"__!++ZZ-RC89W6GN:V&JJN3OROQ.I*":_SRTZAY-]
MSFB5"9)V,R](,[A+W)XD<<)I>96(8C 9C+WT#ES]_K8!@CNA[;99<_:C28$K
MM/'3=/+A"%42.3,Z)_#G_P-02P,$%     @ =X""3)"K2LW;#0  '<0  !4
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M'V^R2OV.-XNA,ACY^!%-:Y35QV^&4<3)/([2ZF5$Z?8#3$]N=%$M3+,1O[]
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M&,+1J%5*;\A_YDA@N/(74$L#!!0    ( '> @DQ>^;]>-&T  /-Y"0 5
M9&9F;BTR,#$W,3(S,5]D968N>&UL[;UK<^,XEB;\?2/V/]1;^UE=E959MXGI
MW9!O69YUICRVLW+GTP1-0A*[*4(%4DZK?_T+D+K0,@D<D"!P2",ZHMII ^1Y
MP /@W,^__Y_G5?+=$V%93-._?__N;S]^_QU)0QK%Z>+OWW^YGTSOSZ^OO_\N
MRX,T"A*:DK]_G]+O_\___I__X]__O\GD(TD)"W(2??>X_>YAN4DCPB[HBGSW
M_\[N;KZ;?/?NW;]]^/GVTW=?'LZ_^^G'=[]-?GP_>?_C9/*__SV)TW_^F_C/
M8Y"1[S@1:5;\\^_?+_-\_6\__/#MV[>_/3^RY&^4+7[XZ<<?W_^P'_W];KCX
M:Y0?)E0'__Q#^<?#T%>/_O:^&/ON]]]__Z'XZV%H%M<-Y ]]]\/_^W1S'R[)
M*IC$J5B14-"2Q?^6%;^\H6&0%\NHA/!=XPCQK\E^V$3\:O+NI\G[=W][SJ+O
M^:I_]UVY= $+&4W('9E_M_OQR]WUZ[6(T_R'*%[]L!OS0Y DG.3B"4M&YHVD
M[A=04/"S>/?_JLS,MVO.!EF\6B?D^Q^Z$Q7151"GDQ59/1+6DKS:9Q@G-%Z1
M5.R42?FZMK0V/,8TN4O^/!9N'LGD\,:6%$N>U.,:DWFP2?+NB_SR.8T$[ZD]
M)56\*XKG\XUXVGH9L%7PMY"N^&O?_?KNI_?O?BCHYN=!3O@K\TE*<S)Y]_.$
MD40<C9-UP/+M)&=!F@6A.""REY"B^3R=[!]6T-[F68VP./PXC<78&_[/W6A!
ML@6 )5'D.2?\9MB=7WNZ$AK6?=GBJ\Z#[+'XM)MLL@B"=4'*#R3)L_UOB@6;
M_/AN=S3^K]VO__LBSL*$9AM&'OAKS_A+_CE]S#AMX8$!DN"1)'__7F-&"2,1
MYSMEN\7M%\9=N;2W8F4?*@M;0VP#K!9/L _S/B1IP&+Z)<W6)(SG,8DN7AR)
M)Z"4XP<,H?Z<L@IEO\/Y04&N^8]9$X;&@0Z)WB_L]#E6TETWUB'I#\%C0E0T
MOQ@D(_9XX$]9^!UE7";_^_=<KB]OR'\3NY]$?_\^9YO#XW:7;TM1;<[H"L0<
MM,6IR]]L$U^#:-8 L9:/J/9Y91>C1)AK@/F2]:C6A@)B>V?\^[T\34U_P/K3
MNBO8W2]IFO--<9D4)'*ACBS$#]J+45'9VFQ1V<EC>5>J3QW(>4(-2$='X/_^
M0XUXW9LZ\6$R#V(V>0J2#>$+$0@2Q9^U=0GE@ZPK$D"*O!:A#>.*K^N?8EF/
MU&4JO0$T9\!B]@@@>$W!:PI>4_":@M<4O*;@-86>-04-><B1;O#K) A#OEC1
MA#RO.4^3;!*DT83F2\(FX88Q,3*)@\<XX;0078VA[>-MZQ'=Z+2I74S#D&ZX
M?G,;;,5^F99DWQQ)FZ;13)!=^=61^\Y+*"HYOI^7V!=]1J**>?W%ZR]>?_'Z
MB]=?O/[B]1>OOUC37_J4 ^TK/!$--\4/0K3G_Q_GVTF<SBF?E[\*;Y.I-L '
M651BM"C25U<R$OYM09]^B$@L2/@@?A"+\Z%R7?-?_?>4TQ ).JZ28'%R4S?^
MO:U$ 25JQX97G"^#Y+](P"[3Z((O7 U]JJ%]DWJQ^XPE ;>$'ZG1%?_=J:0&
M&FN76+%:,%)?C;1%Z/5Q0S2)[M#A#DBNDWXA0VV16G)@\]Z2CK-%Y -_CX2V
MZI_[)NFR.*7/^5M9D%SS\_CY_Y)M#6W2<9:(I*L53>]S?H??\[N(9+--7B1U
MQ&G=*0^?9(G\\E2_(VO*<OYV(;'5GE.0X79(KK6--/T9$4FFK#-ZI%W%"6'G
M_#A94-:\A6I'V2'P=O.8Q.%50H-3NZ-TC!WB[L@B%BI FG\.5G6GHVR8'1+_
MI E70P)6?L/FK=LPS@Z17TF2_-^4?DOO29#1E$376;8Y*F*OB%6,[YOH&[((
MDI*2&EN@9$3?A#VP0-P1]]O5(TUJR*K]NS-+G]02)EM%JCK0D9F[0+(F!7 .
M*E.7YA?J9,]J_%(]V[/ 2@W5T2@L?\9FVY8N//5U!H3V$U)H4ET!B.T].FR2
M8Q^(Z0,Z3#![$Q#>S^C@*>5N(+)?D"*#:(I B+\BA2B5J('8?D.*#22  S'^
MCA0CW H#O<_[=U:U0]JH/T.!X9-4FLV24$SX1!2 &1@*#I^, G)T0.'A$U>
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M&=^'*6>'RDH6/W+.D ;]@N>-")+[>.8Z$IM93#':'?E<_'[D=U91.O:UH*=
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M^G61"UC4D-""$;G,ROKBJ^M:S>V"-1BB#/)XHPMVA!_$%!@%AS(TV>35A"%
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MWU\-@2-&4:(,>W^U"WY$PF.H%*/=D'^=\MMX<UJ(I(;R^H&NB5;&7JB&#Q:
M^\T[DOC(&WZ0+ KSQWD@;;+4/- UT<JX#]7PP0)POPL^!<_Q:K.2AJ;4CG%
M*E<:E*36C7$0!B2J+TCVXJN_.R)1'I'T>@1R,MUO)Q\HY0.E?*"4#Y3R@5+H
M,+Z^<RG@KL.(1&5(&%?3#HGV3G4598SX)'H9U56!!ANFI3+1X/,,J?B-ZAN:
M43HUNVT_#'%4!ME494-!QZ;*8X/J.6E0LFBW$Q0#BYH\< R>-/BBH1H,)^CV
M79T\68$A,5.AW&%0V7D@>TGU=9KMG8.-J0(Y']%M([CZXEM=F;C.\#57\+&
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MF]4F$3+K+%\2QL59OK.60KG;]YI7P=.;[P#BP5-R&\3"0Q:LXSQ(Y+ @<UQ
M^<<FRXNV\E>4<47JR%U<F$OYCV'9=%X2QMGJ&:XR:HLSX((\YH<>BA=Q)B20
M#6N,/]>8Z0!6N5OXYKB<STF8S^8G7R!.PW@M>C^6*O-L/HUH805K0MOY@?87
M07R6ZS3C$J1@- FO-@]T3;0RWT\U?+  W >NEXQ^N%\>@N<[?O^\;)0ZS:\(
M5UR"1*@3&T[9]L7@!LP&G^Q@60J575S -.5?3/IQI6,'2+I[ICQ<,V?;PX]_
MQ)Q/6+C<WI GDDC..;W)#L$5+8FS@J+W4@$*,,,AC%WWY5((>K7@4O9K]8PW
M -7]#OQ(:?0M3I+KU9K36%B0:-:TX^2#[1-_I&,VOZ'IXH9?0E'9,_V!G@G9
M=2W,;K-Y Q[M^0X@[J_)R^<UUP_)&4G)O"@JS 75C2BDO.8<519</>@HL_G%
MSLG-)Q9X]DW4FPJD]/4:%PNV,Z.1XFM>IWF0+H1:4W[7L^VGX!^4%79>R=W2
M\BGHX%X^A\E&U-O>;]UV>!L?@P[P\;LH9?4.3WICL-U?4P,J4O6)KZV2U+HQ
M3NII\6,]W]XF02HB_H26L!8G^Y>,S#?)33QOTODT9OJ*6KZBEN5R.%>4D3#(
M%%4JI(,'7,MG!! 0L-+>AWIB.9$)C: YOFB1+UJDB%^T2:S(Q3UZ-Z0'IFSH
MX C7.6$0% =X V58VKE8J0Y_8H0-NS2HPI2/'^=XJNQH^AUH2]LP_H5H:R2C
M!FTP&-=%XH"G3:-PX#.8?=/&.X<NVZS=AJU;!95'#V4FDJ63#D.A 8.<KXJ_
M0<?ERI.(:@?>HF3G;N<R!BXU^3$UPH;M9IGY8A&G,"3N I0;S4JQ"'M;JO=2
M'OBJK'3R?Z/;7EVT#*K,]D"Y!=WH9B.K_F*N@H#%6GY*"V"-N5#F T/)WHYK
M). K[](A004="TL-N57,^EEB*)FY%\OW6(NYJ'VKZ/A9;K%_L8G!"70H&=F,
M+V,@6@'\J[;+]NS*QKY<CXUB"AH9DW:M*"8+GNB%^ME5>HWA;)D,8%>Y,8>V
M4\"W73'9&&A(_HI="<D8-.-)F,!UP%*]Y\C7?2:R !<%7=T?0^GN1_A6:P)]
MF 0AOW2RXD4=2_N GF6[0H\&49T*[9QQJE*295P"?8S38A<<BM$5E:#VA>@N
M@W!YR\A33#=9LOV#)-$7#GLV+^74;!FOKT7%7)(=!,EJ09H>7V.@ODX-=277
M7]$DH=^*2O]L0=AU^G49ATM^A))XS8DZ#[(E5\^%>%<>)B3BHE&T"?/RROQ*
M-TGTP.+%0HCXQ<;B'[@0"8LJ8K?!MM3B@4OFAB@#"WRQ9_]7Y:.KB)M'&2#A
M\IF$&W'>S>;S..2LU$R'8J@!8J[X!^7G:Y!,HZ<X(ZR9%OE($Z10+O6P4G/]
M@R;\LLKXW0?Z7II3#1#+-T HBI4M^*>I% R=;?),F/O$7?XMY2=A#;&:4X=;
M+(P_]N>?ZFMI-?[=P&OO-V'(3ZLK4BVBGIUVFJ@2 IOAHI37X>*](X6-IAF(
MUAP'4+X%+!*F8%D=J[HQ]DG=7W>5E2Q^Y)PA31@"SQL1)/>Y4'4D-K.88K0[
M\BNR5<,.5B""/\!%Y;?F]A>O2KVI>II8K6+$E2RZ):2\H-7)/,KQZ'+SWUC)
M"5^!8905&$ZI_$QR>'$1^%0GP+BFO2K5[>(4_TSS:2)($*X=^8>$3QT=,/<L
M^3G(-TR4W2]-O9*S53+2 =DT9:+U@VCQ<;1!RZA73L "0LI4D"F#!^)^5]P&
MVWTH$=>VFWBJ892#$B.Z[>I."Y!HM[L;+T3WS.>+F* J8D*>"!,-:HHK_%T3
M@/I1#L@5SJ$SSN:1")'B%W4@*>$M'XR%^*GH([,H72QGV^.8W?%;F...-KDT
M$D$VRO.@SU?YA=-\%8)=[NO[^/H^S<1*F@J6O^<BX#UA3W'8*"RV>P@:L&4"
M?C>L\F<X*'\4YZ+CW'4:Q4]QM EDA=*E8Q&0_C7.EX45741E+>/U [U,\SB7
MU]EN^90W M>7M\*&T7A_<OR0ZYW-IZU!>Q5D,2Z+RD%*Y4,E_FZ,: '&2]K&
M1H@1JR^(5;\N<@&$&KK4,2*7.1Y>?'5=1Y)=L 83.4'A(>A2..$',07&MZ),
MX#1Y-6%(XS3(M^JH&71,JR]*TB[!OB@YVKC8W8FM\57(\H5^3GF_.60:)8,/
ML-"/O4QN%(6?\%7W@@:4H-O?(/7P1>D%<*0^RLUM3GD>664N94 7.M;54O%H
MBZP9G QL3O\=6<$N@%,&'0^W-<]0C?Q&E&S<EP%K(&)4U^\.RK&U6WC#9.F]
MYIPZ=#NX5X]+M1P)+$L'Y69WXK;J=!(8*L*"LG+JFZHKZHNYF3_QI)#:5PNP
M:_$S [3WPBQV+2*]+8K+TBMV57*#=;=T<_SL:F[&@+9-!K<KWIJK_BC+$[(K
MGAC#U"6<%0@96P6X#E&M0,2_8T,LRVJ!2BD6%3,8*$#2RQ&;U2)]/T_6NT*Q
M$RXS3<B^2FS'>GVZC[5=NJ\=?; J?F;BCR_(FG$-199+53=DP(EW(X#@LXI\
M5I&,9G!6D?L0R&$']WN;F+>)O3&;F%HJ<"1B_C)9["P)A:P5'TP.DZ"P.704
M-=L^WK;(V8W.3@6DIX_\C31=I207[D N^HKPA#N2$<X2RVD:78BFP+20@$\L
M0LVE08T]U)=Q[5=$493Y0E#*J]+" ]S1XK3T59MGN"CN)?H<' ]R\6IY74[
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MT)52_9[O&0G_MJ!//T0D%J1]$#^(Q?Q0"83BO_KORS3GYUQM"%?3G]M&:O5
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MGKT\0/B_-HQQ"OE!&F<W^Z7COQ;=$KGN'9;GS*$SX@.=KN.P#JHC$NR;V Y
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M*L"[,;T;<TAN3*#:A"Z"14TW;27<H_N,6D"US(CHW,M:4($.$'2>8BV02KL
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MKVG3PB8YR;1Y(6>\L@N(X(@P9!L252IS-(#L]C ,X ^*P7FPCO,@40@Q^@_
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M<Y T]IZ_[9ZX:G7B_MYB/V]+V@WB)$L+T#G".>F*1#/0'/=03GI6*$#4=KA
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MYUM1/:41I=FM/Y8>B =$\X/KZI#H/"(M\8*U36\X]X9S;SBW8#C7,2^@.X6
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M( 17_1*:]&V$IXC6*^ <U^J$"=8,1-2?-3=K1CS=YO)7\/X!NT';9YK_G5]
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MMV<2[D.P(,0KDK#43S5=O;7.\'+M6//8/<">6L1!<L5V#\7R@=]A?F:<Z9?
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M<<B>BI[JX=K#9[=KLJJB<1]\D2]YL&W(NW:2L&<PF?8L2(TOD:M1@8*KI:@
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MI'V;<T\K=,CX06_6GQO!:U]$PH"Z6%6;Q\5K3P2."K>6- D0%860/<5'=TL
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MPT+89Z@HR?5U3MAS"@?.;K,5L(('MI,MFE_F9!-DO]$"$AD5<1AO!>AGMDN
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MO%0[$!E<JD;&.V6ION 7?;!*O#Q8M'$%:Z:+=D@>QQ?M*--GL6@[8M/U%NU
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M!E@*?CHR\Y?P^3N:$@\^.C:7&7,E%C.)6[OG, 9M@AI?FHY;:RC8UZ8& [H
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M'R#71G_'UHLL=FW%%7$_&[$"EYD^ZSSE :GKK0?)+<MC\30X+&0ZGT[-$C)
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M&_C!T_B@>67\ Z25I;]C!\:6RK7B*,QQ@LW%Y'"PN7=67&4%4TL[]4Y&'[G
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M[H&B?%.SQ>G%*2T^V=N#3()V2AQS0(1,S6'\H8A[MN#(M%K-A]3XD!J+0FI
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MU4/5#[%?4G(([*$2R4Z&:4*Z831,@1B7O\2[V+R+K24N$ T5M](#W4&HG9Z
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M^8N9!UN!]@^<990=-3:L)G]7\U6-B]VD2?JK.7ZNZ!=PFV;T2N9.RF836/-
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M;BTR,#$W,3(S,2YX<V102P$"% ,4    " !W@(),D*M*S=L-   =Q   %0
M            @ '>0 $ 9&9F;BTR,#$W,3(S,5]C86PN>&UL4$L! A0#%
M  @ =X""3%[YOUXT;0  \WD) !4              ( ![$X! &1F9FXM,C Q
M-S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( '> @DP"*RY,$H0  # &!P 5
M          "  5.\ 0!D9F9N+3(P,3<Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" !W@(),9_02QS)M  "FI@D %0              @ &80 ( 9&9F;BTR,#$W
B,3(S,5]P<F4N>&UL4$L%!@     &  8 B@$  /VM @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
